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Abstract
The rapid and accurate detection of biological threat agents is required to allow medical 
counter-measures to be administered in a timely fashion for military and civil defence.
An electrospray mass spectrometer (ESMS)-based biological detection system was 
proposed, with the aim of identifying toxins, viruses and bacteria on the basis of the 
molecular weight of a biomarker protein. As bacterial and spore samples are considered 
to be the most challenging targets due to their complexity compared with toxins and 
viruses, this investigation focused on the isolation and identification of potential bacterial 
biomarker proteins from Gram-negative bacterial species and Bacillus spores. 
Immunoaffinity was used as a preparative method to isolate biomarker proteins for ESMS 
analysis, utilizing antibodies that recognised conserved epitopes of the bacterial 
biomarker proteins.
Monoclonal antibodies were produced that recognised a conserved epitope of either 
adenylate kinase or heat shock protein 60 (HSP60), two potential Gram-negative bacterial 
biomarker proteins. The ESMS successfully measured the molecular weight of HSP60 
purified from the lysates of three Gram-negative bacterial species {Escherichia coli 
JM109, Yersinia pseudotuberculosis 32953 and Pantoea agglomerans 9381 Graham 
Brice) and this information could be used to identify the bacterial species. HSP60 was 
also identified as a potential biomarker protein for Bacillus spores. In an attempt to 
produce alternate immunoaffinity ligands, single-chain antibody fragments (scFvs) that 
recognised a conserved epitope of a bacterial biomarker protein were unable to be 
isolated from naive antibody phage display libraries. Due to this, it was impossible to 
attempt to generate an X-ray crystallographic structural model of a scFv-biomarker 
protein complex. Crystallisation trials failed to produce crystals of the biomarker proteins 
that were suitable for X-ray crystallographic study.
Mass spectrometry has promise as a biological detection technique, but it is unknown 





1.1 Aims of the project
The eventual aim of this programme of work was to develop a generic biological 
detection system that was capable of identifying toxins, viruses and bacteria from a wide 
range of sources, whether from atmospheric sampling, clinical samples, swabs from 
surfaces, contaminated liquids or other material.
The aim of this project was to provide the proof of principle research to allow the 
development of a generic biological electrospray mass spectrometer (ESMS)-based 
detection system. Toxins, viruses and bacteria would be identified on the basis of the 
molecular weight (MW) of a biomarker protein. As bacterial and spore samples were 
considered to be the most challenging targets due to their higher complexity compared 
with toxins and viruses, this investigation focused on the isolation and identification of 
potential bacterial biomarker proteins from Gram-negative bacterial species and Bacillus 
spores.
This project had two sections. The first was to provide the proof of principle research to 
demonstrate that bacterial species could be identified by the measurement of the MW of a 
highly conserved bacterial biomarker protein with the ESMS. ESMS analysis of 
environmental samples required a clean-up and concentration processing step. 
Immunoaffinity purification of the biomarker protein from a bacterial lysate was 
proposed. By using a cross-reactive antibody as the capture ligand, capable of purifying a 
biomarker protein from several bacterial species, the aim was to develop a generic 
bacterial detection system. The proof of principle research required:
1. An interface between the immunoaffinity system and the ESMS to allow the 
biomarker protein to be eluted from the immunoaffinity column and injected into 
the electrospray ion source.
2. Antibodies that recognised conserved epitopes of the bacterial biomarker proteins 
for use in the immunoaffinity column.
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3. A biomarker protein to be purified from at least two bacterial lysates and analyzed 
by ESMS.
The second section of the project was to develop immunoaffinity ligands for future use in 
the detection system. The initial development of the system used monoclonal antibodies 
(mAbs), and it was believed that single-chain antibody fragments (scFvs) would 
eventually be used as the immunoaffinity ligand. To allow future directed design of a 
scFv, an X-ray crystallographic structural model of a complex of a bacterial biomarker 
protein and the scFv was required. The development of scFv ligands required:
1. ScFv that recognised conserved epitopes of the bacterial biomarker proteins to be 
isolated from naive human antibody phage display libraries.
2. The conversion of suitable monoclonal cell lines into scFvs.
3. Crystallization of a scFv-bacterial biomarker protein complex and the production 
of a crystallographic structural model.
1.2 Biological weapons
Effective biological weapons (BW) are highly infectious or toxic, stable, able to be 
aerosolized and, while not necessarily causing high rates of mortality, highly debilitating 
(Kortepeter and Parker, 1999). The impact of a release of BW is not limited to those 
directly affected by the organism or toxin, but also the disruption caused by treating 
casualties and public panic (Bhalla and Warheit, 2004). The covert dissemination of an 
infectious BW agent may only be detected when clinical symptoms appear, allowing the 
disease to be widely spread within hours (Peruski and Peruski, 2003; Klietmann and 
Ruoff, 2001). BW include bacteria, spores, viruses and toxins. The rapid and accurate 
detection of BW is required to allow effective medical counter-measures to be 
administered in a timely fashion for military and civil defence.
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1.3 Existing biological detection technologies
A range of technologies are currently employed to detect and identify biological agents 
(Lim et al., 2005; Luppa et al., 2001; Iqbal et al., 2000). Most detection systems are based 
on two components; a recognition element to specifically bind to a target and a 
mechanism to report that a binding interaction has occurred. The exceptions to this are 
techniques based on the measurement of a physical property, for example, molecular 
weight (mass spectroscopy) or a Raman spectrum (surface-enhanced Raman scattering 
[SERS]).
Affinity-ligand based detection systems can use several types of capture ligand and many 
reporting technologies, which will not be described here (Luppa et al., 2001). Antibodies 
(and antibody fragments) are widely utilized capture ligands for bacterial cells, spores, 
viruses and toxins (Luppa et al., 2001). Carbohydrates have also been successfully 
employed as capture ligands (Ngundi et al., 2006; Khan et al., 2004). DNA probes have 
been used as capture ligands exploiting DNA hybridization (Mannelli et al., 2005), 
particularly in DNA microarrays (Bodrossy and Sessitsch, 2004; Sergeev et al., 2004).
Polymerase-chain reaction based assays rely on the amplification of a specific DNA 
sequence and can result in extremely high sensitivities compared to other methods (Wang 
et al., 2004; Makino et al., 2003; Oliveira et al., 2002). However, this sensitivity can be a 
disadvantage due to false positives from contamination of the assay (Johnson, 2000) and 
PCR can be sensitive to inhibition by material in environmental samples, requiring a 
DNA preparation method (Kuske et al., 1998). Also, PCR does not necessarily confirm 
the presence of viable cells or viruses, and indirect detection of toxins is reliant on DNA 
from the parent organism being present in the toxin sample, and cannot be used as 
confirmation of the presence of toxin.
The advantage of physical methods is that they do not require a specific ligand (such as 
an antibody or PCR primer) that recognises a threat agent. Mass spectrometry is a
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technique that can be used to detect chemical and biological threat agents from across the 
threat spectrum based on molecular weight, from chemical agents and toxins to intact 
bacterial cells (Lebedev, 2005). SERS can be used as a detection technique for bacteria 
and proteins based on Raman spectra (Stuart et al., 2005; Zhang et al, 2005).
1.4 The requirement for a generic biological detection system
The eventual aim of this project is to produce a generic biological detection system that 
can detect and identify toxins, and viral and bacterial pathogens. A range of technologies 
are currently employed to detect and identify biological agents (Lim et al., 2005; Luppa et 
al., 2001; Iqbal et al., 2000), however each assay requires specific ligands to identify a 
single target. This leads to a high logistical burden both in equipment and reagents to 
maintain a capability to detect and identify a wide range of biological agents, as each 
threat agent requires its own set of reagents. Microbiological agents are still often 
identified by cell culture, which is time consuming and requires skilled personnel 
(Klietmann and Ruoff, 2001). A single biological detection system based around generic 
ligands would limit the logistical burden and, particularly if automated, would simplify 
the training and knowledge required by the operators.
1.5 The proposed biological detection system
Mass spectrometry is a technique that has been used for the identification of chemical and 
biological weapons (Lebedev, 2005). Mass spectroscopy has the potential to identify a 
wide range of targets on the basis of the measurement of the molecular weight of a 
biomarker protein. A biomarker protein is a protein whose identification reveals the 
identity of the agent. In this application, the biomarker protein's MW needs to be unique 
to allow the identification of the agent. The toxin biomarker protein would be the toxin 
itself. The most probable biomarker protein for viruses would be a capsid protein 
(Thomas et al., 1998). Heat shock protein 60 (HSP60) and adenylate kinase (AdK) have 
been identified as potential biomarker proteins for Gram-negative bacteria, as they are 
both highly conserved, ubiquitous proteins (Zeilstra-Ryalls et al., 1991; Schulz et al.,
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allowed identification of the threat agent by the measurement of the biomarker protein's 
molecular weight by mass spectrometry. An electrospray mass spectrometer (ESMS)- 
based detection system has been proposed. A processing system was required to isolate 
the biomarker protein from complex samples and present it to the ESMS. Immunoaffinity 
was proposed as a technique capable of purifying a biomarker protein from a complex 
protein mixture for ESMS analysis. In this system the ESMS would provide the 
identification of the threat agent, rather than individual antibodies that specifically 
recognised each target agent. This would allow an antibody that recognised a conserved 
epitope of a biomarker protein to be used as the immunoaffinity ligand. This would avoid 
using a separate antibody for each target biomarker protein; each with unique 
characteristics which would have to be taken into account when designing the fluidics of 
the detection system and selecting immunoaffinity buffers. Ideally a panel of a limited 
number of antibody ligands would be effective against biomarker proteins across the 
biological threat agent spectrum.
The envisaged detection system will comprise of an atmospheric collection device to 
present an atmospheric sample in a liquid phase, or a port to allow injection of liquid 
samples. A cell disruption technique that can be incorporated into a flow-through system 
is required and the most promising technology for this step is sonication (Borthwick,
2005). The disrupted sample requires filtering to remove large particles and debris that 
could block the immunoaffinity column. Biomarker proteins can then be isolated by 
immunoaffinity purification and injected into the ESMS for analysis. The sample 
collection, cell disruption and filtration stages of the system are not examined in this 
project.
1.6 Biological mass spectrometry
Mass spectrometry determines the molecular weight (MW) of a compound by separating 
molecular ions on the basis of their mass/charge (m/z) ratio with the use of magnetic and 
electric fields. Electron ionization is the oldest ionization technique and is effective for 
small molecules below 1000 Da, but the sample must be thermally stable and volatile.
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The sample is vapourized into the gas phase and exposed to a beam of electrons. An 
electron collision can result in the formation of a molecular ion, which may have 
sufficient excess energy to decompose further into fragment ions. However, electron 
ionization is unsuitable for proteins, due to thermal decomposition as electron ionization 
requires the sample to be heated to produce gas phase material for ionization. The 
development of'soft' ionization techniques (electrospray and matrix-assisted laser 
desorption/ionization [MALDI]) allowed mass spectrometer analysis of large protein 
molecules (Siuzdak, 1996).
1.6.1 Electrospray ionization
Electrospray mass spectrometry has been used extensively in the study of large 
biomolecules. Liquid samples are injected through a fine hollow needle held at 4000 V, 
creating a spray of highly charged droplets. The solvent is evaporated in a stream of dry 
gas, increasing the density of the charge on the droplet surface, which leads to the 
formation of multiple charged ions as the droplet evaporates. The ions are directed to a 
detector by a quadrupole mass analyser (Fenn et al., 1989; Amott, 1993; Jonsson, 2001). 
The quadrupole acts as a mass filter, only allowing ions with a specific m/z to reach the 
detector. The radio frequency potential across the quadrupole can be varied, altering the 
m/z ratio ions that reach the detector (Siuzdak, 1996).
An electrospray mass spectrometer (ESMS) analyses proteins in a liquid phase which 
makes this technology ideal for incorporation into a biological detection system. However 
ESMS requires the biomarker protein to be relatively pure, as salts and detergents 
interfere with the electrospray process or interpretation of results (Bajic et al., 2000), so 
crude environmental samples cannot be injected directly in the mass spectrometer. 
Immunoaffinity is a purification technique that has the capability to purify the biomarker 
protein from complex mixtures and present it in a suitable form for ESMS analysis. A 
crude sample still requires processing to lyse bacterial cells and remove debris before it 
can be loaded onto an immunoaffinity column.
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Electrospray mass spectrometry (ESMS) has been used to study toxins, viruses and 
bacteria; for example, to characterise the heterogeneity of ricin (Despeyroux et al., 1999), 
identify Vaccinia virion proteins (Yoder et al., 2006) and identify bacterial species on the 
basis of crude bacterial lysates (Vaidyanathan et al., 2001).
1.6.1.1 Liquid chromatography-ESMS
As samples are injected into the ESMS in the liquid phase, ESMS can be readily 
combined with a liquid chromatography system. The use of liquid chromatography has 
the advantage of separating proteins before ionization. This simplifies data processing 
and molecular ion identification by separating each molecule's m/z spectrum from other 
molecular species m/z peaks. As ESMS typically results in multiple charges on each 
molecule, if all molecular species were detected at the same time point it would 
complicate data interpretation, particularly for protein mixtures. The interface of liquid 
chromatography and ESMS is well established and has been widely reported (Gelpi,
1995; Niessen, 1998; Marquet and Lachatre, 1999; Lim and Lord, 2002). Liquid 
chromatography-ESMS systems have been used to analyse small molecules and proteins 
from complex matrices such as serum (Sen et al., 2003; Lacey et al., 2001) and human 
urine (Cai and Henion, 1996). The design and development of the fluidic interface 
between the immunoaffinity column and the ESMS should be straightforward, but the 
immunoaffinity methods need development and characterization to ensure the delivery of 
the immunoaffinity elution fraction containing the biomarker protein to the ESMS.
1.6.1.2 ESMS analysis of toxins
There are numerous examples of toxin characterization and detection by ESMS. 
Staphylococcal enterotoxin B has been detected when spiked into apple juice as a 
representative food matrix, using liquid chromatography to introduce the sample into the 
electrospray ion source (Callahan et al., 2006). Trichothecene mycotoxins were detected 
from rice samples in which Fusarium graminearum had been cultured, again using liquid 
chromatography to introduce the sample into the electrospray ion source (Sagawa et al.,
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2006). Immunoaffinity was successfully used to extract alfltoxin Mi spiked into milk 
before ESMS analysis (Chen et al., 2005). Clostridium perfringens alpha toxin had been 
successfully immunoaffinity purified from water samples at Dstl (Helen Jones, Dstl 
Porton Down, unpublished data). Due to the relative simplicity of toxins compared with 
either viruses or bacteria and the successful purification of alpha toxin at Dstl, the 
purification of toxin by ESMS was considered to be less challenging than either viruses 
or bacteria, and would be studied at a later date. It is probable that an immunoaffinity 
clean-up and concentration step would require specific ligands that recognised each 
individual toxin.
1.6.1.3 ESMS analysis of viruses
Limited study to date has been made of using ESMS to detect and identify viruses by 
ESMS, with most reports using MALDI (Zachertowska et al., 2006; Thomas et al., 1998; 
She et al., 2001). Due to the well-characterized nature of most viruses, identification of 
the virus can be made by comparing the measured MW of the capsid proteins with 
database values (Siuzdak, 1998). However, the possibility of using a cross-reactive 
antibody to capture capsid proteins or viral particles would be less likely than with 
bacteria due to the simplicity of the structure of viruses in contrast with bacteria and 
variation in viral antigens (Finlay and McFadden, 2006; Wahl et al., 2000). It is likely 
that specific ligands would be required against each viral target.
1.6.1.4 ESMS analysis of bacterial cells and lysates
ESMS has been used to generate unique mass spectrum 'fingerprints' consisting mainly of 
low MW proteins (2 kDa - 20 kDa) from whole bacterial cells (Goodacre et al., 1999; 
Krishnamurthy et al., 1999) and bacterial lysates (Vaidyanathan et al., 2001; 
Vaidyanathan et al., 2002) that were used to identify the bacterial species or strain. In all 
of these studies, considerable sample preparation was required, particularly washing the 
cells to remove buffers, salts and detergents that may have interfered with the ESMS. A
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pre-processing step is required to allow environmental samples to be analyzed by the 
ESMS to allow near-real time identification.
1.6.2 Matrix-assisted laser desorption/ionization (MALDI)
MALDI has been used extensively for the study of peptides and proteins. The sample is 
mixed with a matrix (3,5-dimethoxy-4-hydroxy-cinnamic acid is commonly used with 
large peptides and proteins) and spotted onto a target plate. When the spot has dried, a 
pulsed laser beam is used to ionize the sample. The ionization mechanism is unclear; the 
matrix absorbs energy and enters the gas phase with the protein, where the protein 
becomes ionized (Siuzdak, 1996; Jonsson, 2001). Most mass spectrometer investigations 
of bacterial cells and lysates have used MALDI (van Baar, 2000). MALDI is not as 
amenable as ESMS to be incorporated into a detection system due to the sample 
preparation required, although as each ion typically only carries one or two charges, 
MALDI is better suited than ESMS for analysis of complex mixtures.
1.6.2.1 MALDI analysis of bacterial cells and lysates
MALDI has been used to generate unique mass spectrum 'fingerprints' consisting mainly 
of low MW proteins (2 kDa - 20 kDa) from whole bacterial cells and bacterial lysates that 
was used to identify the bacterial species or strain. Using an algorithm, Arnold and Reilly 
(1998) were able to distinguish between 25 different strains of E. coli. Blind trials of a 
selection of bacterial mass spectra lead to the correct identification of the bacterial species 
when compared to reference spectra (Holland, et al., 1996). Salmonella choleraesuis was 
identified after being spiked into river water, human urine, chicken blood and bacterial 
mixtures (Madonna et al., 2001). In each case though, considerable sample preparation 
was required to spot the bacteria onto the target plate and MALDI is not considered as a 
suitable technology at the present time for use in a near-real time biological detection 
system.
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1.6.2.2 MALDI analysis of Bacillus spores
Small, acid-soluble spore proteins (SASPs) have been exploited as biomarker proteins for 
the identification of specific Bacillus species. The SASPs were released from the spore by 
either acid hydrolysis (Swatkoski et al., 2006) or tryptic digestion (Pribil et al., 2005) and 
analyzed by MALDI, and the Bacillus species was identified by database analysis. One 
aim is to assess whether a biomarker protein for Bacillus spores can be made accessible 
without extensive preparation of the spore sample. Extractable antigen 1, EA1 (Williams 
and Tumbough, 2004) and HSP60 (Redmond et al., 2004) may be able to be exploited as 
biomarker proteins for Bacillus bacteria and spores. There are no examples of ESMS 
detection and identification of spores in the literature at this present time.
1.7 The bacterial biomarker proteins
The most challenging class of agent to identify by a mass spectrometer-based detection 
system is believed to be bacteria and bacterial spores, due to the higher complexity of the 
organism compared to viruses and toxins. Identifying two or more bacterial species on the 
basis of the ESMS-measured MW of a biomarker protein purified from crude bacterial 
lysates will be the proof of principle for a generic bacterial detection system. The 
objective of the immunoaffinity processing step is to isolate a bacterial biomarker protein 
in a form that could be analyzed by the ESMS. The antibody used in the immunoaffinity 
purification must display cross-species recognition of the bacterial biomarker protein for 
the system to be effective as a generic bacterial detector. A suitable biomarker also needs 
to be identified for Bacillus spores.
1.7.1 Identification of a generic bacterial biomarker protein
One early aim of the program was to identify potential bacterial biomarker proteins. For a 
protein to be an effective bacterial biomarker for use in a generic detection system, the 
chosen protein must have certain characteristics. The protein must be highly conserved 
across several bacterial species. The protein must be expressed in all growth conditions
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and it must be present in high quantities within the cell. The function of the protein was 
unimportant as long as the protein was accessible from a bacterial lysate. As antibodies 
were to be raised against the proteins for use in immunoaffinity purification, this protein 
ideally should be highly immunogenic. Heat shock protein 60 (HSP60) and adenylate 
kinase (AdK) were proposed as potential biomarker proteins for Gram-negative bacteria.
HSP60 was identified as a potential biomarker protein by immunoblotting a bacterial 
lysate with polyclonal antibodies that had been raised against a lysate from a different 
bacterial species. Mouse polyclonal antibodies were raised against the whole cell lysates 
of Salmonella typhimurium and Yersinia pestis. Western blots were performed of 2D gels 
of the bacterial lysates from both these species which were blotted with the alternative 
polyclonal antibody; for example the S. typhimurium cell lysate was run on a 2D gel and 
blotted with the Y. pestis polyclonal antibody. Two large spots were seen which were 
identified as HSP60 and outer membrane protein A by a combination of in-gel digestion, 
peptide mapping and database searching. When a third lysate from Francisella tularensis 
was tested only the spot corresponding to HSP60 was visible (K. Anderson, Dstl Porton 
Down, personal communication). Further investigation showed that HSP60 was present 
in S. typhimurium in all growth conditions tested, such as different temperatures, growth 
medias and when the bacterium was grown under anaerobic conditions (K. Anderson,
Dstl Porton Down, personal communication). Although this approach only identified one 
protein as a potential generic bacterial biomarker protein, theoretically any protein with 
conserved structure across several bacterial species is a candidate as a generic biomarker. 
Adenylate kinase was therefore also chosen as a second potential biomarker because of its 
high degree of conservation across bacterial species (also recombinant proteins were 
available at Dstl). HSP60 has been used as the basis of an identification system before by 
PCR of a 600 base pair hyper-variable region of the HSP60 gene (Wong and Chow,
2002). There was sufficient variability within this region to enable the identification of 
bacteria to the genus or species level.
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1.7.2 HSP60
HSP60 is a member of the molecular chaperonin family, a group of proteins that mediate 
the ATP-dependant folding of polypeptide chains to their native state, preventing the 
misfolding of proteins under conditions that would otherwise lead to aggregation of the 
polypeptide chains (Braig, 1998; Bukau and Horwich, 1998; Fink, 1999; Sigler et al., 
1998). HSP60 assists the correct folding of newly synthesized polypeptides and allows 
protein to unfold in a sheltered environment. HSP60 also assists the assembly and 
dissociation of protein complexes. HSP60 (or GroEL in E. coli) was first identified in 
bacteria due to increased expression under stress conditions. GroEL and its co-chaperonin 
GroES have since been shown to be essential for bacterial growth at all temperatures 
(Fayet et al., 1989). HSP60 is present as 1.6% (w/w) of the total cell protein, rising to 
15% (w/w) when the cell is subjected to temperatures of45-47°C (Neidhardt et al., 1984). 
Expression levels of HSP60 rise during an infection in both the infected tissues and the 
pathogen (Ziigel and Kaufmann, 1999).
There is evidence of the involvement of autoimmunity directed against HSP60 by the 
immune system in the early development of atherosclerosis. Exposure to bacteria will 
induce an immune response against bacterial HSP60, which shares a 34% amino acid 
identity and 71% homology with human HSP60 (Wick et al., 2001). Infections with 
Helicobacter pylori have been linked with an increased risk of coronary atherosclerosis 
(Bimie et al., 1998). Endothelial cells do not express HSP60 on their surface under 
normal conditions; however HSP60 has been detected on the cell surface of stressed 
endothelial cells by atomic force and confocal microscopy (Pfister et al., 2005). This is 
thought to lead to endothelial damage and the development of atherosclerotic lesions 
(Wick et al, 2001). The presence of T lymphocytes that recognise a conserved epitope of 
HSP60 does not necessarily ensure the onset of disease (Munk et al., 1989). This does 
indicate that there are conserved HSP60 epitopes available to raise antibodies against.
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1.7.2.1 Structural studies on HSP60
The crystal structure for the E. coli HSP60 has been resolved to 2.8 A (Braig et al., 1994). 
Xu et al., (1997) resolved the structure for the GroEL-GroES-(ATP) 7  complex to 3.0 A. 
GroEL is a double ring structure with a large central cavity where it has been shown that 
polypeptide chains are bound (Buckle et al., 1997). Each ring consists of seven subunits 
of molecular weight 57 kDa, which are stacked back to back. Each subunit has three 
domains. The largest is the equatorial domain that provides the majority of the 
interactions between each subunit and all the interactions between each ring. The ATP 
binding site is also found in this domain. The intermediate domain is the smallest and acts 
as a linker between the equatorial and apical domains. The apical domain contains several 
segments that could not be resolved, indicating a high degree of flexibility that could be 
necessary to allow binding to non-native polypeptides. The entire subunit has the 
potential for large conformational changes due to the hinge regions between the 
intermediate domain and the equatorial and apical domains. This is seen upon the binding 
of the co-chaperonin GroES to the apical region that changes the shape of the central 
cavity, hiding the hydrophobic binding surfaces so releasing bound polypeptide into the 
cavity. The increased hydrophilic nature of the cavity promotes the folding of a 
polypeptide to its native state by favouring the burial of hydrophobic surfaces. Braig et 
al., (1994) found that the best crystals for HSP60 were formed with a protein with two 
mutational changes, R13G and A126V. Both of these amino acids are in the equatorial 
domain and these mutations may have given the protein additional structural stability.
The protein appeared to function normally in a GroEL deficient E. coli strain.
1.7.3 Adenylate kinase
AdK catalyses the following reaction (Rhoads and Lowenstein, 1968):
Mg2+ATP + AMP «• Mg2+ADP +ADP
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This reaction is the only method available in the cell to recover AMP. There are three 
types of AdK that have been studied from vertebrates: AK1 from the cytosol of muscle 
cells, AK2 from the mitochondrial inter-membrane space and AK3 from the 
mitochondrial matrix (Fukami-Kobayashi et al., 1996). AK1 is a ’short type' AdK, while 
AK2 and AK3, as well as most microbial AdKs, are 'long type' enzymes that are 27 
amino acids longer (Fukami-Kobayashi et al., 1996; Yan and Tsui, 1999). The AdKs 
from most gram-positive bacteria contain a zinc finger motif (Glaser et al, 1992; Yan and 
Tsui, 1999). The AdKs from the Archea bacteria have a low homology compared to 
AdKs from other sources (Ferber et al., 1997).
1.7.3.1 Structural studies on adenylate kinase
The crystal structures for the bacterial AdKs from E. coli and Bacillus stearothermophilus 
have been resolved with bound AMP and ADP or with an inhibitor (Berry, 1995; Berry et 
al., 1994; Berry and Phillips, 1998; Muller and Schulz, 1992). All the crystal structures 
for nucleoside monophosphate kinases, regardless of the source, have shown a very 
similar structure (Tsai and Yan, 1991; Yan and Tsai, 1999). All of the enzymes have a 
five-stranded /? sheet with a helix on each side. AdK is a highly flexible protein that 
undergoes significant conformational change when substrates are bound (Berry et al., 
1994). This is illustrated by the three conformations of the mammalian protein that have 
been crystallised: with no substrates bound, with AMP bound and with the substrate 
analog Ap5A bound.
Most AdKs are monomeric, but the archaeal AdK from Sulfolobus acidocaldarius was 
found to be trimeric. Although there was little sequence homology between this AdK and 
other bacterial or mammalian AdKs, the S. acidocaldarius AdK was shown to resemble 
their structure (Vonrhein et al., 1998). The S. acidocaldarius AdK structure is believed to 




Polyclonal antibodies (pAbs) are produced by immunizing an animal with the target 
protein in the presence of an adjuvant in order to stimulate the immune system (Harlow 
and Lane, 1988; Schunk and Macallum, 2005). The polyclonal antibodies were produced 
for this project in order to screen for hybridoma cell lines secreting antibody. Due to the 
mixture of antibodies with differing affinities and specificities, it is not believed that 
polyclonal antibodies would be suitable in an immunoaffinity column (Jack, 1994).
1.8.2 Monoclonal antibodies
Monoclonal antibodies (mAbs) produced by hybridoma cells created by fusing a B 
lymphocyte from an immunized animal with a myeloma cell. The hybridoma cell is 
immortal and will continue to divide and secrete antibody indefinitely. Cells have two 
pathways to produce purine and pyrimidine; de novo and salvage. Successful fusions are 
selected for on the basis of aminopterin inhibiting dihydrofolate reductase by competing 
with folate for the enzyme. This forces the cell to use the salvage pathway to synthesize 
both purine and pyrimidine. The myeloma cell line has a hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) deficiency, disabling the salvage pathway. In the 
presence of aminopterin, the myeloma cells will die. B lymphocyte cells cannot 
propagate, so only the hybridoma cell utilizing the salvage pathway supplied from the B 
lymphocyte, using the hypoxanthine and thymidine precursors for purine and pyrimidine 
synthesis, can prosper and expand (Harlow and Lane, 1988; Kohler and Milstein, 1975).
As polyclonal antibodies are a mixture of antibodies recognising different epitopes with 
varying affinities and avidities they are unsuitable for use as an immunoaffinity ligand 
(Jack, 1994). Monoclonal antibodies are a homogenous preparation. It should therefore be 
possible to disrupt all the interactions between the antibody and the biomarker protein 
under identical conditions, resulting in a concentrated elution peak from the
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immunoaffinity column. The cell fusion technique has an extremely poor efficiency, with 
only a small fraction of the spleenocytes fusing with hybridoma cells to produce stable 
hybridoma cell lines, and most spleenocytes will be lost. The cell lines that are produced 
will favour epitopes that generate the highest immune response, and these epitopes may 
not be conserved among bacterial species. The standard method used to generate 
monoclonal cell lines after cell fusion, limiting dilution, tend to select for cell lines that 
produce antibodies with high affinities and high avidities that may not be suitable for use 
as an immunoaffinity ligand (Harlow and Lane, 1988). Antibody fragment phage display 
techniques offer an alternative that allows a vast number of potential ligands to be 
screened quickly and easily.
1.8.3 Single chain antibody fragments (scFvs)
There are several advantages in the use of single-chain antibody fragments (scFvs).
Single chain antibodies can be produced from naive or immunised phage display libraries 
(Hoogenboom et al, 1998), or they can be derived from existing monoclonal cell lines 
(Krebber et al., 1997). The naive human phage display libraries Tomlinson I+J (de Wildt 
et al, 2000) and Griffin (Griffiths et al, 1994) have 3xl0 8 and approximately 1.2xl09  
different immunoglobulin genes respectively. The Griffin library was based on human 
heavy and light variable chain genes that had been used in vivo, with diversity introduced 
by PCR using synthetic oligonucleotides. The heavy and light chain repertoires were 
recombined in bacteria (Griffiths et al, 1994). The Tomlinson library was based on a 
single human framework (germline heavy-chain genes V3-23/DP-47 and Jn4b and the k -  
light chain genes 012/02/DPK9 and J*l), with diversity introduced at 18 positions in the 
antigen binding site that had been shown to be in contact with the antigen based on 
crystallographic models (de Wildt et al, 2000).
Single chain antibodies can be produced more cheaply and quickly than monoclonal 
antibodies as scFvs are produced in a bacterial expression system rather than tissue 
culture. As scFvs consist of the heavy and light chain variable regions of an antibody 
joined by a linker, they are approximately the third of the size of a monoclonal antibody,
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so a greater density of binding sites could in theory be achievable in an immunoaffinity 
column than with mAbs. It is possible to genetically modify scFvs to increase the 
structural stability of the antibody (Young et al., 1995; Worn and Pliickthun, 2001) and to 
alter the specificity, affinity and avidity of an antibody so it is better suited for the 
required application (Miyazaki et al., 1999; Nevanen et al., 2003). Multivalent scFvs are 
also possible by selection of the correct linker between variable domains, resulting in 
higher affinity (Hudson and Kortt, 1999).
Before choosing to alter the properties of the scFv by protein engineering, it is possible to 
tailor the panning methods to select for phage displaying scFv with the desired properties. 
ScFvs with increased thermostability and increased stability in the presence of 
guanidinium chloride were selected for if the phage were panned under reducing 
conditions (Brockmann et al., 2005). ScFvs with increased thermostability were also 
isolated if the phage were panned under increased temperature (Jung et al., 1999).
1.8.4 Modification of single chain antibodies
It is possible to alter an antibody to change its specificity, affinity or avidity to an epitope 
(Hudson and Souriau, 2003). A random (phage display) or a rational approach (on the 
basis of a structural model) can be taken to change an antibody’s characteristics. Phage 
display allows codon-based mutagenesis to generate a large number of variants of a 
particular single chain antibody (Glaser et al., 1992). However phage display techniques 
may prove to be unsuitable. An X-ray crystallographic structural model is essential to 
study the interactions of an antibody-antigen interface to allow a rational approach to 
altering the characteristics of an antibody binding site. A crystallographic model that 
allows the assessment of point mutations within the antibody binding site will be critical 
to generating variations of antibodies for immunoaffinity.
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1.9 Immunoaffinity chromatography
An on-line processing step is necessary before a sample can be introduced into the 
electrospray ion source to remove buffers, salts and detergents that would otherwise 
interfere with either the electrospray process or data analysis. Immunoaffinity 
chromatography was chosen as the processing step with the aim of using a cross-reactive 
antibody to purify and concentrate a conserved bacterial biomarker protein from a 
selection of bacterial lysates. The identification of the protein's MW would be the basis of 
a generic bacterial detection system that may be capable of sensitive detection of a 
bacterial species from a complex bacterial mixture or matrix.
Affinity chromatography offers a one step clean-up purification process based on a 
biological interaction rather than a physical property of the target protein, unlike other 
purification techniques (Hage, 1999). Immunoaffinity takes advantage of the interaction 
between an antibody and antigen (Jack, 1994; Yarmush et al., 1992). Prior to the 
development of monoclonal antibodies, a standard strategy to isolate immunoaffinity 
ligands was the fractionation of polyclonal serum against the antigen (Campbell et al., 
1951). However polyclonal antibodies are often unsuitable for use as an immunoaffinity 
ligand, as the conditions required for successful elution of the target protein may denature 
the target protein or the antibody (Jack, 1994, Harlow and Lane, 1988). It was only with 
the development of monoclonal antibodies that immunoaffinity purification became 
widespread (Chase, 1983), due to the ready supply of a ligand with identical binding 
characteristics.
Immunoaffinity chromatography has proven suitable for the isolation of several targets 
from complex environmental samples (Van Emon et al., 1998). Examples include the 
isolation of mycotoxin from food and liquids (Scott and Trucksess, 1997); 
phosphinothricin-N-acetyltransferase from samples of genetically modified maize and 
rape (Xu et al., 2005) and the purification of hepatitis B surface antigen from yeast 
(Agraz, A.).
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The matrix used within the column ideally should be rigid to resist compression, 
hydrophilic to limit non-specific binding to the column, stable, non-toxic, porous to 
provide a large surface area to volume ratio (but the pores must be large enough to admit 
large proteins) and display low non-specific adsorption (Jack, 1994). One of the most 
common matrices is Sepharose (cross-linked agarose), but cellulose, cross-linked 
dextrans, agarose, polyacrylamide, porous glass and ceramics, silica and 
hydroxyalkylmethacrylate have all been used and each has it's own advantages and 
disadvantages (Van Emon, 1998). Chip surfaces are also now being used as an 
immunoaffinity support (Phillips and Wellner, 2006).
There are several techniques for the attachment of the antibody to the matrix, which either 
attach the antibody randomly or in a specific orientation (Nisnevitch and Firer, 2001).
The advantage of orientating the antibody is that most of the binding sites will be 
available and there will effectively be a higher density of capture ligand, compared with 
random orientation. Orientated binding can be via protein A, which binds to the Fc region 
and the protein A and antibody are cross-linked by a bifunctional coupling reagent. 
Random attachment is typically through coupling amine groups on the antibody with 
cyanogen bromide or N-hydroxysuccinimide activated beads, although there are several 
available chemistries (Jack, 1994; Harlow and Lane, 1988).
The chosen antibody must be stable and retain its activity during coupling and elution. 
High affinity antibodies may be used if there is an effective elution buffer (Jack, 1994). 
The choice of elution buffer is typically empiric and needs to be tested on the 
immunoaffinity column, but information can be gathered by screening potential elution 
buffers by ELISA (Bonde et al., 1991) or immunodot (Puerta et al., 2004). Common 
classes of elution buffers in increasing order of stringency are low pH, high pH, 
chaotropic agents (thiocyanate, iodine), high salt concentrations, detergents, denaturing 
agents and organic solvents (Firer, 2001; Yarmush et al., 1992, Jack, 1994). The elution 
buffers are tested on the immunoaffinity column in the order of least stringent to most 
stringent to select the buffer that causes the least amount of damage to the antibody,
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prolonging the column lifespan. The selected elution buffer also had to be compatible 
with ESMS, which eliminated high salt concentrations and detergents as potential buffers.
1.10 Structure studies on antibody-antigen complexes
One aim of the project was to produce a crystallographic structural model of a scFv/ 
biomarker protein binding, with the intention of using the structural information of the 
scFv variable regions for directed design of the scFv. The structures of several antibody- 
antigen complexes have been described. These include monoclonal antibody-antigen 
complexes (Amit et al., 1986; Sheriff et al., 1987) and the complex of single chain 
antibodies with their antigen (Braden, et al., 1994; Bhat, 1990). A comparison has been 
made between two single chain antibodies that recognise the same epitope of an influenza 
peptide (Churchill et al., 1994) or guinea fowl lysozyme (Lescar et al., 1995). This 
demonstrated that in order for an antibody to recognise the same epitope as another there 
does not have to be any sequence homology between the two binding sites.
There are several examples of the structure of an antibody fragment in complex with its 
antigen being used as the basis of the directed design of the antibody fragment. The effect 
on affinity of substitutions in the binding site of scFv and Fab fragments on antibody 
affinity has been studied, based on crystal structures of the Fv and Fab in complex with 
their antigen (Dougan et al, 1998). Of particular interest to this programme is that site- 
directed mutagenesis has been used to reduce a Fab fragment's affinity and alter its 
specificity based on crystallographic models for use in immunoaffinity chromatography 
(Nevanen et al, 2003).
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Chapter Two 
General Materials and Methods
2.1 Materials
All materials were purchased from Sigma-Aldich Company Ltd., Fancy Road, Poole, 
Dorset, UK, unless otherwise stated. Recombinant Francisella tularensis and Yersinia 
pestis adenylate kinases and recombinant F. tularensis and Burkholderia pseudomallei 
heat shock protein 60 (HSP60) were gifts from N. Walker, Microbiology Department, 
Dstl Porton Down. Bacterial lysates of Esherichia coli JM109, Yersinia enterocolitica 
YeOc, Yersinia tuberculosis 32953, Staphylococcus aureus 3750 Mrs. Fox and Pantoea 
agglomerans 9381 Graham Brice were gifts from C. Underwood-Fowler, Microbiology 
Department, Dstl Porton Down. The bacterial culture method is detailed in Section
2.2.9.1 and the bacterial lysis method is described in Section 2.2.9.2 for reference.
2.2 Methods
2.2.1 Enzyme-linked immunosorbant assay (ELISA)
2.2.1.1 Indirect ELISA
Immulon 2HB 96 well microtitre plates (Thermo Labsystems, 8  East Forge Parkway, 
Franklin, MA, USA) were coated with antigen at 10 pg/ml in phosphate-buffered saline 
(PBS, purchased from Gibco, Paisley, UK), 100 pi per well and the plate was incubated 
for either 1 hour at 37°C or 16 hours at 4°C. A plate sealer (B.I.S. Ltd., Kirkham, UK) 
was used during each incubation step. The plate was washed three times with PBS 
containing 0.05% (v/v) Tween 20 (PBST) using an ELx405 autoplate washer (Bio-Tek 
Instruments, Swindon, Wiltshire, UK). The plate was blocked with 200 pi of 1% (w/v) 
skimmed milk powder (Tescos PLC, Cheshunt, Hertfordshire, UK) in PBS (MPBS), and 
the plate incubated for 1 hour at 37°C. After washing, 100 pi of an antibody was added to 
each well at a concentration of 10 pg/ml in MPBS and the plate incubated for 1 hour at 
37°C. Either the coating antigen or the antibody was triple diluted across the plate 
depending on the aim of the experiment. The plate was washed as before and an anti­
species horseradish peroxidase (HRP) conjugate was used at 1:1000 dilution in MPBS.
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Four anti-species HRP conjugates were frequently used; a rabbit anti mouse IgG, cat no. 
P0260, lot 101 (DAKO, Glostrup, Denmark), a goat anti rabbit IgG, cat no. P0448, lot 
051 (DAKO), a goat anti rabbit IgG, cat no. 172-1013, control 82775 and a goat anti 
mouse IgG, cat no. 172-1011, control 98041, both supplied by Bio-Rad Laboratories 
(Hercules, CA, USA). The conjugate was added to the plate at 100 pi per well, and the 
plate was incubated for 1 hour at 37°C.
After five washes with PBST (ELx405 autoplate washer), three tablets of 2,2'-azino- 
bio(3-ethylbenzthiazoline-6-sulfonic acid), ABTS, were added to 50 ml of 50 mM sodium 
citrate, pH5.5 containing 2 pi of a 30% (w/w) solution of H2O2 . The ABTS substrate was 
added to the plate at 100 pi per well. The assay was read at 414 nm on a Multiskan 
Ascent plate reader (Thermo Labsystems, Hanover Business Park, Altrincham, Cheshire, 
UK) once the absorbance of the negative control wells had reached an optical density at 
414nm of 0.1.
2.2.1.2 Capture ELISA
The method for capture ELISAs was based on that for an indirect ELISA (Section 
2 .2 .1 .1 ) with the following alteration; an antibody was used as a capture ligand before the 
antigen was applied. A 96-well microtitre plate (Thermo Labsystems) was coated with 
antibody at 10 pg/ml in PBS in a volume of 100 pi per well. The plate was incubated for 
either 1 hour at 37°C or for 16 hours at 4°C. The plate was washed three times with PBST 
and then blocked as for an indirect ELISA. Antigen was typically applied at 10 pg/ml in 
MPBS. The antigen was applied in 150 pi of MPBS to the first well and triple diluted 
across the plate. Detection and reporting antibody steps, as well as development, were as 
described for an indirect ELISA.
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2.2.1.3 Capture ELISA screen of potential elution buffers for immunoaffinity 
purification
Potential immunoaffinity elution buffers were screened by their effectiveness at 
disrupting the binding of the antibody with the antigen in a capture ELISA format. The 
method used was as that for the capture ELISA (Section 2.2.1.2), but with an additional 
step. After the antigen was removed by washing, 100 pi of an elution buffer was added to 
each well and the plate was incubated at room temperature for 10 minutes. The plate was 
then washed three times with PBST before the addition of the detection antibody.
2.2.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
2.2.2.1 SDS-PAGE (NuPAGE® system)
All gels, buffers, molecular weight (MW) markers, the colloidal blue stain, drying 
solution, cellophane and gel equipment were purchased from Invitrogen Ltd. (Inchinnan 
Business Park, Paisley, UK). The gels were ran in a XCell Surelock™ Mini-cell with a 
PowerEase™ power supply. Samples were mixed with NuPAGE® sample buffer (and 
dithiothreitol (DTT). The final sample contained 25% (v/v) sample buffer and 10% (v/v) 
500 mM DTT. Each sample was heated at 95°C for 5 minutes on a QBD digital block 
heater (Grant Instruments Ltd., Cambridge, UK), centrifuged at 10000 rpm for 5 seconds 
in a benchtop centrifuge to collect the sample in the bottom of the epppendorf tube and 
either 10 pi, 20 pi or 30 pi of sample was loaded onto a NuPAGE® Novex® 4-12% Bis- 
Tris 1.0 mm 10 well gel, together with 5 pi of either SeeBlue2 or Magic Mark MW 
markers. The gel was ran in 2-(N-morpholino)ethanesulphonic acid (MES) buffer (50 
mM MES, pH7.2, 50 mM Tris base, 0.1% [v/v] SDS and 1 mM ethylenediamine 
tetraacetic acid [EDTA]) for 35 minutes at 200 V (the current limit was set at 120 mA). 
The gel was stained for 16 hours at room temperature on a STR9 Gyro-rocker (Stuart 
Scientific, Staffordshire, UK) with a colloidal blue staining kit. The stain consisted of 20 
ml Stainer A, 20 ml methanol and 5 ml Stainer B, made up to 100ml with distilled water. 
After 16 hours, the gel was washed with hourly changes of distilled water until unbound
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stain had been removed. The gel was incubated for 5 minutes at room temperature with 
100 ml of Gel-Dry™ drying solution on a rocker set at 60 rpm, then placed between 2 
sheets of cellophane to air dry.
2.2.2.2 SDS-PAGE (Laemmli system)
The final sample contained 50% (v/v) sample buffer and 10% (v/v) 500 mM DTT. Each 
sample was heated at 95°C for 5 minutes on a QBD digital block heater (Grant 
Instruments Ltd.), centrifuged at 10000 rpm for 5 seconds in a 5417C Eppendorf 
centrifuge (Fisher Scientific UK, Leicestershire, UK) to collect the sample in the bottom 
of the eppendorf tube and 10 pi, 20 pi or 30 pi of sample was loaded onto a Novex® 4- 
20% Tris-glycine 1.0 mm 10 well gel, together with 5 pi of either SeeBlue2 or Magic 
Mark MW markers. The gel was run in Tris-glycine running buffer (25 mM Tris base,
192 mM glycine, pH8.3 and 0.1% [v/v] SDS) for 90 minutes at 125 V the current limit 
was set at 35 mA). The gel was stained and dried as described for the NuPAGE® system.
2.2.3 Western blots
Proteins separated either on a 4-20% Tris-glycine or 4-12% Bis-Tris NuPAGE gel were 
transferred to a nitrocellulose membrane (0.2pm pore size; Invitrogen Ltd.) in an Xcell 
II™ blot module (Invitrogen Ltd.). After blotting the membrane was left to air dry for 5 
minutes and then blocked for 16 hours at 4°C in 2% (w/v) MPBS. The membrane was 
washed three times in PBST for 5 minutes on a STR9 Gyro-rocker (Stuart Scientific) set 
at 60 rpm. 2 0  ml of a detection antibody was added at a concentration of lOpg/ml in 2 % 
(w/v) MPBS. The membrane was incubated at room temperature for 1 hour on the rocker, 
then washed three times. The reporting antibody was added, 20mls of an anti-species 
HRP conjugate at a dilution of 1:1000 in 2% (w/v) MPBS. The membrane was incubated 
at room temperature for 1 hour on the rocker, then washed three times in PBST. The 
membrane was developed with an ECL reagent kit (Amersham Biosciences UK Limited, 
Amersham Place, Little Chalfont, Buckinghamshire, UK) and exposed to photographic 
film. 5mls of reagent A and an equal volume of reagent B of the ECL kit was mixed and
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the membrane was exposed to this solution for 1 minute at room temperature. The 
membrane was wrapped in clingfilm (Tescos) and placed inside an exposure cassette with 
a sheet of high sensitivity photographic film for a specific exposure time (typically 5, 10, 
20 or 30 seconds). The film was developed using developer and fixer (Kodak, purchased 
through Sigma-Aldrich Company Ltd.). The film was agitated by hand in the tray 
containing development solution for 1 minute, then washed in tap water in a second tray 
and transferred to the fixer in a third tray for 1 minute. The film was washed in tap water 
and hung up to air dry.
2.2.4 Measurement of antibody concentration by spectrophotometry
The antibody concentration was estimated from a measurement of the optical density at 
280 nm (OD2 8 0) with an UV-1601 UV-visible spectrophotometer (Shimadzu, Albert-Hahn 
Street, Duisberg, Germany). Dilutions of antibody with PBS were assayed at 280 nm in 
acyl-cuvettes (Sarstedt, Niimbrecht, Germany). The antibody solution was assayed 
undiluted at first, then diluted if the OD2 8 0  did not fall within the range of 0.4 to 1.2 
absorbance units (AU). The spectrophotometer was zeroed against PBS. The protein 
concentration estimation was based on an antibody dilution that gave an OD2 8 0  of 
between 0.4 AU and 1.2 AU and calculated using an IgG extinction coefficient of 1.35 
mg/ml (Harlow and Lane, 1988).
2.2.5 Measurement of protein concentration by bicinchoninic acid (BCA) assay
The BCA assay kit was purchased from Pierce (Perbio Science UK Ltd.,
Northumberland, UK). One volume of reagent A was mixed with 50 volumes of reagent 
B, and 2 ml of the mixed reagent was added to 100 pi of the sample. The assays were 
incubated at room temperature for 2 hours or 37°C for 30 minutes. The optical density at 
562 nm was measured (UV-1601 spectrophotometer, Shimadzu), and the OD562 of a 
negative control of the buffer the protein is stored in was subtracted. The protein 
concentration was estimated by comparison to the OD562 of a calibration curve of bovine
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serum albumin (BSA; Pierce). The calibration curve typically used concentrations of 
BSA of 0.4 mg/ml, 0.8 mg/ml, 1.2 mg/ml 1.6 mg/ml and 2.0 mg/ml.
2.2.6 Production of immunoaffinity columns
The antibody to be bound to the 1 ml NHS-activated Sepharose 4 Fast Flow Hi-Trap™ 
column (Amersham Biosciences UK Limited) was first dialysed into a coupling buffer, 
0.2 M NaHCC>3 , 0.5 M NaCl, pH8.3. The antibody was injected into a 10,000 molecular 
weight cut-off (MWCO) Slide-A-Lyzer dialysis cassette (Pierce). The antibody was 
dialysed against 3 volumes of 4 litres of the coupling buffer at 4°C for 3 hours per 
volume. The antibody was recovered from the dialysis cassette and the protein 
concentration estimated by UV spectrophotometry. The optimal volume for coupling the 
antibody to the column was 1 ml while the optimal concentration is between 1 and 1 0  
mg/ml. Columns were made with either 1 mg or 4-5 mg of antibody.
All solutions were loaded onto the column via syringe by hand. The flow rate was limited 
to a drop every two seconds to avoid compressing the matrix. Two drops of ice cold 1 
mM HC1 was placed on the top of the HiTrap™ column to avoid air bubbles. The column 
was washed with 6  ml of 1 mM HC1 to remove the storage solution (isopropanol). The 
antibody was then loaded onto the column. By using two syringes, one at each end of the 
column, a volume greater than 1 ml can be used by recycling the antibody through the 
column. The column was incubated at room temperature for 30 minutes. The column was 
washed and deactivated by washing alternatively with buffer A (0.5 M ethanolamine, 0.5 
M NaCl, pH8.3) and buffer B (0.1 M acetate, 0.5 M NaCl, pH4.0). The column was 
washed with 6  ml of buffer A, then 6  ml of buffer B followed by 6  ml of buffer A. The 
column was incubated for 30 minutes at room temperature. The column was then washed 
with 6  ml of buffer B, 6  ml of buffer A followed by 6  ml of buffer B. The column was 
stored in 20 mM sodium phosphate, pH7.5 containing 0.1% (w/v) sodium azide.
The efficiency of the coupling reaction was estimated by calculating the protein content 
of the initial wash fraction by measuring the optical density at 280 nm. In order to do this
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the N-hydroxysuccinimide group released during the coupling reaction that shows strong 
absorbance at 280 nm needs to be separated from the antibody. A wash volume 0.5 ml 
greater than the volume of the antibody solution used in the coupling reaction was 
collected to ensure the fraction contained any unbound antibody. The antibody was 
recovered from the wash fraction using a PD-10 desalting column (Amersham 
Biosciences UK Ltd.). The PD-10 column was equilibrated with 6  volumes of 5 ml of 
PBS and 1 ml of the sample loaded. A further 1 ml of PBS was loaded onto the column 
once the sample had entered the matrix. The antibody was recovered with 3 ml of PBS. 
Three fractions were collected in eppendorf tubes; the first of 1.1 ml, the second of 1.6 ml 
and the remainder. Most of the antibody was found in the second fraction and the 
antibody content of this fraction can be estimated by measurement of the optical density 
at 280 nm against a blank of PBS.
2.2.7 The electrospray mass spectrometer-based detection system
2.2.7.1 The interface between the immunoaffinity system and the electrospray mass 
spectrometer
The AKTAprime chromatography system (Amersham Biosciences UK Ltd.) was used for 
fluid handling in all immunoaffinity purifications. A schematic for the interface between 
the AKTAprime system with the immunoaffinity column and the Quattro II™ 
electrospray tandem quadrupole mass spectrometer (Micromass UK Ltd., Manchester, 
UK) is shown in Figure 2.1. Valve A was a two outlet valve of the AKTAprime system 
used to divert the fluid flow to either the fraction collector or to waste. When the 
AKTAprime system was connected to the interface, the tubing that usually led to the 
fraction collector was connected to valve B, a six-port, two position valve (model C2- 
1006; Valeo, Houston, Texas, USA). This allowed a sample to be diverted into a 2 ml 
holding loop (Valeo). Valve B allowed the loop to be isolated from the immunoaffinity 
system. The immunoaffinity column was regenerated while the sample held in the 










Figure 2.1 Schematic of the interface between the immunoaffinity column and the mass 
spectrometer.
The flow path shown is when the sample loop is being filled with the protein sample. The sample 
can be diverted by valve A to waste or to the 2ml holding loop. Valve B allows the loop to be 
isolated from the immunoaffinity column and the sample can then be directed onto a C8  reverse 
phase trapping cartridge (C8  10x1 mm). The immunoaffinity column can now be regenerated 
while the sample is eluted from the C8  cartridge and injected into the electrospray mass 
spectrometer (MS). The HPLC pump controls the fluidics through the protein trapping cartridge 
and into the mass spectrometer.
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held within a custom holder (Hichrom, Reading, Berkshire, UK) before analysis by mass 
spectrometry.
A HP 1100 Series high performance liquid chromatography (HPLC) system binary pump 
(Agilent Technologies UK Ltd., Stockport, Cheshire, UK) was used to deliver the solvent 
for the C8  column and delivery to the mass spectrometer. The program used with the 
HPLC system is shown in Table 2.1. Solvent A was 0.1% (v/v) trifluoroacetic acid (TFA) 
in water, while solvent B was acetonitrile containing 10% (v/v) of the 0.1% (v/v) TFA in 
water solution. Protein on the C8  column was eluted by stepping to solvent B and the 
flow rate was reduced from 1000 pl/min to 25 pl/min. The C8  column allows the protein 
to be placed into a buffer that may be more compatible with the electrospray mass 
spectrometer than the elution buffer used in the immunoaffinity purification. The fluid 
flow could be diverted either to waste or the mass spectrometer by valve C, a six-port, 
two position valve (model 8125; Rheodyne, California, USA). The outlet line to the mass 
spectrometer was a 75 pm internal diameter fused silica capillary (Micromass UK Ltd, 
Manchester, UK).
2.2.7.2 Electrospray mass spectrometer analysis
Data collection and processing was performed by the biological mass spectrometer group 
at Dstl. The mass spectrometer used was a Quattro II™ tandem quadrupole mass 
spectrometer equipped with a standard electrospray ionization source (Micromass UK 
Ltd, Manchester, UK). Instrument control and data collection and processing were carried 
out with MassLynx™ software (Micromass UK Ltd.).
Typical conditions for sample analysis with the electrospray mass spectrometer are as 
follows: capillary voltage was 3.0 kV and the source temperature was 80°C; data 
collection was performed in continuum mode and spectra were scanned from m/z 700 to 
2000 over 5 seconds; cone voltage was ramped from 33 V to 74 V over this scan range. 












0.00 80:20 1000 Inject Waste
2.40 80:20 1000 Load Waste
2.60 80:20 1000 Load Waste
3.00 10:90 1000 Load Waste
3.05 10:90 25 Load Waste
3.25 10:90 25 Load Mass
spectrometer
Table 2.1 Interface HPLC program to administer the immunoaffinity sample to the mass 
spectrometer for analysis.
The table shows which parameter was altered at each time point of the program. Solvent A was 
0.1% (v/v) trifluoroacetic acid (TFA) in water, while solvent B was acetonitrile 
containing 10% (v/v) of the 0.1% (v/v) TFA in water solution. The inject position of 
valve B diverts the contents of the holding loop onto the C8 column, while the load 
position closes the loop and the fluid flow is directly through the C8 column. Data 
collection began at time point 2.60 and typically continued for 20 minutes.
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solvent A. This protein was injected into the mass spectrometer through the interface 
using the same method as immunopurified samples.
2.2.13 Off-line immunoaffinity purification runs
The standard programs used in purifications off-line with the mass spectrometer are 
shown in Table 2.2 (5 ml wash) and Table 2.3 (15 ml wash). These programs were 
specific for a 1ml volume column. The flow path through the AKTAprime system did not 
allow the sample loop to be filled when the fluid flow was directed onto the column. This 
means that two programs (load/wash and elution/regeneration) are required to allow the 
sample loop to be refilled with elution buffer as the fluid flow has to be stopped. In these 
programs 1 ml tractions were collected, from which aliquots were taken for analysis by 
SDS-PAGE and Western blot. Fractions of interest were loaded by syringe into the 
holding loop of the interface, mimicking an on-line purification run, before mass 
spectrometer analysis. Samples were analyzed by mass spectrometer immediately after 
purification to limit possible protein degradation.
Samples were loaded onto the immunoaffinity column through a 5 ml sample loop 
(Amersham Biosciences Ltd. UK). The loop was filled manually with the load/wash 
buffer, 20 mM sodium phosphate, pH7.5, followed by 1 ml of sample (typically 1 pg of 
protein). When the flow path was diverted through the loop and onto the 1 ml column, the 
sample entered the column first, followed by the rest of the contents of the loop. The 
loading/wash program ran as follows. The program diverted the flow path through the 
loop at volume point 0.5 ml. The loop was switched out of the flow path at volume point 
6.0 ml and was followed by 10 column volumes (10 ml) as the wash step. The flow rate 
was 1 ml/min and all the flow-through was collected in 1.0 ml fractions. The volume of 
the wash buffer was either 10 ml or 20 ml.
After the loading run was completed the 5 ml sample loop was filled with the elution 














0.0 1.0 0.5 Load 0
0.5 1.0 0.5 Inject 0













0.0 1.0 0.5 Inject 0
6.0 1.0 0.5 Load 0
10.0 1.0 0.0 Load 100
20.0 1.0 0.0 Load 100
20.1 1.0 0.0 Load 0
30.0 1.0 0.0 Load 0
Table 2.2 AKTAprime programs with a 5 ml column wash step.
Each table shows which parameter was altered at each volume point of a program. A 5 ml sample 
loop was attached to the injection valve of the AKTAprime system and used to load both the 
sample and the elution buffer. Two programs were required to allow the sample loop to be refilled 
with elution buffer as the buffer flow needs to be stopped. The sample loading program is shown 
in (a), and the elution program in (b). The loading program injects the entire volume of the 
sample loop. The elution volume includes a column regeneration step between volume points 10 














0.0 1.0 1.0 Load 0
0.5 1.0 1.0 Inject 0
6.0 1.0 1.0 Load 0













0.0 1.0 1.0 Inject 0
6.0 1.0 1.0 Load 0
10.0 1.0 1.0 Load 100
20.0 1.0 0.0 Load 100
20.1 1.0 0.0 Load 0
30.0 1.0 0.0 Load 0
Table 2.3 AKTAprime programs for an off-line immunoaffinity purification (15 ml column 
wash step).
Each table shows which parameter was altered at each volume point of the program. A 5 ml 
sample loop was used to inject both the sample and the elution buffer. Two programs are required 
to allow the sample loop to be refilled with elution buffer as the fluid flow must be stopped. The 
sample load/wash program is shown in (a), and the elution/regeneration program in (b). These 
programs are specific for a 1 ml column.
The sample volume, typically 1 ml, was loaded into the loop filled with 20 mM sodium 
phosphate, pH7.5. As die fluid flow is reversed when the loop is switched in line with the column, 
this means that the sample is loaded onto the column first, followed by the remaining buffer in the 
loop. 1 ml fractions were collected throughout the load/wash program and until the 10 ml point of 
the elution program.
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fractions were collected into tubes containing 50 pi 1 M Tris/HCl, pH8.5 if an acidic 
elution buffer was used. The program began with the flow path directed through the loop, 
loading 5 ml of the elution buffer onto the column (5 column volumes). At 6.0 ml the 
flow path was switched back onto the column. The buffer used in this section of the 
program was 20 mM sodium phosphate, pH7.5. Fraction collection stopped at the 10 ml 
point. At the 10 ml mark there was a regeneration stage to remove any residual bound 
protein, where 10 ml of elution buffer flowed through the column (10 column volumes), 
loaded from the buffer valve of the AKTAprime system. This was followed at the 20 ml 
point with 10 ml of loading buffer in preparation for the next sample. The holding loop 
was flushed manually at this time with loading buffer in preparation for the next sample. 
Typically one set of experiments consisted of a blank run, followed by a sample run then 
a second blank run.
2.2.7.4 On-line immunoaffinity purification runs
When the AKTAprime system was interfaced with the mass spectrometer, the same 
programs used in the off-line purification runs were used with the exception that one 2 ml 
fraction was sent to the holding loop in the elution method (Table 2.4). No other fractions 
were collected. Offline purifications showed that material was always eluted at the same 
volume point and the highest concentration of protein was in the initial 2 ml of the elution 
peak. The sample was captured on the C8 trapping cartridge and, after a wash to remove 
residual salts, the sample was eluted with a 90% (v/v) acetonitrile + 0.1% (v/v) 
trifluoroacetic acid solution and injected into the mass spectrometer. Typically one set of 
experiments consisted of a blank run, followed by a sample run then a second blank run.
2.2.8 Sequence analysis with Align and ClustalW
Two protein sequences were aligned with the Align tool available from the European 
Bioinformatics Institute (EBI) website (www.ebi.ac.uk, Jan. 2006). The Needleman- 
Wunsch algorithm was used for global alignment of closely related sequences, while the 














0.0 1.0 0.0 Load 0
0.5 1.0 0.0 Inject 0
6.0 1.0 0.0 Load 0













0.0 1.0 0.0 Inject 0
1.5 1.0 2.0 Inject 0
3.5 1.0 0.0 Inject 0
6.0 1.0 0.0 Load 0
10.0 1.0 0.0 Load 100
20.0 1.0 0.0 Load 100
20.1 1.0 0.0 Load 0
30.0 1.0 0.0 Load 0
Table 2.4 AKTAprime programs for an on-line immunoaffinity purification.
Each table shows which parameter was altered at each volume point of the program. A 5 ml 
sample loop was used to inject both the sample and the elution buffer. Two programs are required 
to allow the sample loop to be refilled with elution buffer as the fluid flow must be stopped. The 
sample load/wash program is shown in (a), and the elution/regeneration program in (b). These 
programs are specific for a 1 ml column.
The sample volume, typically 1 ml, was loaded into the loop filled with 20 mM sodium phosphate 
pH7.5. As the fluid flow is reversed when the loop is switched in line with the column, this means 
that the sample is loaded onto the column first, followed by the remaining buffer in the loop. A 2 
ml fraction containing most of the eluted protein from the column was diverted into the holding 
loop of the mass spectrometer interface.
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with both algorithms: the open gap penalty was 10; the gap extend penalty was 0.5 and 
the matrix was Blosum62.
Multiple protein sequences were aligned using the ClustalW tool available from the EBI 
website (www.ebi.ac.uk, Jan. 2006). The default settings were used for ClustalW: the gap 
open penalty was 10; the gap extension penalty was 0.2; matrix was Gonnet; the gap 
closure penalty was -1 and the gap separation penalty was 4.
Protein sequences were obtained from the National Center for Biotechnology Information 
(NCBI) website (www.ncbi.nlm.nih.gov), through the Entrez protein portal. The 
accession numbers for the protein sequences are: Esherichia coli JM109 HSP60: 
AAS75782; Burkholderia pseudomallei S13 HSP60: ZP00501440; Yersinia 
pseudotuberculosis HSP60: YP068948; Y. pseudotuberculosis DNA binding protein HU- 
alpha: YP068843; Francisella tularensis Schu S4 adenylate kinase: CAG45794 and 
Yersinia pestis adenylate kinase: NP668395. The protein sequence of the recombinant F. 
tularensis HSP60, and hexa-his tagged F. tularensis and Y. pestis adenylate kinase was 
determined by the Microbiology Department at Dstl Porton Down.
2.2.9 Production of bacterial lysates
2.2.9.1 Culture of bacterial species for lysis
The bacterial cultures were produced by C. Underwood, Microbiology Department, Dstl 
Porton Down. The bacterial culture method is included here for reference. All bacterial 
strains (E. coli JM109, Yersinia enterocolitica YeOc, Yersinia tuberculosis 32953, 
Staphylococcus aureus 3750 Mrs. Fox and Pantoea agglomerans 9381 Graham Brice) 
were obtained from the European Collection of Cell Cultures (ECACC), based at the 
Health Protection Agency, Wiltshire, UK.
All bacterial strains were cultured in 500 ml Erlenmeyer flasks with vented lids (Coming, 
supplied through Sigma-Adrich Company Ltd.). One ml of an overnight culture in Luria
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broth (L-broth) was used to inoculate 100 ml L-broth and grown to an OD6 0 0  of between
1.9 and 2.0 at 37°C with shaking at 200 rpm. L-broth was made with 10 g/1 (gram/litre) 
Difco tryptone peptone (Becton Dickinson UK Ltd., Oxford, UK), 5 g/1 Difco bacto yeast 
(Becton Dickinson UK Ltd.) and 5 g/1 NaCl in distilled water. The media was sterilised 
by autoclaving for 15 minutes at 121°C. The bacteria were pelleted by centrifugation at 
6000 rpm for 15 minutes (Sorvall RC5C Plus with a SLA-3000 rotor, Kendro Laboratory 
Products pic, Hertfordshire, UK) and the supematent removed. The pellet was 
resuspended in 4 ml PBS.
2.2.9.2 Sonication of bacterial culture
This procedure was performed by C. Underwood-Fowler and the method is supplied for 
reference. The bacteria were sonicated with a Soniprep 150 (Sanyo Gallenkamp pic, 
Leicester, UK). A 9.5 mm small solid probe was used. The bacteria were sonicated for a 
total of 1 minute, with 30 second pulses. The spores were incubated on ice for 30 seconds 
between sonication pulses. Cell debris was pelleted by centrifugation at 6000 rpm for 15 
minutes and the supematent filtered through a 0.2 pm syringe filter (Sartorius UK,
Surrey, UK).
The preparation was sterility checked by plating out samples of the sonicated preparation 
onto L-agar plates (as L-broth, but with the addition of 20 g/1 Difco bacto agar [Becton 
Dickinson UK Ltd.]) and the confirmation of no bacterial growth after 72 hours at 37°C. 
The lysate was discarded if bacterial growth was observed.
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Chapter Three 
Developing an immunoaffinity system
40
3.1 Introduction
The proposed electrospray mass spectrometer-based biological detection system capable 
of analyzing crude environmental samples requires several processing stages. The first is 
a sample collection and intake stage to present samples in a liquid state, followed by a 
lysis step to disrupt bacteria. A filtration step is then required to remove particulates and 
debris before the sample can be loaded onto an immunoaffinity column. The 
immunoaffinity column captures and concentrates biomarker proteins from the sample, 
before the protein is eluted for analysis by electrospray mass spectroscopy (ESMS).
An interface is needed between the immunoaffinity system and the mass spectrometer. 
While in theory the elution fraction from the immunoaffinity column could be injected 
directly into the mass spectrometer it is not the most elegant approach. The elution 
volume from the chosen 1ml HiTrap™ immunoaffinity column is likely to be of milliliter 
volumes, while the ESMS can only accurately process microlitre volumes within an 
acceptable timeframe of 10 minutes. The time to analyze a sample would be reduced if 
the sample was presented to the ESMS in a smaller volume. The immunoaffinity eluent 
can be concentrated on a protein trapping cartridge, which will also exchange the purified 
protein into a buffer that is compatible with the ESMS. An effective immunoaffinity 
elution buffer may not be compatible with the ESMS. It is also desirable to be able to 
isolate the immunoaffinity system from the ESMS to allow the column to be regenerated 
while the sample is analyzed. This will reduce the delay before a second sample could be 
processed on the immunoaffinity system. The interface needed to be designed so that the 
sample is injected into the ESMS in an optimal volume and buffer.
The combination of liquid chromatography and ESMS for the analysis of biological 
molecules is an established technique (Gelpi, 1995). The basis of the interface between 
the immunoaffinity system and the ESMS is not novel, but the interface needs to be 
designed to complement the chosen system components and requirements. Reversed- 
phase high pressure chromatography (HPLC) systems have been in conjunction with 
ESMS systems (Strege, 1999). An immunoaffinity column has been incorporated into a
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HPLC-ESMS system to isolate and identify transferrin isoforms from serum (Lacey et al., 
2001). This system and the described interface are similar to the interface required for 
this project.
The immunoaffinity purification process needed to be investigated and characterized to 
allow the design of an interface between the immunoaffinity system and the electrospray 
mass spectrometer. Standard immunoaffinity methods also needed to be developed to 
provide the information to allow the detection system to be automated in the future. As 
the targets of the detection system will include toxins, viruses and bacteria, the 
immunoaffinity methods need to be applicable to a selection of antibodies which 
recognize different ligands. A model antigen/antibody pair was required to characterize 
the immunoaffinity purification, to establish parameters such as the elution volume and 
effective wash volumes and to develop standard immunoaffinity methods.
As several weeks would be required to generate ligands against the bacterial biomarker 
proteins, Clostridium perfringens alpha toxin and the monoclonal antibody (mAh) X 
(Dstl in house-produced antibody) was selected as a model system to allow 
characterization of the immunoaffinity purification on the AKTAprime system purchased 
from Amersham Biosciences UK and 1ml HiTrap™ NHS-activated columns. This toxin 
and mAh had previously been used in immunoaffinity purification of alpha toxin from 
water samples with the antibody immobilized on magnetic beads (Helen Jones, Dstl 
Porton Down, unpublished data). C. perfringens alpha toxin and the mAh X were 
available from this project. As X had already been used successfully as an 
immunoaffinity ligand, it was likely to be successful in a column format. A polyclonal 
antibody, rabbit anti-MS2 (Dstl in house-produced antibody), was also used in a test 
column for experiments which may have damaged the X mAb column.
Alpha toxin is produced by the bacterium C. perfringens. It is of interest due to the role it 
plays in gas gangrene. An infection of the bacteria in deep wounds or surgical incisions 
leads to destruction of the tissue and the formation of a necrotic area (Chapnick and 
Abter, 1996). Alpha toxin is one of twelve toxins that the anaerobic bacterium produces
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to maintain its environment (Stevens, 2000). Alpha toxin is a phospholipase C and is 
thought to damage the cell by rapid cleavage of phospholipids in the cell membrane.
The aims of this section were to:
1. compare different buffer loading methods on the AKTAprime system
2. develop the alpha toxin immunoaffinity purification method
3. identify suitable wash volumes and expected elution volumes for the alpha toxin 
purifications
4. develop the interface between the AKTAprime system and the ESMS
5. test the interface by purifying alpha toxin on-line with the ESMS
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3.2 Materials and Methods
3.2.1 Materials
All chemicals were purchased from Sigma-Aldrich Company Ltd., Fancy Road, Poole, 
Dorset, UK, unless stated. The C. perfringens alpha toxin was a gift from H. Jones, 
Microbiology Department at Dstl Porton Down. Anti-alpha toxin mAbs X and Y, and 
rabbit anti-MS2 polyclonal antibody were gifts from T. Webber, Detection Department at 
Dstl Porton Down.
3.2.2 Methods
3.2.2.1 Bromophenol blue dye characterization of the AKTAprime system
A 5 ml sample loop was used with the AKTAprime system (Amersham Biosciences UK 
Ltd., Amersham Place, Little Chalfont, Buckinghamshire, UK). The column was a NHS- 
activated 1 ml HiTrap™ column (Amersham) containing 1 mg of rabbit anti-MS2 
bacteriophage polyclonal antibody. The load/wash buffer was 20 mM sodium phosphate, 
pH7.5. Each run was controlled manually via the AKTAprime interface. Bromophenol 
blue was loaded onto the column with the 5 ml sample loop to represent the sample. The 
elution buffer was represented by the dye either loaded through the sample loop or via the 
buffer valve of the AKTAprime system. The flow rate was 1 ml/min and 1 ml fractions 
were collected. The optical density of each fraction was measured at 591 nm. When the 
elution buffer was loaded through the buffer valve a 2 ml sample of 0.8% (w/v) 
bromophenol blue in 20 mM sodium phosphate, pH7.5 was loaded into the sample loop. 
The sample was injected at volume point 2.5 ml, followed by an 8.5 ml wash. At the 13 
ml volume point the dye representing the elution buffer was introduced through the 
buffer valve. At the 25.5 ml volume point the buffer was switched back to 20 mM sodium 
phosphate, pH7.5. A total volume of 40 ml was collected. The optical density of 
undiluted dye at 591nm was 0.291AU.
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When the sample loop was used to administer the elution buffer a 2 ml sample of 1% 
(w/v) bromophenol blue in 20 mM sodium phosphate, pH7.5 was loaded into the sample 
loop. The sample was injected directly onto the column followed by 10 ml of wash 
buffer. The run was paused and the sample loop filled with 5 ml of dye, representing the 
elution buffer. The dye was injected directly onto the column from the loop, followed by 
13 ml of wash buffer for a total volume of 30 ml. The optical density of the undiluted dye 
at 591 nm was 0.392 AU.
3.2.2.2 pH profiling of a immunopurification run
The purification run was controlled by two methods programmed into the AKTAprime 
system (Amersham) described in the General materials and methods (Chapter 2, Table 
2.2). These 5 ml wash programs were later used in immunopurification runs. A 5 ml 
sample loop was used to inject both the sample and the elution buffer. A 1 mg rabbit anti- 
MS2 polyclonal 1 ml HiTrap™ (Amersham) column was used. The load/wash buffer was 
20 mM sodium phosphate, pH7.5, while the elution buffer was 100 mM citric acid, 
pH2.0. The flow rate was 1 ml/min and 0.5 ml fractions were collected. The 5 ml sample 
loop was filled with elution buffer and the citric acid was injected onto the column at the 
6 ml volume point. The flow then reverted to 20 mM sodium phosphate, pH7.5. The pH 
of each fraction was measured with a handheld pocket pH meter Checker 1 (Jencons 
PLS, Forest Row, East Sussex, UK).
3.2.2.3 Purification of C perfringens alpha toxin on a X monoclonal antibody 
column
A 1 ml HiTrap™ column (Amersham) containing 1 mg X was produced following the 
methods described in Section 2.2.6. Elution buffers for use with X were screened by 
capture ELISA as described in Section 2.2.1.3. The buffers tested are shown in Figure 
3.4. A 1 ml sample of a 50 pg/ml solution of C. perfringens alpha toxin in 20 mM sodium 
phosphate, pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. The 
wash/load buffer was 20 mM sodium phosphate, pH7.5, while 100 mM citric
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acid, pH2.7 was used as the elution buffer. The purification was controlled by the 5 ml 
wash programs (Table 2.2). Elution fractions were collected in tubes containing 50 pi 1 
M Tris-HCl, pH8.5. Samples were assayed for alpha toxin by capture ELISA (Chapter 2, 
Section 2.2.1.2).
Immulon 2HB 96 well microtitre plates (Thermo Labsystems, Franklin, USA) were 
coated with X at 10 pg/ml in PBS, 100 pi per well. Samples of 100 pi from each fraction 
were applied. The detection antibody was a biotinylated anti-alpha toxin mAh, Y, at 10 
pg/ml in MPBS, 100 pi per well, while streptavidin-peroxidase at 1 pg/ml in MPBS, 100 
pi per well, was used as the reporting enzyme. The assay for each fraction was duplicated 
on the microtitre plate.
This method was revised for subsequent alpha toxin purifications. Based on the retention 
of foetal calf serum on the column (Figure 3.6), the wash step was increased by 10 ml. 
The toxin quantity was increased to 100 pg. The wash buffer was still 20 mM sodium 
phosphate pH7.5, but the elution buffer was changed to 100 mM glycine pH2.0. The 
AKTAprime programs were altered to those described for off-line purifications in the 
General materials and methods (Chapter 2, Section 2.2.13). The protein content of the 
fractions was assessed by Laemmli SDS-PAGE (Chapter 2, Section 2.2.2.T) rather than 
capture ELISA. Samples from selected fractions were run on a 4-20% Tris-glycine 
Novex® gel (Invitrogen, Inchinnan Business Park, Paisley, UK).
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3.3 Results
3.3.1 Characterization of the AKTAprime system
A bromophenol blue solution was used to represent the sample and elution buffer 
solutions in a simulated purification run through a polyclonal antibody (pAb) column. 
The dye gave a visual marker as to when each change of buffer entered the column and 
was used to assess two methods of loading the elution buffer; either via the 5 ml sample 
loop or the buffer valve of the AKTAprime system (Figure 3.1). When the elution buffer 
was loaded through the buffer valve (Figure 3.1a), there was notable dilution of the 
bromophenol blue dye over a volume of 10 ml until the optical density of the fractions 
approached that of the undiluted dye. There were also traces of the dye present in 
fractions collected 10 ml after the buffer had reverted to the sodium phosphate buffer. 
When the 5 ml sample loop is used to load the elution buffer (Figure 3.1b), the interface 
of the elution buffer with the wash buffer is more distinct; the optical density of the 
fractions approached that of the undiluted dye within 2 ml. Using the 5 ml sample loop to 
load the elution buffer gave 3 ml of relatively undiluted dye (the optical density of 
fractions 13-15 were greater than 0.35 AU compared to the optical density of the 
undiluted dye of 0.392 AU). The dye was also cleared from the column in a smaller 
volume than when the buffer valve was used to load the elution buffer.
An acidic elution buffer had previously proved successful with the anti C. perfringens 
alpha toxin monoclonal antibody (mAb) X in an immunoaffinity application (Helen 
Jones, Dstl Porton Down, unpublished data). A trial was run loading 100 mM citric acid, 
pH2.0 through the sample loop onto a 1 mg rabbit anti-MS2 bacteriophage 1 ml column 
to get a pH profile of a purification run in this format (Figure 3.2). A sharp drop in pH 
was seen in fraction 15, and the pH remained at approximately pH2 for the next 5.5 ml. 
This was similar to the abrupt change in conditions seen then the bromophenol blue was 
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Figure 3.1 Comparison of the use of a sample loop or buffer valve of the AKTAprime
system to introduce an elution buffer, represented by bromophenol blue dye.
A 5 ml sample loop was attached to the injection valve of the AKTAprime system and a 1 mg 
rabbit anti-MS2 polyclonal antibody HiTrap column was used as the test column. The flow rate 
was 1 ml/min, 1 ml fractions were collected and the optical density of each fraction was measured 
at 591 nm. The wash buffer was 20 mM sodium phosphate, pH7.5.
In a), a 2 ml sample of 0.8% (v/v) bromophenol blue in sodium phosphate buffer was loaded into 
the sample loop. The sample was injected at 2.5 ml, followed by an 8.5 ml wash. At 13 ml the 
dye representing the elution buffer was introduced through the buffer valve. At 25.5 ml the buffer 
was switched back to sodium phosphate. A total volume of 40 ml was collected. The optical 
density of undiluted dye at 591 nm was 0.291 AU.
In b), a 2 ml sample of 1% (v/v) bromophenol blue in sodium phosphate buffer was loaded into 
the sample loop. The sample was injected directly onto the column followed by 10 ml of wash 
buffer. The run was paused and the sample loop filled with 5 ml of dye, representing the elution 
buffer. The dye was injected directly onto the column from the loop, followed by 13 ml of wash 
buffer for a total volume of 30 ml. The optical density of the undiluted dye at 591 nm was 0.392 
AU.
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Figure 3.2 pH profile of a purification run on the AKTAprime system.
A 5 ml sample loop was connected to the injection valve of the AKTAprime system and a 1 mg 
rabbit anti-MS2 polyclonal antibody column was used. The load/wash buffer was 20 mM sodium 
phosphate, pH7.5, while the elution buffer was 100 mM citric acid, pH2.0. The AKTAprime 
programs are shown in Table 2.2. The flow rate was 1 ml/min and 0.5 ml fractions were 
collected. The 5 ml sample loop was filled with elution buffer and the citric acid was injected 
onto the column at the 6 ml volume point. The flow then reverted to the sodium phosphate buffer. 




3.3.2 ELISA assessment of anti C, perfringens alpha toxin monoclonal antibody, X
Stocks of two purified anti C. perfringens alpha toxin mAbs, X and biotinylated Y, as 
well as C. perfringens alpha toxin were available from a previous project and had been 
stored at -80°C in PBS. The viability of the antibodies and toxin as well as confirmation 
of the suitability of X as a capture ligand was assessed by a capture ELISA (Figure 3.3).
X was used as the capture ligand, the detection antibody was Y and streptavidin- 
peroxidase was used as the reporting enzyme. Alpha toxin was successfully captured by 
X in this format, to a detection limit (defined as the mean of the optical densities of the 
negative control wells plus two standard deviations) of 37 ng/ml.
A capture ELISA in the same format was also used to screen for potential elution buffers 
for X (Figure 3.4). Acidic buffers and 3 M urea resulted in a loss in signal from the 
ELISA.
3.3.3 Immunoaffinity purification of C. perfringens alpha toxin
A 1 mg X monoclonal antibody column was produced. Antibody X (1 mg) was bound to 
a 1 ml NHS-activated column at a coupling efficiency of 90%. The first purification run 
with the alpha toxin was with a large quantity of toxin, 50 pg in a 1 ml volume of wash 
buffer, in order to ensure that the presence of toxin in the wash and elution fractions 
could be detected. The AKTAprime programs used in the pH profiling trial were used 
(Table 2.2). Elution fractions were collected in tubes containing 50 pi of 1 M Tris-HCl to 
partially neutralize the acidic elution buffer. The Tris-HCL would reduce any degradation 
of the alpha toxin due to the elution buffer and reduce the acidity of the elution fractions 
prior to assessment by capture ELISA. The capture antibody was X, biotinylated Y was 
the detection antibody and streptavidin-peroxidase was used as the reporting conjugate. 
The ELISA assessment of the alpha toxin purification is shown in Figure 3.5. The ELISA 















Figure 3.3 Capture ELISA of Clostridium perfringens alpha toxin using monoclonal 
antibody X as the capture ligand.
A 96-well microtitre plate was coated with X at 10 (ig/ml. Alpha toxin was applied at 1 pg/ml 
and triple diluted across the plate. A biotinylated monoclonal antibody, Y, was used as the 
detection antibody, while a streptavidin-peroxide conjugate was used as the reporting enzyme. 
Each assay was duplicated on the microtitre plate and error bars calculated by standard deviation. 
The background signal was defined as the mean of the optical densities of the two negative 
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Buffer
1 1% (w/v) skimmed milk powder in PBS
2 20 mM sodium phosphate, pH7.5
3 100 mM glycine, pH2.0
4 10 mM formic acid
5 100 mM citric acid, pH2.7
6 3 M urea, pH8.0
7 3 M urea, pH2.0
8 1% (w/v) SDS in PBS
9 0.05% (v/v) Tween 20 in PBS
10 5M NaCl
11 20% (w/v) polyethylene glycol 4000
12 Water
12
Figure 3.4 Capture ELISA screen of potential immunoaffinity elution buffers for the anti 
Clostridium perfringens alpha toxin monoclonal antibody X.
A 96-well microtitre plate was coated with X at 10 pg/ml. Alpha toxin was applied to the plate at 
1 pg/ml in MPBS. After unbound toxin was washed off the plate, 100 pi of the potential elution 
buffer was added to the plate. The plate was incubated for 10 minutes at room temperature, before 
the plate was washed three times with PBST. A biotinylated monoclonal antibody, Y, was used as 
the detection antibody and the reporting conjugate was strepavidin-peroxidase. Each assay was 
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Figure 3.5 Capture ELISA analysis of a Clostridium perfringens alpha toxin purification on 
an X monoclonal antibody immunoaffinity column.
A 1 ml sample of a 50 pg/ml solution of alpha toxin in 20 mM sodium phosphate, pH7.5 was 
loaded with a 5 ml sample loop onto a 1 mg X immunoaffinity column. The load/wash buffer was 
20 mM sodium phosphate, pH7.5, while the elution buffer was 100 mM citric acid, pH2.7. The 
purification was controlled by the 5 ml wash immunoaffinity programs (Table 2.2). Elution 
fractions were collected in tubes containing 50 pi 1 M Tris-HCl pH8.5. Samples were assayed for 
alpha toxin content by capture ELISA, shown in (a).
Microtitre plates were coated with X at 10 pg/ml in PBS. 100 pi samples from each fraction were 
applied. A biotinylated monoclonal antibody, Y, was used as the detection antibody while the 
reporting conjugate was streptavidin-peroxidase. Each assay was duplicated on the microtitre 
plate and error bars calculated by standard deviation. The background signal was defined as the 
mean of the optical densities of the negative control wells plus 2 standard deviations. A 
calibration curve for the alpha toxin capture ELISA is shown in (b). The alpha toxin was applied 
to the microtitre plate at 1 pg/ml and triple diluted across the plate. The calibration curve was 
duplicated on the microtitre plate and error bars calculated by standard deviation. The background 
signal was defined as above.
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the limited amount of toxin seen in the wash fractions (approximately 10 ng/ml of alpha 
toxin in fractions 5-12). Most of the alpha toxin eluted from the column in fractions 14- 
17. A second toxin peak was seen in fractions 28-30 as the buffer interface between the 
elution and wash buffers passed through the column. The amount of toxin in each 
fraction could not be accurately quantified. All fractions were assayed by capture ELISA 
and 20% of the fraction volume was used as each sample. The ELISA for the entire 
purification accounts for less than 1 pg of toxin, indicating a total of 5 pg alpha toxin in 
all the collected fractions. This leaves 45 pg of alpha toxin unaccounted for by ELISA 
analysis of the purification run.
Before attempting to purify alpha toxin from a complex protein mixture, an indication of 
the volume of the wash required to remove contaminating proteins from the 1 ml column 
was needed to allow a standard purification method to be developed. Fetal calf serum was 
used as the contaminating protein and 1 ml was loaded via the sample loop onto a blank 
sealed 1 ml NHS-activated HiTrap™ column. The 1 ml volume was chosen as this would 
be the selected volume of most samples loaded onto the column. The column was washed 
and fractions collected. The optical density at 280 nm of each fraction was measured 
(Figure 3.6). The same cuvette was used in all measurements, so a background optical 
density was taken at the end of the experiment to account for protein that had adhered to 
the plastic. The optical density returned to the baseline within 6 mis after the protein 
sample had been loaded onto the column. Based on this information a wash of 10 ml, or 
10 column volumes, was used in subsequent purifications.
A further pure alpha toxin purification was performed, before attempting to recover the 
alpha toxin from a complex protein mixture. As the purification method had been altered, 
the fractions containing the alpha toxin needed to be identified. A SDS-PAGE gel was 
used to assess the protein content of each fraction rather than a capture ELISA. A 1 ml 
sample of 100 pg/ml of alpha toxin in 20 mM sodium phosphate, pH7.5 was loaded 
through the sample loop onto the 1 mg X column. The wash buffer was 20 mM sodium 
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Figure 3.6 Fetal calf serum loading on a 1 ml NHS-activated HiTrap column to assess 
protein retention on the column.
Fetal calf serum (1 ml) was loaded into a 5 ml sample loop attached to the injection valve of the 
AKTAprime system. The sample was injected at volume point 1.0 ml onto a sealed blank HiTrap 
column that contained no bound antibody. The wash buffer was 20 mM sodium phosphate, 
pH7.5, the flow rate was 1 ml/min and 1 ml fractions were collected. The optical density of each 
fraction was measured at 280 nm. The background optical density was taken from a measurement 
at the end of the experiment of sodium phosphate buffer in the cuvette that had been used to 
measure the optical density of all the fractions to account for adhesion of the protein to the 
plastic. This experiment was not repeated.
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1 See Blue Plus 2 marker
2 1 pg alpha toxin
3 Fraction 2 (Load)
4 Fraction 3 (Load)
5 Fraction 13 (Wash)
6 Fraction 17 (Elution)
7 Fraction 18 (Elution)
8 Fraction 19 (Elution)
9 Fraction 20 (Elution)
10 Fraction 21 (Elution)
Figure 3.7 SDS-PAGE gel of a Clostridium perfringens alpha toxin purification on a X 
immunoaffinity column.
A 1 ml sample of a 100 pg/ml solution of alpha toxin in 20 mM sodium phosphate pH7.5 was 
loaded through a 5 ml sample loop on a 1 mg X immunoaffinity column. The load/wash buffer 
was 20 mM sodium phosphate pH7.5 and the elution buffer was 100 mM glycine pH2.0. The 
standard AKTAprime programs for an off-line purification were used (Table 2.3). Samples were 
taken from selected fractions and analysed by SDS-PAGE.
Samples were run on a 4-20% Tris-glycine Novex® gel. Samples were incubated at 95°C for 5 
minutes with 50 mM dithiothreitol (DTT) and 20 pi of the reduced sample were loaded per well 
(equivalent to 10 pi of the fraction). The gel was run for 1.5 hours at 125 V. The gel was stained 
with colloidal blue stain. The gel, running buffer, reducing agent, See Blue Plus 2 marker and 
stain were purchased from Invitrogen.
standard AKTAprime programs for an off-line purification were used (Table 2.2). Protein 
content of selected 1 ml fractions were analysed by taking 30 pi samples and running 
them on a 4-20% Tris-glycine Novex gel (Figure 3.7). No protein was visible in the load 
or wash fractions tested. The elution peak was seen in fractions 18 and 19, from 1.5 ml to 
3.5 ml of the elution volume, as the first fraction (fraction 17) of the elution program 
collected by the AKTAprime is 1.5 ml rather than 1 ml.
Alpha toxin was spiked into a lysate of E. coli JM109 (Section 2.2.9) to simulate a 
bacterial lysate containing a biomarker protein. A 1 ml sample of 100 pg alpha toxin with 
100 pg of an E. coli JM109 lysate in 20 mM sodium phosphate, pH7.5 was loaded onto 
the 1 ml X column through the sample loop. The same conditions were used as the 
previous pure alpha toxin purification. Samples were taken from selected fractions and 
visualised on a SDS-PAGE gel (Figure 3.8). The contaminating protein was seen in wash 
fractions 3 and 4. No protein was visible with the colloidal blue stain in wash fraction 15. 
The elution peak was seen in fractions 18 and 19. No other contaminating proteins were 
visible with the colloidal blue stain in the elution fractions.
3.3.4 The interface between the immunoaffinity system and the mass spectrometer
The interface between the immunoaffinity system and the electrospray mass spectrometer 
is described in detail in the general methods. A schematic is shown in the General 
materials and methods (Figure 2.1).
The alpha toxin purification elution volume that contained most of the protein was 2 ml, 
or two column volumes of the 1ml HiTrap™ column. Purifications with the 
bacteriophage MS2 with a rabbit pAb bound to a 1 ml column gave similar results 
(results not shown). A 2 ml holding loop was chosen to receive the elution fraction from 
the immunoaffinity system prior to concentration on a protein trapping cartridge. The low 
pressure fluid handling was done by the AKTAprime system, while a HPLC pump 
controlled the fluidics though the trapping cartridge and into the electrospray mass 











Lane 1 2 3 4 5 6 7 10
Lane
1 See Blue Plus 2 marker
2 1 pg alpha toxin
3 20 pi of loaded sample
4 Fraction 2 (Load)
5 Fraction 3 (Load)
6 Fraction 4 (Wash)
7 Fraction 15 (Wash)
8 Fraction 17 (Elution)
9 Fraction 18 (Elution)
10 Fraction 19 (Elution)
Figure 3.8 SDS-PAGE gel of a Clostridium perfringens alpha toxin purification from a 
spiked bacterial lysate on a X immunoaffinity column.
A 1 ml sample of 100 pg/ml alpha toxin with 100 pg of a lysate of E. coli JM109 in 20 mM 
sodium phosphate, pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 1 mg 
X immunoaffinity column was used, the wash/load buffer was 20 mM sodium phosphate, pH7.5 
and the elution buffer was 100 mM glycine, pH2.0. The standard AKTAprime programs for an 
off-line purification were used (Table 2.3). Samples were taken from selected fractions and 
analysed by SDS-PAGE.
Samples were run on a 4-20% Tris-glycine Novex® gel. 20 pi of sample was added to 20 pi of 
loading buffer and 4 pi of 500 mM DTT. Samples were incubated at 95°C for 5 minutes and 30 pi 
of reduced sample was loaded per well. The gel was run for 1.5 hours at 125 V and was stained 
with colloidal blue stain. The gel, running buffer, reducing agent, See Blue Plus 2 marker and 
stain were purchased from Invitrogen.
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pressure sides of the system. Valve B also allowed the holding loop to be filled manually, 
so that an on-line purification experiment could be simulated through the trapping 
cartridge. The protein trapping cartridge was a C8 reverse phase 10x1 mm column. This 
column is not specific and will capture any protein presented to it. The captured protein is 
eluted in a high organic content buffer and injected into the mass spectrometer. The C8 
column reduces the volume from 2 ml down to a few microlitres and also allows the 
protein to be injected into the mass spectrometer in a ESMS-compatible buffer.
3.3.5 Alpha toxin purifications on the ESMS
Selected fractions of an off-line alpha toxin purification run were analyzed by the ESMS 
to confirm the distribution of toxin in the fractions shown by SDS-PAGE (Figure 3.7). 
ESMS analysis was performed by the Detection Department at Dstl Porton Down. The 
standard off-line purification methods were followed (Table 2.3), the wash buffer was 20 
mM sodium phosphate, pH7.5 and the elution buffer was 100 mM glycine, pH2.0. A 
reduced quantity of alpha toxin was loaded, 5 pg in a 1 ml volume onto the 1 mg X 
column. Individual 1 ml fractions were loaded manually into the 2 ml holding loop of the 
interface and injected into the ESMS. Alpha toxin could not be detected in the flow­
through and wash fractions tested (fractions 3-5). Alpha toxin was detected in the elution 
fractions 18-20, with the majority of the toxin found in fractions 18 and 19. Alpha toxin 
was detected by the ESMS in the same fractions as it was seen on the SDS-PAGE gel.
An on-line alpha toxin experiment was performed, with the AKTAprime system coupled 
to the ESMS by the interface. The 2 ml volume corresponding to elution fractions 18 and 
19 diverted into the holding loop of the interface for analysis by the ESMS. The standard 
methods for an on-line experiment were followed (Table 2.3). The column and buffers 
were as described for the off-line purification, but the amount of alpha toxin in the 
sample was reduced to 2 pg. Alpha toxin was successfully detected in the elution fraction 
by the ESMS (Figure 3.9). The experimentally derived molecular weight (MW) of the 
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Figure 3.9 ESMS analysis of the elution peak of an on-line immunoaffinity purification of 2 
jig C. perfringens alpha toxin.
Analysis with the ESMS of a 2 ml volume which was diverted into the interface holding loop 
during the elution phase of an alpha toxin purification. The contents of the holding loop were 
concentrated on a C8 reverse phase guard column and injected into the ESMS. The total ion 
chromatogram is shown in (a), (b) is the raw data from the peak at 6.3 min in the total ion 
chromatogram and c) is the deconvoluted mass spectrum from the raw data shown in b.
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The on-line alpha toxin purification was repeated with 2 pg of alpha toxin spiked 1 ml of 
100 pg/ml of the lysate of E. coli JM109. The total ion chromatogram of the elution 
fraction shows three overlapping peaks (Figure 3.10). The first peak corresponds to alpha 
toxin, with an experimental MW of42526±3.4 Da, which is within the accuracy of the 
instrument (±0.01% of the measured MW) when compared to the previous MW obtained 
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Figure 3.10 ESMS analysis of the elution peak of an on-line immunoaffinity purification of 2 
pg C. perfringens alpha-toxin spiked into E. coli lysate.
Analysis with the ESMS of the contents of a 2 ml volume which was diverted into the interface 
holding loop during the elution phase of an alpha toxin purification. The contents of the holding 
loop were concentrated on a C8 reverse phase guard column and injected into the ESMS. The 
total ion chromatogram is shown in (a), (b) is the raw data from the peak at 6.3 min in the total 
ion chromatogram and c) is the deconvoluted mass spectrum from the raw data in b.
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3.4 Discussion
The aim here was to develop standard immunoaffinity methods for purifications with the 
AKTAprime system, based on a 1 ml NHS-activated HiTrap™ column as the 
immunoaffinity matrix. An interface was also required between the immunoaffinity 
system and the ESMS to allow immunoaffinity elution samples to be readily processed. 
Alpha toxin from C. perfringens was successfully purified with monoclonal antibody X 
on the AKTAprime system and detected directly by the ESMS. This model system 
allowed the immunoaffinity methods to be developed and gave the parameters (such as 
the elution volume from the immunoaffinity column) that allowed the design of the 
interface with the ESMS. The interface can accept samples directly from the 
immunoaffinity system, or samples can be injected directly into the holding loop to 
mimic an on-line purification. A similar interface between an immunoaffinity system and 
ESMS, incorporating a reversed-phase trapping column, has since been described for the 
identification of amyloid disease markers in biological liquids (Sen et al., 2003).
Basic information was gathered about the AKTAprime system from trial runs with 
bromophenol blue dye (Figure 3.1) and pH measurements (Figure 3.2) when an acidic 
buffer was used as the elution buffer. Loading the elution buffer through the buffer valve 
led to the change from wash to elution buffer occurring over a 10 ml volume. This is due 
to mixing of the buffer interface in the tubing of the AKTAprime system before the 
buffers reach the column, inadvertently producing an elution buffer gradient. Although an 
elution buffer gradient could be used to elute from the immunoaffinity column, there are 
two potential problems. An elution buffer gradient that successfully elutes a protein from 
antibody A may not elute a protein from antibody B at the same time point, even if the 
elution buffer is effective for both antibodies. This is due to variations in the interactions 
of the binding site between antibodies A or B and the target protein. Low pH buffers 
were shown by ELISA to disrupt the binding of a panel of mAbs with soy bean trypsin 
inhibitor, but the degree of disruption was not consistent at buffer pH values between 
pH2.5 and pH5.0 across the panel of mAbs (Bonde et al., 1991). Although the 
purification method could be optimized for each antibody-antigen pair, this is an
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additional complication that is best avoided. The proposed detection system is intended to 
use multiple antibodies against toxin, viral and bacterial biomarker proteins, and it would 
be ideal if these antibodies had similar characteristics.
The second potential problem is that an elution buffer gradient may lead to a broadening 
of the elution peak compared to a step elution. A dilution of the eluted target protein 
would reduce the sensitivity of the detection system if not all the protein in the elution 
peak was presented to the ESMS. The use of a fixed volume holding loop in the 
AKTAprime/ESMS interface requires the elution peak to be presented within the volume 
of the holding loop. As various antigen/antibody pairings will be used in the 
immunoaffinity column with standardized methods, a step elution seems the most 
appropriate to try and ensure this.
By loading the elution buffer through the 5ml sample loop the bromophenol blue 
experiment (Figure 3.1) indicates this method gives a step elution in the smallest volume 
on the column, which is supported by the abrupt change in pH seen when an acidic buffer 
was loaded through the loop. A step elution will elute the target protein from the column 
in the smallest volume and shortest time. The disadvantage is that an abrupt shift into the 
elution buffer will mean that any protein non-specifically bound to the column will be 
eluted along with the target protein. The C8 trapping cartridges binds all protein 
presented to it, so all non-specific protein eluted from the immunoaffinity column will 
either be seen as individual proteins or contribute to noise on the total ion chromatogram 
generated by the ESMS, effectively increasing the background signal to the detection 
system and reducing sensitivity.
The immunoaffinity methods were designed from the system characteristics as well as 
results from the alpha toxin purifications. All the methods were based on the use of a 1 
ml immunoaffinity column to reduce the time required for system development. The 5 ml 
sample loop was chosen to load both the sample and the elution buffer to allow a step 
elution. A 10 ml (10 column volumes) wash was chosen as it was a volume in excess of 
that which appeared effective in clearing a protein contaminant from a 1 ml HiTrap™
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column (Figure 3.6). These methods were successful in recovering pure alpha toxin from 
wash buffer and a bacterial lysate.
A suitable elution buffer for the mAb X was screened for by capture ELISA (Figure 3.4), 
similar to the method described by Bonde et al., 1991. Acidic buffers reduced the capture 
ELISA response, indicating that these may be suitable elution buffers. However the loss 
in response could be due to either the denaturation of the capture antibody or the toxin, or 
the elution buffer stripping the capture antibody from the microtitre plate. A capture 
ELISA is useful as an indicator of possible elution buffers and reduces the time spent in 
trial and error experiments, as well as limiting the possibility of damage to the 
immunoaffinity column, but these buffers must be tested in a column format.
The first method chosen to detect the presence of alpha toxin in purification fractions was 
a capture ELISA (Figure 3.5). The ELISA could only account for a small proportion of 
the toxin loaded onto the column. While useful as an indicator as to which fractions 
contained toxin, the ELISA was a poor quantitative measure. The elution buffer was 
acidic, and although partially neutralized with 1 M Tris-HCl, pH8.5, either interfered 
with the binding of the capture antibody in the ELISA with the toxin or denatured the 
antibody or toxin. Also the ELISA will not provide information about proteins in each 
fraction that the antibodies do not recognize. The ELISA did indicate that though most of 
the toxin was captured by the column, not all the toxin was eluted from the column by the 
100 mM citric acid, pH2.7, as toxin was present in fractions 28-30. This indicated that a 
regeneration step was necessary to ensure that there was no carry-over between 
purification runs. The stringency of the elution buffer was increased by using 100 mM 
glycine, pH2.0 in subsequent alpha toxin purifications to improve the efficiency of the 
elution step. No alpha toxin was detected by the ESMS in either of the blank runs 
completed before or after an alpha toxin purification, indicating the more stringent 
elution buffer and regeneration step were successful in removing alpha toxin bound to the 
column.
Subsequent off-line purifications were analyzed by SDS-PAGE. This allowed assessment 
of the purifications by Western blot. The next step of the immunoaffinity purification
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development was to isolate potential biomarker proteins from bacterial lysates. The 
quantity of the biomarker protein recoverable from lysate samples may be low. SDS- 
PAGE and Western blots were used to assess off-line purifications. SDS-PAGE gels 
display proteins within the sensitivity of the stain used and highlight potential problems 
with contaminating proteins in each fraction, while not positively identifying the proteins 
present. This can be achieved by Western blots, a sensitive method to detect proteins that 
are recognized by an antibody. By probing a blot membrane with the antibody used as the 
capture ligand in the immunoaffinity application, proteins that are specifically recognized 
by the antibody can be identified.
Alpha toxin was detected in the elution fractions of purifications from wash buffer and 
when spiked into an E. coli lysate by the ESMS, in both off and on-line purifications 
(Figure 3.9). In each case the elution point and volume of the alpha toxin was 
reproducible. Alpha toxin was isolated from a lysate when the contaminating proteins 
were in excess (2pg of toxin with lOOpg of lysate). GroEL and GroES comprise 2% of 
the total protein content of E. coli grown at 37°C (Fayet et al., 1989). Although the alpha 
toxin was clearly identified on the basis of MW calculation, two other proteins were 
detected which had a higher relative intensity on the total ion chromatogram (Figure 
3.10). Contaminating proteins may complicate the identification of biomarker proteins 
when attempting to isolate biomarker proteins from bacterial lysates.
In summary, immunoaffinity methods and an interface between the immunoaffinity 
column and the ESMS were developed that would allow a target protein to be isolated 
from a complex mixture and analyzed by the ESMS.
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Chapter Four




The future application of immunoaffinity purification within a mass spectrometer-based 
biological detection system is likely to use single chain antibodies (scFvs) as a capture 
ligand. ScFvs have several advantages over conventional monoclonal antibodies (mAbs); 
the increased density of binding sites obtainable in a matrix or on a chip surface (Howell 
et al., 1998), the ease and low cost of production (Binz and Pliickthun, 2005) and the 
scope for genetic modification of the scFv (Hudson and Souriau, 2003). Genetic 
engineering allows the optimisation of the binding affinity and specificity of an antibody 
fragment (Nevanen et al., 2003), optimal linkage to the support matrix (Piervincenzi et 
al., 1997) and increased thermostability (Young et al., 1995) or structural stability of the 
protein (Worn and Pliickthun, 2001). However conventional monoclonal antibodies 
(mAbs) are a widely employed technology (Lipman et al., 2005) and have been utilized 
extensively as ligands for immunoaffinity purification (Jack, 1994).
For the initial development of the system I decided to generate mAbs rather than scFvs.
In order to generate monoclonal cell lines a polyclonal serum was required to screen for 
clones secreting antibody by capture ELISA. It has been noted in our laboratory that cell 
lines producing antibodies suitable for use in detection systems and as capture ligands are 
more likely to be identified when screened as the detection ligand by capture ELISA (T. 
Webber, Dstl Porton Down, personal communication). ScFvs against potential bacterial 
biomarker proteins adenylate kinase (AdK) and heat shock protein 60 (HSP60) would be 
generated at a later point.
Rabbit polyclonal antibodies (pAbs) are unlikely to be effective ligands for 
immunoaffinity chromatography, due to the range of affinities and types of interactions 
present in the antibody pool (Jack, 1994). The stringent elution buffers often required to 
ensure elution of the target protein from a pAb immunoaffinity column are likely to result 
in damage of the antibody and target protein (Burgess and Thompson, 2002). MAbs 
represent an alternative to pAbs, assuming a suitable cell line could be isolated by fusion 
techniques from the B-cell splenocyte population from a hyper-immune mouse (Kohler
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and Milstein, 1975). Monoclonal cell lines were required to be produced against each of 
the recombinant target proteins and the clones screened by capture enzyme-linked 
immunosorbant assays (ELISAs). The rabbit polyclonal antibody raised against each 
corresponding recombinant protein was used as the capture ligand. Successful clones 
were screened by ELISA to assess whether antibodies display cross-species recognition 
and antibodies of interest were characterised by BIAcore analysis.
The BIAcore system was used to assess the binding kinetics of each of the monoclonal 
antibodies (Karlsson et al., 1991; Johne et al., 1992; Malmborg and Borrebaeck, 1995). 
As the intended application of the antibodies was as an immunoaffinity ligand, ELISA 
and BIAcore analysis can give information on each antibody when immobilised as a 
capture ligand. Potential immunoaffinity elution buffers for each antibody can be 
indicated by identifying suitable regeneration buffers for the chip surface. Kinetic studies 
would be performed to calculate affinity constants for the monoclonal antibodies. It was 
of interest if there was any relationship between the affinity constants and the 
performance of the mAb as an immunoaffinity capture ligand.
For most applications highly specific mAbs are required, particularly for detection to 
enable an accurate identification of a BW threat agent. There are few applications that a 
widely cross-reactive antibody can be used for as most applications rely on the highly 
specific interactions antibodies provide. The requirements of this study were for mAbs 
that displayed cross-species recognition towards the potential bacterial biomarker 
proteins. When producing a panel of mAbs against a target antigen it is not uncommon to 
produce mAbs that display some degree of cross-reactivity, particularly with closely- 
related antigens (T. Webber, Dstl Porton Down, personal communication). This may be a 
problem when attempting to raise species-specific antibodies; six mAbs were produced 
against the fungus Stachybotrys chart arum, of which five were cross-reactive for other 
Stachybotrys species as well as several other non-related fungi species (Schmechel et al., 
2006). In a second example, 24 mAbs were produced against avian coccidia. Of these, 
seven were species-specific, while 17 displayed some degree of cross-reactivity with 
other species of coccidia (Danforth and Augustine, 1983). These reports indicate that
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standard hybridoma techniques are sufficient to generate cross-reactive antibodies, 
particularly if the target antigens are closely related.
My aim was to generate mAbs that displayed cross-species recognition for each of the 
selected bacterial biomarker proteins, HSP60 and AdK. The available proteins were three 
recombinant bacterial HSP60s from Escherichia coli (HEC), Francisella tularensis 
SCHU4 (HFT) and Burkholderia pseudomallei 4845 (HBP), and two recombinant 
bacterial AdKs from F. tularensis SCHU4 (AdKFT) and Yersinia pestis C092 (AdKYP). 
A sequence comparison with EMBOSS-Align using the Needleman-Wunsch algorithm 
(Needleman and Wunsch, 1970) of AdKFT and AdKYP is shown in Figure 4.1. An 
unintentional insert of a 5 amino acid sequence (DRWGS), at residue 32 after the 
enterokinase cleavage site of the hexa-his tag (DDDDK), was accidentally incorporated 
during cloning of the gene for both recombinant AdK proteins. The alignment indicates a 
62% identity for the amino acid sequence, suggesting that it is probable that 
immunogenic epitopes are conserved between AdKYP and AdKFT.
A comparison of the three bacterial HSP60 sequences with ClustalW (Thompson et al., 
1994) showed a high degree of sequence identity (Figure 4.2). A mouse pAb raised 
against a lysate of Y. pestis recognised a protein identified as HSP60 in a Western blot of 
a 2D gel of a lysate of F. tularensis (K. Anderson, Dstl Porton Down, personal 
communication), indicating the presence of at least one conserved bacterial HSP60 
epitope. A panel of mAbs have also been generated against Chlamydia trachomatis 
HSP60. HSP60 antibodies were produced which were identified as genus-specific, 
species-specific, or cross-reactive against several bacterial species (Yuan et al., 1992). 
This proves that it is possible to raise mAbs which recognise a conserved bacterial 
HSP60 epitope.
70
AdKYP 1 mrgshhhhhhgmasmtggqqmgrdlyddddkdrwgsmri i 1 lgap gagk g  
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
50
AdKFT 1
1 1 II II 1 1 II 1 1 1 II II II 1 1 1 II 11 II II II 1 II II II II II 1 II II 1 1 
mrgshhhhhhgmasmtggqqmgrdlyddddkdrwgsmri i 1 lgap gagk g 50
AdKYP 51 tq a q fim e k y g ip q is tg d m lr a a v k a g se lg lk a k e im d a g k lv td e lv  
I I I -  1 -II 1 1 I 1 1 1 1•1 •1•1 1 II • 1 • • • 1 II • II • 1 1 •
100
AdKFT 51
1 | | . . | . . | | . | . . | | | | | | . | . . . | . | | . | | . . . | . . . | | | . | | . | | . . 
t q a k iie q k y n ia h is tg d m ir e t ik s g s a lg q e lk k v ld a g e lv s d e f i 100
AdKYP 101 i a 1v k e r itq e d c r d g f11d g fp rtip q a d a m k ea g ik v d y v le fd v p d e  
1 • 1 1•1 1•• 1 1 - 1 1 1 1 1 1 1 1 1  IIII  • • 1 • • 1 1 • • 1 I I I
150
AdKFT 101
1 • • 1 1 • 1 1 • • • 1 1 • • 1 1 1 1 1 1 • 1 1 1 1 1 1 1.............1 • • • 1 1 • • 1 • 1 1 • 1 •
ik iv k d r i  sk n d cn n g f1ld g v p r t ip q a q e ld k lg v n id y iv e v d v a d n 150
AdKYP 151 1 iv er iv g r rv h a a sg rv y h v k fn p p k v ed k d d v tg e e1t ir k d d q e a tv  
1 • • 1 1 1 1 1 1 • 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II
200
AdKFT 151
1 • • 1 II • 1 1 1 • 1 • 1 1 II • 1 1 • 1 1 1 1 1 1 1 • 1 1 1 1 1 1 1 1 • 1 • • 1 • 1 1 • 1 • 1 1 
l l ie r i tg r r ih p a s g r ty h tk fn p p k v a d k d d v tg e p l it r td d n e d tv 200
AdKYP 201 r k r lie y h q q ta p lv s y y h k e a d a g n t---- q y fk ld g tr n v a e v s a e la t
• • I I  1 1 1 1 1 1 • • 1  - - I I  •1 1 • • 1 • 1 • 1 1 • •
247
AdKFT 201
• • 1 1 • • 1 1 • 1 1 1 • 1 • • • 1 .............II • 1 • 1 • • 1 • • • 1 • • 1 1............
k q r ls v y h a q ta k lid fy -r n f  s s tn tk ip k y ik in g d q a v e k v s q d ifd 249








Gaps: 6/255 ( 2.4%)
Score: 857.0
Figure 4.1 Alignment of the recombinant Y pestis and F. tularensis adenylate kinase amino
acid sequences (AdKYP and AdKFT respectively) with EMBOSS-Align.
The sequences were aligned with the EMBOSS-Align tool (Needleman-Wunsch algorithm), 
accessed through the European Bioinformatics Institute website. The matrix was Blosum62, the 
open gap penalty was 10.0 and the gap extension penalty was 0. An identical amino acid is 
indicated with " | ", conserved substitutions with ":" and semi-conserved substitutions with ".".
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HEC MAAKDVKFGNDARVKMLRGVNVLADAVKVTLGPKGRNWLDKS FGAPTITKDGVSVAREI 60
HFT MAAKQVLFSDEARAKMLDGVNTLANAVKVTLGPKGRNWLDKSFGTPTITKDGVSVAKEI 60
HBP MAAKE11FHDGARAKLVEGVNLLANAVKVTLGPKGRNWLERS FGS PWTKDGVSVAKE160



























*   ^  ^ *  *  *  *  *  • *  *  j * *  . *  * * * * * *  * . *  *   ^ *  *  *  # *  . * * * * * * *
HEC ATEEYGNMIDMGILDPTKVTRSALQYAASVAGLMITTECMVTDLPKNDAADLGAAGGMGG 540
HFT ANDTYGDMVEMGILDPTKVTRSALQHAASIAGLMITTEAMIGEIK- -EAAPAMPMG- -GG 536
HBP ATGEYGDLVESGVLDPTKVTRTALQNAASIAGLLLTTDATVHEAP-KDAPPTAPAGVPGA 539




Figure 4.2 Alignment of the HSP60 sequences from E. coli JM109 (HEC), F. tularensis 
(HFT) and B. pseudomallei SI3 (HBP) with ClustalW.
The sequences were aligned with ClustalW, accessed through the European Bioinformatics 
Institute website. Align was not used as it only accepts 2 sequences. The default settings were 
used with full alignment. An identical amino acid is indicated with conserved substitutions 
with ":" and semi-conserved substitutions with ".".
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The aims of this section were to:
1. produce rabbit pAb against each available biomarker protein and characterise 
each pAb by ELISA
2. produce mAb against each available biomarker protein and characterise each mAh 
by ELISA
3. screen mAb cell lines by ELISA for antibodies that display cross-species 
recognition
4. characterise mAbs of interest by BIAcore analysis
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4.2 Materials and Methods
4.2.1 Materials
All chemicals were purchased from Sigma-Aldrich Company Ltd., Fancy Road, Poole, 
Dorset, UK, unless stated. HFT, HBP, AdKFT and AdKYP were gifts from the 
Microbiology Department at Dstl. Both AdK recombinant proteins incorporated a hexa- 
his tag by which the protein was purified on a nickel-chelating column, as was HBP. HFT 
was purified by anion exchange and gel filtration chromatography. All proteins were 
supplied in phosphate buffered saline (PBS). These proteins were produced and purified 
by N. Walker, Microbiology Department, Dstl Porton Down. HEC was purchased from 
Sigma-Aldrich as a lyophilized powder, and reconstituted with PBS (Gibco, Paisley,
UK). MAb 1VYD 120.3 was a gift from the Detection Department at Dstl. An anti-C. 
trachomatis HSP60 mAh was purchased from Affinity Bioreagents, Inc (supplied 
through Cambridge Bioscience, Cambridge, UK). A Burkholderia pseudomallei urease 
with a hexa-his tag was a gift from the Microbiology Department at Dstl.
4.2.2 Methods
4.2.2.1 Immunisation of rabbits with HSP60/AdK
A 1:1 emulsion was made of the protein in PBS (Gibco) with Freund’s Complete 
Adjuvant (FCA) by repeatedly drawing the solution through a 0.6 mm x 25 mm (23G1) 
needle (Becton Dickinson UK Ltd, Oxford, UK) with a 10 ml ground glass syringe 
(Popper and Sons, inc, New York, USA). An increase of the solution viscosity indicated 
that the emulsion had formed. A primary injection of lOOpg protein in a 1:1 emulsion 
with FCA was administered by two 0.5 ml subcutaneous injections to the rump of a 
female, 1.8-2.0 kg New Zealand White rabbit (Harlan, Shaw's Farm, Blackthorn,
Bicester, Oxon, UK). Two further intramuscular boosts of 100 fig protein in a 1:1 
emulsion with Freund’s Incomplete Adjuvant (FLA) were given at three-week intervals. 
Serum titres of ear bleeds were assessed by indirect ELISA.
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4.2.2.2 Immunisation of mice with HSP60/AdK
A 1:1 emulsion was made of the protein in PBS (Gibco) with FCA by repeatedly drawing 
the solution through a 0.5 mm x 16 mm (25G5/8) needle (Becton Dickinson UK Ltd.) 
with a 2 ml ground glass syringe (Popper and Sons, inc). An increase of the solution 
viscosity indicated that the emulsion had formed. A primary 50 pi interperitoneal (i.p.) 
injection of 10 pg of protein in a 1:1 emulsion with FCA was administered to a female, 8- 
10 week old Balb/c mouse (Charles River Laboratories, Manston Road, Margate, Kent, 
UK). Two further i.p. booster injections of 10 pg of protein in a 1:1 emulsion with FLA 
were given at two-week intervals. Serum titres of tail bleeds were tested by indirect 
ELISA. Fusions to raise hybridoma cell lines were begun a month after the final 
immunisation and proceeded at a rate of approximately one mouse from each immunised 
group every two weeks. Four days before fusions to produce hybridoma cells, a pre- 
fusion boost of 10 pg of protein in 50 pi PBS was administered intravenously via the tail 
vein.
4.2.2.3 Antibody purification
Polyclonal and monoclonal antibodies were purified on a 5 ml protein G column 
(Amersham Pharmacia Biotech, Uppsala, Sweden). All buffers were filtered and 
degassed under reduced pressure with a pump (KNF Neuberger Laboport, KNF 
Neuberger GmbH, Trenton, NJ, USA) for 2 hours using Nalgene bottle-top 0.2 pm filters 
(Nalge Nunc International, New York, USA). Rabbit serum or cell culture supernatant 
was diluted 1:1 with 20 mM sodium phosphate, pH7.5 and loaded onto the column using 
a Gradifrac system (Amersham Pharmacia Biotech). Ascetic fluid was diluted 1:10 with 
phosphate buffer prior to loading onto the protein G column. The flow rate was 1 ml/min 
throughout the purification run. Antibody was eluted with 100 mM citric acid, pH2.7 
once the absorbance at 280 nm had returned to baseline and 1 ml fractions were collected 
in tubes containing 50 pi 1 M Tris-HCl, pH8.5. The elution fractions were injected into a 
10,000 molecular weight cut-off (MWCO) Slide-A-Lyzer dialysis cassette (Pierce, 
Rockford, IL, USA). The antibody was dialysed against 4 litres PBS, pH7.4 (Oxoid,
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Basingstoke, Hampshire, UK) for 16 hours at 4°C. The next day the PBS was changed 
twice at 3 hour intervals. The antibody was recovered from the dialysis cassette and the 
protein concentration estimated by spectrophotometry (Section 2.2.4). The antibody was 
stored at -80°C.
4.2.2.4 Generation of monoclonal cell lines
Mouse monoclonal cell lines were raised by methods based on those described by Kohler 
and Milstein, 1975. An immunised mouse was euthanised by overdose of anaesthetic. 
The mouse received an i.p. injection of 100 pi of Euthatal (Rhone Merieux Ltd, Harlow, 
Essex, UK) and left until no response was evident when the mouse’s foot was pinched. 
Blood was collected by cardiac puncture. The spleen was harvested from the mouse and 
any associated fat removed. The spleen was pressed through a metal tea strainer 
(Woolworth’s Group pic, Woolworth House, London, UK) into 5 ml of serum free 
Dulbecco's modified eagles medium (DMEM) to disrupt the tissue. The cells were 
pelleted by centrifugation for 5 min at 214 x g, in a Sorvall Legend RT centrifuge 
(Kendro Laboratory Products pic, Stortford Hall Park, Bishop's Stortford, Hertfordshire, 
UK). The supematent was removed and the splenocytes resuspended in 5 ml serum free 
DMEM, and lxlO7 X63 Ag8.653 myeloma cells (Kearney et al., 1979), (originally 
obtained from Flo Ltd, UK, no longer trading) in 10 ml serum free DMEM were added. 
The cells were pelleted by centrifugation for 5 min at 214 x g and the supematent 
removed. 1 ml of 30% (v/v) polyethylene glycol (PEG) 1300-1600 MW was added to the 
cell mixture and incubated for 1 minute at room temperature. The cells were pelleted by 
centrifugation for 5 min at 214 x g and the supematent removed. The total exposure time 
to the PEG was 8 minutes. The cell pellet was gently disrupted by pipetting with 5 ml of 
serum-free DMEM. When the cells were in suspension, 5 ml of 20% (v/v) foetal calf 
serum (FCS; Harlan Bioproducts, Indianapolis, USA) in DMEM was added. The cells 
were pelleted by centrifugation for 5 minutes at 214 x g and resuspended in 100 ml 
selective hypoxanthine-aminopterin-thymidine (HAT) media (0.1 mM hypoxanthine, 1 
pM aminopterin and 16 pM thymidine) in complete DMEM. Complete DMEM 
contained 10% (v/v) FCS, 2 mM L-glutamine with 100 units of penicillin and 0.1 mg
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streptomycin per 1 ml media. Penicillin-streptomycin-L-glutamine (PSG) contained 
10000 units of penicillin, 10 mg streptomycin and 200 mM L-glutamine per ml. The cells 
were plated out on 96 well Costar cell culture plates (Coming, distributed through Sigma- 
Aldrich Company Ltd), 100 pi in each well. After a 16 hour incubation at 37°C and 7% 
(v/v) CO2 in a CO2 incubator (Nuaire DH Autoflow, The Nuaire group, Western 
Industrial Estate, Caerphilly, UK) the wells were topped up with 100 pi HAT media and 
returned to the incubator.
Antibody-secreting clones were identified by capture ELISA after two weeks and cloned 
by limiting dilution. Potential clones were recovered and triple diluted across feeder 
plates in hypoxanthine-thymidine (HT) media (0.1 mM hypoxanthine and 16 pM 
thymidine) in complete DMEM so that clones could be picked in the next screening 
round that had originated from a single cell. Feeder plates were set up using peritoneal 
macrophages from a mouse interperitoneal wash to condition the media, which increases 
the likelihood of a clone successfully growing. A mouse was euthanised by neck 
dislocation and the abdomen washed in 20% (v/v) ethanol to sterilize the working area. 
The skin covering the upper portion of the abdomen was tented and cut with scissors, 
avoiding damage to the peritoneal membrane. The skin was tom away to expose the 
abdominal cavity. A wash of 10 ml of serum-free DMEM at 4°C was injected into the 
peritoneal cavity and gently agitated by moving the mouse. The wash was recovered with 
a sterile squeeze-bulb pipette through a small incision in the peritoneal membrane. The 
cells were pelleted by centrifugation at 214 x g for 5 minutes and resuspended in 30 ml 
complete DMEM. One mouse provides enough cells to coat three 96-well micro-culture 
plates at 100 pi per well. The plates were incubated at 37°C for 16 hours to allow the 
cells to adhere to the micro-culture plates. Three cloning rounds were completed for each 
potential cell line before expansion in 25ml tissue culture flasks (Coming). Each cloning 
round was screened by ELISA to confirm continued secretion of antibody.
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4.2.2.5 Capture ELISA screen of hybridoma clones
Cell culture supematent was screened for specific antibody by capture ELISA (Section 
2.2.1.2). Rabbit polyclonal antibody was used as the capture antibody, while culture 
supematent was applied undiluted as the detection antibody. An anti-mouse IgG HRP 
conjugate (DAKO, Glostrup, Denmark) was used as the reporting antibody. A sample of 
100 pi of the supematent was taken from the cell culture plate and transferred to the 
microtitre plate. The plate was incubated for 1 hour at 37°C. The cell culture plate was 
replenished with 100 pi of complete DMEM.
4.2.2.6 Cell culture
Standard aseptic techniques were followed for the culturing of all cell lines. Cells were 
typically grown in 75 ml vented top flasks (Coming) in complete DMEM.
Integra bioreactors (Integra Biosciences, distributed through SLS, Nottingham, UK) were 
used to culture mAh before purification on a protein G column. Cells were cultured in 
75ml vented flasks until a 90% confluent monolayer of cells were achieved, monitored 
with a phase contrast microscope (Divert microscope, Leitz Wetzlab, Germany). The 
cells were recovered by washing the cells free from the flask surface by pipetting, 
pelleting the cells by centrifugation in a Sorvall Legend RT centrifuge (Kendro 
Laboratory Products pic) for 5 minutes at 214 x g and resuspending with 15 ml of 
DMEM with 20% (v/v) FCS and 1% (v/v) PSG. The membrane of the cell compartment 
of the bioreactor was wetted with 20 ml DMEM containing 1% (v/v) FCS and 1% (v/v) 
PSG. The cells were introduced into the cell compartment and air bubbles were removed. 
The media reservoir was filled with 1 litre of DMEM with 1% (v/v) FCS and 1% (v/v) 
PSG and the bioreactor was incubated in a CO2 incubator at 37°C in a 5% (v/v) CO2 
atmosphere (Jencons Millennium, Jencons-PLS, East Sussex, UK). After two weeks, the 
cell compartment was tapped by removing 10 ml of cells and replacing with 10ml of 
DMEM with 20% (v/v) FCS and 1% (v/v) PSG. The reservoir media was also changed at 
the same time. The cells in the tap were removed by centrifugation at 214 x g for 5 
minutes. Further taps were harvested at least every week, sooner if the cell compartment
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was becoming confluent with cells. Cell growth was monitored with a phase contrast 
microscope (Divert microscope, Leitz Wetzlab). The reservoir media was changed every 
two weeks. Taps were assessed by indirect ELISA before purification on a protein G 
column (Section 4.2.2.3).
Library stocks of the cell lines were laid down in liquid nitrogen. Cells were grown until 
90% confluent in a 75 ml vented top flask. The cells were washed from the flask by 
pipetting and pelleted by centrifugation at 214 x g for 5 minutes in a Sorvall Legend RT 
centrifuge (Kendro Laboratory Products pic). The supematent was poured off and the 
cells were resuspended in 10 ml DMEM containing 20% (v/v) FCS, 1% (v/v) PSG and 
10% (v/v) dimethyl sulphoxide (DMSO). The cell suspension was aliquoted into 1 ml 
Nunc Cryotubes (Nalge Nunc International, Rochester, NY, USA) and placed in a 
styrofoam box. The box was placed in a -80°C freezer for 48 hours to allow the 
temperature to equilibrate to -80°C. The cells were then transferred to liquid nitrogen.
Cell lines were recovered from liquid nitrogen by thawing the cells rapidly in a 37°C 
waterbath. The cells were resuspended in 10 ml serum-free DMEM and pelleted by 
centrifugation at 214 x g for 5 minutes. The supematent was poured off. The cells were 
resuspended in 10 ml complete DMEM and introduced into a 25 ml vented top flask 
(Coming) and placed in a CO2 incubator at 37°C.
4.2.2.7 Isotyping monoclonal cell lines
Isostrips (Roche Diagnostics Corporation, Indianapolis, USA) were used to isotype the 
monoclonal cell lines, and used in accordance with the manufacturer's instructions. Cell 
culture supernatant was diluted 1:10 with PBS and 150 pi added to the beads in the tube. 
The beads were incubated for 30 seconds at 16°C, then vortexed for 10 seconds. The 
isostrip was added and left at room temperature until the control bands had developed.
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4.2.2.S BIAcore™ analysis
BIAcore International (Biacore AB, Church Farm, Eyeworth, Bedfordshire, UK) supplied 
all buffers and reagents unless stated. Assays were performed on a BIAcore 3000 system. 
CM5 chips were used for all antibodies with HBS-EP buffer (10 mM HEPES, pH7.4, 150 
mM NaCl, 3.4 mM EDTA and 0.005% [v/v] Surfactant P20). Data was processed and 
interpreted with the BIA evaluation 3.2 software.
When the CM5 chip was docked, the system was primed with either 10 mM Na-acetate, 
pH4.0 when antibody was to be bound to the surface or HBS-EP buffer prior to kinetic 
experiments. When a new chip was docked, the chip surface was normalized with 40% 
(v/v) glycerol solution to account for variation between chip surfaces. Docking, priming 
the system and normalization of the chip surface were performed via the system prompts. 
The chip surface was activated with 35 pi of EDC/NHS buffer (a 1:1 mixture of 400 mM 
1-ethyl-3-[dimethylaminopropyl] carbodiimide and 100 mM N-hydroxysuccinimide).
The flow rate used throughout activation was 7 pl/min. The antibody was applied at 1 
pg/ml in 10 mM Na-acetate buffer, pH4.0 and sufficient protein was injected to result in 
a 300-400 response unit rise on the chip for kinetic experiments. The 10 mM Na-acetate, 
pH4.0 buffer was used for all antibodies immobilised. The chip surface was capped with 
35 pi 1 M ethanolamine, pH8.5. Regeneration buffers were identified by screening in 
order of increasing stringency against immobilised antibody. Buffers that were screened 
were 100 mM glycine buffers in the pH range of 1.5-4.5 in 0.5 increments and 10 mM 
KOH (Sigma-Aldrich Company Ltd.). The flow rate used in regeneration experiments 
was 5 pl/min. The buffer was injected for 1 minute after an injection of 35 pi of antigen 
at 1 pg/ml. Buffers were selected by assessing whether the signal returned to baseline 
after the regeneration step and if the antibody appeared damaged. This was assessed by 
two subsequent antigen injections and regeneration steps and whether a similar increase 
in response units was seen with all three antigen injections.
A method was programmed into the BIAcore system for kinetic experiments. The system 
was programmed to inject increasing concentrations in the range of 10-200 pg/ml of the
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target protein over the immobilised antibody on the chip surface. Each concentration 
scale was repeated once. The flow rate used was 30 pl/ml to minimize mass transport 
effects. The protein was injected for five minutes followed by 5 minutes of HBS-EP 
buffer to collect dissociation data. The chip surface was then regenerated before the next 
run. Each experiment consisted of 17 runs. Three blank runs were followed by 5 runs of 
increasing protein concentration (10, 50, 100, 150 and 200pg/ml). After two blank runs 
the protein scale was repeated and followed by two further blank runs. Monoclonal 
antibodies were immobilized in such a way on the four flowcells on each single chip so 
that an experiment with one antigen-antibody pair had an unrelated antibody available on 
a flowcell to act as a negative control. That antibody was also chosen so that the 
regeneration buffer was compatible. The negative control antibodies were AKYP3, 
HFT2, a commercial anti C. trachomatis HSP60 antibody (A57-E4) and 1VYD 120.3, a 
monoclonal antibody that had been raised against V antigen from Y. pestis.
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4.3 Results
4.3.1 Production of adenylate kinase rabbit polyclonal antibody
Two groups of New Zealand White rabbits were immunised with AdKYP or AdKFT, two 
rabbits for each group. Ulcers formed at the site of the primary injection due to the use of 
FCA. No further ulceration was observed with subsequent injections with FLA and the 
ulceration did not appear to cause the rabbits undue distress. Ear bleeds were collected a 
week after the third injection and the serum titre assessed by indirect ELISA (Figure 4.3). 
Serum titres were defined as the highest dilution factor of the serum that gave a positive 
result when screened by indirect ELISA. A positive result in an indirect ELISA was 
defined as an optical density at 414 nm greater than that of the background signal (the 
mean absorbance of the negative control wells plus two standard deviations). Each assay 
was completed in duplicate on the microtitre plate, and each assay contained a negative 
control well. The assay background was based on the mean plus 2 standard deviations of 
all negative controls on the assay plate. Serum titres were above 1:1000000 for the 
AdKYP group, while for the AdKFT immunised rabbits the titres were over 1:100000. 
The titres were deemed acceptable and the rabbits were exsanguinated by cardiac 
puncture, with approximately 50 ml of serum collected from each rabbit.
The serum from each rabbit from both groups was tested by indirect ELISA against both 
AdKFT and AdKYP to confirm the presence of antibody that recognised conserved 
bacterial AdK epitopes. These results are shown in Figure 4.4 for the serum raised against 
AdKYP and Figure 4.5 for the serum raised against AdKFT. These ELISAs confirmed 
that the serum from all the animals contained antibody that displayed cross-species 
recognition of bacterial AdK. A similar immune response was produced by both rabbits 
in each group, allowing the serum from both rabbits to be pooled. Polyclonal antibody 
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Figure 4.3 Adenylate kinase (AdK) immunised rabbit test bleeds assessed by indirect 
ELISA.
Test bleeds from both groups of two rabbits immunised with recombinant AdK from a) V pestis 
and b) F. tularensis assessed against their corresponding antigen two weeks after the third 
immunisation. Individual rabbits were identified by microchip, the number of which is shown in 
the key. The microplate was coated with recombinant protein at 1 pg/ml in PBS and the serum 
was triple diluted across the plate from an initial dilution of 1:100 in MPBS. An anti-rabbit HRP 
conjugate (Bio-Rad, Hertfordshire, UK) was used as the reporter antibody. Each sample was 
repeated in duplicate and the error bars calculated by standard deviation. The background signal 
was defined as the mean absorbance of all 4 negative control wells plus 2 standard deviations.
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Figure 4.4 Recognition of adenylate kinase (AdK) recombinant proteins by rabbit serum 
raised against Y. pestis AdK by indirect ELISA.
The 96-well microtitre plate was coated with recombinant adenylate kinase proteins at 1 pg/ml in 
PBS and the serum triple diluted across the plate from an initial dilution of 1:100 in MPBS. The 
serum from rabbits 215B and 5455 was assessed against the recombinant AK from both Y. pestis 
(AdKYP) and F. tularensis (AdKFT). The numbers 215B and 5455 are identification numbers 
from microchips inserted in each rabbit. An anti-rabbit HRP conjugate (Bio-Rad) was used as the 
reporting antibody. Each sample was repeated in duplicate and the error bars calculated by 
standard deviation. The background signal was defined as the mean absorbance of all 8 negative 
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Figure 4.5 Recognition of adenylate kinase (AdK) recombinant proteins by rabbit serum 
raised against F. tularensis AK assessed by indirect ELISA.
The 96-well microtitre plate was coated with recombinant adenylate kinase protein at 1 pg/ml in 
PBS and the serum triple diluted across the plate from an initial dilution of 1:100 in MPBS. The 
serum from rabbits 10A7 and 62D5 was assessed against the recombinant AdK from both Y. 
pestis (AdKYP) and F. tularensis (AdKFT). The numbers 10A7 and 62D5 are identification 
numbers from microchips inserted into each rabbit. An anti-rabbit HRP conjugate (Bio-Rad) was 
used as the reporting antibody. Each sample was repeated in duplicate and the error bars 
calculated by standard deviation. The background signal was defined as the mean absorbance of 
all 8 negative control wells plus 2 standard deviations.
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4.3.2 ELISA assessment of adenylate kinase rabbit polyclonal antibody
The purified AdK rabbit pAbs were assessed by indirect ELISA against both recombinant 
AdK proteins (Figures 4.6 and 4.7). In the first assay, the rabbit pAb was diluted against a 
constant concentration of AdK protein, shown in Figure 4.6. Each polyclonal antibody 
recognised the protein that the rabbit had been immunised with to a higher degree than 
the AdK from the other bacterial species, shown by the fact that the antibody could be 
diluted further and still give an optical density higher than the background signal (the 
mean of the optical density plus 2 standard deviations of all the negative control wells). 
Both pAbs displayed similar characteristics to each other in this ELISA format against 
their corresponding antigens. The detection limit of the pAb against the AdK that it had 
been raised against was approximately 4 ng/ml, while the concentration required for a 
positive assay was closer to 100 ng/ml against the cross-reactive AdK from the other 
bacterial species tested.
A similar result was seen when the recombinant AdK proteins were diluted against a 
constant concentration of pAb in the indirect ELISA shown in Figure 4.7. The antibody 
recognised a lower concentration of the AdK protein that it had been raised against (less 
than 1 ng/ml; the ELISA response did not fall to the baseline within the range of AdK 
concentrations tested) compared with the cross-reactive AdK from another bacterial 
species (approximately 10 ng/ml).
4.3.3 Production of adenylate kinase monoclonal cell lines
Two batches of 10 Balb/c mice were immunised with either AdKFT or AdKYP. One 
mouse from the AdKYP group received an inadvertent bladder injection and was 
immediately culled. One week after the third injection tail bleeds were collected and 
tested by indirect ELISA to assess the immune response (Figures 4.8 and 4.9). The serum 
was diluted against a constant concentration of AdK. The serum from each group of mice 
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Figure 4.6 Indirect ELISA analysis of a serial dilution of purified rabbit polyclonal antibody 
raised against recombinant adenylate kinase (AdK) tested against both Y pestis and F. tularensis 
AdK proteins.
Both of the rabbit polyclonal antibodies produced against the recombinant AK proteins from Y 
pestis (AdKYP) and F. tularensis (AdKFT) were tested. Each of the polyclonal antibodies was 
tested against both recombinant AdKYP and AdKFT proteins. The 96-well microtitre plates were 
coated with either AKYP or AKFT at 1 pg/ml in PBS. Polyclonal antibody was applied to the 
plate at 10 pg/ml and triple diluted across the plate in MPBS. An anti-rabbit HRP conjugate (Bio- 
Rad) was used as the reporter antibody. Each assay was duplicated on the microtitre plate and 
error bars calculated by standard deviation. The background signal was defined as the mean of the 
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Figure 4.7 Indirect ELISA analysis of purified rabbit polyclonal antibody raised against 
recombinant adenylate kinase (AdK) against a serial dilution of recombinant AdK from F. 
tularensis (AdKFT) and Y pestis (AdKYP).
Both of the rabbit polyclonal antibodies produced against AdKYP and AdKFT were tested. Each 
of the polyclonal antibodies was tested against both AdKYP and AdKFT proteins. The 96-well 
microtitre plates were coated with AKYP or AKFT at 10 pg/ml in PBS and triple diluted across 
the plate. Polyclonal antibody was applied at 10 pg/ml in MPBS. An anti-rabbit HRP conjugate 
(Bio-Rad) was used as the reporter antibody. Each assay was duplicated on the microtitre plate 
and error bars calculated by standard deviation. The background signal was defined as the mean 
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Figure 4.8 Indirect ELISA of recombinant Y. pestis adenylate kinase (AdKYP) immunised 
mouse tail bleeds against recombinant adenylate kinase F. tularensis (AdKFT) and AdKYP. 
Mouse tail bleeds were taken two weeks after the third immunisation and assessed by indirect 
ELISA. Each mouse was identified by a microchip inserted by subcutaneous injection. The chip 
numbers are displayed in the figure key. The serum was assayed against both (a) AdKYP and (b) 
AdKFT. The highest and lowest response in each ELISA is shown from a group of 9 mice. The 
96-well microtitre plates were coated with either AdKYP or AdKFT at 1 pg/ml in PBS. The 
serum was applied at a 1:100 dilution and triple diluted across the plate in MPBS. An anti-mouse 
HRP conjugate (DAKO) was used as the reporter antibody. No repeats were used in this assay 
due to the limited amount of serum and the background signal was defined as the mean of the 
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Figure 4.9 Indirect ELISA of F. tularensis adenylate kinase (AdKFT) immunised mouse tail 
bleeds assessed against recombinant AdK from Y pestis (AdKYP) and AdKFT.
Mouse tail bleeds were taken two weeks after the third immunisation and assessed by indirect 
ELISA. Each mouse was identified by a microchip inserted by subcutaneous injection. The serum 
was assayed against both (a) AdKFT and (b) AdKYP. The highest and lowest response in each 
ELISA is shown from a group of 10 mice. The 96-well microtitre plates were coated with either 
AdKYP or AdKFT at 1 pg/ml in PBS. The serum was applied at a 1:100 dilution and triple 
diluted across the plate in MPBS. An anti-mouse HRP conjugate (DAKO) was used as the 
reporter antibody. No repeats were used in this assay due to the limited amount of serum and the 
background signal was defined as the mean of the optical densities of all 10 negative control 
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shown in Figure 4.8, while those immunised with AdKFT are shown in Figure 4.9. The 
mice serum with the highest and lowest response in each ELISA is shown to demonstrate 
the range of diversity of response within each group of mice. The serum titres are defined 
as the highest dilution of serum that gave an optical density above the assay background 
signal (the mean of the optical densities of all negative control wells plus 2 standard 
deviations). The serum titre for both pAbs when tested against the AdK protein the mice 
were immunised against was greater than 1:1000000 (shown in Figure 4.8a for the mouse 
anti-AdKYP versus AdKYP and Figure 4.9a for the mouse anti-AdKFT versus AdKFT). 
The bleeds taken from mice immunised with AdKYP (Figure 4.8a) all had very similar 
titres, however noticeably more variation between individual mouse serum samples was 
seen within the AdKFT group (Figure 4.9a). A fourth injection of 10 pg AdKFT was 
administered to try and produce a more homogeneous immune response from these mice. 
When the serum was tested against the AdK that was not used to immunise the mice 
(Figures 4.8b and 4.9b), the ELISA indicated titres above 1:10000. The titres also showed 
more variation in the ELISA response of the serum of individual mice against the cross­
reactive AdK protein compared to the ELISA of the mouse serum against the AdK used 
in the immunisation.
No cell lines were isolated until the eighth fusion procedure from either the AdKYP or 
AdKFT mouse group, when after three rounds of cloning one cell line was isolated from 
a fusion of a spleen taken from a mouse immunised with AdKFT while four cell lines 
were produced from a fusion with a spleen taken from a mouse immunised with AdKYP. 
The cell lines were expanded into tissue culture flasks and the cell culture supematent 
was screened by indirect ELISA for cell lines producing antibody that recognised both 
recombinant AdKs (Figure 4.10). Clones AKFT1 and AKYP3 secreted antibody that 
recognised both recombinant AdK proteins. All the cell lines were isotyped and library 
stocks were laid down in liquid nitrogen. AKFT1 and AKYP3 were used to seed Integra 
bioreactors in order to produce 30 mg of monoclonal antibody. A summary of the AdK 
antibodies is shown in Table 4.1. The isotype of the mAb was determined with Isostrips. 
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Figure 4.10 Indirect ELISA screen of adenylate kinase (AdK) monoclonal cell line 
supematents to identify clones that produce antibody that recognise both recombinant Y.pestis 
(AdKYP) and F. tularensis (AdKFT) AdK proteins.
The 96-well microtitre plates were coated with either (a) AdKYP or (b) AdKFT at 1 pg/ml in 
PBS. The supematent was applied undiluted and triple diluted down the plate in MPBS. 
Polyclonal serum from an AdK immunised mouse was applied at a 1:100 dilution in MPBS and 
triple diluted across the plate as a positive control. An anti-mouse HRP conjugate (DAKO) was 
used as the reporting antibody. Each assay was duplicated on the microtitre plate and error bars 
calculated by standard deviation. The background signal was defined as the mean of the optical 
densities of all 12 negative control wells plus 2 standard deviations.
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AKFT1 IgGl ++ ++
AKYP2 IgGl + ++
AKYP3 IgGl ++ ++
AKYP4 IgGl - ++
AKYP5 IgGl - +4-4-
Table 4.1 A summary of anti-adenylate kinase (AdK) monoclonal cell lines based on 
screening the cell culture supematent by indirect ELISA against recombinant AdK from 
F. tularensis (AdKFT) and Y. pestis (AdKYP).
Each monoclonal antibody (mAb) was scored according to the indirect ELISA response;
+++ very strong signal (Am 2.5-3.0)
++ strong signal (Am 1.5-2.5)
+ moderate (Am 0.5-1.5)
+/- faint (A4 14 background-0 .5)
- no recognition
This is an arbitrary scale based on the response of the cell line supematent in an indirect 
ELISA (see Figure 4.10). The isotype of the mAb was determined with Isostrips.
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No further cell lines were isolated from the three remaining fusions, however bone 
marrow was harvested and frozen as a source of RNA if at a later date it was decided to 
produce an antibody phage display library.
4.3.4 ELISA assessment of adenylate kinase monoclonal antibodies
The monoclonal cell lines discussed have been selected from clones as a detection ligand 
in a capture ELISA screen. I needed to confirm that these antibodies could be used as 
capture ligands and this was assessed by capture ELISA (Figure 4.11). MAbs AKFT1 
and AKYP3 were used to coat a microtitre plate and were tested against serial dilutions 
of AdKFT and AdKYP. Both AKFT1 and AKYP3 successfully captured both 
recombinant bacterial AdK proteins in a capture ELISA format.
Both recombinant proteins were designed with a hexa-his tag to provide a convenient 
purification method. However there was a possibility that the AKFT1 and AKYP3 mAbs 
recognise the his tag, rather than a conserved epitope of the AdK protein. An indirect 
ELISA was used to assess whether this was the case. The 96-well microtitre plates were 
coated with AdKFT, AdKYP, recombinant E. coli HSP60 and a recombinant urease from 
Burkholderia pseudomallei with a hexa-his tag. The recombinant HSP60 did not have a 
his tag, while the urease had been purified by metal chelating chromatography, indicating 
that the his tag was accessible. The two anti-AdK mAbs were applied to the plate at 10 
pg/ml and triple diluted across the plate. There was no indication that AKFT1 and 
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Figure 4.11 Capture ELISA to assess whether AKFT1 and AKYP3 anti-adenylate kinase 
(AdK) monoclonal antibodies (mAbs) could be used as capture ligands in an ELISA format.
The 96-well microtitre plates were coated with either AKFT1 or AKYP3 mAb at 10 pg/ml in 
PBS. Each monoclonal antibody was tested against both recombinant AdK proteins. Recombinant 
AK proteins from either Y. pestis (AdKYP) or F. tularensis (AdKFT) were triple diluted across 
the plate from a starting concentration of 1 pg/ml in MPBS and the corresponding rabbit 
polyclonal antibody (pAb) was used as the detection antibody at 10 pg/ml in MPBS (an anti- 
AdKYP rabbit pAb was used as the detection antibody if the assay used AdKYP and likewise for 
AKFT). An anti rabbit HRP conjugate (Bio-Rad) was used as the reporting antibody. Each assay 
was duplicated on the microtitre plate and error bars calculated by standard deviation. The 
background signal was defined as the mean of the optical densities of all 8 negative control wells 
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Figure 4.12 Indirect ELISA to confirm that AKFT1 and AKYP3 monoclonal antibodies 
(mAbs) do not recognise the hexa-his tag on the recombinant adenylate kinase (AdK) proteins. 
The 96-well microtitre plates were coated with recombinant AdK from Y. pestis (AdKYP) and F. 
tularensis (AdKFT), a recombinant BP3 protein with a hexa-his tag and recombinant HSP60 from 
E. coli as a negative control at 1 pg/ml in PBS. MAb was applied at 10 pg/ml in MPBS and triple 
diluted across the plate. An anti-mouse HRP conjugate (DAKO) was used as the reporting 
antibody. The assay for AKFT1 is shown in a), while that for AKYP3 is shown in b). Each assay 
was duplicated on the microtitre plate and error bars calculated by standard deviation. The 
background signal was defined as the mean of the optical densities of all 8 negative control wells 
plus 2 standard deviations.
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4.3.5 Production of anti heat shock protein 60 (HSP60) rabbit polyclonal antibody
Following immunisation of the rabbits with HSP60 in FCA, small ulcers formed at the 
site of the primary injection due to the use of complete adjuvant. No further damage was 
caused by subsequent injections with FIA and the rabbits did not seem to suffer undue 
distress. Ear bleeds were collected a week after the third injection and the serum titre 
assessed by indirect ELISA (Figure 4.13). The serum titres of all the animals in each of 
the groups were above 1:1000000 and all the rabbits were exsanguinated.
The serum from each rabbit was assessed by indirect ELISA against the three 
recombinant HSP60 proteins (from E. coli [HEC], F. tularensis [HFT] and B. 
pseudomallei [HBP]) to confirm the presence of antibodies that recognised conserved 
epitopes of bacterial HSP60 (Figure 4.14). The serial dilution of rabbit serum was tested 
against a constant concentration of recombinant HSP60. The ELISAs indicated broadly 
similar recognition of all the HSP60 proteins available regardless of which protein a 
rabbit had been immunised with. The assay indicated that the serum from each pair of 
rabbits in each experimental group showed a similar endpoint titre, so the serum from 
both rabbits was pooled. Polyclonal antibody was purified on a protein G column using a 
Gradifrac system.
4.3.6 ELISA assessment of HSP60 rabbit polyclonal antibody
Each of the three purified HSP60 polyclonal antibodies were assessed by indirect ELISA 
against the three recombinant HSP60 proteins (Figure 4.15). A constant concentration of 
antibody was tested against a dilution series of HSP60. Each of the polyclonal antibodies 
recognised all of the recombinant bacterial HSP60 proteins available to a detection limit 
of between 0.5 ng/ml and 10 ng/ml. The detection limit was defined as an optical density 
at 414 nm in the ELISA greater than that of the background signal (the mean absorbance 
of the negative control wells plus two standard deviations). The assays showed a lower 
detection limit with HEC (below 1 ng/ml) compared to HFT or HBP (both above 1 
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Figure 4.13 Indirect ELISA assessment of recombinant heat shock protein 60 (HSP60) 
immunised rabbit test bleeds two weeks after the third immunisation.
The immune response from each group of rabbits was assessed by indirect ELISA analysis of 
serum taken from an ear bleed. The assay for the rabbits immunised with E. coli HSP60 is shown 
in a), the F. tularensis group results are shown in b) and the results from the B. pseudomallei 
group are shown in c). The 96-well microtitre plates were coated with recombinant HSP60 
proteins from E. coli, F. tularensis and B. pseudomallei at 1 pg/ml in PBS. Serum was triple 
diluted across the plate from a 1:100 dilution in MPBS. An anti-rabbit conjugate (Bio-Rad) was 
used as the reporting antibody. Each assay was duplicated on the microtitre plate and error bars 
calculated by standard deviation. The background signal was defined as the mean of the optical 
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Figure 4.14 Indirect ELISA of recombinant heat shock protein 60 (HSP60) immunised rabbit 
serum to confirm cross-species recognition of recombinant bacterial HSP60 proteins.
Serum from each group of two rabbits immunised with recombinant HSP60 from either E. coli 
(HEC), F. tularensis (HFT) or B. pseudomallei (HBP) was tested against all three recombinant 
HSP60 proteins; a) HEC b) HFT and c) HBP by indirect ELISA. Each rabbit was identified by a 
coloured tag, which is noted in the figure key. The 96-well microtitre plates were coated with 
HSP60 protein at 1 pg/ml in PBS and the serum was triple diluted across the plate from a 1:100 
dilution in MPBS. An anti-rabbit HRP conjugate (Bio-Rad) was used as the reporting antibody. 
Each assay was duplicated on the microtitre plate and error bars calculated by standard deviation. 
The background signal was defined as the mean of the optical densities of all 6 negative control 
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Figure 4.15 Indirect ELISA assessing cross-species recognition of recombinant heat shock 
protein 60 (HSP60) from different bacterial species by each of the purified rabbit polyclonal 
antibodies (pAbs).
Each purified anti-HSP60 rabbit pAb was tested against three recombinant HSP60 proteins. The 
96-well microtitre plates were coated with the recombinant HSP60 protein from E. coli (HEC), F. 
tularensis (HFT) and B. pseudomallei (HBP) at 1 pg/ml in PBS and triple diluted across the plate. 
Polyclonal antibody raised against a) HEC b) HFT and c) HBP was applied to each plate at 10 
pg/ml in MPBS. An anti-rabbit HRP conjugate (Bio-Rad) was used as the reporting antibody. 
Each assay was duplicated on the microtitre plate and error bars calculated by standard deviation. 
The background signal was defined as the mean of the optical densities of all 6 negative control 
wells plus 2 standard deviations.
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4.3.7 Production of HSP60 monoclonal cell lines
A group of 10 female, 6-10 week old Balb/c mice were immunised with each of the 
recombinant HSP60 proteins. Tail bleeds were collected two weeks after the third 
injection and the serum titre assessed by indirect ELISA (Figure 4.16). Three mouse 
serum samples were selected from each group. A serial dilution of serum was tested 
against a constant concentration of HSP60. All of the mouse sera had an endpoint titre of 
1:1000000 or greater. All 10 mice responded in a similar fashion (data not shown).
In total four fusion procedures were completed from each HSP60 mouse group, leading 
to the production of 20 monoclonal cell lines. Each cell line was screened by capture 
ELISA and isotyped. Library stocks were laid down in liquid nitrogen. The remaining 
mice received a pre-fusion booster injection and were culled four days later. The spleens 
were harvested and laid down in liquid nitrogen. A summary of the cell lines is shown in 
Table 2. The isotype of the mAbs were determined with Isostrips. All the mAbs had 
kappa heavy chains.
Three cell lines (HEC2, HFT2 and HFT7) displayed a notable response to all three 
recombinant HSP60 proteins when screened by indirect ELISA (Figure 4.17). Cell 
culture supematent was tested against HEC, HFT and HBP. Cell culture supernatant was 
applied neat and triple diluted against a constant concentration of HSP60 protein. All 
three mAbs displayed a strong ELISA response against two recombinant HSP60s, and a 
weaker response to one of the proteins. All three cell lines were cultured in Integra flasks 
with the aim of producing between 30 mg and 50 mg of monoclonal antibody. HEC2 did 
not secrete antibody in high quantities in Integra flasks and also proved to be unstable, 
ceasing production of antibody over time when Integra taps were assessed by indirect 
ELISA. The same behaviour was seen when this cell line was recovered from liquid 
nitrogen stocks. Both HFT2 and HFT7 could be grown in Integra flasks easily, but HFT7 
secreted limited amounts of antibody (each protein G antibody purification of two pooled 
Integra flask taps only yielded 1-2 mg of dilute protein). However several milligrams of 
antibody (10-15 mg) could be purified on a protein G column from two pooled taps from
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Figure 4.16 Indirect ELISA assessment of mouse serum from tail bleeds two weeks after the 
third immunisation with recombinant heat shock protein 60 (HSP60).
The 96-well microtitre plates was coated with a) E. coli, b) F. tularensis and c) B. pseudomallei 
recombinant HSP60 at 1 pg/ml in PBS. Individual mice were identified by microchip numbers, 
which are shown in the key. Serum from three mice selected out of each immunised group of ten 
was tested against the corresponding recombinant HSP60 at a dilution of 1:100 in MPBS and 
triple diluted across the plate. An anti-mouse HRP conjugate (DAKO) was used as the reporting 
antibody. No repeats were used in this assay and the background signal was defined as the mean 
of the optical densities of all 3 negative control wells plus 2 standard deviations.
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HEC1 IgG2a +++ +/- +
HEC2 IgG2a +++ + ++
HEC3 IgG2a +++ - -
HEC4 IgG2b +++ - +/-
HEC5 IgGl +++ +/- +
HFT1 IgG2b - ++ -
HFT2 IgGl +++ +++ ++
HFT5 IgG2b +++ +/- +
HFT6 IgG2a - + -
HFT7 IgGl +++ +++ +
HFT8 IgGl - ++ -
HFT9 IgG2b - + -
HFT10 IgG2b - +++ -
HBP1 IgGl ++ - +
HBP2 IgGl - - ++
HBP3 IgGl - - +
HBP4 IgG2a - - +/-
HBP5 IgG2a +++ - -
HBP6 IgG2a - - +++
HBP7 IgGl - - ++
Table 2 A summary of anti heat shock protein 60 (HSP60) monoclonal cell lines
based on screening of cell culture supematent by indirect ELISA against recombinant 
HSP60s from E. coli, F. tularensis and B. pseudomallei.
Each monoclonal antibody (mAb) was scored according to the indirect ELISA response;
+++ very strong signal (A4 1 4  above 3.0)
++ strong signal (A4 1 4 1.5-3.0)
+ moderate (A4 1 4  0.5-1.5)
+/- faint (A4 14 background-0.5)
- no recognition
This is an arbitrary scale based on the response of the cell line supematent in an indirect 
ELISA (see Figure 4.17). The isotype of the mAb was determined with Isostrips.
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Figure 4.17 Indirect ELISA screen of cell culture supematent produced from heat shock 
protein 60 (HSP60) monoclonal cell lines tested against three recombinant HSP60 proteins. 
Recombinant HSP60 protein from E. coli (HEC), F. tularensis (HFT) and B. pseudomallei (HBP) 
was used to coat 96-well microtitre plates at 1 pg/ml in PBS. Cell culture supematent was applied 
undiluted and triple diluted across the plate in MPBS. An anti-mouse HRP conjugate (DAKO) 
was used as the reporting antibody. Each assay was duplicated on the microtitre plate and error 
bars calculated by standard deviation. The background signal was defined as the mean of the 
optical densities of all 6 negative control wells plus 2 standard deviations.
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the HFT2 Integra flask. I decided to concentrate all future work on the immunoaffinity 
proof of principal on HFT2.
4.3.8 ELISA assessment of heat shock protein 60 (HSP60) monoclonal antibodies
While the HSP60 monoclonal cell lines were being produced, a commercial Chlamydia 
trachomatis HSP60 monoclonal antibody (Affinity Bioreagents, Inc.) that displayed cross- 
species recognition was identified. To allow initial immunoaffinity experiments to begin, a 
quantity of this antibody was purchased. The antibody was supplied in ascetic fluid and 
was purified on a protein G column. A capture ELISA was used to assess the possibility of 
using this antibody as a capture ligand and to confirm recognition of three recombinant 
bacterial HSP60s (Figure 4.18). A constant concentration of the C. trachomatis antibody 
was assessed against a dilution series of HEC, HFT and HBP. Rabbit polyclonal antibody 
was used as the detection antibody. The C. trachomatis HSP60 successfully captured each 
of the recombinant bacterial HSP60 proteins tested in this ELISA format. The detection 
limit of the antibody was 10 ng/ml or lower for each of the HSP60 proteins. The detection 
limit was defined as an optical density at 414 nm in the ELISA greater than that of the 
background signal (the mean absorbance of the negative control wells plus two standard 
deviations).
Indirect and capture ELISA assessment of the purified HFT2 monoclonal antibody is 
shown in Figure 4.19. With the indirect ELISA (Figure 4.19a) a constant concentration of 
antibody was assessed against a dilution series of HEC, HFT and HBP. The detection limit 
of HFT2 in this ELISA format was to a dilution of at least 20 ng/ml of each of the HSP60s 
tested. For the capture ELISA (Figure 4.19b) the microtitre plate was coated with a 
constant concentration of antibody assessed against a dilution series of the three 
recombinant HSP60s. Rabbit polyclonal antibody was used as the detection antibody. This 
assay confirmed the possibility of using HFT2 as a capture ligand for bacterial HSP60.
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Figure 4.18 Capture ELISA to assess the commercial anti Chlamydia trachomatis heat shock 
protein 60 (HSP60) monoclonal antibody (mAb) as a capture ligand.
The 96-well microtitre plate was coated with C. trachomatis mAb at 10 pg/ml in PBS. 
Recombinant HSP60 proteins from E. coli (HEC), F. tularensis (HFT) and B. pseudomallei (HBP) 
was applied to the plate at 10 pg/ml in MPBS and triple diluted across the plate. The corresponding 
rabbit polyclonal antibody raised against each HSP60 was used as the detection antibody at 10 
pg/ml in MPBS, while an anti rabbit HRP conjugate (Bio-Rad) was applied as the reporting 
antibody. Each assay was duplicated on the microtitre plate and error bars calculated by standard 
deviation. The background signal was defined as the mean of the optical densities of all 6 negative 
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Figure 4.19 Indirect and capture ELISAs of heat shock protein 60 (HSP60) monoclonal 
antibody HFT2 against recombinant HSP60 from three bacterial species.
For the indirect ELISA (a) the microtitre plate was coated with each of the three recombinant 
HSP60 proteins from E. coli (HEC), F. tularensis (HFT) and B. pseudomallei (HBP). The HSP60 
was applied at 1 pg/ml in PBS and triple diluted across the plate. HFT2 was applied at 10 pg/ml in 
MPBS and an anti-mouse HRP conjugate (DAKO) was used as the reporting antibody. For the 
capture ELISA (b) the microtitre plate coated with HFT2 at 10 pg/ml in PBS. Each of the 
recombinant HSP60s was applied at lpg/ml in MPBS and triple diluted across the plate and the 
corresponding rabbit polyclonal antibody was used as the detection antibody. An anti-rabbit HRP 
conjugate (Bio-Rad) was used as the reporting antibody.
For both ELISAs each assay was duplicated on the microtitre plate and error bars calculated by 
standard deviation. The background signal was defined as the mean of the optical densities of all 6 
negative control wells plus 2 standard variations.
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4.3.9 BIAcore™ analysis of AK monoclonal antibodies
In order to identify an effective regeneration buffer, the antibody AKFT1 was 
immobilised onto a chip surface, as described in Section 4.2.2.8. The increase in response 
units (RU) after coupling was 5728. A 100 mM glycine buffer pH 1.5 was effective at 
regenerating the chip surface but resulted in degradation of the antibody, identified by a 
reduction in the capacity of the antibody surface to capture antigen. Potassium hydroxide 
(10 mM) proved to be an effective elution buffer without damaging the antibody for both 
AKFT1 and AKYP3 (results not shown).
For kinetic studies, each antibody was immobilised on new flow cell chip surfaces (302 
RU for AKFT1 and 437 RU for AKYP3). Five concentrations of antigen were used to 
collect association and dissociation data. The data was processed with the BLAevaluation 
3.2 software. Processed data for AKFT1 is shown in Figure 4.20, while data for AKYP3 
is shown in Figure 4.21. Calculated association (ka), dissociation (kd) and affinity 
constants (KD) are shown in Table 4.3.
4.3.10 BIAcore™ analysis of HSP60 monoclonal antibodies
The commercial anti C. trachomatis HSP60 mAb and HFT2 antibodies were assayed 
against E. coli HSP60 using the same method described for the AdK mAbs. Each 
antibody was immobilised onto chip surfaces (an increase of 470 RU for HFT2 and that 
of 471 RU for the C. trachomatis mAb). However, under these experimental conditions 
HFT2 did not appear to capture any antigen, while the response seen with immobilised C. 
trachomatis HSP60 antibody was very weak. A kinetic experiment was completed for the 
C. trachomatis mAb (Figure 4.22) and processed with the BIAevaluation 3.2 software. 
With such a weak response during the experiment and a poor fit of the data, any kinetic 
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Figure 4.20 BIAcore™ association and dissociation data o f recombinant AdKFT with AKFT1 monoclonal antibody. The 
monoclonal antibody was immobilised on the chip surface and AdKFT flowed across the surface at increasing concentrations. 
Protein injection started at 0 s and ended at 300 s. The concentration scale was repeated after two blank runs. Data 
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Figure 4.21 BIAcore™ association and dissociation curves o f  AdKYP with AKYP3 monoclonal antibody. The monoclonal 
antibody was immobilised on the chip surface and AdKYP flowed across the surface at increasing concentrations. Protein injection 
started at 0 s and ended at 300 s. The concentration scale was repeated after two blank runs. Data manipulation and assessment was 




ka (1/Ms) kd (1/s) KD (M)
AKFT1 6.48x10s 5.15x10 s 7.94xl0'v
AKYP3 1.62x10s 2.51x10 s 1.55x10-°
Table 4.3 Anti-adenylate kinase (AdK) monoclonal antibody kinetic constants derived from 
data analysis of a BIAcore™ experiment.
Each antibody was assayed with the corresponding antigen (AKFT1 with AdK from F. tularensis 
and AKYP3 with AdK from Y. pestis). Antibody was immobilised on the chip surface and 
antigen injected at 10,50,100,150 and 200 pg/ml for 5 minutes at 30 pl/min. The chip surface 
was washed with HBS-EP buffer for 5 minutes after the injection was ended. Data was processed 
with BIAevaluation 3.2 software.
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Figure 4.22 BIAcore™ association and dissociation curves of recombinant E. coli HSP60 with commercial HSP60 
monoclonal antibody. The monoclonal antibody was immobilised on the chip surface and HSP60 flowed across the surface at 
increasing concentrations. Protein injection started at 0s and ended at 300s. The concentration scale was repeated after two blank runs. 
Data manipulation and assessment was performed on BIAevaluation 3.2 software, assuming 1:1 (Langmuir) binding.
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4.4 Discussion
The objective of this section was to produce capture ligands that displayed cross-species 
recognition against the potential bacterial biomarker proteins. These ligands were to be 
used in an immunoaffinity step to purify adenylate kinase (AdK) and heat shock protein 
60 (HSP60) from bacterial lysates for analysis by electrospray mass spectrometry. Rabbit 
polyclonal antibodies were produced against each of the recombinant proteins available 
and several monoclonal cell lines produced that displayed cross-species recognition of 
either the recombinant AdKs or HSP60s.
Initial immunisation of the rabbits with Freund's complete adjuvant (FCA) resulted in 
tissue damage at the site of injection, in the form of ulcers. Freund's complete adjuvant is 
noted for causing distress and tissue damage (Stills, 2005), but is a common choice of 
adjuvant due its success in promoting an immune response with a wide range of antigens 
(Stills and Bailey, 1991). Alternative adjuvants are now available that can promote a 
similar immune response to FCA but with less severe side effects, for example 
TiterMax® Gold, now the adjuvant of choice in our laboratory (Beck et al., 2003).
The serum titres for the both the AdK and HSP60 immunised rabbits were all above 
1:100000, indicating all the rabbits produced a strong immune response against the 
antigens. Although the immune response between individual animals can vary, the 
indirect ELISAs of the rabbit serum indicated that the immune response was similar (the 
AdK assay is shown in Figure 4.3, the assay for HSP60 shown in Figure 4.13), so the 
serum from each group of two rabbits was pooled.
Indirect ELISAs of each purified rabbit pAb raised against AdK from F. tularensis 
(AdKFT) or Y. pestis (AdKYP) confirmed that each antibody recognised both bacterial 
AdK proteins (Figures 4.6 and 4.7). Each antibody produced a larger ELISA signal 
against the antigen it had been raised with compared with the cross-reactive AdK antigen, 
but the assays do indicate that AdK does contain at least one conserved immunogenic
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epitope. This showed it should be possible to raise monoclonal cell lines that produce 
antibody which display cross-species recognition against both AdKFT and AdKYP.
Indirect ELISA screens of tail bleeds of the two groups of mice immunised with either 
AdKYP (Figure 4.8) or AdKFT (Figure 4.9) confirmed the presence of antibody in the 
serum that recognised conserved adenylate kinase epitopes. However it was only until the 
eighth fusion procedure that anti-AdK monoclonal cell lines were isolated. This failure to 
generate monoclonal cell lines from the early fusion procedures is not unusual. It has 
been noted that the most successful fusions are often those from mice that received the 
pre-fusion booster injection several months after the primary immunisation schedule (T. 
Webber, personal communication). However, the optimal immunisation schedule may 
vary for each antigen and boosters are usually administered after the serum titre has 
stopped increasing or has begun to fall (Leenaars and Hendriksen, 2005), but the serum 
titres are often not measured after each immunisation. The pre-fusion booster stimulates 
the secondary immune response, with an increase in the proportion of IgG within the 
secondary immune response in comparison to the primary response, and an increase in 
the affinity and avidity of the antibodies (Schunk and Macallum, 2005).
Five anti-AdK mAbs were isolated, with two (AKFT1 and AKYP3) displaying cross­
species recognition against AdKFT and AdKYP. Both mAbs displayed a similar response 
against both AdK proteins when tested by capture ELISA (Figure 4.11), confirming that 
the antibodies could be used as capture ligands in an ELISA format. This indicates that 
either antibody could be an effective capture ligand in an immunoaffinity column, 
although the suitability of an antibody for use in an ELISA does not ensure that they will 
be effective in other assay formats. In an immunoaffinity column the liquid is a mobile 
rather than a stationary phase as in an ELISA, the antibodies are covalently attached to 
the column matrix rather than adhering to the plastic and it is unknown if it would be 
possible to elute the target protein from the column in a buffer that is compatible with 
electro-spray mass spectrometry.
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Similar results were seen with the ELISA analysis of the HSP60-immunised rabbit serum 
and purified antibody compared to the AdK pAb. Each rabbit's serum displayed a strong 
response against all three recombinant HSP60 proteins from E. coli, F. tularensis and B. 
pseudomallei (Figure 4.14). What is noticeable is the lack of the variation in the serum 
titre shown by all the HSP60 rabbit serum when compared to the serum from the AdK 
immunised animals (Figure 4.4). All the sera showed a similar response to both of the 
cross-reactive HSP60 proteins as well as against the HSP60 the rabbits had been 
immunised with. This suggests a high degree of conservation of immunodominant 
epitopes for HSP60 and indicated that it would be possible to generate monoclonal cell 
lines that produce antibody that displayed cross-species recognition of bacterial HSP60.
Indirect ELISA screens of mouse serum from the three groups of HSP60 immunised mice 
(Figure 4.16) shows that the serum contains antibodies that display cross-species 
recognition against HSP60. Four fusion procedures were completed, generating 20 
monoclonal cell lines. Indirect ELISA screens of cell culture supematents (summarised in 
Table 4.2) showed a range of different recognitions of the three recombinant HSP60 
proteins. Clone HFT2 displayed strong recognition of all three HSP60s and could be 
produced in milligram quantities from cell culture. Other isolated cell lines either only 
recognised one or two of the HSP60 proteins in indirect ELISA, indicating recognition of 
epitopes that are not conserved across all three bacterial species, or were unable to be 
successfully cultured to produce milligram quantities of antibody. A capture ELISA 
confirmed that antibody HFT2 could capture all three recombinant HSP60s in this assay 
format (Figure 4.19) but this cannot be used as confirmation that HFT2 would be a 
successful ligand in other applications.
BIAcore™ analysis confirmed that monoclonal antibodies AKFT1 and AKYP3 could 
successfully capture AdK when covalently linked to a biosensor chip surface. Potassium 
hydroxide was also identified as a potential elution buffer for use in immunoaffinity 
chromatography for both of these antibodies, but it is unknown how much damage the 
antibodies will suffer due to repeated exposure to such a stringent buffer over a longer 
time scale. HFT2 did not successfully capture HSP60 protein on the chip surface under
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the experimental conditions used. A limited amount of antibody is bound to the chip 
surface for kinetic studies to limit mass-transport or steric hindrance (Yarmush et al., 
1996). The antibody density on the chip surface did not appear high enough to capture 
HSP60.
Several cross-reacting mAbs have been reported that recognise either HSP60 or a HSP60 
homologue. The Mycobacterium tuberculosis HSP65 has been shown to correspond to 
HSP60 (Shinnick et al., 1987). A panel of twenty-three mAbs which recognised the M. 
leprae HSP65 were used to screen lysates of twenty-three Mycobacterium species by 
Western blot. Several mAbs were identified that could recognise the HSP65 of between 8 
and 25 Mycobacterium species (Buchanan et al, 1987). A panel of mAbs has previously 
been raised against C. trachomatis HSP60 (Yuan et al., 1992). These antibodies were 
species-specific, genus-specific or cross-reactive against HSP60, although the extent of 
cross-species recognition for each antibody was not fully defined due to the degree of 
conservation of HSP60 (the commercial anti-C. trachomatis HSP60 mAb that was 
purchased was described in this paper). A mAb has been raised against Helicobacter 
pylori HSP60 that also recognised the HSP60 from several other bacterial species 
(Yamaguchi et al, 1997). It would have been surprising if no cross-reactive anti-HSP60 
mabs were raised against the three recombinant HSP60s due to the highly conserved 
nature of the protein (Dasch et al., 1990). The immunogenic properties of adenylate 
kinase have not been studied as extensively as HSP60, due to the role HSP60 has in 
autoimmunity (Feige and van Eden, 1996).
It is impossible to predict whether any of the monoclonal antibodies would be suitable 
capture ligands in an immunoaffinity column until they are tested in that format. Fusion 
procedures are random in the regard of which cells are fused with myelomas and tend to 
reflect any immunodominance by particular epitopes of the antigen displayed in the 
polyclonal serum. Also the screening method is critical in identifying useful monoclonal 
antibodies, depending on how the antigen is presented (Leenaars and Hendriksen, 2005). 
This may mean that the most suitable ligands for an application may not be generated. 
One alternative approach to generating capture ligands is to screen naive antibody phage
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display libraries. These libraries are not predisposed to particular antigens and it may be 
possible to select for single chain antibodies that recognise epitopes that could not be 
identified by traditional monoclonal cell culture methods. This approach will be 
discussed in Chapter 6.
Future work would include the epitope mapping of the mAbs, and continued production 
of anti-HSP60 mAbs from the remaining immunised material. Sufficient immunised 
material remained to create antibody phage display libraries against both AdK and 
HSP60. Also it would be interesting to confirm if there was any difference in the kinetic 
constants of the binding of the AdK mAbs with cross-reactive AdKs, compared with the 
values for the AdK the mAb was raised against.
In summary, two anti-Adk mAbs were raised that recognised two AdKs from different 
bacterial species and one anti-HSP60 mab has been raised that recognised three HSP60s 
from different bacterial species. These antibodies may be suitable as immunoaffinity 





The proposed detection system relies on the measurement of the molecular weight (MW) 
of bacterial biomarker proteins to identify bacteria. However, an electrospray mass 
spectrometer (ESMS) is unable to directly analyse proteins from clinical or 
environmental samples without a sample preparation method. Bacterial cells need to be 
disrupted to release the biomarker protein prior to analysis by mass spectrometry. 
Sonication is a method of cell disruption that can be incorporated into an in-line detection 
system, resulting in a complex protein mixture (Borthwick et al., 2005). The protein 
mixture requires filtering to remove debris before a purification step to purify and 
concentrate the biomarker protein prior to mass spectrometer analysis.
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry has been used to generate mass spectra 'fingerprints' from lysed 
(Krishnamurthy et al., 1996) and whole bacterial cells (Holland et al., 1996; Welham et 
al., 1998). Each study identified a selection of unique protein biomarkers, typically in the 
range of 2 kDa to 20 kDa, which could be used to identify bacterial species. An algorithm 
was developed to allow the comparison of mass spectra 'fingerprints' that allowed twenty- 
five different strains of E. coli to be distinguished (Arnold and Reilly, 1998). However, at 
that time MALDI-TOF was unsuited for use in an automated detection system as the 
bacterial sample in each study had to be mixed with the matrix and dried onto the sample 
support. Each bacterial sample required considerable preparation prior to analysis. Also 
each bacterial species used in each study was an idealized cultured sample; there was no 
investigation of the effect of different growth conditions, possible phase and antigenic 
variation of biomarker proteins (van der Woude and Baumler, 2004), mixtures of 
different bacterial species, or the effect that contaminants from a crude environmental or 
clinical sample would have on the MALDI-TOF analysis.
High performance liquid chromatography (HPLC) has been successfully combined with 
ESMS for a number of years (Gelpi. 1995). HPLC offers a high-resolution method of 
separating complex protein mixtures and electrospray ionization allows the protein
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sample to be injected directly into the mass spectrometer from the column (Strege, 1999; 
Shi et al., 2004). Bacterial protein profiles have been obtained by MALDI-TOF analysis 
of sonicated bacterial lysates that were separated with HPLC on a Cl 8  reversed-phase 
capillary column (Liang et al., 1996). Fractions from the HPLC separation were mixed 
air-dried onto the probe tip. Again this method still requires several processing stages, 
including centrifugation, which could not easily be incorporated into an automated 
detection system. HPLC-ESMS has been used to analyse bacterial lysates and identify the 
bacterial species previously (Krishnamurthy et al., 1999). This system used HPLC with a 
C l 8  reversed-phase capillary column to separate bacterial proteins before injection into 
the ESMS. The bacterial samples were reconstituted from lyophilized cultured samples. 
One mixture of two bacterial lysates was analysed, which resulted in a complicated mass 
spectrum, but biomarker proteins were distinguished for both bacterial species. There was 
no assessment of other bacterial mixtures, or of environmental or clinical samples. The 
use of ESMS rather than MALDI allows the system to be more easily automated.
It is probable that these complex clinical or environmental samples are will require a 
processing step prior to ESMS analysis due to contaminating material. Immunoaffinity 
chromatography could extract a specific biomarker protein from the bacterial lysate, 
allowing contaminating bacterial proteins and other contaminants to be removed before 
ESMS analysis. This may increase the sensitivity of the detection system by increasing 
the proportion of the biomarker protein compared with other proteins. Immunoaffinity 
purification may improve the sensitivity of the detection system by concentrating the 
biomarker protein from dilute samples. Immunoaffinity chromatography was used to 
isolate protein isoforms from crude serum for analysis by ESMS (Lacey et al., 2001; Sen 
et al., 2003), which indicated that the technique should be suitable for this application.
The aim of this project is to develop an ESMS-based detection system that is capable of 
analysing complex environmental and clinical samples by utilizing immunoaffinity 
purification with a cross-reactive antibody to present bacterial biomarker proteins to the 
ESMS for identification. This novel strategy for the identification of bacterial species is 
protected by patent (Titball and Despeyroux, 2002).
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The desired characteristics of the detection system, the nature of the interface of the 
immunoaffinity system with the ESMS, and the ESMS itself dictated the design of the 
purification experiments. The choice of buffers is restricted by their compatibility with 
each processing step. Sodium phosphate buffers have been successfully used as a loading 
buffer for protein purifications (Jack, 1994) and are compatible for the sonication and 
filtration steps. Both alkaline and acidic buffers as well as detergents, high salt buffers 
and chaotropic agents have successfully been used as elution buffers in immunoaffinity 
applications (Yarmush et al., 1992). However there are restrictions on the buffers that can 
be employed as elution buffer for the immunoaffinity step. Ionic detergents such as SDS 
will coat tubing and exposed surfaces, becoming difficult to remove from the system 
once they have been introduced. Detergent contamination of the ESMS results in a strong 
series of mass/charge peaks that interfere with protein analysis (K. Anderson, personal 
communication). High salt concentrations can also be problematic due to precipitation 
and deposits within the system (Bajic et al., 2000). This is due to physical blockage of the 
electrospray tip. Salt cluster ions can also interfere with protein analysis (Hao et al., 
2001). A further consideration of the experimental design is the time taken to perform an 
analysis of an unknown sample of several millilitres. The flow rate needs to be kept 
relatively high to enable a sample to be processed in an acceptable timeframe (within 1 
hour is the target processing time limit). However these flow rates (the initial rate chosen 
was 1 ml/min) may not be the most efficient in allowing optimal capture of the target 
protein by an immunoaffinity column (Jack, 1994). It is probable that the flow rate will 
also affect the efficiency of the disruption of bacterial cells by sonication, but developing 
the disruption technique is not an objective of this study.
Adenylate kinase (AdK) and heat shock protein 60 (HSP60) have both been identified as 
potential Gram-negative bacterial biomarker proteins. This is due to their ubiquitous 
nature within bacterial species and high degree of sequence conservation between these 
proteins from different bacterial species. Polyclonal and monoclonal antibodies which 
display cross-species recognition have been raised against both potential biomarker 
proteins (Chapter 4). To allow the immunoaffinity characterization work to begin while 
monoclonal cell lines were being produced a commercial anti-Chlamydia trachomatis
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HSP60 was purchased. This antibody has been shown to recognise the HSP60 proteins 
from all three Chlamydia species, Escherichia coli, Salmonella typhimurium, Neisseria 
gonorrhoeae and Coxiella burnetti (Yuan et al., 1992). Epitope mapping indicates the 
antibody binds to a linear sequence (117-122) of C. trachomatis HSP60 (Yuan et al., 
1992). Several Gram-negative bacterial species were selected to produce bacterial lysates. 
Due to safety considerations, particularly transport of bacterial samples between different 
laboratories, all selected strains were category 2  or lower.
There was a requirement to be able to detect and identify bacterial spores which present a 
challenge compared to vegetative cells, due to the difficulty of extracting an 
identification factor, whether DNA or protein, from the spore. A potential biomarker 
protein needed to be identified for Bacillus spores for use in this detection system. 
Bacillus spore preparations were screened with the anti-HSP60 cross-reactive mAb HFT2 
(described in Chapter 4) to assess if HSP60 was present.
The aims of this section were to:
1 . confirm the presence of biomarker proteins in the bacterial lysates
2 . identify immunoaffinity elution buffers for the monoclonal antibodies
3. provide a proof of principle for an immunoaffinity-ESMS-based detection system 
by measuring the MW of a biomarker protein from at least two bacterial species
4. assess whether there is a suitable protein biomarker for Bacillus spores that can be 
exploited for this detection system
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5.2 Materials and Methods
5.2.1 Materials
All chemicals were purchased from Sigma-Aldrich Company Ltd., Fancy Road, Poole, 
Dorset, UK, unless stated.
All bacterial lysates were a gift from C. Underwood-Fowler, Microbiology Department, 
Dstl Porton Down, with the exception of the lysate of Salmonella typhimurium SL 1344 
which was a gift from S Bailey, Microbiology Department, Dstl Porton Down. Lysates 
were supplied of Escherichia coli JM109, Yersinia enterocolitica YeOc, Yersinia 
pseudotuberculosis 32953, Staphylococcus aureus (3750 Mrs. Fox), Pantoea 
agglomerans (9381 Graham Brice) and S. typhimurium (SL 1344). The source of the 
bacterial strains was the National Collection of Type Cultures (NCTC), based at the 
Health Protection Agency, Wiltshire, UK. A detailed bacterial lysate production method 
is provided for reference in the General Materials and Methods (Chapter 2, Section 
2.2.9). In summary, all bacterial cell preparations were disrupted by sonication, followed 
by centrifugation and filtration through a 0 . 2  pm syringe filter to remove intact cells and 
debris. The exception was the lysate preparation of S. typhimurium, where the bacteria 
were killed by heat shock at 60°C, followed by chemical lysis. This method is detailed in 
this chapter (Section 5.2.2.1).
S-layer preparations from Bacillus pumilus and Bacillus cereus (NCTC 9946 and NCTC 
11145), as well as spore preparations from Bacillus anthracis UM23CL2 (which lacks 
the virulence plasmids pXOl and pX02), B. pumilus and B. cereus (NCTC 9946 and 
NCTC 11145) were all gifts from T. Love, Detection Department, Dstl Porton Down.
The production methods are detailed in this section for reference. Biotinylated rabbit anti- 
B. anthracis polyclonal antibody was a gift from the Detection Department at Dstl Porton 
Down.
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A monoclonal anti-C. trachomatis HSP60 antibody, catalog number MA3-022, clone 
A57-E4 (Cambridge Bioscience, Newmarket Road, Cambridge, UK) was purchased to 
provide a capture ligand for immunoaffinity purifications while anti-HSP60 monoclonal 
cell lines were produced. The production of this monoclonal cell line is described by 
Yuan et al., 1992. A monoclonal anti-ovalbumin antibody, 8C9, was a gift from the 
Detection Department at Dstl Porton Down.
5.2.2 Methods
5.2.2.1 S. typhimurium lysate preparation
The S. typhimurium lysate was a gift from S. Bailey, Microbiology Department, Dstl 
Porton Down. The culture and lysis methods are provided here for reference. 2 ml of an 
overnight culture in Luria broth (L-broth) was used to inoculate 200 ml L-broth and 
grown to mid-log phase at 37°C. L-broth was made with 10 g/1 (gram/litre) Difco 
tryptone peptone (Becton Dickinson UK Ltd., Oxford, UK), 5 g/1 Difco bacto yeast 
(Becton Dickinson UK Ltd.) and 5 g/1 NaCl in Milli-Q® distilled water. The media was 
sterilised by autoclaving for 15 minutes at 121°C. The bacteria were pelleted by 
centrifugation at 10000 x g for 20 minutes and the supematent removed. The cells were 
washed three times by resuspension in PBS pH7.2, followed by centrifugation at 5300 
rpm for 20 minutes in a Labofuge 200 centrifuge (DJB Labcare Ltd., Buckinghamshire, 
UK) to remove traces of culture media. The pellet was resuspended in 2 ml PBS and 
incubated at 60°C for 1 hour in a water bath to kill the bacteria. The preparation was 
sterility checked by plating out samples of the heat-killed preparation onto L-agar plates 
(as L-broth, but with the addition of 20 g/1 Difco bacto agar [Becton Dickinson UK Ltd.]) 
and the confirmation of no bacterial growth after 72 hours at 37°C. The cells were 
pelleted by centrifugation at 5300 rpm for 20 minutes (Labofuge 200) and resuspended 
with 2ml of lysis buffer (Amersham Pharmacia Biotech, Uppsala, Sweden). The lysate 
was centrifuged at 5000 x g for 20 minutes to separate the cell debris from the soluble 
proteins. The typical protein yield from 200 ml L-broth culture was 2 ml of 4-5 mg/ml.
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5.2.2.2 S-layer preparations from Bacillus spores
S-layer preparations of Bacillus pumilus and Bacillus cereus (NCTC 11145 and NCTC 
9946) were a gift from T. Love, Detection Department, Dstl Porton Down. The S-layer 
production method is provided here for reference. Bacterial cultures were grown 
overnight in 50 ml SPY media (60 mM di-potassium hydrogen phosphate, 45 mM 
potassium di-hydrogen phosphate, 15 mM ammonium sulphate, 10 mM magnesium 
sulphate, 2.4 mM sodium citrate, 0.2% (w/v) glucose and 0.2% (w/v) Difco Bacto yeast 
extract [Becton Dickinson UK Ltd.] in Milli-Q® distilled water). The culture was 
centrifuged at 8000 x g for 30 minutes at 4°C (Harrier 18/80, Sanyo, Loughborough, UK) 
and the pellet resuspended in 5 M guanidine hydrochloride in 50 mM Tris-HCl pH7.2. 
The bacteria were incubated at 20°C for 2 hours with shaking, and then centrifuged at 
6000 x g for 10 minutes at 4°C. The supematent was removed and dialysed against 4 
litres of 50 mM Tris-HCl pH7.5, overnight at 4°C. S-layer self-assembly products were 
sedimented by centrifugation at 6000 x g for 30 minutes at 4°C. Soluble S-layer proteins 
were concentrated by ultrafiltration and filtered through a 0.45 pm syringe filter 
(Sartorius). The S-layer proteins were further purified on a HiLoad 16/60 Superdex 200 
column (Amersham, Little Chalfont, Buckinghamshire, UK) with an AKTA FPLC 
system (Amersham). The purity of the S-layer proteins were assessed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and the protein concentration 
determined by bicinchoninic acid protein assay (BSA, supplied by Pierce, distributed 
though Perbio Science UK, Northumberland, UK.).
5.2.2.3 Bacillus spore preparations
Spore preparations of Bacillus anthracis UM23CL2, Bacillus brevis and Bacillus cereus 
(NCTC 9946 and NCTC 11145) were a gift from T. Love, Detection Department, Dstl 
Porton Down. The production method is supplied here for reference. LB broth, 50 ml, (10 
g/1 Difco Bacto tryptone [Becton Dickinson UK Ltd.], 5 g/1 Difco Bacto yeast extract 
[Becton Dickinson UK Ltd.], 10 g/1 NaCl) was inoculated with a single bacterial colony 
and incubated for 6  hours at 37°C. B. anthracis spores were grown in new sporulation
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media (25 g/1 Difco Bacto yeast extract [Becton Dickinson UK Ltd.], 3 g/1 tryptone 
[Oxoid], 6  g/1 bacteriological peptone [Oxoid], 3 g/1 yeast extract [Oxoid], 1.5 g/1 Lab 
Lemco powder [Oxoid] and 1 ml/1 of a 0.1%[w/v] solution of MnCl2 .4 H2 0 ). Other 
Bacillus species were grown in isolation agar ( 6  g/1 nutrient broth No. 2 [Oxoid], 0.3 g/1 
MnS0 4 .H2 0 , 0.25 g/1 KH2PO4  and 12 g/1 technical agar No. 3 [Oxoid]). Vent capped 150 
ml tissue culture flasks (Coming, distributed through Sigma-Aldrich Company Ltd.) 
containing 75 ml of either new sporulation media or isolation agar were inoculated with 
between 2.5 ml to 5 ml of the 6  hour bacterial culture and incubated at 37°C until the 
culture contained at least 95% phase bright spores, monitored by phase contrast 
microscopy. The spores were recovered by resuspension in 15 ml ice-cold sterile distilled 
water (Gibco) and harvested by centrifugation at 10000 x g for 10 minutes at 4°C (Harrier 
18/80, Sanyo). The pellet was resuspended in ice-cold sterile distilled water.
5.2.2.4 Washing spores
This procedure was performed by T. Love and the method is supplied for reference. 
Spores were washed by centrifugation at 10000 x g for 10 minutes at 4°C (Harrier 18/80, 
Sanyo). The supematent was discarded and the spores resuspended in ice-cold sterile 
distilled water. This was repeated 10 times to remove vegetative cells and debris. Spore 
samples were either sonicated or purified further with Urografin 370 before sonication 
with a standard probe sonicator.
5.2.2.5 Urografin purification
This procedure was performed by T. Love and the method is supplied for reference. 
Washed B. anthracis UM23CL2 spores were purified using Urografin 370 (Schering 
Health Care Ltd., West Sussex, UK). 20 ml of 50% (w/v) Urografin in distilled water was 
placed in a centrifuge tube. 2 ml of 20% (w/v) Urografin 370 was gently layered on top 
and 5ml of the spore suspension was then added. The spores were centrifuged at 11000 
rpm for 30 minutes at 4°C (Harrier 18/80, Sanyo). The spores were then washed three 
times as described with ice-cold sterile distilled water.
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5.2.2.6 Sonication of spores with a standard probe sonicator
This procedure was performed by T. Love and the method is supplied for reference. The 
spore sonication was performed with Misonix XL2020 ultrasonic liquid processor 
(Misonix Inc., New York, USA). This system provided a 550 W output with a 20 kHz 
convertor and 1/2" tapped horn. A 3.2 mm microtip probe was used. The spores (5ml at 
109 spores / ml) were sonicated for a total of 7 minutes, with 1 minute pulses at 40% 
amplitude. The spores were incubated on ice between sonication pulses.
5.2.2.7 Biotinylation of rabbit anti-F. tularensis adenylate kinase
A vial containing 5.8 pmol of dinitrophenyl-biotin (Molecular Devices, Wokingham, 
Berkshire, UK) was reconstituted with 1 ml of dimethylformamide (DMF). The biotin 
was added to a 1 mg/ml solution of rabbit anti-F tularensis adenylate kinase (see Chapter 
4) in PBS at a molar coupling ratio of 15:1 biotin:antibody. The solution was incubated 
for 2 hours at room temperature in the dark. The coupling reaction was split into 1 ml 
aliquots to avoid local concentration of DMF when the biotin is added to the antibody, 
which can lead to protein denaturation and precipitation (H. Burnell, personal 
communication). Labelled antibody was recovered on PD-10 columns (Amersham 
Biosciences UK Limited, Buckinhamshire, UK). The PD-10 column was equilibrated 
with 6 volumes of 5 ml PBS and 1 ml labelled antibody was loaded. A further 1 ml of 
PBS was loaded onto the column once the sample had entered the matrix. The antibody 
was recovered with 3 ml of PBS. Three fractions were collected in eppendorf tubes; the 
first of 1.1 ml, the second of 1.6 ml and the third was the remaining volume. Most of the 
antibody was found in the second fraction. The concentration of the recovered antibody 
and the molar incorporation ratio of the biotin can be calculated based on optical density 
measurements at 280 nm and 362 nm (Threshold® System Operator’s manual, Molecular 
Devices. 1990). Labelled antibody was stored at -80°C to avoid degradation.
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The above method was also used for the rabbit anti-HSP60 polyclonal antibodies. Trials 
of 5:1, 10:1, 15:1 and 20:1 (biotin : antibody) molar coupling ratios were completed to 
identify the ratio that gave the best balance between incorporation of biotin and recovery 
of the antibody.
5.2.2.8 Electrospray mass spectrometer (ESMS) analysis
All ESMS sample analysis and molecular weight determination was performed by the 
Biological Mass Spectrometry group at Dstl Porton Down. The mass spectrometer 
methods are described in Section 22.1.2.
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5.3 Results
5.3.1 Adenylate kinase immunopurification
5.3.1.1 Presence of adenylate kinase in bacterial lysates
The presence of accessible adenylate kinase (AdK) in the bacterial lysates was assessed 
by SDS-PAGE and Western blot (Figure 5.1). The Western blot would also confirm if the 
AKFT1 and AKYP3 monoclonal antibodies (Chapter 4) recognised AdK from a range of 
bacterial lysates. The lysates were loaded undiluted to present as much AdK as possible 
in the blot. The proteins within each lysate were separated on 4-12% Bis-Tris NuPAGE 
gel ran in MES buffer and transferred to a nitrocellulose membrane. The blots were 
probed with the rabbit polyclonal (pAb) anti-T. pestis AdK and monoclonal antibodies 
(mAbs) AKFT1 and AKYP3. When the blot was probed with the rabbit pAb, bands at 25 
kDa were visible in the lysates of E. coli, Y. enterocolitica, Y. pseudotuberculosis and S. 
typhimurium and at 50 kDa in the S. aureus lysate. No bands were visible in the P. 
agglomerans lysate. Both mAbs showed similar results, with single bands at 
approximately 25 kDa visible in the E. coli, Y. enterocolitica and Y. pseudotuberculosis 
lysates. No bands were visible in the P. agglomerans, S. aureus or S. typhimurium lysates 
when probed with AKFT1 or AKYP3.
5.3.1.2 Adenylate kinase monoclonal antibody elution buffer screens
Potential elution buffers for the AdK mAbs were screened by capture enzyme-linked 
immunosorbent assay (ELISA), shown in Figure 5.2. Acidic pH buffers caused a 
reduction in the ELISA response in this format for both AdK mAbs. The assay signal was 
also reduced when exposed to 1% (w/v) sodium dodecyl sulphate (SDS). Both AKFT1 
and AKYP3 were tested against both recombinant AdK proteins from Y. pestis (AdKYP) 
and F. tularensis (AdKFT) and the ELISA response for each antibody with both AdKs 























Lane 1 MW markers
Lane 2 AdKFT (1 pg)
Lane 3 AdKYP (1 pg)
Lane 4 E. coli lysate
Lane 5 Y. enterocolitica lysate
Lane 6 Y. pseudotuberculosis lysate
Lane 7 P. agglomerans lysate
Lane 8 S. aureus lysate
Lane 9 S. typhimurium lysate
c)
Figure 5.1 SDS-PAGE gel stained with colloidal blue (a) of bacterial lysates assessed by Western 
blot with anti-adenylate kinase (AdK) antibodies.
Samples were run on 4-12% Bis-Tris Novex® gels in MES buffer. 25 pi of each lysate was added to 12.5 
pi loading buffer, 5 ul 500 mM dithiothreitol (DTT) and 7.5 pi water. The positive controls were 1 pg of 
recombinant AdK proteins from F. tularensis (AdKFT) and Y. pestis (AdKYP). Samples were incubated at 
95°C for 5 minutes and 10 pi of the reduced sample was loaded per well. The molecular weight (MW) 
marker was 5 pi of SeeBlue® Plus2 (Invitrogen), or MagicMark™ (Invitrogen) on the gels that were ran 
for Western blots. Three gels were blotted onto nitrocellulose membranes and probed with 20 ml of the 
following antibodies at 10 pg/ml; (b) rabbit anti-AdKYP, (c) AKFT1 and (d) AKYP3. Anti-mouse HRP 
(DAKO) and anti-rabbit HRP (Bio-Rad) conjugates were used as the reporting antibodies and the blots 
were developed with ECL reagents, with 60 second exposure times for the monoclonal antibodies and a 2 







Buffer 1 10 mM sodium phosphate pH7.5 7
2 Water 8
3 100 mM citric acid pH2.7 9
4 100 mM citric acid/Tris 10
5 100 mM glycine pH2.0 11
6 10 mM formic acid 12
3 M urea pH2.0 
3 M urea pH8.0 
PBS + 1% (w/v) SDS 
PBS + 0.05% (v/v) Tween 20 
20% (w/v) PEG 4000 
5 M NaCl pH7.5
Figure 5.2 Capture ELISA elution buffer screen of anti-adenylate kinase (AdK) monoclonal 
antibodies (a) AKFT1 and (b) AKYP3.
A 96-well microtitre plate was coated with either AKFT1 or AKYP3 at 10 pg/ml, 100 pi per 
well. Recombinant AdK from both Y. pestis (AdKYP) and F. tularensis (AdKFT) was applied at 
plate at 1 pg/ml. After unbound protein was washed off the plate, 100 pi of a potential elution 
buffer was added to each well. The plate was incubated for 10 minutes at 20°C, before the plate 
was washed. A rabbit anti-AdK antibody was used as the detection antibody and the reporting 
antibody was an anti-rabbit HRP conjugate (Bio-Rad). Each assay was duplicated on the 
microtitre plate and error bars calculated by standard deviation.
5.3.1.3 Recombinant adenylate kinase purifications on a polyclonal antibody column
While generating anti-AdK monoclonal cell lines, both rabbit pAbs raised against 
AdKYP and AdKFT were assessed as immunoaffinity ligands on 1 ml HiTrap™ 
columns. These experiments were completed before the purification methods, elution 
buffer screening method and analysis of protein content of each purification fraction by 
SDS-PAGE and Western blot had been finalized. To allow analysis of the AdK content 
of the fractions by capture ELISA, the rabbit anti-AdKFT pAb was biotinylated for use as 
a detection ligand. This was because the rabbit anti-AdKFT pAb also had to be used as 
the capture ligand, meaning an anti-rabbit IgG HRP conjugate could not be used as the 
reporting enzyme conjugate. The molar incorporation ratio of the biotinylation reaction 
was 4:1 (biotin : antibody) and the recovery from an initial antibody concentration of 1 
mg/ml was 0.48 mg/ml.
The purification trials using the rabbit anti-AdKFT pAb as the capture ligand are 
described here. A pAb immunoaffinity column was made by immobilising 4 mg of rabbit 
anti-AdKFT pAb to a 1 ml NHS-activated HiTrap™ column with 96% coupling 
efficiency. An acidic buffer, 100 mM glycine pH2.0, had previously shown to be 
effective as an elution buffer in MS2 bacteriophage purifications on a rabbit anti-MS2 
pAb column (data not shown) was selected as the initial elution buffer. The 5 ml wash 
AKTAprime programs were used (Chapter 2, Table 2.2). A 1 ml sample of 10 pg/ml 
AdKFT was loaded onto the rabbit anti-AdKFT column. The AdKFT content of the 
fractions was assessed by capture ELISA (Figure 5.3a). The AdKFT purification run was 
followed by three consecutive blank runs, all assessed by capture ELISA shown in Figure 
5.3b. AdK was seen in the wash volume (fractions 5-13) and was still leaching from the 
column when the elution buffer reached the column. The majority of the elution peak was 
in fractions 14 and 15, and the ELISA response fell to baseline by fraction 19. Three 
blank runs using the same method followed and were assessed by ELISA (Figure 5.3b).
In the first blank run, AdKFT was detected in both fractions 14 and 15, and only in 
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Figure 5.3 Purification of recombinant F. tularensis adenylate kinase (AdKFT) on a rabbit 
anti-AdKFT polyclonal antibody column, followed by three consecutive blank runs.
A 1 ml sample of 10 pg/ml solution of AdKFT in 20 mM sodium phosphate pH7.5 was loaded 
with a 5 ml sample loop onto a 4 mg rabbit anti-AdKFT polyclonal antibody (pAb) column. The 
wash/load buffer was 20 mM sodium phosphate pH7.5 and the elution buffer was 100 mM 
glycine pH 2.0. The purification was controlled by the 5 ml wash AKTAprime programs (Chapter 
2, Table 2.2). The flow rate was 1 ml/min and 0.5 ml fractions were collected. Elution fractions 
were collected in tubes containing 50 pi 1 M Tris-HCl pH8.5. Samples were assayed for AdKFT 
content by capture ELISA, shown in (a). Three subsequent blanks runs were completed and 
assessed by capture ELISA, shown in (b).
Microtitre plates were coated with rabbit anti-AdKFT at 10 pg/ml in PBS. 100 pi samples from 
each fraction were applied. A biotinylated rabbit anti-AdKFT pAb was used as the detection 
antibody while streptavidin-peroxidase was used as the reporting enzyme. Each assay was 
duplicated on the microtitre plate and error bars calculated by standard deviation.
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indicating AdKFT was being removed from the column.
Similar results were observed when AdKYP was loaded onto the column. A 4 mg rabbit 
anti-AdKYP 1 ml Hi-Trap™ column was also made as previously described. Purification 
experiments with AdKFT and AdKYP gave similar results on this column as with the 
rabbit anti-AdKFT column (data not shown).
Both rabbit anti-AdKFT and AdKYP columns were used in purification runs when 
connected on-line with the ESMS. A modification of the 5 ml wash AKTAprime method 
(Chapter 2, Table 2.2) was made so that a 2 ml volume (fractions 14-17) was injected into 
the holding loop. Each sample contained 10 pg AdK. Each rabbit pAb column was used 
in purification runs with both AdKFT and AdKYP. A weak signal was seen with the 
AdKFT purification on the anti-AdKFT polyclonal column. The molecular weight (MW) 
measured matched that previously recorded for the AdKFT protein (data not shown). No 
protein was detected with the AdKYP purification on the rabbit anti-AdKFT column. 
There was a technical problem with the ESMS with the AdKYP purification on the rabbit 
anti-AdKYP column, and no protein was detected with the AdKFT purification on the 
rabbit anti-AdKYP column.
In these experiments 100 mM glycine pH2.0 was used as the elution buffer, but failed to 
remove all of the captured AdK. More stringent elution buffers (3M urea pH8.0 and 
pH2.0) were assessed to see whether they would be more effective. This proved to be the 
case; however the same characteristic of retained antigen on each column was still seen 
(data not shown).
5.3.2 Heat shock protein 60 immunopurification
5.3.2.1 Presence of heat shock protein 60 in bacterial lysate samples
The presence of accessible heat shock protein (HSP60) in the bacterial lysates was 
assessed by SDS-PAGE and Western blot (Figure 5.4). The Western blot would also
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Figure 5.4 SDS-PAGE (a) of bacterial lysates assessed by Western blot with anti-heat shock 
protein 60 (HSP60) monoclonal antibodies.
Samples were run on 4-12% Bis-Tris Novex® gels in MES buffer. 25 pi of each lysate was added 
to 12.5 pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive control was 1 pg of 
recombinant E. coli HSP60. Samples were incubated at 95°C for 5 minutes and 10 pi of the 
reduced sample was loaded per well. The molecular weight (MW) marker was 5pl of SeeBlue® 
Plus2 (Invitrogen) or MagicMark™ (Invitrogen) on the gels that were run for Western blot. Two 
gels were blotted onto nitrocellulose membranes and probed with 20 ml of the following 
antibodies at 10 pg/ml; (b) HFT2 and (c) commercial anti-C. trachomatis HSP60 antibody. Anti­
mouse HRP (DAKO) and anti-rabbit HRP (Bio-Rad) conjugates were used as the reporting 












confirm if HFT2 and the commercial anti-C. trachomatis HSP60 mAb recognised HSP60 
from lysates from a range of bacterial species. The proteins within each lysate were 
separated on 4-12% Bis-Tris NuPAGE gel run in MES buffer and transferred to a 
nitrocellulose membrane. Recombinant E. coli HSP60 was used as a positive control. The 
blots were probed with the HFT2 and commercial anti C. trachomatis HSP60 mAb. Both 
antibodies recognised proteins at approximately 60 kDa in the E. coli, Y. enterocolitica,
Y. pseudotuberculosis, P. agglomerans and S. typhimurium lysates and at 50 kDa in the
S. aureus lysate. Smaller molecular weight proteins of approximately 25 kDa and below 
20 kDa were recognised by HFT2 in the Y. enterocolitica, Y. pseudotuberculosis and S. 
typhimurium lysates, and at approximately 80 kDa in the S. aureus lysate. These proteins 
were not seen on the commercial anti-C. trachomatis HSP60 antibody blot.
5.3.2.2 HSP60 antibody elution buffer screens
An effective elution buffer for the commercial anti-C. trachomatis HSP60 mAb was 
identified through purifications of recombinant E. coli HSP60 assessed directly by the 
ESMS, as antibodies were not available to use as a detection ligand in a capture ELISA at 
this time. These purifications are described in Section 5.3.2.3.
Potential elution buffers for the HFT2 antibody were screened by capture ELISA (Figure 
5.5). Forty-eight buffers were screened, spread over two 96-well microtitre plates. A 
selection of buffers are shown here, but the information can only be used for indication as 
ELISA assays on two different plates cannot be directly compared due to variations in the 
assay response. The concentration of recombinant HSP60 used in the ELISA had to be 
reduced to 40 ng/ml from 1 pg/ml to allow any disruption of the assay by the elution 
buffers to be seen. The greatest disruption to the assay was caused by alkaline buffers, 
KOH or NaOH and the detergent SDS. Acidic buffers and urea also disrupted the assay to 
a lesser extent.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Elution buffer
1 PBS + 1% (w/v) SDS 12 PBS + 0.05% (v/v) Tween 20
2 3 M urea pH2.0 13 Water
3 1 M ammonium sulphate 14 3 M ammonium sulphate
4 lOmMHCl 15 10 mM KOH
5 50 mM HC1 16 50 mM KOH
6 100 mM citric acid pH2.0 17 200 mM KOH
7 100 mM citric acid pH3.0 18 PBS + 1% (w/v) milk powder
8 100 mM citric acid pH4.0 19 1 M guanidine + 3 M urea
9 1 M guanidine 20 1 mMNaOH
10 3 M urea 21 10 mM NaOH
11 PBS 22 50 mM NaOH
Figure 5.5 Capture ELISA elution buffer screen of anti-heat shock protein 60 (HSP60) 
monoclonal antibody HFT2.
A 96-well microtitre plate was coated with HFT2 at 10 pg/ml, 100 pi per well. Recombinant E. 
coli HSP60 was applied at plate at 40 ng/ml, 100 pi per well. After unbound protein was washed 
off the plate, 100 pi of a potential elution buffer was added to each well. The plate was incubated 
for 10 minutes at 20°C, before the plate was washed. Rabbit anti-is. coli HSP60 was used as the 
detection antibody and the reporting antibody was an anti-rabbit HRP conjugate (Bio-Rad). Each 
assay was duplicated on the microtitre plate and error bars calculated by standard deviation.
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5.3.2.3 HSP60 purification with the anti C. trachomatis-HSP60 mAb
Initial HSP60 purifications used the commercial anti-C trachomatis HSP60 mAb, 
supplied as diluted ascities, to allow immunopurification experiments to begin while 
polyclonal and monoclonal antibodies were being produced against HSP60. A capture 
ELISA indicated that this antibody is a potential cross-reactive immunoaffinity ligand for 
Gram negative bacterial HSP60 (Chapter 4, Figure 4.19). These experiments were 
performed prior to the alpha toxin characterisation work and contributed to the 
development of the purification methods. Ten aliquots of 100 pi ascitic fluid were 
dialyzed into coupling buffer prior to the production of an immunoaffinity column. The 
total protein concentration after dialysis was estimated by spectroscopy as 8.5 mg/ml, in a
1.3 ml final volume. The dialyzed ascitic fluid was bound to a 1 ml NHS-activated 
HiTrap™ column with 85% efficiency. Later purifications of IgG from the ascitic fluid 
with a protein G column indicated the concentration of IgG in the ascitic fluid was 0.46 
mg/ml. Assuming the coupling efficiency of IgG is similar to that of the contaminating 
proteins and no loss of IgG when the ascitic fluid was dialyzed in a 10 kDa MW cut-off 
cassette, this indicates the antibody content of the column was 0.39mg together with 9mg 
of contaminating protein from the ascitic fluid.
The first purification experiments investigated the capture and elution of recombinant E. 
coli HSP60. At the time of these experiments, anti-HSP60 antibodies were not available 
to allow screening for effective elution buffers by capture ELISA. The quickest method 
to identify an effective elution buffer for the anti C. trachomatis HSP60 antibody was to 
test elution samples for the presence of HSP60 with the ESMS. The elution fractions of 
the purifications were loaded through the interface to mimic an on-line purification. 
Elution buffers were tested in order of increasing stringency. Each purification used 1 pg 
of recombinant E. coli HSP60 in a 1 ml volume loaded through the 5 ml sample loop.
The AKTAprime programs described in table 2.2 in the General Materials and Methods 
were used. An acidic buffer, lOOmM glycine pH2.0, was assessed but no protein was 
detected in the elution fraction. Two urea buffers, 3M urea pH8.0 and pH2.0 were tested, 
and recombinant HSP60 was detected by the ESMS (data not shown).
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A S. typhimurium lysate had been produced for use in purification trials. The bacteria 
were killed by heat shock and chemically disrupted to produce the lysate. The anti C. 
trachomatis HSP60 antibody column was used to attempt to purify HSP60 from this 
lysate. The total protein concentration of the S. typhimurium lysate was estimated at 200 
pg/ml by BCA. A sample of 1 pg of lysate in a 1ml volume was loaded through the 5ml 
sample loop onto the anti-C trachomatis HSP60 mAb column. The purification was 
controlled by the AKTAprime programs described in Chapter 2, Table 2.2. The 
purification was assessed by capture ELISA. Rabbit anti-2s. coli HSP60 had to be used as 
both capture and detection antibodies, requiring the detection antibody to be biotinylated 
as an anti-species antibody HRP conjugate could not be used. A range of small scale 
biotinylation coupling experiments using different ratios of biotin to antibody was 
completed to identify the most efficient coupling ratio. A molar coupling ratio of 10:1 
(biotin : antibody) gave the best balance between biotin incorporation and antibody 
recovery (results not shown), and the coupling reaction was scaled up to provide the 
biotinylated polyclonal antibody. The ELISA (Figure 5.6) indicates a high proportion of 
HSP60 in the wash that was not captured on the column. HSP60 was eluted in fractions 
14 and 15.
The S. typhimurium lysate purification was repeated with the AKTAprime system 
connected to the ESMS via the interface. Several lysate purification experiments were 
completed but a protein of approximate 60 kDa was not detected by the ESMS in the 
elution fractions, irrespective of increased lysate loading or increased column wash 
volumes to attempt to reduce non-specific binding. Recombinant E. coli HSP60 was 



















Figure 5.6 S.typhimurium heat shock protein 60 (HSP60) purification from a S. typhimurium 
lysate on an anti-C. trachomatis HSP60 monoclonal antibody column assessed by capture ELISA. 
A 1 ml sample of 1 pg S. typhimurium lysate in 20 mM sodium phosphate, pH7.5 was loaded 
with a 5 ml sample loop on the AKTAprime system. The anti-C. trachomatis HSP60 
immunoaffinity column was used; the load/wash buffer was 20 mM sodium phosphate pH7.5, 
while the elution buffer was 3 M urea pH2.0. The purification was controlled by the 5 ml wash 
AKTAprime programs (Chapter 2, Table 2.2). Elution fractions were collected in tubes 
containing 50 pi 1 M Tris-HCl, pH8.5. Fractions were assayed for HSP60 content by capture 
ELISA.
A 96-well microtitre plate was coated with rabbit anti-£. coli HSP60 at 10 pg/ml in PBS. lOOpl 
samples from each fraction were applied to the plate. Biotinylated rabbit anti-£. coli HSP60 was 
used as the detection antibody while streptavidin-peroxidase was the reporting enzyme. Each 
assay was duplicated on the microtitre plate and error bars calculated by standard deviation. The 
background signal was defined as the mean of the optical densities of the six negative control 
wells plus two standard deviations.
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5.3.2.4 Assessment of non-specific binding to a 1ml HiTrap™ column
The on-line ESMS experiments with the S. typhimurium lysate indicated that the non­
specific binding of proteins to the immunoaffinity column to be higher than anticipated.
A purification of recombinant E. coli HSP60 on the anti-C trachomatis HSP60 mAb 
column was compared to an equivalent loading of HSP60 onto a 1 mg anti-ovalbumin 
mAb (8C9) column to gauge the extent of non-specific binding to an antibody column. 
The wash volume was increased from 5 ml to 15 ml (Chapter 2, Table 2.3). Blank runs on 
each column were assessed for HSP60 with a capture ELISA before the recombinant 
HSP60 was loaded, which indicated there was no HSP60 contamination from previous 
purifications. The anti-ovalbumin mAb did not recognise the recombinant E. coli HSP60 
in an indirect ELISA (data not shown). The presence of HSP60 in the fractions from the 
purification runs on both columns was assessed by capture ELISA (Figure 5.7). The 
quantity of HSP60 eluted from both columns in the expected elution peak between 
volume points 17 ml -18 ml was similar. There were two main differences between the 
HSP60 loadings on the two columns. The purification on the specific antibody column 
had a secondary elution peak that was not present in the HSP60 loading onto the non­
specific antibody column, while the wash fractions of the non-specific column contained 
notable quantities of HSP60 which was not apparent in the wash of the specific antibody 
column. The second elution peak was seen at the interface between the elution buffer and 
the wash buffer (between volume points 23.5 ml - 25 ml) of the purification on the anti C. 
trachomatis HSP60 antibody column.
5.3.2.5 HSP60 purifications from bacterial lysates with the HFT2 monoclonal 
antibody
HFT2 was a monoclonal antibody that was raised from a mouse immunised with 
recombinant F. tularensis HSP60 (Chapter 4). This antibody was shown to recognise 
recombinant HSP60s from E. coli, B. pseudomallei and F. tularensis in indirect and 
capture ELIS As (Chapter 4, Figure 4.19) and HSP60 from several bacterial lysates in a 
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Figure 5.7 Comparison between a recombinant E. coli HSP60 purification on (a) the anti-C. 
trachomatis HSP60 antibody column and (b) an anti-ovalbumin monoclonal antibody column, assessed by 
capture ELISA.
A 1 ml sample of 1 pg recombinant E. coli HSP60 in 20 mM sodium phosphate pH7.5 was loaded with a 5 
ml sample loop on the AKTAprime system. The anti-C. trachomatis HSP60 and 3 mg 8C9 anti-ovalbumin 
immunoaffinity columns were used; the load/wash buffer was 20 mM sodium phosphate, pH7.5, while the 
elution buffer was 3 M urea pH2.0. The purification was controlled by the AKTAprime programs detailed 
in Table 2.3, Chapter 2. These purifications had an increased wash step of a total volume of 15 ml 
compared with 5 ml of previous purifications. Elution fractions were collected in tubes containing 50 pi 1 
M Tris-HCl, pH8.5. Fractions were assayed for HSP60 content by capture ELISA.
A 96-well microtitre plate was coated with rabbit anti-£. coli HSP60 at 10 pg/ml in PBS. lOOpl samples 
from each fraction were applied to the plate. Biotinylated rabbit-anti E. coli HSP60 was used as the 
detection antibody while streptavidin-peroxidase was the reporting enzyme. Each assay was duplicated on 
the microtitre plate and error bars calculated by standard deviation. The background signal was defined as 





capture ELISA screen (Figure 5.5). A stock of 60 mg of HFT2 was purified on a 5 ml 
protein G column from several Intergra™ flask taps.
Bacterial lysates were produced from E. coli, Y. entercolitica, Y. pseudotuberculosis, P. 
agglomerans and S. aureus. The efficiency of the cell lysis was estimated at between 10- 
20% by visual inspection. This made it difficult to relate the initial cell count to the total 
protein concentration measured by BCA as there was variation in the protein 
concentration of each bacterial batch. An earlier S. typhimurium bacterial lysate had been 
produced by a different method where the bacteria were killed by incubation at 60°C and 
chemically lysed.
The aim of this section was to measure the molecular weight (MW) of the HSP60 from at 
least two bacterial lysates on the ESMS to provide proof of principle that the MW of the 
HSP60 could be used to distinguish between and identify bacterial species. Each 
purification was completed off-line to allow SDS-PAGE gel and Western blot analysis. 
Five 1 mg HFT2 HiTrap™ columns were made with a coupling efficiency in the range of 
88% to 93%. The HSP60 purifications from each bacterial species used a separate 
column to avoid the risk of contamination from proteins from different species. 
Purifications were completed with lysates from E. coli JM109, P. agglomerans, Y. 
pseudotuberculosis, S. aureus and Y. enterocolitica. As the objective was to detect 
HSP60 and sensitivity was not an issue at that time, the samples consisted of undiluted 
crude lysate mixed with an equal volume of 20 mM sodium phosphate, pH7.5. The 
standard off-line AKTAprime methods (15 ml wash) were used in all the purifications 
(Chapter 2, Table 2.3). The elution buffer was 10 mM potassium hydroxide. The SDS- 
PAGE and Western blots are shown for the E. coli (Figure 5.8) and P. agglomerans 
(Figure 5.9) purifications on 1 mg HFT2 columns.
A large quantity (7.2 mg) of the E. coli lysate was used in the first purification to attempt 
to ensure that there was sufficient HSP60 in the samples to be detected by SDS-PAGE 
and Western blot (Figure 5.8). Only 1.4% of the protein content of each 1 ml fraction 
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Figure 5.8 HSP60 purification from a lysate of E. coli on a 1 mg HFT2 column assessed by 
(a) SDS-PAGE and (b) Western blot.
A 3 ml sample of a lysate of E. coli JM109 (7.2 mg of total protein) in 20 mM sodium phosphate, 
pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 1 mg HFT2 
immunoaffinity column was used, the wash/load buffer was 20 mM sodium phosphate, pH7.5 and 
the elution buffer was 10 mM potassium hydroxide. The 15 ml wash off-line AKTAprime 
programs were used (Chapter 2. Table 2.3). Samples were taken from selected fractions and 
analysed by SDS-PAGE.
Samples were run on two 10-20% Tris-glycine gels. 40 pi of each fraction was added to 40 pi 
loading buffer and 8 pi of 500 mM DTT. The positive control was a sample of the loaded lysate. 
Samples were incubated at 95°C for 5 minutes and 30pl of the reduced sample was loaded per 
well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or 
MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel was blotted onto a 
nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP 
conjugate (DAKO) was used as the reporting antibody and the blot were developed with ECL 
reagents, with a 3 s exposure time.
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available for analysis by ESMS, ignoring non-specific protein adsorption to the plastic of 
the collection tube. Most of the protein from the E. coli lysate washed through the 
column in fractions 2 and 3, however a weak smear could be seen in lane 5 (fraction 13) 
indicating protein was still being washed from the column after a 10ml wash volume. A 
weak band at approximately 60 kDa could also be seen in the blot from this fraction. A 
distinct band was visible at approximately 60 kDa in fractions 18 and 19. A smear of 
protein could also be seen in both lanes. The Western blot showed that most of the 
HSP60 passed through the column without being captured, but confirmed a protein at 60 
kDa in fractions 17 and 18 that was recognised by the HFT2 antibody.
However a protein of MW of approximately 60 kDa could not be detected by SDS-PAGE 
gel or the Western blot in the elution fractions from any of the purifications with the other 
bacterial lysates. The P. agglomerans purification is shown in Figure 5.9 as an example. 
The Western blots confirmed the presence of a protein of approximately 60 kDa in all of 
the bacterial lysates that were loaded onto the columns, but there was no indication that a 
60 kDa protein was either captured or eluted. A similar protein smear was visible in 
fractions 18 and 19 of each purification, similar to that seen in the E. coli purification.
5.3.2.6 HSP60 purification from a lysate of E. coli on a 5 mg HFT2 column
As the amount of HSP60 seen in the elution fractions was low compared to the quantity 
of HSP60 visible in the flow-through fractions, I decided to increase the density of the 
ligand in the column. Five 5 mg HFT2 HiTrap columns were made with coupling 
efficiencies in the range of 85-90% of an initial 5.5 mg of HFT2. Again, one column was 
made for each bacterial lysate. A summary of the bacterial purifications on the 5 mg 
HFT2 columns and ESMS analysis is shown in Table 5.1.
The SDS-PAGE and Western blot of a HSP60 purification from E. coli on the 5 mg 
HFT2 column is shown in Figure 5.10. Most of the lysate was washed through the 
column in the first few fractions and minimal protein could be seen in fractions 13 and 17 




















































Figure 5.9 HSP60 purification from a lysate of P. agglomerans on a 1 mg HFT2 column 
assessed by (a) SDS-PAGE and (b) Western blot.
A 3 ml sample of P. agglomerans lysate (3.3 mg of total protein) in 20 mM sodium phosphate, 
pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 1 mg HFT2 
immunoaffinity column was used, the wash/load buffer was 20 mM sodium phosphate, pH7.5 and 
the elution buffer was 10 mM potassium hydroxide. The standard AKTAprime programs for an 
off-line purification with a 15 ml wash were used (Chapter 2, Table 2.3). Samples were taken 
from selected fractions and analysed by SDS-PAGE.
Samples were run on two 10-20% Tris-glycine gels. 40 pi of each fraction was added to 40 pi 
loading buffer and 8ul of 500 mM DTT. The positive control was a sample of the loaded lysate. 
Samples were incubated at 95°C for 5 minutes and 30 pi of the reduced sample was loaded per 
well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or 
MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel was blotted onto a 
nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP 
conjugate (DAKO) was used as the reporting antibody and the blot were developed with ECL 
reagents, with a 30 s exposure time.
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Bacterial species Molecular weight of 60 kDa protein 
measured by ESMS (Da)
E. coli (JM109) 57226.1 ±2.2
P. agglomerans (9381 Graham Brice) 57346.6 ±3.2
Y. pseudotuberculosis (32953) 57301.1 ±2.2
Y. enterocolitica (YeOc) Not detected
S. aureus (3750 Mrs. Fox) Not detected
S. typhimurium (SL 1344) Not detected
Table 5.1 Summary of the molecular weights (MW) of 60 kDa proteins detected with the 
ESMS from elution fractions of bacterial lysate purifications.
The isolation of HSP60 was attempted from lysate samples of six bacterial species with 5 mg 
HFT2 mAb columns. Elution fractions were assessed with the ESMS. Proteins of approximately 
60 kDa were detected from three lysate samples. Of these, the lysates of P. agglomerans and Y 
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Figure 5.10 HSP60 purification from a lysate of E. coli on a 5 mg HFT2 column assessed by 
(a) SDS-PAGE and (b) Western blot.
A 1 ml sample of a lysate of E. coli JM109 (2.4 mg of total protein) in 20 mM sodium phosphate, 
pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 5 mg HFT2 
immunoaffinity column was used, the wash/load buffer was 20 mM sodium phosphate pH7.5 and 
the elution buffer was 10 mM potassium hydroxide. The standard AKTAprime programs for an 
off-line purification with a 15 ml wash were used (Chapter 2, Table 2.3). Samples were taken 
from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 
pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive control was a sample of 
the loaded lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the reduced sample 
was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 
(Invitrogen) or MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel was 
blotted onto a nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti­
mouse HRP conjugate (DAKO) was used as the reporting antibody and the blot were developed 
with ECL reagents, with a 3 s exposure time.
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showed two distinct bands at approximately 55 kDa and 60 kDa along with notable non- 
specific binding from lysate proteins to the column. The bands at 55 kDa and 60 kDa 
were also visible in fraction 20 and 21 (lanes 9 and 10). The Western blot indicated a 
much higher proportion of the 60 kDa protein was captured by the 5 mg HFT2 column 
than the lmg HFT2 column (Figure 5.8). The blot confirmed the majority of the 60 kDa 
protein was found in fractions 18 and 19, but was also present in fractions 20 and 21. 
After samples had been taken from fractions 18 and 19 to run on gels, 8.5pi of 1 M HC1 
was added to each fraction so that the pH of the fraction was slightly acidic prior to 
analysis by ESMS. Fractions 18 and 19 were pooled and loaded into the holding loop of 
the ESMS interface for analysis by the mass spectrometer (Figure 5.11). The first peak 
seen on the total ion chromatogram consisted of two smaller proteins of MW 9225.8±0.1 
Da and 9535.2±0.0 Da. The second peak consisted of a protein of MW 57226.1±2.2 Da.
5.3.2.7 HSP60 purification from a lysate of P. agglomerans on a 5 mg HFT2 column
The SDS-PAGE and Western blot of a HSP60 purification from a P. agglomerans lysate 
are shown in Figure 5.12. A similar pattern was seen on the SDS-PAGE gel for the P. 
agglomerans lysate purification compared to the E. coli purification in that most of the 
lysate proteins passed through the column, with minimal protein apparent in fractions 13 
and 17 (lanes 5 and 6). Non-specific proteins from the lysate associated with the column 
were eluted in fractions 18 and 19 (lanes 7 and 8). A band of increased intensity 
compared to the contaminating proteins was visible in fractions 18 and 19, but this band 
was above the 62 kDa molecular weight marker. The Western blot showed three distinct 
bands at 60k Da, 25 kDa and at a low molecular weight in the P. agglomerans lysate 
(lane 2). Most of the 60 kDa protein was not captured on the column, but a band at 60 
kDa could be seen in lanes 7 and 8 (fractions 18 and 19). The three protein bands visible 
in the lysate were also present in the elution fractions but their relative proportions have 
altered. The 60 kDa band is less prominent when compared to the 25 kDa and low MW 
bands. The elution fractions 18 and 19 were pooled and analysed by ESMS, however a 
protein with a MW in the region of 60 kDa could not be distinguished above the protein 
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Figure 5.11 ESMS analysis of the elution fractions of a HSP60 purification from a lysate of 
E. coli on a 5 mg HFT2 column.
Analysis with the ESMS of elution fractions 18 and 19 from the HSP60 purification from an E. 
coli JM109 lysate on a HFT2 column (shown in Figure 5.10). The elution sample was loaded in 
0.1%(v/v) trifluoroacetic acid (TFA). The total ion chromatogram is shown in (a), while the 
deconvoluted data is shown in (b).
150
a)
Lane 1 MW markers
Lane 2 P. agglomerans 
^  f lysate






Lane 4 Fraction 3 
(Wash)
  v H  Lane 5 Fraction 13
28 ■  (Wash)
    - Lane 6 Fraction 17
(Elution)
14 ‘ ’ Lane 7 Fraction 18
(Elution)
6 H P  Wm  Lane 8 Fraction 19
(Elution)
1 2 3 4 5 6 7 8 9  10 Lane 9 Fraction 20
b) (Elution)









Figure 5.12 HSP60 purification from a lysate of P. agglomerans on a 5 mg HFT2 column 
assessed by (a) SDS-PAGE and (b) Western blot.
A 1 ml sample of P. agglomerans lysate (1.1 mg of total protein after dialysis in a 50 kDa 
MWCO membrane) in 20 mM sodium phosphate, pH7.5 was loaded into a 5 ml sample loop on 
the AKTAprime system. A 5 mg HFT2 immunoaffinity column was used, the wash/load buffer 
was 20 mM sodium phosphate, pH7.5 and the elution buffer was 10 mM potassium hydroxide. 
The standard AKTAprime programs for an off-line purification were used (Chapter 2, Table 2.3). 
Samples were taken from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 
pi loading buffer, 5 pi of 500mM DTT and 7.5 pi water. The positive control was a sample of the 
loaded lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the reduced sample was 
loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or 
MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel was blotted onto a 
nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP 
conjugate (DAKO) was used as the reporting antibody and the blot were developed with ECL 
reagents, with a 30 s exposure time.
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As smaller MW proteins seemed to be purified from the lysate in preference to the 60 
kDa protein, the P. agglomerans bacterial lysate was dialysed with a 50 kDa MW cut-off 
(MWCO) membrane to remove or reduce the quantity of small MW proteins present. The 
SDS-PAGE gel and Western blot of the dialysed lysate of P. agglomerans HSP60 
purification are shown in Figure 5.13. The amount of protein on the SDS-PAGE gel was 
lower than previously and it is difficult to gauge whether there was an enhancement of 
the protein band visible at 60 kDa in the elution fractions (lanes 8 and 9). The Western 
blot showed that the low MW proteins that were visible in the crude lysate (lane 2) were 
not seen in the dialysed lysate, and the 60 kDa protein was still present in the dialysed 
lysate. The 60 kDa protein was present in the flow through fraction (lane 5), indicating 
that not all the 60 kDa protein present was retained on the column. A band at 
approximately 60kDa was present in fractions 18 and 19 (lanes 8 and 9). Bands were not 
apparent at 25kDa or at low MW in the elution fractions. Fractions 18 and 19 were 
pooled and loaded into the ESMS interface holding loop for analysis by mass 
spectroscopy.
The ESMS analysis of the pooled elution fractions 18 and 19 from the dialysed lysate of 
P. agglomerans HSP60 purification is shown in Figure 5.14. The total ion chromatogram 
contained two main peaks, the first containing proteins of MW 9507±0.2 Da,
17417.0±0.9 Da and 18092±0.5 Da. The second peak at 7.76 minutes contained a protein 
of MW 57346.6±3.2Da. As the MW of a 60 kDa protein from P. agglomerans was 
successfully measured by the ESMS, the lysates from Y. pseudotuberculosis, Y. 
enterocolitica, S. aureus and S. typhimurium were also dialysed with a 50 kDa MWCO 
membrane as the presence of the 25 kDa and low MW proteins seemed likely to interfere 
with the purification of the HSP60 from lysates of these bacterial species.
The SDS-PAGE gel and Western blot from the dialysed Y. pseudotuberculosis lysate 
HSP60 purification are shown in Figure 5.15. The SDS-PAGE gel showed non-specific 
contaminating lysate proteins in fraction 18 and 19, but no obvious refinement or 
concentration of a particular protein. Dialysis in a 50 kDa MWCO membrane did not 
appear to significantly alter the amount of the smaller MW proteins in the dialysed lysate
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Figure 5.13 HSP60 purification from a dialyzed lysate of P. agglomerans on a 5 mg HFT2 
column assessed by (a) SDS-PAGE and (b) Western blot.
A 2 ml sample of dialyzed P. agglomerans lysate (1.2 mg of total protein after dialysis in a 50 
kDa MWCO membrane, then concentration in a 10 kDa MWCO Vivaspin unit) in 20 mM sodium 
phosphate pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 5 mg HFT2 
immunoaffmity column was used, the wash/load buffer was 20 mM sodium phosphate, pH7.5 and 
the elution buffer was 10 mM potassium hydroxide. The standard AKTAprime programs for an 
off-line purification were used (Chapter 2, Table 2.3). Samples were taken from selected fractions 
and analysed by SDS-PAGE.
Samples were run on two 10% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 pi 
loading buffer, 5 pi of 500mM DTT and 7.5 pi water. The positive controls were samples of the 
crude and dialyzed lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the reduced 
sample was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 
(Invitrogen) or MagicMark™ (Invitrogen) on the gel that was ran for Western blot. The gel was 
blotted onto a nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti­
mouse HRP conjugate (Bio-Rad) was used as the reporting antibody and the blot were developed 
with ECL reagents, with a 3 s exposure time.
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Figure 5.14 ESMS analysis of HSP60 purification from a lysate of P. agglomerans (dialyzed 
in a 50 kDa MWCO membrane) on a 5 mg HFT2 column.
ESMS analysis of a 1100 pi loading of the pooled elution fraction 18 and 19 of the HSP60 
purification from a dialysed P. agglomerans lysate shown in Figure 5.13. The sample was loaded 
in 0.1%(v/v) TFA. The total ion chromatogram is shown in (a), while the deconvoluted data is 
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Figure 5.15 HSP60 purification from a dialyzed lysate of Y. pseudotuberculosis on a 5 mg 
HFT2 column assessed by (a) SDS-PAGE and (b) Western blot.
A 2 ml sample of a lysate of Y. pseudotuberculosis (2.8 mg of total protein after dialysis in a 50 
kDa MWCO membrane) in 20 mM sodium phosphate, pH7.5 was loaded into a 5 ml sample loop 
on the AKTAprime system. A 5 mg HFT2 immunoaffmity column was used, the wash/load 
buffer was 20 mM sodium phosphate, pH7.5 and the elution buffer was 10 mM potassium 
hydroxide. The standard AKTAprime programs for an off-line purification were used (Chapter 2, 
Table 2.3). Samples were taken from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 
pi loading buffer, 5 pi of 500mM DTT and 7.5 pi water. The positive control was a sample of the 
loaded lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the reduced sample was 
loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or 
MagicMark™ (Invitrogen) on the gel that was ran for Western blot. The gel was blotted onto a 
nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP 
conjugate (DAKO) was used as the reporting antibody and the blot were developed with ECL 
reagents, with a 30 s exposure time.
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when compared to the crude lysate, based on the intensity of each band in the flow- 
through fraction on the SDS-PAGE gel (lane 4), although the low MW protein is reduced 
slightly. The Western blot with HFT2 of the crude lysate (lane 2) showed several bands; 
80 kDa, 60 kDa, 49 kDa, and the two bands previously seen in other bacterial lysates at 
25 kDa and at a low MW. Most of the 80 kDa protein loaded onto the column was not 
captured. All four bands were visible in the elution fraction 18 (lane 7). Fractions 18 and 
19 were analysed by the ESMS (Figure 5.16). A protein was measured in the Y. 
pseudotuberculosis of 57301.1±2.2 Da. Proteins of MW 6852.6±0.1 Da, 9267.1±0.6 Da, 
9583.0±0.3 Da, 9661.3±0.1 Da, 10298.9±0.2 Da, 10560.0±0.6 Da, 11053.8±0.8 Da, 
11216.0±0.1 Da, 13379.3±0.5 Da, 15183.9±0.8 Da, 17443.2±1.9 Da and 25696.5±2.2 Da 
were also detected by the ESMS. No protein with an approximate MW of 80 kDa was 
detected.
5.3.2.8 HSP60 purification from a lysate of Y. enterocolitica on a 5 mg HFT2 column
The SDS-PAGE gel and Western blot probed with HFT2 of the dialysed Y. enterocolitica 
lysate are shown in Figure 5.17. The SDS-PAGE gel showed a reduction in the low MW 
proteins in the lysate dialysed with a 50 kDa MWCO membrane (lane 3) compared to the 
crude Y. enterocolitica lysate (lane 2). The gel showed non-specific contaminating lysate 
proteins in fraction 18 and 19, but no obvious refinement or concentration of a particular 
protein above the background protein in each fraction. The Western blot showed that the 
HFT2 recognises three proteins in the crude Y. enterocolitica lysate (lane 2); 60 kDa, 25 
kDa and a low MW protein. Dialysis of the lysate slightly reduced the quantity of the 25 
kDa and low MW proteins (lane 3). Most of the HSP60 in the lysate sample passed 
through the HFT2 column (fractions 4 and 5). Four bands were visible in the elution 
fraction (lane 9); 60 kDa, 45 kDa, 25 kDa and the low MW proteins. The dominant 
protein band eluted from the HFT2 column was the low MW proteins. ESMS analysis of 
fractions 18 and 19 from the Y. enterocolitica HSP60 purification could not distinguish a 
protein of approximately 60 kDa above the protein background, but numerous other 
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Figure 5.16 ESMS analysis of HSP60 purification from a lysate of Y pseudotuberculosis 
dialysed on a 5 mg HFT2 column.
ESMS analysis of a 100 pi loading of the pooled elution fractions 18 and 19 of the HSP60 
purification from a dialysed lysate of Y. pseudotuberculosis shown in figure 5.15. The sample 
was loaded in 0.1% (v/v) TFA. The total ion chromatogram is shown in (a), while the 

















































Figure 5.17 HSP60 purification from a dialyzed lysate of Y. enterocolitica on a 5 mg HFT2 
column assessed by (a) SDS-PAGE and (b) Western blot.
A 2 ml sample of Y. enterocolitica lysate (10.4 mg of total protein after dialysis in a 50 kDa 
MWCO membrane) in 20 mM sodium phosphate, pH7.5 was loaded into a 5 ml sample loop on 
the AKTAprime system. A 5 mg HFT2 immunoaffmity column was used, the wash/load buffer 
was 20 mM sodium phosphate, pH7.5 and the elution buffer was 10 mM potassium hydroxide. 
The standard AKTAprime programs for an off-line purification were used (Chapter 2, Table 2.3). 
Samples were taken from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi o f each fraction was added to 12.5 
pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive controls were samples of 
the crude and dialyzed lysate. Samples were incubated at 95°C for 5 minutes on a heat block and 
20 pi of the reduced sample was loaded per well. The molecular weight (MW) marker was 5 pi of 
SeeBlue® Plus2 (Invitrogen) or MagicMark™ (Invitrogen) on the gel that was run for Western 
blot. The gel was blotted onto a nitrocellulose membrane and probed with 20 ml of HFT2 at 10 
pg/ml. An anti-mouse HRP conjugate (DAKO) was used as the reporting antibody and the blot 
were developed with ECL reagents, with a 20 s exposure time.
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5.3.2.9 HSP60 purification from a lysate of S, aureus on a 5 mg HFT2 column
The SDS-PAGE gel and Western blot probed with HFT2 of the dialysed S. aureus lysate 
are shown in Figure 5.18. The SDS-PAGE gel showed a reduction in the low MW 
proteins in the lysate dialysed with a 50 kDa MWCO membrane (lane 3) compared to the 
crude S. aureus lysate (lane 2). The gel showed non-specific contaminating lysate 
proteins in the elution fraction (lanes 8 and 9), and a concentration of a protein of 
approximately 80 kDa. The Western blot showed that the HFT2 mAb recognises three 
proteins in the crude lysate, at approximately 80 kDa, 50 kDa and 25 kDa. The protein 
band at 25 kDa is not visible in the dialysed lysate (lane 3). The flow through fraction 
(lane 5) shows a reduction in the 80 kDa protein but most of the 50 kDa protein passes 
through the column. The elution fractions 18 and 19 (lanes 8 and 9) show clearly that the 
80 kDa protein has captured and eluted from the HFT2 column. ESMS analysis of 
fractions 18 and 19 from the S. aureus HSP60 purification could not distinguish a protein 
of approximately 60 kDa or 80 kDa above the protein background, but numerous other 
proteins of upto 25 kDa MW were detected (data not shown).
5.3.2.10 HSP60 purification from a lysate of S. typhimurium on a 5 mg HFT2 
column
The SDS-PAGE gel and Western blot probed with HFT2 from a dialysed S. typhimurium 
HSP60 purification are shown in Figure 5.19. Unfortunately a staining artefact obscures a 
section of the gel but there was insufficient S. typhimurium lysate available to repeat the 
purification. The SDS-PAGE gel does show a 60 kDa band in the elution fractions 18 and 
19 (lanes 8 and 9). The Western blot shows that the HFT2 recognises a strong band at 60 
kDa in the crude lysate, with weaker bands visible at 40 kDa and 25 kDa. The 60 kDa 
protein is visible in the flow through fraction 3 (lane 5), but most of the 60 kDa protein 
has been captured by the HFT2 column and is visible in the elution fractions 18,19 and 
weakly in 20 (lanes 8, 9 and 10). A weak band at 25 kDa is also visible in fractions 18 
and 19. ESMS analysis of fractions 18 and 19 from the S. typhimurium HSP60 
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Figure 5.18 HSP60 purification from a dialyzed lysate of S. aureus on a 5 mg HFT2 column 
assessed by (a) SDS-PAGE and (b) Western blot.
A 3 ml sample of dialyzed lysate of S. aureus (1.2 mg of total protein after dialysis in a 50 kDa 
MWCO membrane) in 20 mM sodium phosphate, pH7.5 was loaded into a 5 ml sample loop on 
the AKTAprime system. A 5 mg HFT2 immunoaffmity column was used, the wash/load buffer 
was 20 mM sodium phosphate, pH7.5 and the elution buffer was 10 mM potassium hydroxide. 
The standard AKTAprime programs for an off-line purification were used (Chapter 2, Table 2.3). 
Samples were taken from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 
pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive controls were samples of 
the crude and dialyzed lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the 
reduced sample was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® 
Plus2 (Invitrogen) or MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel 
was blotted onto a nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti­
mouse HRP conjugate (DAKO) was used as the reporting antibody and the blot were developed 
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Figure 5.19 HSP60 purification from a lysate of S. typhimurium on a 5 mg HFT2 column 
assessed by (a) SDS-PAGE and (b) Western blot.
A 4 ml sample of S. typhimurium lysate (0.32 mg of total protein after dialysis in a 50 kDa 
MWCO membrane) in 20 mM sodium phosphate, pH7.5 was loaded into a 5 ml sample loop on 
the AKTAprime system. A 5 mg HFT2 immunoaffmity column was used, the wash/load buffer 
was 20 mM sodium phosphate, pH7.5 and the elution buffer was 10 mM potassium hydroxide. 
The standard AKTAprime programs for an off-line purification were used (Chapter 2, Table 2.3). 
Samples were taken from selected fractions and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi of each fraction was added to 12.5 
pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive controls were samples of 
the crude and dialyzed lysate. Samples were incubated at 95°C for 5 minutes and 20 pi of the 
reduced sample was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® 
Plus2 (Invitrogen) or MagicMark™ (Invitrogen) on the gel that was run for Western blot. The gel 
was blotted onto a nitrocellulose membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti­
mouse HRP conjugate (DAKO) was used as the reporting antibody and the blot were developed 
with ECL reagents, with a 20 s exposure time.
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background, but numerous other proteins of up to 25 kDa MW were detected (data not 
shown).
5.3.2.11 Sequence comparison between Y. pseudotuberculosis HSP60 and DNA 
binding protein HU alpha
There appeared to be a conserved epitope recognised by HFT2 between the bacterial 
species HSP60 and the 9.5 kDa proteins tentatively identified as DNA binding proteins 
HU alpha and beta. A sequence alignment between the Y. pseudotuberculosis HSP60 and 
the Y. pseudotuberculosis DNA binding protein HU alpha using EMBOSS-align with the 
Water algorithm (Smith and Waterman, 1981) is shown in Figure 5.20. There was 22.8% 
sequence identity and 39.2% similarity between the DNA binding protein HU alpha and 
the HSP60 sequence between amino acids 393 and 471.
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HSP60 393 karvedalhatraaveegwagggvaliraahaiaglkgdnedqnvgikv 442
I • : : • I I • : I * I I : • I • : • I • • I • I *  |
HU alpha 18 kvqakaalestlaaiteslkegdpvqlv gfgtfkvnhrnertg  60
HSP60 443 alramesplrqiwnageeasviankvka 471
• : I . . | | . . : . | | |









Figure 5.20 Alignment of the Y. pseudotuberculosis HSP60 and DNA binding protein HU 
alpha sequences with EMBOSS-Align.
The sequences were aligned with the EMBOSS-Align tool (Water algorithm), accessed through 
the European Bioinformatics Institute website. The matrix was Blosum62, the open gap penalty 
was 10.0 and the gap extension penalty was 0.5. An identical amino acid is indicated with " | ”, 
conserved substitutions with ": ” and semi-conserved substitutions with ”. ”.
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5.3.3 Assessment of HSP60 as potential biomarker proteins for Bacillus spores
The suitability of HSP60 as biomarker proteins for Bacillus spores was assessed. HFT2 
was used as the immunoaffmity ligand against HSP60.
5.3.3.1 Screen of sonicated spore and S-layer preparations by Western blot
Sonicated supematents from Bacillus anthracis, B. brevis and B. cereus (NCTC 9946) 
spores were screened as well as S-layer preparations from B. pumilus and both B. cereus 
(NCTC 9946) and B. cereus (NCTC 11145). The samples were separated on a 4-12% 
Bis-Tris gel and the Western blots probed with HFT2 (an anti-HSP60 antibody). This blot 
is shown in Figure 5.21.
The HFT2 blot showed a protein at approximately 60 kDa in both the washed and 
Urografin purified B. brevis spore preparation, the washed spore preparation from B. 
cereus (NCTC 9946) and the S-layer preparation from B. pumilus.
5.3.3.2 HSP60 purification from a sonicated washed B. brevis spore preparation
A 5 mg HFT2 1 ml HiTrap™ was produced with a coupling efficiency of 86% from an 
initial 5.4 mg HFT2. The general off-line purification methods (Chapter 2, Table 2.3) 
were used and 10 mM potassium hydroxide was used as the elution buffer. The SDS- 
PAGE gel and Western blot probed with HFT2 from a sonicated washed B. brevis spore 
HSP60 purification are shown in Figure 5.22.
The protein concentration in the elution fractions was too low to see any protein when 
stained with colloidal blue stain. The sonicate was visible as a protein smear in lane 3, 
and most of the protein was washed through the column in fractions 2 and 3 (lanes 4 and 
5). The Western blot showed that HFT2 recognises a 60kDa protein in the sonicate (lane 
3). Most of the HSP60 was washed through the column in fraction 3 (lane 5), but faint 
bands were visible in the elution fractions 18 and 19 (lanes 8 and 9). ESMS analysis of 
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Figure 5.21 SDS-PAGE (a) of S-layer and sonicated spore preparations of several Bacillus 
species assessed by Western blot with (b) an anti-HSP60 monoclonal antibody (mAb), HFT2.
Samples were run on 4-12% Bis-Tris Novex® gels in MES buffer. Each sample was 1 pg of a 
spore preparation (assessed by BCA). Samples (40 pi containing 4 pg of protein) were incubated 
at 95°C for 5 minutes and 10 pi of the reduced sample was loaded per well. The molecular weight 
(MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or MagicMark XP™ (Invitrogen) on the 
gels that were run for Western blots. Two gels were blotted onto nitrocellulose membranes and 
probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP conjugate (DAKO) was used as the 
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Figure 5.22 HSP60 purification from a sonicated washed B. brevis spore preparation on a 5 
mg HFT2 column assessed by (a) SDS-PAGE and (b) Western blot.
A 1 ml sample of 100 pg sonicated washed B. brevis spore preparation in 20 mM sodium 
phosphate, pH7.5 was loaded into a 5 ml sample loop on the AKTAprime system. A 5 mg HFT2 
immunoaffmity column was used, the wash/load buffer was 20 mM sodium phosphate, pH7.5 and 
the elution buffer was 10 mM potassium hydroxide. The standard AKTAprime programs for an 
off-line purification were used (Chapter 2, Table 2.3). Samples were taken from selected fractions 
and analysed by SDS-PAGE.
Samples were run on two 4-12% Bis-Tris Novex™ gels. 25 pi o f each fraction was added to 12.5 
pi loading buffer, 5 pi of 500 mM DTT and 7.5 pi water. The positive controls were 1 pg 
recombinant E. coli HSP60 and a sample of the B. brevis spore preparation. Samples were 
incubated at 95°C for 5 minutes and 20 pi of the reduced sample was loaded per well. The 
molecular weight (MW) marker was 5 pi of SeeBlue® Plus2 (Invitrogen) or MagicMark XP™ 
(Invitrogen) on the gel that was run for Western blot. The gel was blotted onto a nitrocellulose 
membrane and probed with 20 ml of HFT2 at 10 pg/ml. An anti-mouse HRP conjugate (DAKO) 




The molecular weights of HSP60 from three Gram-negative bacterial species, E. coli 
(JM109), Y. pseudotuberculosis (32953) and P. agglomerans (9381 Graham Brice) were 
measured by electrospray mass spectrometry from immunoaffmity purified samples from 
crude lysates. There is sufficient diversity in the molecular weight (MW) of each 
bacterial species HSP60 to allow each species to be distinguished from the other bacterial 
species assessed and identified. The immunoaffmity step enhanced and concentrated the 
HSP60 from each bacterial lysate to a point where the electrospray mass spectrometer 
(ESMS) could distinguish the HSP60 above the other contaminating lysate proteins in 
these three bacterial species. This provides the proof of principal that an ESMS-based 
bacterial detection system with an immunoaffmity sample processing step is possible. 
Evidence was also obtained that HSP60 could be exploited as a biomarker for Bacillus 
spores.
The presence of adenylate kinase (AdK) in the bacterial lysates was assessed by Western 
blot (Figure 5.1). Both AKFT1 and AKYP3 monoclonal antibodies (mAbs) recognised a 
25 kDa band believed to be AdK in the E. coli, Y. enterocolitica and Y. 
pseudotuberculosis lysates. The rabbit polyclonal antibody (pAb) also recognised a 25 
kDa protein in the S. typhimurium lysate and a 50 kDa protein in the S. aureus lysate. No 
band was seen in the P. agglomerans lysate. The P.agglomerans lysate was at a lower 
concentration than other lysates available and there may not have been sufficient AdK 
present to be detected by Western blot. Alternatively, none of the antibodies used to 
probe the blot recognised the P. agglomerans AdK but this is less likely in the case of the 
pAb due to the range of specificities of the antibodies likely to be present. The 50 kDa 
band in the S. aureus lysate may indicate a dimer of AdK, however the lysate was 
reduced and there is no indication in the literature that S. aureus AdK exists as a dimer.
The S. aureus lysate also provided an unexpected result when probed for the presence of 
HSP60. A band at 60 kDa was visible when the blot was probed with HFT2 or the 
commercial anti C. trachomatis HSP60 monoclonal antibody in all lysates screened
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(Figure 5.4), except for the S. aureus lysate where bands at 50 kDa and 80 kDa were 
visible. The commercial anti-C. trachomatis HSP60 mAh recognised an epitope of 117- 
KRGIDK-122, which is highly conserved (see Chapter 4, Figure 4.2). The S. aureus 
sequence differs at this point though (117-RQGIDK-122), and these substitutions seem 
sufficient to prevent the antibody binding. HFT2 did not recognise the S. aureus HSP60 
either, however the epitope HFT2 recognises is unknown.
Later S. aureus lysate HSP60 purification experiments saw purification of the 80 kDa 
protein (Figure 5.18) but ESMS analysis of the elution fractions did not detect a protein at 
either 50 kDa, 60 kDa or 80 kDa (Section 5.3.2.9). The expected MW of S. aureus 
HSP60 was 57853 Da (accession number BAA03533).
Polyclonal antibodies were briefly considered as potential immunoaffinity ligands, 
although it was expected that their suitability would be limited due to the range of 
antibodies displaying different affinities and types of binding with the target protein 
within the antibody population (Jack, 1994). However, pAbs have been used recently in 
an immunoaffinity column to purify phosphinothricin-N-acetyltransferase from maize 
and rape samples before ELISA analysis (Xu et al, 2005). The rabbit anti-AdK pAbs 
were assessed on NHS-activated 1 ml columns with recombinant AdK proteins (Section 
5.3.1.3). Initial purification runs were unsuccessful; effectively each polyclonal column 
had to be primed with protein before any reproducible results could be seen. Blank runs 
through the column after a purification resulted in false positives. High stringency elution 
buffers could be used to try and ensure that all the target protein was removed from the 
column, but this could lead to damage to the antibody and the buffer required may be 
incompatible with the mass spectrometer (Jack, 1994; Burgess and Thompson, 2002).
One approach to select for a useful fraction of antibody ligands from a polyclonal serum 
would be to capture the pAb with the target protein on a column and elute antibody from 
the column with the desired elution buffer (Campbell et al., 1951). However, this would 
be time consuming and there would be variation between the properties of the antibody 
recovered from each batch. A suitable monoclonal antibody would be a much more 
desirable ligand.
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The immunoaffinity work focused on HSP60 as this target seemed to offer the greatest 
chance of success. Comparing the AdK (Figure 5.1) and HSP60 Western blots (Figure 
5.2) indicated either a higher quantity of HSP60 in the bacterial lysates than AdK, or a 
stronger recognition of the HSP60 with the available antibodies. HSP60 was expected to 
be present in the lysate in higher quantities than AdK due to the function HSP60 provides 
in the cell (Fayet et al., 1989) and previous 2D gel work. HSP60 seemed a more suitable 
candidate as a biomarker protein than AdK and gave the greatest chance of success of 
enriching a biomarker protein from a bacterial lysate to the point that the protein's MW 
could be determined.
The first immunopurification trials with HSP60 used the commercial anti-C. trachomatis 
HSP60 mAb. ESMS analysis of a S. typhimurium lysate HSP60 purification indicated 
that non-specific retention of contaminating proteins on an antibody column would be a 
more significant problem than anticipated based on the manufacture's instructions 
(Amersham). The limited value of pure recombinant HSP60 purifications to mimic lysate 
purifications on an immunoaffinity column was demonstrated by loading recombinant 
HSP60 onto an anti-ovalbumin mAb column, which gave very similar results as seen 
with the specific antibody columns due to non-specific adherence of protein (Figure 5.7). 
The most suitable test of the immunoaffinity columns was to isolate HSP60 from a 
bacterial lysate. At this point of the development of the detection system, the sensitivity 
was not a priority, although the sample processing time was kept close to 1 hour. The 
initial aim was to measure the molecular weight of at least two different HSP60s from 
bacterial lysates, with little concern as to the amount of lysate used in each purification. 
HFT2 was used as the immunoaffinity ligand as it was not financially viable to use the 
commercial HSP60 mAb in the quantities required on the 1ml columns.
The first HFT2 columns produced contained 1 mg of antibody. HSP60 was seen in the 
elution fractions of the E. coli JM109 purification by SDS-PAGE gel and Western blot 
(Figure 5.8). However ESMS analysis of the elution fraction did not identify a 60kDa 
protein. No HSP60 was identified by SDS-PAGE gel, Western blot or detected with the 
ESMS from purification trials on the 1 mg HFT2 columns with lysates from four other
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bacterial species. The effectiveness of the columns in capturing the target protein may 
have been increased by reducing the flow rate from 1 ml/min, or halting the liquid flow 
when the sample was on the column (Jack, 1994), but these steps would increase the time 
taken to process a sample. A logical step was to increase the density of the binding sites 
available by increasing the amount of antibody on the column from 1 mg to 5 mg. This 
improved the effectiveness of the HFT2 immunoaffinity columns in capturing HSP60 
(Figure 5.10). The MW of the HSP60 from E. coli was determined by the ESMS in the 
elution fraction from an E. coli JM109 purification (Figure 5.11).
The measured MW of the E. coli JM109 HSP60 was 57226.1±2.2 Da. This did not agree 
with the MW value in Swiss-Prot at the time for HSP60 from E. coli of 57197 Da. The 
mass difference of 29 Da was too great to be accepted within the accuracy of the ESMS. 
The JM109 HSP60 gene was sequenced by C. Underwood, Microbiology Department, 
Dstl Porton Down and it was discovered that there is a conservative change from 126 
alanine to valine in the JM109 sequence that accounts for a mass increase of 28 Da 
compared to the Swiss-Prot E. coli HSP60 MW value.
The MW of HSP60 from other bacterial lysates purified on the 5 mg HFT2 columns 
could not be determined and smaller proteins of approximately 9500 Da dominated the 
ESMS analysis of the elution fractions. These proteins were tentatively identified as HU 
alpha and HU beta DNA binding proteins based on molecular weight comparisons in the 
SWISS-PROT database. The enhancement of the proportion of the smaller MW proteins 
was also indicated by Western blot. These smaller proteins were specifically recognised 
by the HFT2 antibody (Figure 5.4) and competed with the HSP60 on the immunoaffinity 
column, based on the change in intensity of the protein bands from each fraction seen in 
the Western blots (an example is shown in Figure 5.12). The HSP60 was being washed 
through the column while the smaller proteins were retained in preference to HSP60. This 
was probably due to faster permeation through the immunoaffinity column due to their 
smaller size, although HFT2 may have a higher affinity for these smaller proteins. There 
was not sufficient HSP60 retained on the column to be detected in the elution fractions 
with the ESMS for lysates of bacteria other than E. coli.
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By reducing the quantity of these smaller contaminating proteins in the lysate by 
dialysing the lysates against a 50 kDa MWCO membrane, the MW of the HSP60s from 
P. agglomerans (9381 Graham Brice) and Y. tuberculosis (32953) were measured by 
ESMS (Figures 5.14 and 5.16 respectively). There was sufficient variation in the 
molecular weights of the HSP60 from these two bacterial species and that from E. coli to 
allow each bacterial species to be distinguished and identified.
A sequence alignment of the Y. pseudotuberculosis HSP60 and HU alpha DNA binding 
protein is shown in Figure 5.20 which showed a degree of similarity (22.8% identity and 
39.2% similarity) between the HU alpha sequence and the HSP60 sequence between 
amino acid residues 393 and 471. There is a possibility the epitope that HFT2 recognises 
in located in this region.
The SDS-PAGE gel and Western blot of the S. typhimurium HSP60 purification indicated 
the presence of a strong band at 60kDa (Figure 5.19). ESMS analysis of the elution 
fractions could not identify a protein at 60kDa. The band on the blot at 60kDa was more 
intense than that seen in the P. agglomerans and Y. pseudotuberculosis blots, with fewer 
contaminating proteins, so it was surprising that the HSP60 could not be detected by the 
ESMS. The S. typhimurium lysate used in this purification was produced by a different 
method than the other lysates; the bacteria were killed by heat shock and chemically 
lysed rather than sonicated. The presence of lysis buffer did not appear to interfere with 
the purification of the HSP60, but sufficient damage may have been caused to the protein 
to make an accurate mass determination of the HSP60 impossible.
A band at 60 kDa was seen in the Western blot of the Y. enterocolitica HSP60 
purification (Figure 5.17), however a 60 kDa protein was not detected by ESMS. The 
small MW protein were abundant in the elution fractions 17 and 18, and these may have 
been sufficient to mask the presence of HSP60 in the ESMS. In both the S. typhimurium 
and Y. enterocolitica purifications, HSP60 appeared to be present in the elution fractions 
presented to the ESMS, but was not detected. It was unknown why this was the case, but
171
the failure to identify HSP60 from these two species raises concerns about how generic a 
detection system based on the identification of a single bacterial protein can be.
HFT2 specifically recognised multiple proteins from several bacterial lysates, which 
required pre-treatment of the lysate to enable HSP60 to be distinguished from other 
proteins by the ESMS. HSP60 purification trials from bacterial lysates demonstrated that 
this antibody is not an ideal ligand for this application. If HFT2 was used as the capture 
ligand, the sample processing techniques would have to be designed around the 
characteristics of the antibody, adding undesired complexity to the detection system. The 
anti-C. trachomatis mAb may have proved to be more suitable immunoaffinity ligand, 
but it was too expensive to produce a 5 mg 1 ml HiTrap™ column.
The vegetative protein HSP60 were identified as a potential biomarker protein for 
Bacillus spores. Western blots of various spore sonicates and S-layer preparations from 
vegetative cells indicated the presence of HSP60 in washed sonicated B. brevis spore 
preparations (Figure 5.21). The most likely location of the HSP60 was trapped in the 
spore coat which was then disturbed by the sonication. Sonication of B. subtilis spores 
resulted in increased sensitivity of detection of the spore by ELISA and resonant mirror, 
without fragmentation of the spore (Borthwick et al., 2005). This was attributed to release 
of soluble antigen from the spore coat. The spores were washed ten times in distilled 
water prior to sonication so it seems unlikely that all the HSP60 was loosely associated 
with the spore surface. The quantity of HSP60 present was low, and although a very faint 
60kDa band can be seen in the elution fractions of a HSP60 purification on a HFT2 
column from a washed sonicated B. brevis spore preparation (Figure 5.22), ESMS 
analysis of the elution fractions could not detect a 60kDa protein.
As the focus of this work was primarily to provide the proof of principle for bacterial 
identification based on the MW of a biomarker protein, there was little scope for 
optimization and assessment of the immunoaffinity columns and altering the system 
configuration. The system was designed with the sole aim of providing the proof of 
principle work and is not necessarily the most effective combination of components. If
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developmental work continues there will be significant alteration of the design to allow 
the detection system to be automated. Several areas should be addressed in the future.
All of the bacterial lysate purification runs used high quantities of material; no work was 
completed to test the detection limits of the current system. The immunoaffinity 
purification step has the potential to be optimized to greatly improve the sensitivity of the 
detection system. Immunoaffinity/ESMS systems are capable of very sensitive detection; 
serum amyloid P was detected from 150 pi of serum (Sen et al., 2003), lysergic acid 
diethylamide (LSD) was detected at levels of 2.5 parts per trillion in human urine (Cai 
and Henion, 1996). Both of these studies used capillary chromatography columns; Cai 
and Henion (1996) used flow rates of between 2.5 ml/min and 4 ml/min successfully 
through a 2.1 mm x 3.3 mm immunoaffinity column. This flow rate is suitable for the 
proposed detection system. Changing the 1 ml HiTrap™ column to a smaller capacity 
column could possibly increase the sensitivity of the system by reducing the elution 
volume and also reduce the degree of non-specific binding. It would also be more 
practical to increase the density of the ligands within the column if the column volume 
was smaller. A five-fold increase in the density of HFT2 in a 1 ml HiTrap™ column 
improved the efficiency of HSP60 purification from a lysate of E. coli (Figure 5.10). 
However, the ligand density on the immunoaffinity column was not optimized, and this 
could be completed with a lower cost in reagents on a smaller column. An alternative 
method to increase the ligand density would be to use single-chain antibody fragments 
(scFvs) or single-domain antibody fragments (Verheesen et al., 2003). The single-domain 
antibodies also displayed resistance to denaturation when bound to the matrix; the 
column was subjected to more than 2000 regeneration cycles without loss of capacity 
(Verheesen et al., 2003). High-density immobilization of scFv improved the response of a 
biosensor compared to the use of mAbs on a biosensor surface (Howell et al., 1998), 
which may also apply to immunoaffinity chromatography. The production of scFvs 
against bacterial biomarker proteins will be discussed in Chapter 6.
As the analysis of each lysate used a separate HFT2 column, each column was only used 
a limited number of times and there is no information available on the column’s lifespan.
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This needs to be addressed due to the high stringency of the elution buffer (10 mM 
potassium hydroxide). A long lifespan of a column for use in an automated system is 
important to limit the system maintenance and logistical burden. A column’s lifespan can 
be short depending on the antibody and the elution buffer. A column lasted up to 30 runs 
before a loss in recovery, using 3 M KSCN as the elution buffer (Agraz et al., 1994). The 
leakage of antibody from the column may also be an issue (Jack, 1994).
The purification of AdK from bacterial lysates on mAb columns also needs to be 
assessed. This work was not completed due to time constraints, as the weak recognition 
of AdK from the bacterial lysates by Western blot (Figure 5.1) meant that HSP60 seemed 
a more promising biomarker protein due to the larger quantity of protein available in the 
cell. However, the AKFT1 and AKYP3 mAbs may be suitable ligands for the purification 
of AdK from lysates of E. coli, Y. enterocolitica and Y. pseudotuberculosis.
All the purification experiments described in this chapter used cultured bacterial lysates. 
Environmental and clinical samples representative of samples expected to be encountered 
during the intended use of the system need to be examined. Mixtures of different 
bacterial species also need to be assessed to confirm if all the bacteria present can be 
identified. As limited analyses of complex bacterial samples have been reported to date 
by MALDI or ESMS, it is uncertain whether an immunoaffinity step to purify a specific 
protein is actually required in a successful mass spectrometry-based bacterial detection 
system. Bacterial species have been identified on the basis of bacterial protein profiles 
from cultured samples by MALDI-TOF (Krishnamurthy et al., 1996; Holland et al., 1996; 
Liang et al., 1996) and by ESMS (Krishnamurthy et al., 1999). What may be more 
appropriate could be an immunoaffinity purification step to concentrate whole bacteria 
from dilute samples (Molloy et al., 1995) before analysis by ESMS.
In summary, the MW of HSP60 from three bacterial species (E. coli [JM109], Y. 
pseudotuberculosis [32953] and P. agglomerans [9381 Graham Brice]) were measured 
by the ESMS from fractions purified from bacterial lysates with a HFT2-based 
immunoaffinity column. However, HSP60 was not detected by ESMS from a further
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A decision was made to use monoclonal antibodies (mAbs) for the initial work in 
developing the immunoaffinity application to purify a bacterial biomarker protein prior to 
analysis by electrospray mass spectrometry. This was due to the high probability of 
success in raising monoclonal cell lines that produce antibodies that recognised a 
conserved epitope of either of the two potential Gram-negative bacterial biomarker 
proteins chosen, heat shock protein 60 (HSP60) and adenylate kinase (AdK). However, 
mAbs have limitations in the proposed immunoaffinity application; in particular they are 
expensive to produce compared with single-chain antibody fragments (Binz and 
Pluckthun, 2005) and cannot be genetic modified. Single-chain antibody fragments 
(scFvs) allow genetic modification (Hudson and Souriau, 2003), which can lead to 
increased stability (Worn and Pluckthun, 2001) and affinity (Nevanen et al., 2003). ScFvs 
also allow an increased density of ligands on a matrix or chip surface (Howell et al.,
1998) compared to mAbs. Due to these factors, scFvs may prove to be a more suitable 
ligand that mAbs for immunoaffinity and the aim of this section was to isolate scFv that 
recognised conserved epitopes of the bacterial biomarker proteins for future use.
MAbs are a tested technology that have successfully used by many laboratories in 
different applications over the last thirty years (Lipman et al., 2005) since the method for 
generating a hybridoma cell line that produced monoclonal antibody was described by 
Kohler and Milstein (1975). Monoclonal cell lines are produced by fusing a splenocyte 
from a hyper-immune mouse with an immortal myeloma cell, such as X63 (Kearney et 
al., 1979). The initial quantity of potential clones seen in the cell culture plates from a 
fusion procedure can range from none to thousands (typically between 500 and 1000 
colonies [Harlow and Lane, 1998]) but after cloning and screening a successful fusion 
will typically produce between one and twenty monoclonal cell lines (T. Webber, 
personal communication). Although the splenocytes that are fused are random, the 
standard method used to generate monoclonal cell lines after cell fusion (limiting dilution 
with a capture ELISA screen) will select for cell lines that reflect the mouse B cell 
immune response (Berry, 2005). Immunodominant epitopes will dominate the splenocyte
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population, favouring the generation of monoclonal cell lines against these epitopes (Gani 
et al., 1987). An immunodominant epitope may not be a conserved epitope in a bacterial 
biomarker protein and it may prove difficult to raise a monoclonal cell line against a 
desired epitope. One approach to produce antibodies against small or difficult targets 
using conventional monoclonal technology is to link the target epitope to a carrier protein 
for immunisation (Harlow and Lane, 1988). For peptides this assumes that the epitope is 
linear and continuous, and that the peptide forms a similar secondary structure to that 
seen in the native protein.
ScFvs can be produced from naive (Marks et al., 1991; Nissim et al., 1994) or immunised 
(Clackson et al, 1991) phage display libraries, or they can be derived from existing 
monoclonal cell lines (Krebber et al., 1997). The advantages of panning naive antibody 
phage display libraries are that it eliminates the bias towards immunodominant epitopes 
seen when generating ligands from an immunised source (Hoogenboom et al., 1998), 
whether monoclonal antibodies or an antibody phage display derived from an immunised 
animal. There is the potential to raise a wide range of different ligands against various 
epitopes. The naive human phage display libraries Tomlinson I+J (de Wildt et al, 2000) 
and Griffin (Griffiths et al., 1994) have 3xl08 and approximately 1.2xl09 different 
immunoglobulin genes respectively. Naive libraries can be used to pan against new 
targets in the future and ligands can be produced in a shorter time scale (several weeks 
compared to several months) than monoclonal cell lines or immunised antibody phage 
display libraries that require the immunisation of animals. Naive libraries circumvent the 
need for animal use, particularly when compared to monoclonal cell line production, 
where a large number of mice are required to supply macrophages to condition media to 
assist the growth of immature hybridomas (Sugasawara et al., 1985). It is possible to 
tailor the panning process to select for scFv with specific characteristics (Hoogenboom et 
al., 1998; Bradbury and Marks, 2004). An example of this is shown by panning under 
reducing conditions to select for scFv with improved stability (Brockmann et al., 2005).
The advantage of monoclonal cell lines or immunised antibody phage display libraries are 
that the population of splenocytes in a hyper-immune animal are biased towards
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producing antibody that recognises the antigen, making it extremely likely that ligands 
that recognise the target antigen can be generated (Winter et al., 1994). Due to antibody 
maturation by the animal's immune system, these antibodies may be of high affinity 
(Clackson et al., 1991), although high affinity scFvs have been isolated from naive 
antibody phage display libraries (Vaughan et al., 1996).
The greatest limitation on the use of mAbs in future detection systems is the lack of 
modification and genetic engineering possible to alter a ligand to fit an intended purpose. 
When coupling mAbs to an NHS-activated column through the antibody's primary amine 
groups, there is no control over the orientation of the antibody. This means a proportion 
of the antigen binding sites will be inaccessible due to steric interference, reducing the 
ligand density and capacity of the column (Nisnevitch and Firer, 2001). It is possible to 
genetically modify scFvs to include a specific linker to allow directed coupling onto a 
surface (Piervincenzi et al., 1998), ensuring the majority of the scFv binding sites are 
accessible. It is also possible to increase the structural stability of the scFv (Young et al., 
1995; Worn and Pluckthun, 2001) and to alter the affinity and avidity of an antibody so it 
is better suited for the required application (Nevanen et al., 2003).
Monoclonal antibodies can be converted into scFvs and then modified to suit a particular 
application. Ligands which are not ideal for a system can be used as the basis to generate 
a selection of alternative ligands with different characteristics. Once a promising ligand 
has been found, either isolated from an antibody phage display library or a mAb that has 
been converted into a scFv, a secondary library can be generated and screened for ligands 
with the desired characteristics for an application (Griffiths and Duncan, 1998).
The aims of this section were to:
1. isolate scFvs that display cross-species recognition for the bacterial biomarker 
proteins (HSP60 or adenylate kinase) from naive human antibody phage display 
libraries.
2. convert mAbs raised that recognised a conserved epitope of a bacterial biomarker 
protein into a single chain antibody.
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6.2 Materials and Methods
6.2.1 Materials
All chemicals were purchased from Sigma-Aldrich Company Ltd., Fancy Road, Poole, 
Dorset, UK, unless stated. The Griffin and Tomlinson I+J human naive antibody phage 
display libraries were obtained from the Centre for Protein Engineering, Cambridge, UK.
6.2.2 Methods
6.2.2.1 Panning the naive Griffin and Tomlinson I+J scFv phage display 
libraries
6.2.2.1.1 Rescuing phage from the library
Phage were rescued from frozen bacterial stocks by seeding 50 ml 2xYT media (6.32 g 
per 200 ml) containing 0.1 pg/ml ampicillin and 1% (w/v) glucose in a 250 ml sterile 
flask (Coming, purchased through Sigma-Aldrich Company Ltd.) with sufficient glycerol 
stock library bacteria to give an initial optical density at 600 nm (OD6 0 0) of 0.05. The 
culture was incubated at 37°C with shaking in an Orbital S I50 incubator (Stuart 
Scientific, Staffordshire, UK) until the OD6 0 0  reached 0.4-0.5, when the bacterial culture 
was infected with a total of 1011 M13K07 helper phage (GE Healthcare, 
Buckinghamshire, UK). The culture was incubated at 37°C for 30 minutes with no 
shaking and centrifuged (Harrier 18/80, Sanyo, Loughborough, UK) at 3000 x g for 10 
minutes. The bacterial pellet was resuspended in 50 ml of 2xYT media containing 
0.1%(w/v) glucose, 0.1 pg/ml ampicillin and 0.05 pg/ml kanamycin in a 250ml sterile 
flask. The bacteria were incubated for 16 hours at 30°C. The bacteria were then pelleted 
by centrifugation at 4000 x g for 15 minutes at 4°C. The phage were precipitated when 10 
ml of 20% (w/v) PEG 8000 in 2.5 M sodium chloride was added to 40 ml of the bacterial 
supematent and incubated on ice for 1 hour. The phage were pelleted by centrifugation at 
4000 x g for 10 minutes at 4°C, resuspended in 1 ml PBS, and stored at -20°C.
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6.2.2.1.2 Determining phage titre
The library phage were titred by serial dilution of the phage by a factor of 100, testing the 
dilutions between 10'8 and 10'14. A 100 pi aliquot of the diluted phage was mixed with 
lOOpl log-phase E. coli XL1 Blue (Stratagene, Amsterdam, The Netherlands) and 
incubated for 15 minutes at 37°C. Aliquots of 100 pi were plated out on 2xYT 1% (w/v) 
glucose agar plates containing 0.1 pg/ml ampicillin. The plates were incubated for 16 
hours at 37°C and the colonies counted. The 2xYT agar recipe was 3 g of Bacto agar, 6.32 
g 2x YT media, 4 ml of 50% (w/v) glucose and 0.1 pg/ml ampicillin per 200 ml distilled 
water. The agar was melted and sterilized by autoclaving at 121°C for 15 minutes. The 
glucose and antibiotics were added after the agar had cooled to 50°C.
6.2.2.1.3 Panning
Immunotubes (Nunc A/S, Roskilde, Denmark) were coated with 1 ml of the antigen (10 
pg/ml unless stated) for 16 hours at 4°C. The coated tubes were washed 3 times with PBS 
and blocked with 4 ml of 2% (w/v) MPBS for 2 hours at room temperature. The phage 
were pre-blocked by adding 100 pi of the undiluted library phage to 900 pi of 2% (w/v) 
MPBS and incubating for 30 minutes at room temperature. The immunotube was emptied 
and the pre-blocked phage added. The tube was incubated for 2 hours at room 
temperature with occasional shaking. The immunotube was washed 10 times with 0.1% 
(v/v) Tween 20 in PBS, followed by 10 washes with PBS. The tubes were washed with a 
squeezy bottle by filling the tube with the wash and emptying the liquid into 10% (v/v) 
hypochlorite solution. Bound phage were eluted with 1 ml of 100 mM triethylamine. The 
tube was incubated with 100 mM triethylamine for 8 minutes at room temperature, then 
the solution transferred into a sterile 50 ml falcon tube containing 0.5 ml 1M Tris-HCl 
pH7.5. The phage were used to infect 10 ml of log-phase E. coli XL1 Blue (OD6 0 0  0.4-
0.5). The bacteria were incubated for at 37°C for 30 minutes without agitation, followed 
by 30 minutes with shaking. The eluted phage were titred by plating out a 10 fold dilution 
series of the infected XL1 Blue, down to 10'7, on 2xYT agar plates containing 1% (w/v) 
glucose and 0.1 pg/ml ampicillin. The remainder of the bacteria were pelleted by
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centrifugation at 2500 x g for 10 minutes at 4°C. The bacterial pellet was resuspended in 
1 ml 2xYT media and plated out on a 24cm (Coming) 2xYT agar plate containing 1% 
(w/v) glucose and 0.1 pg/ml ampicillin. The bacteria were recovered by scraping with a 
spreader into 10 ml 2xYT containing 25% (v/v) glycerol. This glycerol stock was then 
used to produce phage for further panning rounds (section 6.2.1.1) or quick-frozen in 
liquid nitrogen and stored at -80°C.
This method was used to pan the Griffin library for ligands that displayed cross-species 
recognition against bacterial HSP60 at Dstl. A similar method was used to screen the 
Tomlinson I+J and Griffin libraries for ligands that displayed cross-species recognition of 
bacterial adenylate kinase at the University of Aberdeen (Haptogen). The only variation 
was that a different strain of is. coli was used, TGI rather that XL1 Blue.
Panning antibody phage display libraries created from mAh cell lines used the same 
method but different antibiotic selection as the phagemid vector used was pAKlOO rather 
than pHEN2 as in the Griffin and Tomlinson libraries. pHEN2 contains an ampicillin 
resistance gene, while selection with pAKlOO is based on chloramphenicol resistance. 
Chloramphenicol was used at 30 pg/ml. Protein production was also induced with the 
addition of isopropyl-beta-D-thiogalactopyranoside (IPTG) to a final concentration of 1 
mM 30 minutes after the addition of the helper phage when the library phage were being 
recovered from the bacterial stock before each panning round. The immunotubes for the 
single panning step were coated with 2 ml of recombinant HSP60 or adenylate kinase 
(AdK) at 10 pg/ml in PBS.
6.2.2.1.4 Monoclonal phage and reference stock preparation from a pHEN2- 
based library
This method was used when preparing phage isolated from the Griffin or Tomlinson I+J 
naive scFv phage display libraries. Bacterial colonies were picked from the third and 
fourth panning rounds and each colony was used to inoculate a well of a 96-well 
microtitre plate containing 100 pi 2xYT with 50 pl/ml ampicillin and 1% (w/v) glucose.
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The plate was incubated for 16 hours at 37°C with shaking. A 96-well transfer device (a 
metal plate with 96 prongs) was dipped in the culture plate and used to inoculate a new 
96-well plate containing 200 pi 2xYT with 50 pl/ml ampicillin and 1% (w/v) glucose per 
well. Glycerol was added to each well of the first plate to a final concentration of 15% 
(v/v) and frozen at -80°C. The second plate was incubated for 1 hour at 37°C with 
shaking. To each well of the second plate 25 pi 2xYT containing 50 pg/ml ampicillin, 1% 
(w/v) glucose and 109 M13K07 helper phage was added. The plate was incubated at 37°C 
for 30 minutes without shaking, then for a further hour at 37°C with shaking. The bacteria 
were pelleted by centrifugation at 1800 x g for 10 minutes and the supematent removed. 
The bacterial pellet was resuspended in 200 pi of 2xYT containing 50 pg/ml ampicillin 
and 25 pg/ml kanamycin, and the 96-well plate was incubated for 16 hours at 30°C.
6.2.2.2 Monoclonal phage and reference stock preparation from a pAKlOO-
based library
This method was used when preparing monoclonal phage isolated from the scFv phage 
display libraries created from monoclonal cell lines. Colonies were picked from a panning 
round or series dilution plates and used to inoculate 4 ml of 2xYT containing 1% (w/v) 
glucose and 30 pg/ml chloramphenicol in 30ml universal tubes. The culture was 
incubated for 16 hours at 37°C with shaking. Frozen bacterial reference stocks were 
produced by removing 1 ml of the bacterial culture and adding to 1 ml 2xYT containing 
50% (v/v) glycerol. The bacteria were frozen at -80°C. The remaining 3 ml of bacterial 
culture were split into 2 aliquots and centrifuged in the same tube at 6000 x g for 5 
minutes (5417R centrifuge, Eppendorf) to produce a bacterial pellet that was frozen at - 
80°C for later plasmid purification.
A new culture was grown by adding 2 ml of 2xYT containing 1% (w/v) glucose and 30 
pg/ml chloramphenicol to the universal tube used to grow the original culture. The 
culture was incubated for 3 hours at 37°C with shaking, then 200 pi of a solution of 10 
mM IPTG and 2.5 x 1010 pfu/ml M13K07 was added. The culture was incubated for 16 
hours at 30°C with shaking. The bacteria were pelleted by centrifugation of 2ml of the
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overnight culture at 2500 x g for 10 minutes. The phage was harvested by mixing 1.6 ml 
of the supematent with 400 pi of 20% (w/v) PEG8000 with 2.5 M NaCl, and incubation 
on ice for 1 hour. Precipitated phage were pelleted by centrifugation at 12000 x g for 5 
minutes. The phage were resuspended with 400 pi MPBS and stored at -20°C. 
Monoclonal phage preparations when panning the Griffin library with bacterial HSP60 
used the method described in this Section, with the following variations to account for the 
pHEN2 vector. The bacterial colonies were grown in 2xYT with 50 pi ampicillin and 1% 
(w/v) glucose. After the M13K07 helper phage had been added, the culture was 
incubated for 30 minutes at 37°C without shaking followed by 1 hour at 37°C with 
shaking. The bacteria were pelleted by centrifugation at 4000 x g for 10 minutes and the 
bacterial pellet was resuspended with 2xYT containing 50 pg/ml ampicillin and 25 pg/ml 
kanamycin. The culture was for 16 hours at 30°C with shaking before the phage were 
harvested.
6.2.2.3 Indirect M13 phage enzyme-linked immunosorbent assay (ELISA)
The indirect ELISA protocol as described in the General Materials and Methods (Chapter 
2, Section XXX) was followed with the following alterations. The blocking buffer used 
was 2% (w/v) MPBS. The sample was either polyclonal phage from a panning round or 
monoclonal phage that had been cultured from a single bacterial colony grown on 
selective media after a panning round (Section 6.2.2.1.4 and Section 6.2.2.2). The 
monoclonal phage was used undiluted, while the polyclonal phage were diluted 1:10 with 
2% (w/v) skimmed milk powder in PBS. A sheep anti-M13 HRP conjugate (GE 
Healthcare) was used as the reporting antibody.
The ELISAs at Haptogen (University of Aberdeen) were developed with 3,3',5,5'- 
tetramethylbenzidine (TMB) substrate. The TBB buffer was 100 mM sodium acetate 
pH6.0, into which 100 pg/ml TMB was dissolved. Hydrogen peroxide was added to the 
substrate immediately before use (10 pi of a 30% [v/v] solution per 50 ml buffer). The 
assay was developed by the addition of 100 pi substrate to each well. The plate was 
incubated at room temperature until a blue colour had developed (approximately 10
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minutes). The reaction was stopped by adding 50 pi of 1 M sulphuric acid to each well. 
The optical densities at 650 nm and 450 nm were measured and the OD6 5 0  was subtracted 
from the OD4 5 0  to give the assay response.
6.2.2.4 ELISA of protein adherence to the immunotubes
The adherence of the AdK to the plastic of the immunotube was tested by completing an 
ELISA in the immunotube. The tube was coated with 200 pi of a recombinant AdK at 
either 5 or 50pg/ml in PBS. The tubes were washed with a squeezy bottle by filling the 
tube with the wash and emptying the liquid into 10% (v/v) hypochlorite solution. At each 
wash step the tubes were washed with 3 volumes of 0.1% (v/v) Tween 20 in PBS, 
followed by 3 volumes of PBS. The tube was blocked with 1 ml of 2% (w/v) skimmed 
milk powder in PBS, followed after washing with 100 pi of an anti-AdK rabbit polyclonal 
antibody (Chapter 3). The reporting enzyme was 200 pi of a 1:1000 dilution of an anti­
rabbit IgG HRP conjugate (Bio-Rad, Hertfordshire, UK). The assay was developed with 
200 pi of ABTS solution and, after a colour had developed (approximately 15 minutes), 
100 pi was transferred to a microtitre plate to read the optical density at 414 nm. Each 
assay was completed in duplicate.
6.2.2.5 Production of a single-chain antibody from a monoclonal antibody cell 
line
The methods for the cloning of scFvs from monoclonal antibody cell lines are based on 
those described by Krebber et al., 1996.
6.2.2.5.1 Total ribonucleic acid (RNA) purification from a hybridoma cell line
Total RNA was purified from hybridoma cell lines using a RNeasy® Mini kit (Qiagen, 
West Sussex, UK). Hybridoma cells (lxlO7 total cells) were pelleted by centrifugation 
(5417R centrifuge, Eppendorf, supplied by Fisher Scientific UK, Loughborough, UK) at 
300 x g for 5 minutes. The cells were lysed with 600 pi RLT buffer and homogenized by
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repeated pipetting. One volume (600 pi) of 70% (v/v) ethanol in distilled water was added 
to the homogenized lysate. An RNeasy spin column was placed in a 2ml collection tube 
and 700 pi of the lysate was added. The tube was centrifuged at 8000 x g for 15 seconds. 
The remaining lysate was added and the tube centrifuged at 8000 x g for 15 seconds. The 
RNeasy column was washed with 700 pi of RW1 buffer. The tube was centrifuged at 
8000 x g for 15 seconds and 500 pi of RPE buffer was added, followed by centrifugation 
at 8000 x g for 2 minutes. The RNeasy column was placed in a new 1.5 ml collection tube 
and 50 pi of RNase-free water was added. The total RNA was eluted by centrifugation at 
8000 x g for 1 minute.
6.2.2.5.2 Estimation of RNA and deoxyribonucleic acid (DNA) concentration 
by UV spectrometry
The RNA or DNA samples were diluted 1:100 in the buffer the RNA or DNA was 
dissolved in. A negative control of the buffer the RNA or DNA was dissolved in was used 
to measure the difference between the OD2 8 0  and the OD2 6 0  (the OD2 8 0  zero). The OD2 6 0  
and OD2 8 0  were measured for each sample. The concentration of RNA = OD2 6 0  x dilution 
factor x 40 pg/ml. The concentration of DNA = OD2 6 0  x dilution factor x 50 pg/ml. The 
purity of the RNA and DNA was indicated by the OD2 6 0  / (OD2 8 0-OD2 8 0  zero). The ratio 
of OD2 6 0  / OD2 8 0  for pure RNA should be 1.8, and 2.0 for pure DNA.
6.2.2.5.3 cDNA production from total RNA
cDNA was produced from total RNA with a Superscript™ kit (Invitrogen, Paisley. UK). 
Reactions were set up at 25°C, 42°C, 37°C, 65°C and 70°C in a Mastercycler gradient 
thermal cycler (Eppendorf, supplied by Fisher Scientific UK, Loughborough, UK). The 
RNA mix was 5 pg total RNA, 500 ng oligo dT or 125 ng hexamers, 1 pi of 10 mM 
nucleotide mix and water to a total volume of 10 pi in a 200 pi PCR tube. The RNA mix 
was heated to 65°C for 5 minutes minimum, then cooled immediately on ice for 2 
minutes. The following were then added: 2 pi 10X RT buffer, 4 pi of 25 mM MgC^, 2 pi
0.1 M DTT and 1 pi RNAseOUT, and mixed well by pipetting. The reaction mixture was
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incubated at 42°C for 2 minutes, then 1 pi Superscript™ reverse transcriptase added. The 
reaction mixture was incubated at 42°C for 50 minutes, followed by 15 minutes at 70°C to 
inactivate the reverse transcriptase. RNA was degraded with the addition of 1 pi RNase H 
and an incubation of 20 minutes at 37°C. The cDNA was frozen at -20°C.
6.2.2.5.4 Polymerase chain reaction (PCR) amplification of antibody heavy and 
light chains (Diibel method)
PCR was used to amplify the heavy and light chain genes from the cDNA with specific 
mouse light and heavy chain primers (Table 6.1 and Table 6.2 respectively), purchased 
from Sigma-Genosys Ltd., Cambridge, UK. Each PCR contained 2.5 pi cDNA, 1 pi 
forward primer mix, 1 pi backwards primer mix, 5 pi 1 OX Platinum Taq PCR buffer 
(Invitrogen), 2.5 pi of 50 mM MgCb, 1 pi of lOmM dNTP, 0.5 pi Platinum Taq 
(Invitrogen) and water to a final volume of 50 pi. A negative control was also set up, with 
sterile water instead of the cDNA. The reaction was run in a Mastercycler gradient 
thermal cycler (Eppendorf), with the following program (lid temperature of 105°C):
1. 5 minutes at 95°C
2. 5 x (1 minute at 95°C, 1 minute at 55°C, 1 minute at 72°C)
3. 30 x (1 minute at 95°C, 1 minute at 63°C, 1 minute at 72°C)
4. 5 minutes at 72°C
5. Hold at 5°C
The PCR products were assessed with E-gels® and stored at -20°C.
6.2.2.5.5 E-gel® analysis of DNA
The E-gel® (Invitrogen) was pre-run for 2 minutes in a PowerBase™ (Invitrogen). Each 
DNA sample (1 pi - 5pl) was mixed with 4 pi 5X loading buffer (30% [w/v] sucrose in 
distilled water) and made up to 20 pi with TE buffer (50 mM Tris-HCl pH8.0, 1 mM 
EDTA). The 20 pi sample was loaded and the gel was run for 30 minutes. The gel was
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a)
Primer Name Primer Sequence (5’ to 3’)
MLB1 TTACTCGCGGCCCAGCCGGCCATGGCGGACTACAAAG
MLB2 GCCATGGCGGACTACAAAGAYATCCAGCTGACTCAGCC
MLB3 GCCATGGCGG ACTACAAAG AYATT GTTCT C WCCCAGT C
MLB4 GCCATGGCGGACTACAAAGAYATTGTGMTMACTCAGTC
MLB5 GCC AT GGCGG ACTACAAAG AYATT GTRAT G ACM C AGT C
MLB6 GCCAT GGCGGACTACAAAGAYATTM AG ATRAMCC AGT C
MLB7 GCCAT GGCGGACTACAAAGAYATT CAGATGAYDCAGT C
MLB8 GCCAT GGCGGACTACAAAGAYATYCAG AT GACACAG AC
MLB9 GCCATGGCGGACTACAAAGAYATTGTTCTCAWCCAGTC
MLB10 GCC ATGGCGGACTACAAAGAYATT GWGCTSACCC AAT C
MLB11 GCCATGGCGGACTACAAAGAYATTSTRATGACCCARTC
MLB12 GCCATGGCGGACTACAAAGAYRTTKTGATGACCCARAC
MLB13 GCCAT GGCGGACTAC AAAG AYRTTKT GAT G ACCC ARAC
MLB14 GCCATGGCGGACTACAAAGAYATTGTGATAACYCAGGA
MLB15 GCCAT GGCGGACTACAAAGAYATT GTGAT GACCCAGWT
MLB16 GCCATGGCGGACTACAAAGAYATTGTGATGACACAACC
MLB17 GCCATGGCGGACTACAAAGAYATTTTGCTGACTCAGTC
MLB LAM BD GCCATGGCGGACTACAAAGATGCTGTTGTGACTCAGGAATC
b)








CCTAG G AC AGT C AGTTT GG
Table 6.1 PCR primer sequences for the amplification of the antibody light chain gene.
Degenerate (a) forward and (b) backwards PCR primers for the amplification of the murine 
antibody light chain gene.
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Table 6.2 PCR primer sequences for the amplification of the antibody heavy chain gene.
Degenerate (a) forward and (b) backwards PCR primers for the amplification of the murine 
antibody heavy chain gene.
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visualized with a UV trans-illuminator (Syngene, Cambridge, UK).
6.2.2.5.6 Crystal violet agarose gel DNA purification
A 2% (w/v) agarose gel was prepared by heating 150 ml TAE buffer (Fisher Scientific 
UK) to boiling, then adding 3 g low melting point agarose (Invitrogen). The solution was 
allowed to cool to 50°C before the addition of 150 pi of 10 mg/ml crystal violet solution 
in distilled water. The solution was mixed thoroughly and the gel poured. Samples 
consisted of 24 pi of the DNA preparation with 6 pi of 5X loading buffer (30% [w/v] 
sucrose with 100 pl/ml crystal violet in distilled water). The gel was run at 75 V for 
typically 1 hour, until the bands were resolved. The gel was placed on a light box and the 
bands of interest were excised. The DNA was either recovered with a SNAP™ 
purification kit or the gel slice was frozen at -20°C for later purification.
6.2.2.5.7 DNA recovery from agarose gel with a SNAP™ purification kit
The DNA was recovered from the agarose gel with a SNAP™ purification kit 
(Invitrogen). The volume of the gel band was estimated by weight (assuming 1 g = 1 ml). 
A typical band was 100 pi in volume. The gel was melted by incubation at 50°C with 
occasional vortexing with 2.5 volumes of 6.6 M sodium iodide. The gel took 
approximately 5 minutes to melt after which 1.5 volumes (typically 525 pi) of binding 
buffer was added and the solution loaded onto a SNAP purification column. The column 
was centrifuged at 3000 x g for 30 seconds (5417R centrifuge, Eppendorf). The sample 
was loaded back onto the column and the centrifugation was repeated. The flow-through 
liquid was then discarded. The column was washed twice by adding 400 pi of final wash 
solution and centrifugation at 3000 x g for 30 seconds. The resin was dried by 
centrifugation at 10000 x g for 1 minute. The DNA was eluted by adding 40 pi distilled 
water to the column and incubation for 1 minute at room temperature. The column was 
centrifuged at 10000 x g for 1 minute and the DNA stored at -20°C.
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6.2.2.5.8 Assembly PCR for scFvs
PCR was used to link the antibody heavy and light chains together using the scfor and 
scback primers produced by Sigma-Genosys Ltd.
scfor (5' to 3') GGAATTCGGCCCCCGAG
scback (5f to 3') TTACTCGCGGCCCAGCCGGCCATGGCGGACTACAAAG
Each PCR contained 10 ng purified heavy chain DNA, 10 ng purified light chain DNA,
50 pmol scfor, 50 pmol scback, 5 pi 1 OX Platinum Taq PCR buffer (Invitrogen), 1 pi of 
10 mM dNTP, 1.5 pi of 50 mM MgCb, 0.5 pi Platinum Taq (Invitrogen) and water to a 
final volume of 50 pi. Negative controls was also set up, with sterile water instead of the 
DNA, and reaction tubes containing only the light or heavy chain DNA only. The 
reaction was run in a Mastercycler gradient thermal cycler (Eppendorf), with the 
following program (lid temperature of 105°C):
1. 1.5 minutes at 94°C
2. 7 x (1 minute at 94°C, 30 seconds at 63°C, 50 seconds at 58°C, 1 minute at 72°C)
3. 23 x (1 minute at 94°C, 30 seconds at 63°C, 1 minute at 72°C)
4. Hold at 5°C
The PCR products were assessed with E-gels® and stored at -20°C.
6.2.2.5.9 Phenol/chloroform extraction of DNA
An equal volume of 25:24:1 phenol/chloroform/isoamyl alcohol solution (Invitrogen) was 
added to the PCR product and mixed well. The solution was separated by centrifugation 
at 14000 x g for 10 minutes (5417R centrifuge, Eppendorf). The upper, aqueous layer 
containing the DNA was removed.
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6.2.2.5.10 Concentration of DNA by ethanol precipitation
One tenth of the DNA sample volume of 3 M sodium acetate was added to the DNA 
solution, as well as 3.5 volumes of 100% (v/v) ethanol. The DNA was stored at -20°C for 
16 hours. The solution was centrifuged at 14000 x g for 10 minutes (5417R centrifuge, 
Eppendorf) and the ethanol decanted. The DNA was dissolved in the desired volume of 
distilled water.
6.2.2.5.11 Sfil digestion of the scFv assembly PCR product
Each reaction mix contained 5 pi of 10X reaction buffer number 2 (New England 
Biolabs, Hertfordshire, UK), 0.5 pi of 100X bovine serum albumin (New England 
Biolabs), 0.5 pi Sfil (New England Biolabs), 1 pi of the DNA to be cut and distilled water 
to a final volume of 50 pi. The reaction was incubated at 50°C for 16 hours in a 
Mastercycler gradient thermal cycler (Eppendorf).
6.2.2.5.12 Ligation of Sfil-digested scFv assembly DNA into pAKlOO
T4 DNA ligase (New England Biolabs) was used to ligate the Sfil-digested assembly 
PCR product into Sfil-digested pAKlOO. The ligation mixture contained 200 ng Sfil- 
digested pAKlOO vector, 20 ng Sfil-digested scFv DNA, 0.2 pi T4 ligase (1 unit), 2 pi 
10X ligase buffer (New England Biolabs) and distilled water to a final volume of 20 pi. 
The reaction mixture was mixed well and incubated for 16 hours at 16°C in a 
Mastercycler gradient thermal cycler (Eppendorf).
6.2.2.5.13 Desalting ligated plasmid
The plasmid was desalted in Microcon 30™ columns (Millipore, Watford, UK) before 
electroporation. The plasmid sample was made up to 400 pi volume with distilled water. 
The plasmid was loaded onto a Microcon 30™ column and centrifuged at 11000 x g for 8 
minutes (5417R centrifuge, Eppendorf). The flow-through was discarded and the column
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was washed with 400 pi distilled water followed by centrifugation at 11000 x g for 8 
minutes. This wash step was repeated two times (three washes in total). A volume of 
between 20 pi and 50 pi water was left at the top of the column after the third wash. The 
column was inverted and the plasmid eluted by centrifugation at 960 x g for 3 minutes.
6.2.2.5.14 Electroporation of plasmid into E. coli XL1 Blue
An aliquot of 100 pi electrocompetent E. coli XL1 Blue (Stratagene) was thawed on ice. 
As soon as the cells had thawed, the plasmid DNA was added and mixed well by 
pipetting. The cell suspension was transferred to a precooled (on ice) 2 mm gap 
electroporation cuvette (Bio-Rad Laboratories Ltd., Hertfordshire, UK) and the cuvette 
was quickly placed in the loading arm of a Gene Pulser II (Bio-Rad Laboratories Ltd.). 
The cells were pulsed (2500V, 200 ohm, 25 pF) and the time constant noted (should be 
between 4.5 ms and 5 ms). The cells were recovered from the cuvette with the addition of 
900 pi 2x YT media containing 10 mM MgCL, 2.5 mM KC1 and 2% (w/v) glucose. The 
cells were incubated for 1 hour at 37°C with shaking, then plated out on 2x YT agar 
plates containing 1% (w/v) glucose and 30 pg/ml chloramphenicol. The plates were 




6.3.1 Panning naive human scFv phage display libraries for ligands that display 
cross-species recognition of bacterial adenylate kinase
The Tomlinson I+J and the Griffin naive human scFv phage display libraries were panned 
to isolate phage displaying a scFv that recognised the recombinant adenylate kinase 
(AdK) from F. tularensis (AdKFT) and Y. pestis (AdKYP). The strategy chosen was to 
alternate each pan against a different AdK in subsequent panning rounds. The first 
panning round would be against AdKYP, the second AdKFT, the third AdKYP and the 
fourth AdKFT, with the aim that phage displaying scAb that recognised a conserved 
epitope of AdK would be amplified. In the initial pan the immunotubes were coated with 
4 ml of 50 pg/ml AdKYP. The tubes in the second pan were coated with 4 ml of 50 pg/ml 
AdKFT, while the concentration of the AdK in pans 3 (AdKYP) and pan 4 (AdKFT) was 
reduced to 5 pg/ml to select for higher affinity scFvs. The phage titres eluted from each 
panning round are shown in Table 6.3. The polyclonal phage recovered from each 
panning round from both libraries were assessed against both recombinant AdKs by 
indirect ELISA (Figure 6.1). The ELISA signal of the polyclonal phage recovered from 
both Griffin and Tomlinson I+J libraries from each panning round against skimmed milk 
powder was as high as the ELISA signal seen when the phage was tested against both 
AdKs.
Monoclonal phage were grown from bacterial colonies picked from the third and fourth 
panning rounds. Ninety monoclonal phage preparations from each library were screened 
by indirect ELISA (a selection of assays is shown in Figure 6.2). The ELISA signal in 
each monoclonal phage preparation assay was as high against the skimmed milk powder 
as to either AdKFT or AdKYP.
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a)
Pan number Antigen (pg/ml) Initial phage Eluted phage
1 AdKYP (50) >T © N
J 1 I—^ © 1>
J
3.4x10”
2 AdKFT (50) 6.84x10° 7.2x10”
3 AdKYP (5) 1.03xl0l2 2.7x10'
4 AdKFT (5) Not known 4.51x10”
b)
Panning round Antigen (pg/ml) Initial phage titre Eluted phage titre
1 AdKYP (50) lx l0 °-1 0 ° 2.41x10'
2 AdKFT (50) 3.14x10° 3.1x10'
3 AdKYP (5) 5.3x10“ 1.5x10'
4 AdKFT (5) Not known 1.43x10”
Table 6.3 Titres of phage from the panning procedure of the Griffin and Tomlinson 
I+J human scFv phage display libraries against bacterial adenylate kinase.
Both the (a) Griffin and (b) Tomlinson I+J naive human scFv phage display libraries 
were panned against bacterial adenylate kinase (AdK). In order to isolate scFvs that 
recognized a conserved epitope the protein the libraries were panned against was 
alternated between recombinant AdK from Y. pestis (AdKYP) and F. tularensis 
(AdKFT). The initial phage count was the amount of phage used in each panning step, 
while the eluted phage was the number of phage eluted from each panning step. The 
phage titres were measured by infecting TGI E. coli with serial dilutions of phage and 
counting the number of bacterial colonies that grew on selective media. The initial phage 
counts for the fourth panning round were unable to be accurately determined, believed to 
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Figure 6.1 Indirect ELISA of the polyclonal phage recovered from each panning round of 
the (a) Griffin and (b) Tomlinson I+J naive scFv libraries with bacterial adenylate kinase.
The polyclonal phage at each panning round was tested against the recombinant adenylate kinase 
proteins from Y. pestis (AdKYP) and F. tularensis (AdKFT), as well as the blocking agent used in 
each panning step, skimmed milk powder. Immulon 4HBX microtitre plates were coated with 
either the AdK at 5 pg/ml in PBS or 2% (w/v) MPBS. A sheep anti-M13 HRP conjugate (1:1000 
dilution in 2% [w/v] MPBS) was used as the reporting antibody and the substrate was TMB. Both 
the optical densities at 450 nm and 650 nm were measured, as the assay signal derived by 
subtracting the OD650 from the OD450. The negative control was PBS, without phage or antibody. 
Each assay was duplicated on the microtitre plate and error bars calculated by standard deviation. 
The background signal was defined as the mean of the optical densities of the negative control 
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Figure 6.2 Indirect ELISA of anti-adenylate kinase monoclonal phage preparations.
Selected monoclonal phage preparations are shown from the fourth panning round against 
bacterial adenylate kinase (AdK) of the naive (a) Griffin and (b) Tomlinson I+J scFv phage 
display libraries. Selected monoclonal phage preparations were screened against recombinant 
AdK from F. tularensis (AdKFT), Y. pestis (AdKYP) and the blocking agent used during the 
panning rounds, skimmed milk powder. Immulon™ 4HBX microtitre plates were coated with 
either the AdK at 5 pg/ml in PBS or 2% (w/v) MPBS. A sheep anti-M13 HRP conjugate (1:1000 
dilution in 2% [w/v] MPBS) was used as the reporting antibody and the substrate was TMB. Both 
the optical densities at 450 nm and 650 nm were measured, as the assay signal derived by 
subtracting the OD650 from the OD450. The negative controls were PBS, without phage. No repeats 
were used for this assay. The negative controls are the mean signal of four wells and the error bars 
calculated by standard deviation.
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6.3.2 Assessment of the adherence of the adenylate kinase to the plastic-ware used 
while panning naive phage display libraries and screening selected scFv
As no specific scFvs that recognised AdK was isolated, the plastic-ware used in the 
panning and ELISA assessment of scFvs was tested by indirect ELISA to ensure the AdK 
had adhered to the immunotube surface before each panning step. An ELISA was 
completed in immunotubes coated with either 5 pg/ml or 50 pg/ml of AdK. The assay 
gave an optical density at 414 nm of greater than 3, which was similar to the optical 
density at 414 nm developed by a standard indirect ELISA on an Immunlon™ 2HB 
microtitre plate (Figure 6.3). An indirect ELISA using an Immunlon™ 2HB microtitre 
plate with both AdKFT and AdKYP was compared to assays completed on the 4HBX 
plates used in the ELISA screens at Haptogen, Aberdeen (Figure 6.3). The microtitre 
plates were coated with AdK in both PBS and 50 mM carbonate-bicarbonate buffer 
pH9.6. All of the assay's signals were similar, whether the antigen was coated to the plate 
in PBS or carbonate-bicarbonate buffer on either type of microtitre plate tested.
6.3.3 Panning the Griffin scFv phage display library for ligands that recognise a 
conserved epitope of bacterial HSP60
The Griffin naive human scFv phage display library was panned to isolate phage 
displaying scFv that recognised conserved epitopes of bacterial HSP60. The same 
strategy was used as that for the AdK panning; the recombinant HSP60 from two 
different bacterial species used to coat the immunotubes were alternated in subsequent 
panning rounds. The first and third panning round was against recombinant E. coli 
HSP60, the second and fourth against recombinant F. tularensis HSP60. The 
immunotubes were coated with 2 ml of 10 pg/ml HSP60 in PBS in each panning round. 
The phage titres eluted from each panning round are shown in Table 6.4.
The polyclonal phage recovered from each panning round were assessed against 
recombinant E. coli HSP60 in indirect ELISA (Figure 6.4a). The ELISA signal of the 
polyclonal phage recovered from the Griffin library from each panning round against
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Figure 6.3 Indirect ELISA to confirm the adherence of adenylate kinase to the plastic-ware 
used while panning naive phage display libraries and screening selected scFvs.
Immunlon™ 2HB and Immunlon™ 4HBX microtite plates were coated with recombinant 
adenylate kinase (AdK) from both (a) Y. pestis (AdKYP) or (b) F. tularensis (AdKFT). The 
AdKs were used at 10 pg/ml in either PBS or 50 mM carbonate-bicarbonate buffer pH9.6 (ABB) 
and triple-diluted across the microtitre plate. Rabbit anti-AdKYP or rabbit anti-AdKFT were used 
as the detection antibody at 10 pg/ml in MPBS, while an anti-rabbit IgG HRP conjugate (Bio- 
Rad) was used as the reporting antibody. Each assay was repeated in duplicate and the error bars 
calculated by standard deviation. The background signal was defined as the mean absorbance of 
4 negative control wells plus 2 standard deviations.
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Panning round Antigen (pg/ml) Initial phage titre Eluted phage titre
1 HEC (10) 1.4x10“ 2760
2 HFT (10) 7x l0 lu 3504
3 HEC (10) 1.8x10“ 2.08X105
4 HFT (10) 1.9x10“ 9.6x104
Table 6.4 Titres of phage from the panning procedure of the Griffin human scFv
phage display library against bacterial heat shock protein 60 (HSP60).
The Griffin naive human scFv phage display library was panned against bacterial HSP60. 
In order to isolate scFvs that recognized a conserved epitope, the antigen the libraries 
were panned against was alternated between the recombinant HSP60 protein from E. coli 
(HEC) and F. tularensis (HFT). The initial phage count was the amount of phage used in 
each panning step, while the eluted phage was the number of phage eluted from each 
panning step. The phage titres were measured by infecting E. coli XL1 Blue with serial 
dilutions of phage and counting the number of bacterial colonies that grew on selective 
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Figure 6.4 Indirect ELISA of polyclonal and monoclonal phage preparations from panning 
the Griffin phage display library with bacterial HSP60.
The (a) polyclonal phage produced after each panning round and (b) a selection of the 
monoclonal phage preparations picked from the fourth panning round were tested against E. coli 
HSP60 and the blocking agent used in the panning rounds, skimmed milk powder. Microtitre 
plates were coated with either E. coli HSP60 at 10 pg/ml in PBS or 2% (w/v) MPBS. An anti- 
M13 HRP conjugate (1:1000 dilution in MPBS) was used as the reporting antibody. Each assay 
was repeated in duplicate and the error bars calculated by standard deviation. The negative 
controls were PBS, without phage.
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skimmed milk powder was as high as the ELISA signal seen when the phage was tested 
against E. coli HSP60. Fifty bacterial colonies were picked from the 24 cm selective agar 
plate after the fourth panning round and monoclonal phage were produced and screened 
by indirect ELISA (Figure 6.4b). None of the scFv presented on the phage gave a higher 
signal against recombinant E. coli HSP60 than skimmed milk powder in the indirect 
ELISA.
6.3.4 Generation of single chain antibodies from the anti-HSP60 monoclonal cell 
line HFT2 and anti-adenylate kinase monoclonal cell lines AKFT1 and 
AKYP3
Total RNA was purified from the anti-AdK monoclonal antibody cell lines AKFT1 and 
AKYP3, as well as the anti-HSP60 hybridoma cell line HFT2. The concentration of the 
total RNA purified from each cell line was 272 ng/pl for AKFT1, 504 ng/pl for AKYP3 
and 5.4 pg/pl for HFT2. cDNA was produced with Superscript™ reverse transcriptase 
and the antibody heavy and light chains were amplified by PCR using degenerate primers 
at three annealing temperatures (45°C, 50°C and 55°C). The PCR products were assessed 
on 2% (w/v) agarose E-gels® (results not shown). The intensity of each band of the PCR 
products did not appear to be affected by the variation in annealing temperature. The PCR 
products were purified in a crystal violet gel and recovered from the agarose slice using a 
SNAP™ purification kit. The purified PCR products were assessed on 2% (w/v) agarose 
E-gels® (Figure 6.5). Bands at approximately 400 base pairs (bp) were visible in the 
heavy and light chain PCR products from all three monoclonal cell lines.
The heavy and light chains were linked by assembly PCR. The assembly PCR products 
purified by phenol / chloroform extraction and concentrated by ethanol precipitation. The 
assembly PCR products were digested with Sfil in preparation before ligation into Sfil- 
digested pAKlOO. The Sfil-digested assembly PCR products were assessed on 2% (w/v) 
or 1.2% (w/v) agarose E-gels® (Figure 6.6). Bands at approximately 800 bp were visible 
for all three monoclonal cell lines.
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a) 1 100 bp DNA ladder
2 Light chain from AKFT1
3 Heavy chain from AKFT1
b) 1 100 bp DNA ladder
2 Heavy chain from HFT2
3 Light chain from HFT2
4 Light chain from AKYP3
5 Heavy chain from AKYP3
Figure 6.5 E-gel® analysis of the antibody heavy and light chain PCR products from three
monoclonal cell lines.
Monoclonal cell line antibody heavy and light chain PCR products were assessed on 2% (w/v) 
agarose E-gels®. The PCR products from the anti-adenylate kinase monoclonal cell lines AKFT1 
and AKYP3 are shown in (a), while (b) shows the PCR products from the anti-HSP60 cell line, 
HFT2. A 100 base pair (bp) DNA ladder (New England Biolabs) was used, with 0.5 pg of the 
ladder loaded.
1 2 3
a) 1 AKFT1 heavy + light chain b) 1
2 AKYP3 heavy + light chain 2
3 100 bp DNA ladder
Figure 6.6 E-gel® analysis of Sfil-digested assembly PCR products from the monoclonal 
cell lines AKFT1, AKYP3 and HFT2.
Monoclonal cell line antibody heavy and light chain assembly PCR products that had been 
digested with Sfil were assessed on agarose E-gels®. The assembly PCR products from the anti­
adenylate kinase monoclonal cell lines AKFT1 and AKYP3 are shown in (a) on a 2% (w/v) 
agarose gel, while (b) shows the assembly PCR products from the anti-HSP60 cell line, HFT2, on 
a 1.2% (w/v) agarose gel. A 100 base pair (bp) DNA ladder (New England Biolabs) was used, 
with 0.5 pg of the ladder loaded per gel.
1 2
100 bp DNA ladder 
HFT2 heavy + light chain
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The Sfil-digested assembly PCR products were ligated into Sfil-digested pAKlOO, then 
transformed into electrocompetent E. coli XL1 Blue cells. The number of transformed 
colonies that grew from the AKFT1 transformation was 2xl05 colonies and lxlO5 
colonies grew from both the AKYP3 and HFT2 transformations. Phage were produced 
from these bacterial library stocks. Both AKFT1 and AKYP3 phage libraries were panned 
once against AdKFT. The eluted phage titres were 1020 from the AKFT1 library and 
7180 from the AKYP3 library. Ten colonies were picked from each panning round, 
monoclonal phage produced and screened by indirect ELISA (Figure 6.7a and Figure 
6.7b). All twenty monoclonal phage preparations had a greater ELISA signal against 
AdKFT than skimmed milk powder. The HFT2 phage library was panned once against 
E. coli HSP60, resulting in an eluted phage titre of 2536. Twelve colonies were picked, 
monoclonal phage produced and screened by indirect ELISA (Figure 6.7c). Nine 
monoclonal phage preparations had a greater ELISA signal against recombinant E. coli 
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Figure 6.7 Indirect ELISA screen of monoclonal phage preparations isolated by panning 
phage display libraries created from the monoclonal cell lines AKFT1, AKYP3 and 
HFT2. The AKFT1 and AKYP3 monoclonal phage were screened against F. tularensis 
adenylate kinase (AdKFT) and skimmed milk powder. The HFT2 monoclonal phage 
were screened against E. coli HSP60 and skimmed milk powder. An anti-M13 HRP 
conjugate (1:1000 dilution in MPBS) was used as the reporting antibody. The AKFT1 and 
AKYP3 assays were not repeated. The HFT2 assays were repeated in duplicate and the error bars 
calculated by standard deviation.
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6.4 Discussion
There were two aims of this section of work. The first was to isolate single-chain 
antibody (scFv) fragment-presenting phage from human naive scAb phage display 
libraries that recognised a conserved epitope of the potential bacterial biomarker proteins 
HSP60 and adenylate kinase (AdK). The second was to convert monoclonal cell lines that 
produced antibody that had been shown to recognise a biomarker protein from different 
bacterial species into scFvs. Panning the Tomlinson I+J and the Griffin phage display 
libraries against recombinant bacterial HSP60 or AdK failed to isolate phage that 
displayed scFv that specifically recognised either HSP60 or AdK. The three monoclonal 
cell-lines HFT2 (anti-HSP60), AKFT1 and AKYP3 (anti-AdK) were converted into 
scFvs.
The number of eluted phage from the Griffin naive scFv phage display library panned 
against recombinant bacterial AdK showed a modest increase up to the third pan (Table 
6.3a), indicating a possible enrichment of specific phage presenting scFv that recognised 
AdK. The phage titres for the initial and eluted phage for the fourth pan are much higher 
than expected, most likely due to contamination of the pipettes with phage. The number 
of eluted phage from the Tomlinson I+J naive scFv phage display library against AdK did 
not show an increase up to the third pan, indicating no enrichment in the number of 
specific phage (Table 6.3b). Probable phage contamination of the pipettes made the phage 
titres for the fourth panning round flawed. The phage titre for the fourth panning round 
was not repeated as this work was done at Haptogen at the University of Aberdeen and 
my time in this laboratory was limited. Indirect ELISA assessment of monoclonal phage 
produced from individual bacterial colonies picked from the third and fourth pans did not 
identify any phage displaying scFv that recognised either the recombinant F. tularensis or 
Y. pestis AdKs (Figure 6.2). Those phage preparations that gave a positive ELISA result 
when tested against an AdK also gave a positive ELISA signal of similar intensity against 
the negative control, skimmed milk powder. Skimmed milk powder was the blocking 
agent used in the indirect ELISA, and also in each of the phage display panning steps. It 
is probable that the majority of the phage isolated through the panning steps against AdK
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present scFv that recognised milk proteins present in skimmed milk powder. This is 
supported by the polyclonal phage ELISAs of phage produced after each panning round 
with both libraries in which the highest ELISA signal was seen against milk powder, and 
not AdK (Figure 6.1).
The Griffin naive human scFv phage display library was panned against recombinant 
HSP60 proteins with the aim of isolating phage presenting scFv that recognised a 
conserved epitope of bacterial HSP60. The titres of the phage eluted after each panning 
step increased, indicating a possible enrichment of phage presenting scFv that recognised 
a conserved HSP60 epitope (Table 6.4). However, as with the AdK panning experiment, 
all the monoclonal phage preparations screened by indirect ELISA displayed scFvs that 
gave as high an ELISA signal to skimmed milk powder as to the HSP60 (Figure 6.4).
There are several possible explanations why I failed to isolate phage presenting scFv that 
recognised a conserved epitope of a bacterial biomarker protein. The Ml 3 bacteriophage 
is exploited in phage display to present a non-bacteriophage protein on the phage surface 
(Sidhu, 2001). The bacteriophage lifecycle is used to expand the numbers of phage in an 
E. coli bacterial host as the phage multiply, then lyse the bacterium. Phage are harvested 
and panned against a target protein, isolating phage presenting the desired scFv. The 
phage eluted during the panning step are allowed to reinfect bacteria. Bacteria containing 
the scFv plasmid containing an antibiotic resistance gene are cultured, then the bacteria 
are infected with a M l3 helper phage, which incorporates the scFv gene in the phage 
multiplied within the bacterial cell, and release phage for use in the next panning round 
(Winter et al., 1994, Hoogenboom et al., 1998).
The culture of phage displaying a scFv that recognises a conserved epitope of a bacterial 
protein within an E. coli bacterium may not be as efficient as the culture of phage 
displaying a scFv that recognises a protein epitope that is not represented within the E. 
coli proteome. The presence of antibody within the bacterium that binds to conserved 
epitopes of proteins essential for bacterial growth is likely to inhibit bacterial growth, 
compared to phage displaying non-specific scFv. Over the course of a panning round this
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toxicity could mean that the proportion of phage presenting scFv that recognised the 
desired epitope would decline in comparison to the proportion of phage that displayed 
scFv specific against a protein not conserved in E. coli, such as proteins present in the 
skimmed milk powder used as the blocking agent. Another possibility is that the phage 
displaying an anti-bacterial protein scFv released from the E. coli bacterium are 
effectively pre-blocked with protein from the bacterium, making it difficult to capture the 
desired phage during the panning process. The binding of the bacterial protein with the 
scFv presented on the phage particle is reversible, but there may have been enough 
bacterial AdK or HSP60 present from lysed E. coli in the phage preparation to bias the 
panning selection towards the proteins used as blocking agents. The third possibility is 
that the panning strategy relied on the alternation of two recombinant proteins from 
different bacterial species to amplify that phage displayed scFvs that recognised a 
conserved bacterial epitope. The blocking agent used in each panning step remained 
skimmed milk powder. As milk powder proteins were present in each panning step, it was 
more likely to isolate phage displaying scAb that recognised the milk proteins than scAb 
specific against a conserved bacterial epitope.
Further work continued at Haptogen (University of Aberdeen) to isolate a scFv that 
recognised a conserved epitope of a potential bacterial biomarker protein. This work was 
described in a PhD thesis for the University of Aberdeen by Dhillon, 2004. The Griffin 
and Tomlinson I+J libraries were panned against AdK using the same strategy as 
described in this chapter, except that the block agent used in each panning step was 
alternated between skimmed milk powder and bovine serum albumin. No specific anti- 
AdK scFvs were isolated. A selection of different blocking agents was screened in the 
panning procedure. A commercial ELISA blocking agent from Boehringer gave the best 
results although reproducibility was poor. These results indicated that the blocking agent 
used in the panning procedure was not the determining factor that prevented the isolation 
of specific anti-AdK scFvs. A competition strategy using free AdK to elute the phage 
rather than triethylamine gave some promising results and two scFvs were isolated that 
showed a higher response to the AdK in an indirect ELISA than for the blocking agent. 
These scFvs could only be produced at concentrations of 1 mg per litre or lower in a
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bacterial expression system. Attempts to isolate a scFv that recognised a conserved 
epitope of HSP60 from the DBDX library failed (Dhillon, 2004).
The anti-HSP60 monoclonal cell line HFT2 and the anti-AdK cell lines AKFT1 and 
AKYP3 were expressed as single chain antibodies on a phage surface. One panning round 
was completed for each scFv library created from each monoclonal cell line, but as most 
of the phage in the initial phage preparation should have been displaying an anti-HSP60 
or AdK scFv the difficulties seen when panning against the naive libraries were avoided.
It may be possible to generate libraries based on the monoclonal antibodies by 
introducing mutations into the scFv gene. However, the AdK scFvs isolated at Haptogen 
were not produced in a bacterial expression system in high concentrations (above 1 
mg/litre). The scFvs produced from the monoclonal cell lines AKFT1, AKYP3 and HFT2 
have not been expressed at this time, so the levels of expression are unknown. The 
situation of the scFvs recognising E. coli proteins that hampered the panning of the naive 
antibody phage display libraries seem likely to inhibit the expression of anti-HSP60 or 
AdK scFv in a bacterial expression system, but this needs to be investigated further. An 
alternative is to use an eukaryotic expression system, such as Pichia pastoris (Cereghino 
and Cregg, 2000). However, there is still the difficulty of panning naive scFv phage 
display libraries, which are dependant on the use of E. coli as a host for the M13 phage.
There has been a previous attempt to pan a scFv human phage display library created 
from mononuclear cells taken from a blood sample of a Heliobacter py/on-infected 
patient with HSP60 (Reiche et al., 2002). This attempt was unsuccessful. There are few 
other references regarding the panning of scFv against either HSP60 or AdK in the 
literature.
In summary, the difficulty in isolating suitable ligands for use in the immunoaffinity step 
of the mass spectrometer based detection system is a disappointment. Successfully 
screening naive antibody phage display libraries would have been cheaper both in terms 
of time and effort than generating monoclonal cell lines. Monoclonal cell lines may still 
be used as the basis of single chain antibody phage display libraries derived by mutation
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that could provide a useful diversity in potential ligands. However a suitable expression 
system may still have to be found to produce the antibody in sufficient quantity.
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Chapter Seven




The aim of the crystallographic studies in this project was to generate a structural model 
of the binding site of a single-chain Fv antibody (scFv) with either of the two potential 
bacterial biomarker proteins; heat shock protein 60 (HSP60) or adenylate kinase (AdK).
A structural model of the scFv binding site will provide an understanding of the 
interactions between the scFv and the biomarker protein, and may provide information 
that could allow the directed design of the scFv in the future. It is envisaged that the 
immunoaffmity purification step in the future mass spectrometry-based detection system 
will use scFvs as ligands rather than monoclonal antibodies (mAbs). The properties of a 
scFv can be manipulated by genetic engineering to allow the ligand to be tailored for use 
in the immunoaffmity application, which is not possible with mAbs.
There are two strategies by which scFvs can be engineered to improve affinity; to create a 
secondary scFv phage display library from an existing scFv by random mutagenesis or 
gene shuffling to mimic affinity maturation, or by directed design through site-directed 
mutagenesis based on structural information of the scFv (Hudson and Souriau, 2003). 
Directed design of the scFv relies on an accurate molecular model of the antibody-antigen 
binding site to allow suitable residues for site-specific mutagenesis to be selected, and 
several approaches have been used. The effect on affinity of substitutions in the binding 
site of scFv and Fab fragments on antibody affinity has been studied, based on crystal 
structures of the Fv and Fab in complex with their antigen (Dougan et al., 1998). The 
elimination of amino acid residues by site directed mutagenesis can result in an increase 
in the affinity of an antibody, based on molecular modelling combined with site-specific 
mutagenesis (Roberts et al., 1987), and the substitution of residues can increase the 
affinity of a Fv fragment, based on a molecular model produced by nuclear magnetic 
resonance spectroscopy (Riechmann et al., 1992). Site-directed mutagenesis can be used 
to reduce a Fab fragment's affinity and alter its specificity based on crystallographic 
models for use in immunoaffmity chromatography (Nevanen et al., 2003). A molecular 
model of the target protein can allow an antibody to be adapted to bind to that protein. A 
polypeptide designed on the basis of a molecular model of the ricin A chain can be
213
inserted into the complementarity determining region (CDR) of a variable heavy chain 
domain to produce a recombinant antibody that reduced ricin-induced cytotoxicity (Wang 
et al., 2005). Also an attempt has been made to construct an artificial Fab fragment 
against cystatin by modifying the CDRs of an existing Fab fragment based on 
crystallographic structural models but this resulted in a recombinant antibody with no 
affinity for the antigen (Schiweck and Skerra, 1997).
Before attempting to crystallise a bacterial biomarker protein in complex with a single 
chain antibody, the bacterial biomarker proteins were studied individually to see if 
crystals suitable for crystallographic studies could be produced from the available protein 
stocks. The two AdKs that had been used to raise antibodies were investigated; 
recombinant proteins from Y. pestis (AdKYP) and F. tularensis (AdKFT), supplied by the 
Microbiology Department at Dstl. An amino acid sequence comparison of the two AdKs 
is shown in Chapter 4, Figure 4.1. The crystal structure of is. coli AdK has been reported 
previously using the crystals grown in 2.2 M ammonium sulphate, 1% (w/v) PEG 2000 
monomethyl ether, 50 mM MES, pH6.7, lOmM EDTA and 3 mM ADP (Berry, 1995), 
and in the presence of a bound ADP homologue, P1, P5 di(adenosine-5’) pentaphosphate 
(Muller and Schulz, 1992). Amino acid sequence alignments between E. coli 0157 AdK 
and the AdK proteins from F. tularensis Schu 4 and Y. pestis are shown in Figure 7.1. 
There is a high degree of sequence identity between the E. coli 0157 and the F. tularensis 
Schu 4 adenylate kinases (56.6% identity and 73.1% similarity based on a EMBOSS- 
Align alignment with the Needleman-Wunsch global algorithm [Needleman and Wunsch, 
1970]) and between the E. coli 0157 and Y. pestis AdKs (87.4% identity and 93.0% 
similarity). Due to the sequence similarity between the proteins it was thought that the 
conditions that produced E. coli AdK crystals could be used as a starting point to find a 
suitable buffer to grow crystals of related AdKs. The conditions that generated these 
crystals may provide a starting point to crystallise other bacterial AdKs. A 
crystallographic model has not been described for either AdKYP or AdKFT.
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a)
AdK EC 1 mriillgapgagkgtqaqfimekygipqistgdmlraavksgselgkqak 50
I I I I I I I I I I I I I I I I I : • I • : I I • I • • I I I I I I : I • • : I I I I • I I : : • I
AdK FT 1 mriillgapgagkgtqakiieqkyniahistgdmiretiksgsalgqelk 50
AdK EC 51 dimdagklvtdelvialvkeriaqedcrngflldgfprtipqadamkeag 100
AdK FT 51 kvldagelvsdefiikivkdriskndcnngflldgvprtipqaqeldklg 100
AdK EC 101 invdyvlefdvpdelivdrivgrrvhapsgrvyhvkfnppkvegkddvtg 150
AdK FT 101 vnidyivevdvadnllieritgrrihpasgrtyhtkfnppkvadkddvtg 150
AdK EC 151 eelttrkddqeetvrkrlveyhqmtapligyyskeaeagnt kyakvd 197
AdK FT 151 eplitrtddnedtvkqrlsvyhaqtaklidfy-rnfsstntkipkyikin 199 
AdK EC 198 gtkpvaevradlekilg 214




Gaps: 6/219 ( 2.7%)
Score: 653.0
b)
AdK EC 1 mriillgapgagkgtqaqfimekygipqistgdmlraavksgselgkqak 50
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I : II I I I * : I I
AdK YP 1 mriillgapgagkgtqaqfimekygipqistgdmlraavkagselglkak 50
AdK EC 51 dimdagklvtdelvialvkeriaqedcrngflldgfprtipqadamkeag 100
: I I I I I I I I I I I I I I I I I I I I I ■ I I I I I : I I I I I I I I I I I I I I I I I I I I I
AdK YP 51 eimdagklvtdelvialvkeritqedcrdgflldgfprtipqadamkeag 100
AdK EC 101 invdyvlefdvpdelivdrivgrrvhapsgrvyhvkfnppkvegkddvtg 150
I * I I I I I I I I I I I I I I I : I I I I I I I I I * I I I I I I I I I I I I I I I - I I I I I I
AdK YP 101 ikvdyvlefdvpdeliverivgrrvhaasgrvyhvkfnppkvedkddvtg 150
AdK EC 151 eelttrkddqeetvrkrlveyhqmtapligyyskeaeagntkyakvdgtk 200
I I I I • I I I I I I • I I I I I I : I I I I • I I I I : • I I • I I I : I I I I : I • I 5 I I I :
AdK YP 151 eeltirkddqeatvrkrlieyhqqtaplvsyyhkeadagntqyfkldgtr 200
AdK EC 201 pvaevradlekilg 214
• I I I I • I : I • • I I I




Gaps: 0/214 ( 0.0%)
Score: 958.0
Figure 7.1 Alignment of adenylate kinase (AdK) amino acid sequences with EMBOSS- 
Align.
Amino acid sequence comparisons are shown between (a) the E. coli 0157 and F. tularensis 
Schu4 AdK sequences and (b) the E. coli 0157 and Y. pestis AdK sequences. The sequences were 
aligned with the EMBOSS-Align tool (Needleman-Wunsch algorithm), accessed through the 
European Bioinformatics Institute website. The matrix was Blosum62, the open gap penalty was
10.0 and the gap extension penalty was 0. An identical amino acid is indicated with " | ", 
conserved substitutions with ":" and semi-conserved substitutions with ".".
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Recombinant E. coli HSP60 was purchased from Sigma-Aldrich for use in immunisations 
to raise antibodies and was used in the crystallographic trials. The crystal structures of an 
E. coli variant which contained two substitutions, R13G and A126V (Braig et al., 1994), 
and of the wild-type E. coli HSP60 (GroEL) in complex with GroES and ADP (Xu et al., 
1997) are known. If suitable crystals for crystallographic studies were grown for any of 
the biomarker proteins, then the production of crystals of the protein in complex with a 
scFv would have been attempted.
A fourth protein, a thermostable luciferase was also explored as a possible subject for 
crystallography. This protein is of interest as luciferase is used as a reporting enzyme in a 
generic bacterial detection system based on the presence of ATP (Stanley, 1989). 
Adenylate kinase can be used as a bacterial cell marker instead of ATP which effectively 
increases the sensitivity of the luciferase assay if  ADP is used as a substrate to push the 
AdK reaction equilibrium towards the production of ATP (Squirrell and Murphy, 1994; 
Corbitt et al., 2000). However luciferase is not thermostable and requires refrigeration to 
prevent irreversible inactivation, which creates a logistical burden for use in fieldable 
detection kits and other detection applications. This instability is illustrated by a 
comparison of the recombinant wildtype luciferase and a thermostable variant of the 
enzyme (Tisi et al., 2001). The crystal structure of the wild-type Photinus pyralis 
luciferase has been solved by Conti et al. (1996). A thermostable luciferase has been 
developed for use at Dstl that contains two substitutions, E354R and D357Y compared to 
the wild-type P. pyralis enzyme (Squirrell et al., 2003), shown in Figure 7.2. This 
thermostable luciferase produces light at a different wavelength than the native protein 
(White, P. J., unpublished observations). The amino acid substitutions in the thermostable 
luciferase are not located in the active site of the enzyme and a molecular model may 
provide an explanation of the shift in wavelength of the emitted light and the increase in 
thermostability compared to the native enzyme. As the thermostable luciferase had been 
produced by Lucigen for use in assay kits at Dstl, it was available in large quantites (over 
lOOmg) for crystallisation trials.
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a)
1 medaknikkg papfypledg tageqlhkam kryalvpgti aftdahievn ityaeyfems
61 vrlaeamkry glntnhriw csenslqffm pvlgalfigv avapandiyn erellnsmni
121 sqptwfvsk kglqkilnvq kklpiiqkii imdsktdyqg fqsmytfvts hlppgfneyd
181 fvpesfdrdk tialimnssg stglpkgval phrtacvrfs hardpifgnq iip dtailsv
241 vpfhhgfgmf ttlg y licg f rwlmyrfee elflrslqdy kiqsallvpt lfsffa k stl
301 idkydlsnlh eiasggapls kevgeavakr fhlpgirqgy g lte t tsa il  itpegddkpg
361 avgkwpffe akwdldtgk tlgvnqrgel cvrgpmimsg yvnnpeatna lidkdgwlhs
421 gdiaywdede hffivdrlks likykgyqva paelesillq  hpnifdagva glpdddagel
481 paawvlehg ktmtekeivd yvasqvttak klrggwfvd evpkgltgkl darkireili
541 kakkggkskl
b)
His tag: msyyhhhhhh ldstslmeda...
1 medaknikkg papfypledg tageqlhkam kryalvpgti aftdahievn ityaeyfems
61 vrlaeamkry glntnhriw csenslqffm pvlgalfigv avapandiyn erellnsmni
121 sqptwfvsk kglqkilnvq kklpiiqkii imdsktdyqg fqsmytfvts hlppgfneyd
181 fvpesfdrdk tialimnssg stglpkgval phrtacvrfs hardpifgnq iipdtailsv
241 vpfhhgfgmf ttlg y licg f rwlmyrfee elflrslqdy kiqsallvpt lfsffa k stl
301 idkydlsnlh eiasggapls kevgeavakr fhlpgirqgy g lte ttsa il itprgdykpg
361 avgkwpffe akwdldtgk tlgvnqrgel cvrgpmimsg yvnnpeatna lidkdgwlhs
421 gdiaywdede hffivdrlks likykgyqva paelesillq  hpnifdagva glpdddagel
481 paawvlehg ktmtekeivd yvasqvttak klrggwfvd evpkgltgkl darkireili
541 kakkggkskl
Figure 7.2 Amino acid sequences of the wild type and thermo-stable Photinus pyralis
luciferases.
The amino acid sequences of the (a) wild type and (b) thermo-stable luciferases are shown. The 
two amino acid substitutions (E354R and D357Y) in the sequence of the thermo-stable luciferase 
are highlighted in red.
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The aims of this section were to:
1. crystallize and generate a structural model of each of the three potential 
biomarker proteins
2. crystallize and generate a structural model of the biomarker proteins in 
complex with a scFv




All chemicals were purchased from Sigma-Aldrich Company Ltd., Fancy Road, Poole, 
Dorset, UK unless stated.
7.2.1.1 Recombinant E. coli HSP60
The recombinant E. coli HSP60 (lot no. 70K4041) was purchased from Sigma-Aldrich 
Company Ltd. The HSP60 was dialyzed into 100 mM N-2-hydroxyethylpiperazine-N'-2- 
ethanesulfonic acid (HEPES), pH7.0 (3 volumes of 4 litres HEPES buffer, minimum of 2 
hours for each buffer change at 4°C) in a 10000 MWCO dialysis cassette (Pierce, N. 
Meridian Road, Rockford, USA). The protein was concentrated with a Vivaspin 10000 
MWCO concentrator (Vivascience GmbH, Hanover, Germany).
7.2.1.2 Recombinant Y. pestis and F. tularensis adenylate kinases
The AdKFT and AdKYP proteins were supplied by the Microbiology department at Dstl. 
The proteins were produced as described in Section 4.2.1, but the proteins for 
crystallographic study were purified a second time on the nickel chelating column in 
increase the purity of the preparation. Twenty milligrams of each recombinant protein 
was supplied. Each AdK was dialyzed into 100 mM HEPES, pH7.0 (3 volumes of 4 litres 
of HEPES buffer, minimum of 2 hours for each buffer change at 4°C) in a 10000MWCO 
dialysis cassette (Pierce) and concentrated with a Vivaspin 10000 MWCO concentrator 
(Vivascience).
7.2.1.3 Thermostable luciferase
The thermostable luciferase was obtained from stocks produced by Lucigen Limited 
(Porton Down Science Park, Wiltshire, UK) for the Detection department at Dstl. The
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luciferase was supplied at 6.3 mg/ml in a storage buffer consisting of 0.2 M ammonium 
sulphate, 25 mM Tris/HCl, pH 7.8, 25% (v/v) ethylene glycol, 10% (v/v) glycerol, 1 mM 
EDTA and 1 mM DTT.
7.2.2 Methods
7.2.2.1 Hanging drop vapour diffusion crystallization screens
Hanging vapour diffusion drops were used for the initial crystallization studies of each 
protein. Structure screens 1 and 2 (Molecular Dimensions Limited, Northfield Road, 
Soham, Cambridgeshire, UK) were used to screen for suitable precipitant buffers. The 
precipitant buffer (2 pi) was added to 2 pi of the protein solution on a siliconized cover 
slip (Hampton Research, Aliso Viejo, California, USA) and mixed gently. The cover slip 
was inverted and sealed to a well of a 24-well MD3-11 XRL plate (Molecular 
Dimensions Limited) with high vacuum grease (Dow Coming, 65201 Wiesbaden, USA). 
Each well contained 800 pi of precipitant buffer. The plate was incubated at 16°C and 
examined next day under a light microscope and as often as possible (typically at least 
once a week for the first 2 months, then monthly) for signs of crystal growth. Solutions 
for use in precipitation buffers in further trials where the buffer recipe was varied were 
made up in volumetric flasks with high pressure liquid chromatography (HPLC)-grade 
water (Fisher Scientific UK, Leicestershire, UK).
7.2.2.2 Sitting drop vapour diffusion crystallization screens
Sitting drop vapour diffusion drops were set up as described for hanging drops with the 
exception that a microbridge (Hampton Research) was placed in the well and the protein 
and precipitant buffer were mixed in the depression on the microbridge, rather than on the 
coverslip.
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1.2.23 Ammonium sulphate, PEG6000 and 2-methyl 2-4-pentadiol grid
screens
Vapour diffusion hanging drops were set up with increasing concentrations of ammonium 
sulphate, PEG6000 or 2-methyl 2-4-pentadiol with different pH buffers. All buffers were 
at 100 mM concentration. Citric acid was used for pH4 and 5, 2-N-morpholino 
ethanesulfonic acid (MES) for pH6, HEPES for pH7, Tris for pH8 and biscine for pH9. 
Twelve drops were set up at each pH with 0.8, 1.6, 2.4 and 3.0 M ammonium sulphate; 5, 
10,20 and 30% (w/v) PEG6000; and 10,20,40 and 60% (v/v) 2-methyl 2-4-pentanediol.
7.2.2.4 Streak seeding
Six drops were set up containing 2 pi of the precipitating buffer and 2 pi of the chosen 
protein concentration, as described for vapour diffusion drops. A cat whisker attached to a 
200 pi pipette tip was dipped into a drop containing crystals and streaked sequentially 
through each of the six drops. The wells containing 800 pi of the precipitant buffer were 
sealed and the plate incubated at 16°C. Streak seeding experiments were set up as both 
hanging and sitting vapour diffusion drops.
7.2.2.5 Macroseeding
Two 50 pi drops of the reservoir solution from the selected seed crystal's well were 
placed on siliconized cover slips (Hampton Research) as etching drops. A crystal was 
removed from the drop using a cryo-loop and was placed into each of the etching drops 
before being introduced into a drop containing 2 pi precipitating buffer and 2 pi of the 
chosen protein concentration on a siliconated cover slip. The wells, containing 800 pi of 
the precipitant buffer, were sealed and the plate incubated at 16°C.
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1.2.2.6 Data processing
X-ray diffraction data was processed with the DENZO/HKL suite (Otwinowski and 
Minor, 1997). The HKL suite consists of Denzo, XdisplayF and Scalepack. Denzo and 
XdisplayF were used concurrently. X-ray diffraction data was visualised with XdisplayF, 
while Denzo was used to index the diffraction pattern and refine the crystal parameters 
(type of lattice and unit cell dimensions). Once one diffraction image had been processed, 
Denzo can then autoindex the remaining images. Scalepack is used to merge the data 
produced by Denzo and refine the crystal parameters.
7.2.2.7 EKmax™ digestion
EnterokinaseMax™ (EKmax™) was purchased from Invitrogen Ltd, Inchinnan Business 
Park, Paisley, UK. The optimal quantity of EKmax™ to digest the AdK was determined 
by digesting 20 pg aliquots of the fusion protein with 4 units, 1 unit, 0.1 unit, 0.01 unit 
and 0.001 unit of EKmax™. A unit was defined as the quantity of EKmax™ required to 
digest 20 pg thioredoxin chloramphenicol acetyl transferase fusion protein to 90% 
completion in 16 hours at 37°C. The reaction solution contained 20 pg protein, 3 pi 1 OX 
assay buffer (500 mM Tris-HCl, pH8.0, 10 mM CaCh and 1% [v/v] Tween20), EKmax™ 
(1 unit per pi) and deionized water (Gibco, Paisley, Renfrewshire, UK) to a final volume 
of 30 pi. The reaction mixture was incubated for 16 hours at either 4°C or 37°C. The 
digestion was assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). The digestion reaction was scaled up to digest the desired quantity of 
protein once the optimal ratio of EKmax™ to fusion protein had been determined.
The digested protein was separated from undigested protein and cleaved hexa-his tag by 
purification on a nickel-chelating column. The eluted digested protein was treated with 
EK-Away™ resin (Invitrogen) to remove the contaminating EKmax™. The required 
quantity of EK-Away™ resin (30 pi per unit of EKmax™ to be removed) was 
resuspended in 4 times the volume of stripping buffer (0.1 M NaCl, 0.1 M formic acid, 
pH3.0) and placed on a flat-bed rocker for 2 minutes at room temperature. The resin was 
pelleted by centrifugation at 800 x g for 1 minute in a swing-bucket rotor in a Sorvall
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Legend RT centrifuge (DJB Labcare Ltd., Newport Pagnell, Buckinghamshire, UK) and 
the supernatant removed. The wash step with the stripping buffer was repeated, followed 
by two washes as described above with binding buffer (0.5 M NaCl, 0.05 M potassium 
phosphate, pH8.0). The resin pellet was resuspended in binding buffer to make a 50% 
(v/v) slurry. One part 10X binding buffer was added to 9 parts of the digested protein.
The resin was added to the digest and placed on a flat-bed rocker for 15 minutes at room 
temperature. The resin was pelleted from the protein preparation by centrifugation for 2 
minutes at 5000 x g in a swing-bucket rotor in a Sorvall Legend RT centrifuge (DJB 
Labcare Ltd.).
7.2.2.8 Purification on a nickel-chelating column
Hexa-histidine tagged fusion proteins were purified on a nickel-chelating 1 ml Hi-Trap™ 
HP column from a HisTrap kit (Amersham Biosciences UK Ltd., Amersham Place, Little 
Chalfont, Buckinghamshire, UK). All solutions were administered by hand-held syringe, 
with a flow rate of 0.5 ml/min. The column was prepared by washing with 5ml deionised 
water (Gibco), followed by 1 ml 0.1 M nickel sulphate (NiS0 4 ), then 5 ml deionised 
water. The column was equilibrated with 10ml binding buffer (20 mM sodium phosphate, 
pH7.4, 0.5 M NaCl and 10 mM imidazole). The sample was loaded (in a buffer within the 
pH range 7-8) and followed by a further 10 ml binding buffer. Bound protein was eluted 
with 5 ml elution buffer (20 mM sodium phosphate, pH7.4, 0.5 M NaCl and 500 mM 
imidazole). Throughout the purification 1 ml fractions were collected and the protein 
content of selected fractions assessed by SDS-PAGE.
1.2.2.9 Purification on a gel filtration Sephadex™ S-200 column
Purification of luciferase was performed on a gel filtration Sephadex™ S-200 column 
(Amersham Biosciences) with an AKTAprime system (Amersham Biosciences). The 
running buffer was the luciferase storage buffer without ethylene glycol: 200 mM 
ammonium sulphate, 10% (v/v) glycerol, 50 mM Tris-HCl, pH7.0, 1 mM EDTA and 1 
mM DTT. Luciferase samples were introduced onto the column through a 5 ml sample
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loop. The flow rate was 0.5 ml/min and 3 ml fractions were collected. The purification 
was monitored by optical density at 280 nm and the protein content of selected fractions 
was assessed by SDS-PAGE.
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7.3 Results
7.3.1 Crystallography of recombinant E. coli HSP60
After dialysis into 100 mM HEPES, pH7.0, the recombinant E. coli HSP60 was 
concentrated in a Vivaspin column. The concentration of the E. coli HSP60 preparation 
was estimated by BCA to be 10.5 mg/ml. The purity of the protein was assessed by SDS- 
PAGE (Figure 7.3). Other than the band at 60 kDa corresponding to HSP60, no other 
protein bands were apparent within the sensitivity of the colloidial blue stain with a 2 pg 
protein loading. A vapour diffusion hanging drop crystallisation screen was set up with 
Structure Screens 1 and 2. The crystallisation plates were assessed five days later. Some 
degree of precipitation was seen in 67 out of 96 wells (69.8%), while small crystals were 
seen with three precipitant conditions. Small fine needles in star shaped clusters (less than 
0.2 mm in length and approximately 0.01 mm in cross-section) were seen together with a 
high degree of precipitation with 0.2 M magnesium chloride hexahydrate, 0.1 M HEPES, 
pH7.5 and 30% (v/v) PEG400. Similar small, star-shaped clusters of needle-shaped 
crystals, but with a wider girth, with moderate precipitation were also seen with 0.2 M 
magnesium chloride hexahydrate, 0.1 M Tris/HCl, pH8.5 and 3.4 M 1,6 hexanediol. A 
shower of fine, tiny (less than 0.2 mm in length) needle-shaped crystals were seen with
2.0 M sodium chloride and 10% (w/v) PEG6000.
The recipe of the precipitant buffer that grew the most promising crystals (0.2 M 
magnesium chloride hexahydrate, 0.1 M Tris/HCl, pH8.5 and 3.4 M 1,6 hexanediol) was 
varied in an attempt to produce larger crystals. Hanging drops were set up using the 10.5 
mg/ml preparation of E. coli HSP60 with magnesium chloride concentrations 0.1, 0.2 and 
0.3 M, with 0.1 M Tris and 3.4 M 1,6 hexanediol. Concentrations of 3.0, 3.4 and 3.8 M
1.6 hexanediol were also tested with 0.2M magnesium chloride and 0.1M Tris buffer. The 
largest crystals grew in 0.2M magnesium chloride hexahydrate, 0.1M Tris/HCl pH8.5 and 
3.0M 1,6 hexanediol. Ten drops were set up with this precipitant.
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Lane 1. Mark 12 MW marker 
Lane 2. E. coli HSP60 
Lane 3. Y. pestis AdK 
Lane 4. F. tularensis AdK 
Lane 5. SeeBlue2 MW marker
Lane
Figure 7.3 SDS-PAGE gel of concentrated heat shock protein 60 (HSP60) and adenylate 
kinase (AdK) protein preparations for crystallographic studies.
The proteins were run on 4-20% Tris-glycine gel. Samples were reduced by incubation at 95°C 
for 5 minutes on a heat block with 10% (v/v) reducing agent and 10 pi of the reduced sample 
containing 2 pg protein was loaded per well. The molecular weight (MW) markers were 5 pi of 
Mark 12 or SeeBlue® Plus2.
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Two types of E. coli HSP60 crystals formed. Both types, a hexagonal prism (0.4 x 0.2 x 
0.1 mm) with an apparent indentation and the smaller rods of varying sizes (maximum of 
0.3 x 0.05 x 0.05 mm) are shown in Figure 7.4. The larger hexagonal prisms grew within 
2-3 days, while the rods formed within 7 days. The crystals were exposed to synchrotron 
radiation using Station 14.2 at the SRS (Synchotron Radiation Source, Daresbury 
Laboratory). X-ray diffraction data collection was preformed at cryogenic temperatures 
(100 K) which required a cryopreservative to protect the crystal. The cryopreservative 
solution used was 0.2 M magnesium chloride hexahydrate, 0.1 M Tris/HCl, pH 8.5, 3.0 M
1,6 hexanediol with 25% (v/v) glycerol. The crystals were soaked in the cryopreservative 
for 5-10 minutes. The distance between the crystal and detector (an ADSC Quantum 4R 
CCD) was 525 mm and the X-ray radiation wavelength was 0.98 A. The exposure time 
for each image was 30 seconds while the crystal was rotated by 0.5° between each 
exposure. The larger hexagonal crystals diffracted poorly. The diffraction was too weak 
and data were too mosaic to be of use and the full data set was not collected. The rods 
diffracted weakly and degraded quickly when exposed to radiation. A set of ten images 
were collected before the rod crystals deteriorated to the point where no useful diffraction 
images could be collected. The diffraction images indicated a resolution o f 8 A ( l A = 1 0 '  
cm). Analysis of the data with X-ray data processing programs DENZO, XDisplayF and 
SCALEPACK (Otwinowski and Minor, 1997) failed to allow the unit cell dimensions to 
be calculated due to the poor quality of the data. A diffraction image from this crystal is 
shown in Figure 7.5, showing the limited number of discrete diffraction spots visible.
A second rod crystal was exposed to synchrotron radiation in a visit to Station 14.1 at the 
SRS at Daresbury. The distance between the crystal and the ADSC Quantum 4 detector 
was 450 mm. The X-ray radiation wavelength was 1.49 A, the exposure time was 30 
seconds and the crystal was rotated by 1.0° between each exposure. Four data images of a 
rod were collected before the crystal degraded to the point beyond which no useful 
diffraction images could be seen. The diffraction images indicated a resolution of 6 A.
The data was analysed with DENZO, XDisplayF and SCALEPACK (Otwinowski and 
Minor, 1997) but the data was too poor to allow the unit cell dimensions to be calculated. 
No further crystallography work on the recombinant E. coli HSP60 was attempted.
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a)
Figure 7.4 Crystals of recombinant E. coli HSP60.
Crystals of E. coli HSP60 grown with 0.2M magnesium chloride hexahydrate, 0.1M Tris/HCl 
pH8.5, 3.0M 1,6 hexanediol as the precipitant. The two types of crystal; a hexagonal prism with 
an apparent flaw or indentation (a) and (b), and the rod-shaped crystals in (c) were tested for 
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Figure 7.5 Diffraction image from a HSP60 crystal.
Image collected from a rod-shaped HSP60 crystal at the Synchotron Radiation Source, Station 
14.2 under cryogenic conditions on an ADSC Quantum 4R CCD detector. The diffraction image 
was viewed with XDisplayF (Otwinowski and Minor, 1997). The resolution at the edge was 
estimated to be 8 A.
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7.3.2 Crystallography of recombinant Y. pestis and F. tularensis adenylate kinases
A 5 mg sample of AdKYP and AdKFT were each dialysed into 100 mM HEPES, pH7.0 
and concentrated by centrifugation in a Vivaspin 10000 MWCO concentrator. The protein 
concentration estimated by BCA of AdKYP was 13.8 mg/ml and AdKFT was 12.6 
mg/ml. The purity of the protein was assessed by SDS-PAGE (Figure 7.1). For both AdK 
proteins, apart from the band corresponding to adenylate kinase at 30 kDa, no other bands 
were visible within the sensitivity of the colloidial blue stain for a 2 pg loading of protein.
Hanging drop vapour diffusion crystallisation trials were set up for AdKYP with 
Structure Screens 1 and 2. Hanging drop vapour diffusion plates were only set up with 
Structure Screen 2 for AdKFT due to the limited quantity of protein available. No crystals 
were visible within a week of setting up the plates for either adenylate kinase protein. 
Precipitation was seen in 73% of wells for AdKYP and 35% of wells for the AdKFT after 
4 months, but no crystals grew.
Two drops were set up for both AdKFT and AdKYP with 2.2 M ammonium sulphate, 1% 
(w/v) PEG2000 monomethyl ether, 50 mM MES, pH6.7, 10 mM EDTA and 3 mM ADP 
as the precipitant buffer, based on the precipitant buffer successfully used to grow E. coli 
AdK crystals. These buffer conditions did not result in any crystals or protein 
precipitation. The initial 13.8 mg/ml AdKYP preparation had been contaminated with 
either fungi or bacteria and was discarded. Subsequent work focused on AdKFT as there 
was more material available than the AdKYP. I hoped that a successful approach to 
producing AdKFT crystals could provide the basis of conditions to form AdKYP crystals, 
minimising the amount of protein consumed in crystallisation trials.
There was a possibility of producing AdKFT crystals by crystallising the protein with a 
ligand homologue. Hanging drop vapour diffusion drops were set up with Structure 
Screen 2 for AdKFT with 5 mM ApsA. The protein concentration was reduced to 11.3 
mg/ml with the addition of ApsA. One month after setting up the plates no crystals had 
grown and precipitation was seen in 50% (24 of 48) drops.
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The conditions reported by Berry (1995) that formed Bacillus stearothermophilus AdK 
crystals were 2.45 M ammonium sulphate, either 1% (w/v) PEG1000 or 1% (w/v) 
PEG750 monomethyl ether, 50 mM HEPES, pH6.8-7.8, 0.1% (w/v) sodium azide and 2-5 
mM ApsA. The conditions described by Schulz and Muller (1992) that formed E. coli 
AdK crystals were 1.5 M ammonium sulphate, 50 mM MES, pH6.7, 1.5% (w/v)
PEG1500 and 2 mM Ap5A with the adenylate kinase at 20-25 mg/ml in the drop with 2.0-
2.2 M ammonium sulphate and 50 mM MES, pH6.7 in the reservoir. These conditions 
were used as a basis for a selection of buffers to attempt to identify crystallisation 
conditions for AdKFT. Ten drops were set up with the remainder of the 11.3 mg/ml 
AdKFT preparation with 5 mM ApsA using the buffer conditions shown in Table 7.1.
One month after setting up the plate no crystals were visible, while precipitation was seen 
in one drop (drop 6).
7.3.2.1 Removal of hexa-his tag from recombinant adenylate kinases
Screening crystallisation buffers had not so far identified a starting point for optimisation 
of a crystallisation buffer for either AdKFT or AdKYP. The presence of the flexible hexa- 
his tag may be inhibiting the formation of crystals. Cleaving the hexa-his tag from the 
recombinant protein may lead to crystal growth. The enterokinase EKmax™ cleaves after 
the lysine residue of the amino acid sequence -{Asp^Lys which has been incorporated 
into the hexa-his tag.
A trial digestion of AdKFT and AdKYP with EKmax™ was performed to identify an 
effective ratio of EKmax™ to AdK. The initial digestion was of 20 pg AdK with 4, 1,
0.1, 0.01 or 0.001 units of EKmax™ for 16 hours at 37°C. Heavy precipitation was seen 
in the AdK samples containing 1,0.1, 0.01 and 0.001 units of EKmax™. Samples were 
run on a 12% Tris gel to visualise the integrity of the AdK. No protein was visible in 
either digest containing 4 units of EKmax™. Cleavage of the his-tag was seen in the 
digests of AdKFT or AdKYP with lower amounts of EKmax™, though each digestion 
resulted in several bands while a substantial proportion of the protein was lost due to 
precipitation.
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1 2.5 1.0%PEG1000 HEPES
2 2.5 1.0% PEG 1500 HEPES
3 2.0 1.5% PEG1500 MES
4 2.5 1.5%PEG1500 MES
5 2.0 1.0% PEG 1000 HEPES
6 2.0 1.0% PEG 1000 MES
7 2.0 2.0% PEG 1000 HEPES
8 2.0 2.0% PEG 1000 MES
9 2.0 1.0% PEG 1500 MES
10 2.0 2.0% PEG 1500 MES
Table 7.1 Buffers variations screened with the aim of producing F. tularensis adenylate
kinase (AdKFT) crystals.
These buffers were used in hanging drop vapour diffusion crystallization screens with the aim to 
produce AdKFT crystals. The concentration of the AdK was 11.3 mg/ml in 100 mM HEPES, 
pH7.0 containing 5 mM P1, P5 Di(adenosine-5’) pentaphosphate (Ap5A) and each drop consisted 
of 2 pi of protein and 2 pi of precipitant buffer.
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The digestion trial was repeated with a reduction in the incubation temperature with the 
aim to limit the non-specific digestion of the protein. Each digestion was of 20 jag AdK 
with 1, 0.5 or 0.1 units of EKmax™ for 16 hours at 4°C. Samples were run on a 12% Tris 
gel shown in Figure 7.6. The minimum amount of EKmax™ that digested most of the 20 
pg of AdKFT was 0.5 units. Using more than 0.5 units of EKmax™ did not appear to 
result in increased efficiency of the digestion of AdKFT. AdKYP appears more resistant 
to the enterokinase as the ratio of cleaved and non-cleaved protein is approximately equal 
with both digests that contained 0.5 and 1 unit of EKmax™, compared to AdKFT where 
the majority of the protein was successfully digested.
A larger scale digestion of 1 mg both AdKFT and AdKYP was completed to assess the 
separation of digested AdK from the undigested protein and the cleaved hexa-his tag on a 
nickel-chelating column. Most of the AdKFT was successfully digested and recovered in 
the initial wash fractions from the nickel-chelating column, but in comparison the 
recovery of digested AdKYP was much lower. As the amount of protein available was 
limited and the digestion efficiency for the AdKYP lower than that for AdKFT, I decided 
to only digest AdKFT as the trial digestions indicated a large proportion of this protein 
could be successfully digested and recovered.
A large scale digestion of 12 mg AdKFT with 300 units of EKmax™ for 16 hours at 4°C 
in a 10 ml volume was completed. Two aliquots of 5 ml of the digested AdK were 
purified on a nickel-chelating column to separate the cleaved AdK from the cleaved his- 
tag and non-digested protein. EKmax™ was removed from the cleaved AdKFT 
preparation by treatment with EK-Away™ resin. Samples from each processing step are 
shown on a 12% Tris-glycine gel (Figure 7.7). After treatment with AK-Away resin to 
remove EKmax from the preparation the digested AdKFT was dialysed into 100 mM 
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Figure 7.6 SDS-PAGE gel of trial EKmax™ digestions of recombinant adenylate kinase 
from F. tularensis (AdKFT) and Y pestis (AdKYP).
The trial EKmax™ digestions of 20 jig AdKYP or AdKYP were incubated for 16 hours at 4°C. 
Samples from the digests were run on 12% Tris-glycine gel. Samples were reduced by incubation 
at 95°C for 5 minutes on a heat block with 50 mM dithiothreitol and 10 pi of the reduced sample 






Figure 7.7 SDS-PAGE gel of samples taken from different stages of the EKmax™ digestion 
of recombinant F. tularensis adenylate kinase (AdKFT).
The EKmax™ digestion of 12 mg AdKFT was incubated for 16 hours at 4°C. The digest was split 
into two batches to allow the cleaved AdKFT lacking the hexa-his tag to be separated from 
undigested protein and the cleaved his tag on a nickel-chelating column. The protein not retained 
on the nickel-chelating column was treated with EK-Away™ resin to remove EKmax™. Samples 
from the digest and subsequent purification were run on a 12% Tris-glycine gel. Samples were 
reduced by incubation at 95°C for 5 minutes with 50 mM dithiothreitol and 10 pi of the reduced 
sample containing approximately 2 pg protein was loaded per well. The molecular weight (MW) 
marker was 5 pi of SeeBlue® Plus2.
Lane 1: SeeBlue2 marker, lane 2: undigested AdKFT, lane 3: AdKFT digested with 0.5 units of 
EKmax per 20pg protein, lanes 4 and 5: pooled wash fractions from the two separate nickel- 
chelating column purifications, lanes 6 and 7: elution fractions from the two nickel-chelating 
column purifications, lanes 8 and 9: samples before treatment with EK-Away, lane 10: pooled 
AdKFT after EK-Away treatment.
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13.2.2 Crystallisation trials of EKmax™ digested F. tularensis adenylate
kinase
Hanging drop vapour diffusion crystallisation trials were set up for the EKmax™ digested 
AdKFT containing 2 mM ApsA with Structure Screens 1 and 2 from Molecular 
Dimensions. The plates were assessed 10 days later. Precipitation was seen in 27 out of 
96 buffer conditions (28%). Clusters of very small (0.1 mm) needles were seen with two 
precipitant buffers, the first 0.2 M magnesium formate and the second 0.2 M magnesium 
chloride hexahydrate, 0.1 M Tris, pH8.5 and 3.4 M 1-6 hexanediol. Drops based on 
successful AdK precipitation conditions previously reported were also set up, but did not 
result in any crystals.
A second preparation of EKmax digested AdKFT was prepared. As the quantity of 
AdKFT that had been prepared for crystallographic studies was now limited, it was 
supplemented with a cruder AdKFT preparation. This batch was then purified on a 
nickel-chelating column to attempt in increase the purity of the AdK (Figure 7.8). The 
SDS-PAGE gel shows little difference when stained with the commassie blue between 
the AdKFT prepared for crystallographic studies that had been purified twice on a nickel- 
chelating column (lane 2) and the cruder preparation that had been purified once (lane 3). 
The amount of protein visible in the elution fractions is considerably more than has been 
loaded in previous gels and possible contaminating proteins in the AdKFT preparation 
were now visible with the colloidal blue stain. There was insufficient protein left to allow 
further purification techniques to be assessed to improve the purity of the AdKFT 
preparation, but small needle crystals had been produced from a protein preparation of 
similar purity. The AdKFT was digested with 0.5 units of EKmax™ per 20 pg protein as 
before and digested protein was separated from undigested protein and the cleaved hexa- 
his tag with a nickel-chelating column. The digested adenylate kinase dialysed into 100 
mM HEPES, pH7.0 and concentrated, resulting in a 10 mg/ml solution.
Hanging drop vapour diffusion crystallisation trials were set up for the 10 mg/ml 
EKmax™ digested AdKFT with 2 mM ApsA. Variations of the precipitation buffer that
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produced small needles with the 3.3 mg/ml EKmax™-digested AdKFT were used. The 
buffers and results of the screen are shown in Table 7.2. None of the crystals formed were 
large enough for crystallographic studies.
The SDS-PAGE gel of the nickel-chelating column purification of the F. tularensis 
adenylate kinase (Figure 7.8) indicated possible contaminating proteins visible due to the 
high loading of AdK on the gel. Both AdKYP and AdKFT proteins that had been 
supplied for crystallographic studies were assessed by electrospray mass spectrometry to 
determine whether any contaminating proteins could be detected. Analysis of the 
AdKYP showed several low molecular weight proteins in the range of 790-1990 Da. 
Analysis of the AdKFT showed several low MW proteins as well as a protein peak with a 
MW of 54 kDa which would correspond to the expected MW of a AdK dimer.
Three preparations of AdKFT were run on a SDS-PAGE gel in reducing and non­
reducing conditions to assess the degree of covalently-linked AdK in each (Figure 7.9). 
The AdK prepared for crystallography (which had been purified twice on a nickel- 
chelating column) was compared with the 3.3 mg/ml and 10.0 mg/ml EKmax™-digested 
AdK preparations. Although several faint bands were visible as well as the band at 27 
kDa corresponding to AdKFT, the undigested AdKFT did not show a prominent band in 
the 50 kDa region in either reducing or non-reducing conditions. The EKmax™ digested 
AdKFT, lacking the hexa-his tag, under non-reducing conditions a band was visible at 
approximately 60 kDa. This 60 kDa band is of equal or greater intensity than the band at 
27 kDa. There was insufficient AdK remaining to continue screening buffer conditions.
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Drop Salt Precipitant Buffer Crystal formation
1 - 0.2M magnesium 
formate
- No





3 - 0.2M magnesium 
formate
- No




0.1M Tris pH8.5 Small needles




0.1M Tris pH8.5 Small needles




0.1M Tris pH8.5 Small needles




0.1M Tris pH8.5 Small needles














0.1M Tris pH8.5 No
Table 7.2 Buffer variations based on Structure Screen 2.4 with the EKmax™ digested F. 
tularensis adenylate kinase (AdKFT).
Drops 1 and 2 were set up with the first 3.3mg/ml EKmax-digested AdKFT with 2mM Ap5A, the 
rest of the drops were set up with the second lOmg/ml EK-max-digested AdKFT with 2mM 
Ap5A. Drops 1-4 used the precipitation buffers from Structure Screens 1 and 2 supplied by 
Molecular Dimensions, the other drops used solutions made in the laboratory. After 20 days small 

















Lane 3. Cruder AdKFT
preparation
Lane 4. Fraction 6 Wash
Lane 5. Fraction 10 Wash
Lane 6. Fraction 13 Wash
Lane 7. Fraction 14 Elution
Lane 8. Fraction 15 Elution
Lane 9. Fraction 16 Elution
Lane 10. Fraction 17 Elution
10
Figure 7.8 SDS-PAGE gel of samples taken from selected fractions of a nickel-chelating 
column purification of recombinant F. tularensis adenylate kinase (AdKFT).
Two batches of 7 mg AdKFT were purified on a 1 ml nickel-chelating column and 1 ml fractions 
collected. From selected fractions 10 pi samples were taken and made up to 20 pi with loading 
buffer and reducing agent, and run on a 12% Tris-glycine gel. Samples were reduced by 
incubation at 95°C for 5 minutes with 50 mM dithiothreitol, and 10 pi of the reduced sample was 














Lane 1. SeeBlue2 MW marker 
Lane 2. Reduced crystallographic 
AdKFT preparation 
Lane 3. Reduced 3.3 mg/ml 
EKmax™ digested 
AdKFT 
Lane 4. Reduced 10.0 mg/ml
EKmax™ digested AdKFT 
Lane 5. Non-reduced crystallographic 
AdKFT preparation 
Lane 6. Non-reduced 3.3 mg/ml
EKmax™ digested AdKFT 
Lane 7. Non-reduced 10.0 mg/ml 
EKmax™ digested AdKFT
Figure 7.9 SDS-PAGE gel of reduced and non-reduced EKmax™ digested recombinant F. 
tularensis adenylate kinase (AdKFT).
Reduced and non-reduced samples from EXmax™ digested AdKFT were run on a 4-20% Tris- 
glycine gel, 2 pg protein per well. Samples (20 pi) were reduced by incubation at 95°C for 5 
minutes with 50 mM dithiothreitol and 10 pi of the reduced sample was loaded per well. The 
molecular weight (MW) marker was 5 pi of SeeBlue® Plus2.
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7.3.3 Crystallography of a thermo-stable luciferase
The native Photinus pyralis luciferase has been successfully crystallised in the storage 
buffer described in the methods. The stock thermostable luciferase was supplied by 
Lucigen in this buffer and, as the protein is stable and has formed crystals in this buffer, 
the protein was not dialysed into 100 mM HEPES, pH7.0. An SDS-PAGE gel was run to 
assess the purity of the luciferase preparation (Figure 7.10). Apart from the luciferase at 
64 kDa, lower molecular weight bands at 6, 16, 30,45 and 50 kDa were visible with the 
commassie blue stain in both the reduced or non-reduced samples. However as these 
contaminating proteins were barely visible on the SDS-PAGE gel, hanging drop vapour 
diffusion screens were set up to identify promising precipitant buffers and assess whether 
further purification of the luciferase would be required. Hanging drop vapour diffusion 
crystallisation trials were set up with Structure Screens 1 and 2 from Molecular 
Dimensions. This initial screen used the 6.3 mg/ml luciferase preparation with no further 
concentration or buffer exchange. Clusters of small (less than 0.2 mm long and 0.01 mm 
wide) needle crystals had formed within 2 months with Structure Screen 1, buffer 30 (0.1 
M HEPES, pH7.5,2% (v/v) PEG400 and 2.0 M ammonium sulphate). Similar crystals 
are shown in Figure 7.1 la. Variations on this precipitant buffer were set up as well as a 
selection of conditions based on the conditions that produced native luciferase crystals 
(500-540 mM lithium sulphate, 26% (w/v) PEG8000 and 100 mM Tris-HCl, pH7.8). A 
summary of the buffer conditions and resultant product of the hanging drop after 20 days 
is shown in Table 7.3. Small needle crystals were visible in several drops, but none of the 
crystals were large enough for crystallographic studies. No crystals had formed at this 
time point in the buffer conditions that had produced crystals with the native P. pryalis 
luciferase. Ammonium sulphate, PEG6000 and 2-methyl 2-4-pentadiol screens were also 
set up, but no crystals had grown after 20 days.
An attempt was made to produce larger luciferase crystals by streaking six drops 
containing the stock 6.3 mg/ml luciferase sequentially with a hair that had been dragged 
through a crystal containing drop, in the hope of transferring nucleation sites to promote 
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Lane 2. 5pg reduced luciferase 
Lane 3. 2pg reduced luciferase 
Lane 4. 5pg non-reduced luciferase 
Lane 5. 2pg non-reduced luciferase
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Figure 7.10 SDS-PAGE gel of reduced and non-reduced recombinant thermostable P. pyralis 
luciferase.
Reduced and non-reduced samples of luciferase were run on a 4-20% Tris-glycine gel, with 2 pg 
or 5 pg protein loaded per well. Samples (20 pi) were reduced by incubation at 95°C for 5 
minutes with 50 mM dithiothreitol and 10 pi of the reduced sample was loaded per well. The 




Figure 7.11 Thermostable luciferase crystals.
Crystals of the thermostable luciferase grown in a) 0.1 M HEPES, pH7.0, 2% (v/v) PEG400 and 
2.0 M ammonium sulphate, b) 8% (w/v) PEG8000 and 0.1 M Tris/HCl, pH8.5 and c) 3% (w/v) 
PEG8000, 0.1 M Tris, pH8.5. All crystals grew within 7 days.
243
Drop Salt Precipitant Buffer Crystal formation




0.1 M HEPES, 
pH7.0
Clear




0.1 M HEPES, 
pH7.0
Clear




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Precipitation




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Clear




0.1 M HEPES, 
pH7.0
Very fine needles




0.1 M HEPES, 
pH7.0
Clear




0.1 M HEPES, 
pH7.0
Very fine needles




100 mM Tris- 
HCl, pH8.0
Precipitation




100 mM Tris- 
HCl, pH8.0
Precipitation




100 mM Tris- 
HCl, pH8.0
Precipitation




100 mM Tris- 
HCl, pH8.0
Precipitation




100 mM Tris- 
HCl, pH8.0
Precipitation




100 mM Tris- 
HCl, pH8.0
Precipitation
Table 7.3 Hanging drop vapour diffusion screen of precipitant buffer variations of 
thermostable luciferase assessed after 20 days.
Variations of a buffer that produced crystals from Structure Screen 1 (0.1 M HEPES, pH7.5,2% 
(v/v) PEG400 and 2.0 M ammonium sulphate) and a buffer in which the native P. pryalis 
luciferase formed crystals (0.5 M lithium sulphate, 26% (w/v) PEG8000 and 100 mM Tris-HCl, 
pH7.8) were screened by hanging drop vapour diffusion with the 6.3 mg/ml preparation of 
thermostable luciferase. After 20 days, drops were either clear, contained precipitation to some 
degree or small needle crystals (less than 0.3 mm long and 0.1 mm wide).
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and although small needles formed in the streaked drops, they were not larger than those 
previously obtained and formed within the same time-frame as non-streaked drops.
The luciferase crystals obtained with the stock luciferase preparation were too small for 
crystallographic studies. It was hoped that increasing the purity or the concentration of 
the luciferase by further purification could result in the formation of larger crystals. Two 
batches of stock luciferase were concentrated to 9 mg/ml and 20 mg/ml. Hanging drop 
vapour diffusion wells were set up with 2.0 M ammonium sulphate, 3.5% (v/v) PEG400 
and 0.1 M HEPES, pH7.0 as the precipitant buffer with luciferase preparations of 6.3, 9.0 
and 20.0 mg/ml. Small needle crystals formed within 2 days. The higher the 
concentration of the luciferase, the more crystals formed; however the size of these 
crystals was not greater than previously seen. The 20 mg/ml stock preparation suffered 
considerable precipitation at 4°C within 72 hours after concentration. Drops containing 
luciferase at lower concentrations of 4 and 5 mg/ml (with 2.0 M ammonium sulphate, 
3.5% (v/v) PEG400 and 0.1M HEPES, pH7.0 as the precipitant buffer) were set up to try 
and limit the number of crystals formed. Larger crystals did form with the lower 
luciferase concentrations compared to the drops containing luciferase at 6.3 mg/ml, but 
these crystals were still too small for crystallographic studies. The crystals still formed 
within 2 days regardless of the reduction in the protein in each drop.
As variations in the precipitation buffer and the luciferase concentration were not 
producing crystals of sufficient size, I tried to improve the purity of the luciferase 
preparation. The stock luciferase preparation was originally purified by affinity 
chromatography on a nickel-chelating column via a hexa-his tag. It was hoped that a 
further purification on a nickel-chelating column would reduce the amount of 
contaminating proteins. A 6.3 mg sample of the stock luciferase was purified on a nickel- 
chelating column and samples from each fraction assessed by SDS-PAGE (Figure 7.12). 
There was minimal reduction in the proportion of the contaminating proteins at 10,20, 25 
and 28 kDa to the luciferase between the eluted protein and the stock luciferase sample. 
Proteins at 29 and 48 kDa were visible in the stock luciferase sample and the load 
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Lane 5. Fraction 12 Elution 
Lane 6. Fraction 13 Elution 
Lane 7. Fraction 14 Elution 
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Figure 7.12 SDS-PAGE gel of samples taken from fractions collected during a luciferase 
purification on a nickel-chelating column.
Reduced samples from a luciferase purification on a nickel-chelating column were run on a 4- 
12% Bis-Tris gel in MES buffer. A 1 ml aliquot of the stock 6.3 mg/ml stock luciferase was 
captured on a 1 ml nickel-chelating column and washed with 10 ml of 10 mM imidazole with 20 
mM sodium phosphate and 0.5 M sodium chloride. The luciferase was eluted with 5 ml of 500 
mM imidazole with 20 mM sodium phosphate and 0.5 M NaCl. The purification was performed 
by hand-held syringe and 1 ml fractions were collected. Samples were taken from selected 
fractions and reduced by incubation at 95°C for 5 minutes with 50 mM dithiothreitol; 20 pi of the 
reduced sample was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® 
Plus2.
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Gel filtration chromatography was assessed as an alternative purification method to 
improve the purity of the luciferase. An HiPrep™ 16/60 Sephacryl™ S-200 column was 
used with the low pressure AKTAprime system. A sample of a concentrated luciferase 
preparation (1.6 ml at 10 mg/ml) was passed through the Sephacryl column and 2 ml 
fractions were collected. The protein elution was monitored by measurement of the 
optical density at 280 nm. The protein content of each fraction was assessed by SDS- 
PAGE (Figure 7.13). Fractions 25 and 26 contained fewer contaminating proteins than 
the other elution fractions, particularly compared with fractions 26 to 29 which contain a 
similar quantity of protein. Fractions 25 and 26 were kept while the remaining fractions 
containing protein (fractions 27-31) were pooled and concentrated to a 2 ml volume. The 
luciferase was purified through the column a further 3 times and the protein content 
assessed by SDS-PAGE. In each case, fractions 25 and 26 were collected and pooled, 
while the remaining luciferase was recycled. After the fourth purification, insufficient 
luciferase remained in the eluted fractions to make further purifications with this material 
worthwhile. Two further purifications were completed to supplement the recovered 
luciferase. Each purification used 2 ml of the stock luciferase at 6.3 mg/ml and fractions 
25 and 26 were collected and pooled. The pooled luciferase was concentrated, and the 
protein concentration was estimated by BSA to be 9.2 mg/ml. The purity of the luciferase 
preparation was assessed by SDS-PAGE (Figure 7.14). There was a reduction in 
contaminating proteins (particularly low MW proteins) in the luciferase purified on the 
Sephadex S-200 column when compared to the stock luciferase.
A hanging drop vapour diffusion screen with Structure Screen 1 was set up with the gel 
filtration purified luciferase preparation. Small needle crystals were seen in several 
conditions, but all the crystals appeared to be of the same type. The largest crystals 
formed in 8% (w/v) PEG8000 and 0.1 M Tris/HCl, pH8.5 within 3-4 days. Examples of 
these crystals are shown in Figure 7.1 lb. Further vapour diffusion drops were set up with 
variations in pH (in the range of pH6 to pH9) with a constant 8% (w/v) PEG8000, and 
variations in the concentration of PEG8000 (in the range of 1-15% [w/v]) with 0.1 M Tris 
pH8.5. Needle crystals were seen in most drops, but the largest crystals grew at a pH8.5 
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Figure 7.13 SDS-PAGE gel of samples taken from fraction collected during a luciferase 
purification on a Sephadex S-200 gel filtration column.
Reduced samples from a luciferase purification on a Sephadex S-200 column were run on a 4- 
12% Bis-Tris gel in MES buffer. A 1.6 ml aliquot of a 10 mg/ml luciferase preparation was 
passed through the column at a 0.5 ml/min flow rate and 2 ml fractions collected. Samples were 
taken from selected fractions and reduced by incubation at 95°C for 5 minutes with 50 mM 
dithiothreitol; 20 pi of the reduced sample was loaded per well. The molecular weight (MW) 
marker was 5 pi of SeeBlue® Plus2.
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Figure 7.14 SDS-PAGE gel of luciferase purified on a Sephadex S-200 gel filtration column. 
Reduced luciferase samples were run on a 4-12% Bis-Tris gel in MES buffer. Samples were 
reduced by incubation at 95°C for 5 minutes with 50 mM dithiothreitol; 10 pi of the reduced 
sample was loaded per well. The molecular weight (MW) marker was 5 pi of SeeBlue® Plus2.
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between 1-2 mm, with an approximate volume of 4 pi; however the diameter of drops 
with low concentrations of PEG8000 increased in size, up to 5 mm in diameter, 
increasing the volume of the drop. Care had to be taken not to disturb the drops for fear of 
dislodging them from the coverslip.
Sitting vapour diffusion drops were set up to allow easier manipulation of the crystals and 
to assess if larger crystals could be produced. Drops were set up in duplicate with a range 
of pHs between 8.0-8.5 with 5% (w/v) PEG8000 and a range of concentrations of 
PEG8000 in the range of 3-8% (w/v) with 100 mM Tris, pH8.5. Several needle crystals 
up to 1 mm in length formed that, though not large enough for study at a standard 
synchrotron beam line, could be assessed at a micro-focus beam line. The biggest crystals 
in the sitting drop vapour diffusion drops formed in 3% (w/v) PEG8000, 0.1 M Tris, 
pH8.5. Examples of similar sized crystals grown in a hanging drop are shown in Figure 
7.11c.
Crystals were exposed to synchrotron radiation at the ID 13 microfocus beam line at the 
ESRF (European Synchrotron Radiation Facility) in Grenoble. Crystals were taken from a 
sitting drop as they were easier to manipulate than removing them from a hanging drop as 
each hanging drop had developed a film on the surface. X-ray diffraction data collection 
was performed at cryogenic temperatures (99.5K), and 20% (v/v) glycerol proved suitable 
as a cryopreservative. The distance between the crystal and the small MAR CCD 
detection system (MarResearch, Germany) was 200 mm and the X-ray radiation 
wavelength was 0.98 A. The exposure time was 1 second per pass and there were 3 
passes per image. The crystal was rotated by 1° between each exposure. The crystal 
successfully produced diffraction patterns but due to the intensity of the beam 
deteriorated rapidly. Two sets of 35 images were collected from two different positions of 
the first crystal. The diffraction images indicated a resolution of 3 A. Data was collected 
from three further crystals. None of the crystals lasted for long when exposed to the beam 
before the quality of the data had severely degraded. Thirty-five images were collected 
from the second crystal, 11 from the third and 25 images from the fourth. A diffraction 
image from the first data set is shown in Figure 7.15. Initial analysis of the images from
250
1 1 005.m eed
U rlte /P r ln t I A/D te s t
Update pred Show Overf1




date was send, updating p ic tu re  window
Figure 7.15 Diffraction image from a thermostable luciferase crystal.
Image collected from a luciferase crystal at the micro-focus beam line, Station ID 13 at the 
European Synchrotron Radiation Facility, Grenoble, under cryogenic conditions with a small 
MAR CCD detector. The diffraction image was viewed with XDisplayF (Otwinowski and 
Minor, 1997). The resolution at the image edge was estimated to be 3.68A.
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the fourth crystal indicated that the crystal was primitive orthorhombic while the unit cell 
dimensions are a=96A, b=l 19A and c=150A with a=p=7=90°.
Larger crystals were still required to allow more complete data sets to be collected at a 
less intense beam line as the microfocus beam line destroyed the crystal rapidly. Seeding 
and streaking plates were set up to try to promote the growth of larger crystals. The 
streaked drops used a dilution of the gel filtration purified luciferase preparation, each 
drop set up with the luciferase at 4.5 mg/ml rather than 9 mg/ml. Two sets of six drops 
were set up, one as a hanging drop, the other as sitting drops. The precipitant buffer for 
the hanging drops was 2% (w/v) PEG8000 in either 0.1 M Tris, pH8.5 or pH8.9, while 
the buffer for the sitting drops was 3% (w/v) PEG8000 in either 0.1 M Tris, pH8.5 or 
pH8.9. The streaked drops resulted in showers of needles forming with 4 days along the 
path of the hair streaked through the drop, but the growth of no larger crystals.
Seeded drops were set up as sitting drops with a range of buffer conditions (1-3% [w/v] 
PEG8000 with 0.1 M Tris at either pH8.5 or 8.9). It was difficult to manipulate the 
needles to remove them from the original drop, etch the surface of the crystals, and then 
transfer them into the final sitting drop due the size and fragility of the luciferase crystals. 
The needles had a tendency to wrap around the cryo-loop proving difficult to remove. No 
crystals larger than previously produced grew in the seeded drops.
Further hanging drops were set up to assess if lowering the concentration of ethylene 
glycol (normally 25% [v/v]) in the luciferase preparation would affect the number and 
quality of crystals that formed in each drop. Luciferase preparations were tested that 
contained a range of ethylene glycol concentrations from none to 25% (v/v). No crystals 
larger than previously produced grew in any of the drops. Further work could not be 
completed due to time constraints.
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7.4 Discussion
I was unsuccessful in generating a crystallographic structures for the potential bacterial 
biomarker proteins, E. coli HSP60, AdKFT or AdKYP, or the thermostable luciferase. 
The failure to produce scFv fragments against the bacterial biomarker proteins meant that 
I was unable to attempt to co-crystallise the bacterial biomarker proteins with a scFv to 
produce a molecular model of the antibody binding site. Monoclonal antibodies and 
F(ab’)2 fragments are unsuitable for use in co-crystallisation studies due to the flexibility 
of the molecule at the hinge region and because they are bivalent, rather than scFvs and 
Fabs which are monovalent. In turn, scFvs are likely to be more suitable than Fab for co­
crystallization as they lack the flexible elbow region of a Fab fragment (Kovari et al., 
1995).
The E. coli HSP60 formed crystals readily, but these diffracted weakly and to a low 
resolution. The indistinct spots on the diffraction pattern indicated that the crystals were 
highly mosaic, and the life of the crystal once exposed to synchrotron radiation was very 
limited (10 exposures). Previous successful crystallographic studies with E. coli HSP60 
had either used a protein with two amino acid substitutions (Braig et al., 1994) or in 
complex with the co-chaperonin GroES and ADP (Xu et al., 1997). Both approaches 
effectively restricted the flexibility of the HSP60 and resulted in molecular models of 
resolution 2.8 A and 3.0 A respectively. One possible strategy to obtain higher resolution 
data would be to co-crystallise the HSP60 with a scFv. The scFv may have reduced the 
flexibility of the HSP60 and resulted in the production of a more stable crystal. Co­
crystallisation with scFvs has been successful in crystallising difficult targets, particularly 
membrane proteins, where the bound scFv has increased the available hydrophilic area 
(Iwata et al., 1995; Kovari et al., 1995; Hunte and Michel, 2002). However a scFv was 
not available to attempt a co-crystallisation, and there was little value in continuing to 
attempt to crystallise the HSP60 when the E. coli HSP60 has been well characterised. As 
the two types of E. coli HSP60 crystal did not diffract to high resolutions and were 
unstable when exposed to radiation, it was unlikely that wild-type HSP60 crystals from
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which a high resolution crystallographic model could be produced could be grown 
without a co-factor.
The initial crystallisation trials with both AdKs were unsuccessful in identifying 
promising conditions for crystallisation. Co-crystallising with an ADP homologue was 
also unsuccessful. I had been provided with sufficient AdK for the crystallisation trials if 
no further alteration or purification of the protein was required. However without 
promising crystallisation conditions for either AdKFT or AdKYP, two strategies were 
followed to grow crystals; the removal of the flexible tag of the fusion protein and further 
purification of the AdK. The limited amount of AdK available reduced the number of 
approaches that could be assessed.
The presence of the flexible hexa-his tag may have inhibited crystal formation, although 
crystals have been grown of fusion proteins with small (Bucher et al., 2002) and large 
affinity tags (Smyth et al., 2003). Any reduction in the flexibility of domains, loops or the 
substitution of amino acid residue that have flexible side chains (Derewenda, 2004) may 
result in the growth of protein crystals of targets that have otherwise proven reluctant to 
crystallise. As most of the AdKFT was successfully cleaved by the enterokinase, the 
crystallisation trials focused on this protein. The AdKYP was not fully digested by the 
enzyme and there is insufficient information to know why this was the case. A further 
purification of stock AdKFT on a nickel-chelating column did not improve the purity of 
the protein. There was insufficient protein available to assess alternative purification 
strategies.
Crystallisation trials identified two buffers that produced AdKFT crystals; however these 
tiny needles were too small for crystallographic studies. An increase in the concentration 
of the protein did not increase the size of the crystals.
ESMS analysis of AdKYP and AdKFT confirmed the presence of contaminating low 
MW proteins, as well as the presence of an AdKFT dimer. SDS-PAGE analysis 
confirmed that although the dimer was present in the AdKFT fusion protein in small 
quantities. Once the hexa-his tag had been removed, at least half of the AdKFT
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preparation for the crystallisation trials was present in the dimer form. This mixture of 
monomer and dimer is the likely reason why larger crystals would not grow. AdK 
contains one cysteine residue at position 77, and it appears that removal of the hexa-his 
tag made this residue accessible. The addition of 1 mM DTT as a reducing agent would 
have prevented the formation of the dimer. There was insufficient AdK stock available to 
continue crystallisation trials, however this approach appeared promising and with more 
available protein would have been pursued.
A buffer condition that produced small needle crystals of the thermostable luciferase was 
quickly found. The focus was then on producing crystals with sufficient volume for data 
collection. The needle crystals formed quickly, within 1-2 days, and at low protein 
concentrations (6.3 mg/ml and lower). This defeated attempts to control the number of 
nucleation sites that formed. Reduced protein concentrations and lower concentrations of 
the precipitant did slightly reduce the number of crystals that formed within the drop, but 
led to the growth of smaller crystals. Streaking experiments with reduced concentrations 
of luciferase still resulted in showers of small crystals, without larger crystals growing. 
The concentration of the thermostable luciferase could only be increased to 10 mg/ml. At 
higher concentrations the protein precipitated. The wild-type luciferase had been 
successfully used in crystallisation trials at 20mg/ml (Conti et al., 1996), but this protein 
concentration was unobtainable with the thermostable luciferase.
SDS-PAGE had indicated the presence of contaminating proteins in the luciferase 
preparation, and the luciferase was further purified on a gel filtration column. A buffer 
containing PEG8000 was found to be an effective precipitant, and the lower the 
concentration of PEG8000 used, the larger the crystals. At the lower concentrations of 
PEG8000, there was also a significant increase in drop volume within 4 weeks. The 
luciferase was in a buffer containing 10%(v/v) glycerol and 25%(v/v) ethylene glycol 
(5% and 12.5% in the final drop) compared to the concentration of 2-5%(w/v) PEG8000 
in the precipitant buffer. This meant that the direction of vapour diffusion of water was 
from the precipitation buffer reservoir to the drop, diluting the protein. The largest 
crystals were produced in these drops. This dilution of the drop effectively mimics streak
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seeding where the initial drop is in a state of high supersaturation, forming several 
nucleation points. As the volume of the drop increases, the protein and buffer 
concentrations decrease and the drop moves towards a state of low supersaturation where 
protein growth can continue. The drops did grow to an unwieldy size, to the point that 
care had to be taken not to dislodge them from the cover-slip.
The largest luciferase crystals produced were similar to those reported by Conti et al., 
(1996). They describe cluster of fragile needles, up to 1.5 mm long, that produced a 
diffraction pattern consistant with space group P4i2i2 A complete data set could not be 
collected in the time available at the micro-focus beam line due to the short lifespan of a 
crystal when exposed to the micro-focus X-ray radiation. It may be possible to construct a 
complete data set from several crystals at the micro-focus X-ray radiation beam-line 
(Riekel et al., 2005).
In summary, it is likely that further optimisation of the crystallisation conditions with 
pure samples of both adenylate kinases and thermo-stable luciferase might yield better 




The electrospray mass spectrometer (ESMS) successfully measured the molecular weight 
(MW) of HSP60 purified from the lysates of three Gram-negative bacterial species 
(Escherichia coli JM109, Yersinia pseudotuberculosis 32953 and Pantoea agglomerans 
9381 Graham Brice). The HSP60 MW allowed the identification of the bacterial species. 
This provided the proof-of-principle evidence that the identification of bacterial species 
on the basis of the MW of a single biomarker protein is possible. The HSP60s from three 
bacterial species were purified with a single antibody that recognised a conserved HSP60 
epitope, which demonstrated that a generic bacterial detection system incorporating an 
immunoaffinity pre-processing step is possible. The use of generic ligands will reduce the 
number of immunoaffinity ligands required and the complexity of the detection system. 
However, HSP60 was not detected from a further three lysates of bacterial species and it 
is unknown how widely applicable this technique would be across all bacterial species 
with the current antibody. Further work is required to assess different bacterial species, 
preparation methods, different growth conditions and complex samples (particularly 
atmospheric and clinical samples, as well as food and liquids), including mixtures of 
bacteria.
Although the isolation and ESMS analysis of HSP60 from three bacterial species allowed 
each of these bacterial species to be distinguished and identified, this project highlighted 
several issues that need to be addressed before a sensitive generic biological detection 
system based on the strategy of identifying a single biomarker protein is feasible. It was 
regrettable that the only anti-HSP60 ligand available for assessment as a cross-reactive 
immunoaffinity ligand was HFT2, due to the specific recognition by HFT2 of other 
bacterial proteins as well as HSP60 (Section 5.3.2.1). The commercial mti-Chlamydia 
trachomatis HSP60 antibody (Yuan et al., 1992) may have proved to be a more suitable 
ligand as it appeared specific for HSP60, but it was prohibitive to acquire the antibody in 
the required quantities. It was likely that further hybridoma fusions would have produced 
alternate cross-reactive antibodies against HSP60 as considerable immunized material 
remained. In order to accommodate HFT2 as the capture ligand the detection system had 
to be designed around the antibody, rather than selecting the most suitable ligand to fit the
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detection system. The dialysis of the lysates prior to HSP60 purification added a further 
processing stage that, with an alternate ligand, may not have been required.
Single-chain antibody fragments (scFvs) that recognised conserved epitopes of the 
bacterial HSP60 and adenylate kinase were not isolated from naive human antibody 
phage display libraries. This was believed to be due to any phage expressing scFv that 
recognised a conserved epitope of either bacterial biomarker protein also recognised the 
E. coli protein, proving toxic to the host cell. This means that it may prove extremely 
difficult, if not impossible, to use antibody phage display technologies to develop ligands 
against highly conserved epitopes of bacterial proteins. It is unknown what degree of 
similarity between the target protein and E. coli protein will inhibit the selection of scFv. 
Monoclonal cell lines could be converted into scFvs, but their expression levels in E. coli 
is unknown. It was thought that phage display technologies could be used to generate 
libraries based on the mAbs to allow the selection of alternative ligands, but this may 
prove impossible. In this instance the modification of the antibody will require a 
structural model to allow directed design, rather than selection from a randomly created 
phage display library. X-ray crystallographic structural models of the complex between a 
bacterial biomarker protein and a scFv may have been obtainable if the bacterial proteins 
for crystallographic studies were of the required purity and scFv based on the monoclonal 
cell lines were available.
Identification of a bacterial species by mass spectrometry is dependent on the availability 
of accurate information of the MW of an individual biomarker protein such as HSP60 or 
the mass spectra of bacterial species. The HSP60 MWs of all bacterial species and strains 
are not known. There are several examples of matrix-assisted laser desorption/ionisation 
time-of-flight (MALDI-TOF) analysis of bacteria (van Baar, 2000), which greatly 
outnumber reports of ESMS bacterial analysis. ESMS has been used to characterise 
whole bacterial cells (Goodacre et al., 1999; Vaidyanathan et al., 2001); however the 
bacteria had to be thoroughly washed to remove any salts, buffers or detergents that could 
interfere with the electrospray process before analysis. Whole bacterial cells can also be 
identified by MALDI (Holland et al., 1996; Arnold and Reilly, 1998) on the basis of low
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MW biomarker proteins. MALDI spectra have been used to distinguish between bacterial 
species from the same genus, for example Pseudomonas (Holland et al., 1996) and 
Bacillus (Krishnamurphy et al., 1996). There have been several variations on bacterial 
sample preparation and analysis methods to date, which makes it difficult to compare 
mass spectra from different groups (Keys et al., 2004). A database of MALDI-TOF mass 
spectra for the identification of bacteria has been created and will continue to expand 
(Keys et al., 2004). This data includes the mass spectra of bacteria grown under different 
conditions, growth phase, sample storage and sample preparation. A similar database of 
ions generated via electrospray ionization from bacterial lysates would also be required. 
Most reports, including this investigation, used cultured bacterial samples and it is 
uncertain how representative a mass spectrum of a cultured bacterial species is applicable 
to realistic bacterial samples that have grown in a wide range of conditions and 
environments, which is why this study focused on a single biomarker protein. There has 
been minimal assessment to date of the analysis of bacterial samples from environmental 
sources, complex matrices or mixtures of different bacterial species by mass 
spectrometry-based techniques. Bundy and Fenselau (2001) have detected bacteria spiked 
into urine, milk and chicken washes with MALDI, while Krishnamurthy et al., (1999) 
were able to distinguish and identify a mixture of Bacillus anthracis and Brucella 
melitensis lysates with a liquid chromatography/ESMS system. Further assessment of 
complex samples is required.
The measurement of a single biomarker protein's molecular weight (MW) as the 
determining factor for identifying bacterial species restricts the range of bacterial species 
that can be successfully identified by this detection system. It is possible to distinguish 
between different strains of the same species on the basis of the MW of a single protein as 
demonstrated with E. coli JM109 (Section 5.3.2.6), and spectra generated by MALDI 
analysis of whole bacteria have been used to distinguish between 25 strains of E. coli 
using an algorithm to assess the spectra (Arnold and Reilly, 1998). However if there is no 
difference in the HSP60 MW between different bacterial species within a genus it may 
mean that a significant pathogen cannot be distinguished from less harmful bacteria. 
Yersinia pseudotuberculosis and Yersinia pestis have a very close genetic relationship as
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Y. pestis is a clone derived from Y. pseudotuberculosis (Achtman et al., 1999; Chain et 
al., 2004). The HSP60s from both species are identical, and it is impossible to distinguish 
between the two bacterial species solely on the basis of the HSP60 MW. However, there 
may be sufficient variation between other protein ions visible in the mass spectra of the 
lysates of the two Yersinia species to distinguish and identify them. Of the bacterial 
species assessed in this investigation, the HSP60 MW from three bacterial species was 
measured, but a protein of MW of approximately 60 kDa was not detected in elution 
fractions from a further three bacterial lysates. Low MW proteins were visible in the 
spectra of all the bacterial lysates after purification on the HFT2 columns and these 
proteins may prove to be more suitable biomarkers than relying on a single biomarker 
protein such as HSP60, although other biomarker proteins such as adenylate kinase may 
have proved to be a better target.
If bacterial species can be identified on the basis of mass spectra 'fingerprints' of low MW 
proteins (2 kDa - 20 kDa), it calls into question the strategy of basing the identification of 
a bacterial species on the MW of a single protein. One potential advantage of using a 
single, abundant protein such as HSP60 as a biomarker protein may be if the use of 
algorithms (Arnold and Reilly, 1998) were not able to identify the mass spectra 
'fingerprint' of a target bacterial species from a complex mixture of other bacteria or 
contaminating material. Concentrating and measuring the MW of the HSP60s from all 
present bacterial species may be effective in identifying each bacterial species in complex 
samples. An immunoaffinity pre-processing step with cross-reactive ligands is capable of 
isolating a conserved biomarker protein from contaminants and should also be capable of 
concentrating the biomarker protein from dilute samples, increasing the sensitivity of the 
detection system. However, at present it is unknown whether identifying bacteria from a 
complex sample is an issue. Further investigation of the identification of bacterial species 
from complex samples is needed to confirm if individual bacterial species can be 
identified from bacterial mixtures, and also the reproducibility of mass spectra of bacteria 
produced under different growth conditions.
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Although the detection system described here was not optimised for sensitivity, the 
amount of protein from each lysate loaded onto the immunoaffinity column (at least 1 mg 
in each experiment) is a concern. Detection limits of a single Bacillus anthracis cell 
(Makino and Cheun, 2003) and two Salmonella typhimurium cells (Oliveira et al., 2002) 
have been reported with PCR. Antibody based technologies have been reported to detect 
1 x 102 Escherichia coli 0157:H7 (Strachan and Ogden, 2000), 1 x 105 Listeria 
monocytogenes cells/ml (Leonard et al., 2004) and 1 x 105 cfu/ml Bacillus globigii (Rowe 
et al., 1999). In comparison, a combination of immunomagnetic separation and MALDI- 
TOF analysis was able to detect Salmonella choleraesuis from a mixture of bacteria, and 
a concentration of 1 x 109 cells/ml when spiked into river water, human urine and chicken 
blood (Madonna et al., 2001). It is unlikely at the present time that a mass spectrometer- 
based technology could approach the sensitivities of PCR or antibody-based detection 
systems without considerable sample preparation. PCR amplifies specific regions of DNA 
present in a sample; with antibody-based technologies the assay signal is often generated 
by an enzyme (ELISA), a label that allows sensitive detection
(electrochemiluminescence; Bruno and Yu, 1996) or the binding event is detected directly 
via a change in conditions on a chip surface (surface plasmon resonance; Leonard et al., 
2004). The detection limit of a mass spectrometer-based system is based on the amount of 
biomarker protein available in a sample and each processing step will reduce the quantity 
of protein presented to the ESMS. However, attomolar sensitivities have been achieved 
for several neuropeptides (Wei et al., 2004), and for neurotension, cytochrome c and 
apomyoglobin (Zhang and Caprioli, 1996) with MALDI-TOF instruments, and protein 
detection limits will improve as ionization and detection technologies are refined and 
developed. A single human erythrocyte has been successfully analysed by MALDI-TOF 
(Li et al., 1996); the greatest challenge is presenting the sample in a suitable form to the 
mass spectrometer with the minimum manipulation and in a timely fashion for use as a 
detection system. At the present moment in time it is unlikely that ESMS or MALDI 
mass spectrometry would be suitable in a front-line, real-time, high sensitivity biological 
detection system. A more appropriate role would be the analysis of clinical or cultured 
samples in a clinical diagnostic laboratory, where samples can contain large quantities of 
bacteria.
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Mass spectrometer-based detection systems are only likely to be fieldable to assess 
environmental samples once the technology is automated and miniaturized. Electrospray 
was chosen as the ionization technique for this project as it is easily interfaced with liquid 
chromatography (Gelpi, 1995) and therefore can be incorporated into a liquid handling 
system, and more readily automated than MALDI (Vaidyanathan et al., 2002), which 
requires the sample to be mixed with a matrix. However, the degree of automation of 
MALDI is increasing, particularly in regard of robotic sample spotting (Waters 
Corporation, Hertfordshire, UK) and continuous deposition of the sample on to a target 
(Zhang and Caprioli, 1996; Preisler et al., 1998), and may enable MALDI to be 
incorporated into an automated detection system in the near future.
Mass spectrometry is capable of sensitive detection if the sample can be presented to the 
mass spectrometer in a concentrated form. There are several strategies that could be used 
to design a sensitive mass spectrometer-based detection system. Electrospray is still the 
most suitable ionization technique for use in a near-real time biological detection system; 
however it is sensitive to contaminants such as salts and detergents that need to be 
removed. Nano-electrospray (Wilm and Mann, 1996) is an alternative ionization 
technique and is more tolerant to the presence of salt. The difficultly of using 
nanoelectrospray is designing the fluidic system to present a sample in a small volume to 
the ion source due to the low flow rates employed (20-100 nl/min). In-line sonication to 
disrupt bacterial cells is likely to be required if the system uses an electrospray ion 
source, but not if MALDI was employed. Sonication may still be required for analysis of 
spores to release a biomarker protein. A concentration and clean-up step would still be 
required for sensitive detection of threat agents. Using chip-based micro-fluidic 
technologies (Guetens et al., 2000; Dodge et al., 2001; Li et al., 2002; Guzman, 2003; 
Schweigert, 2005; Phillips and Wellner, 2006) may improve sensitivity, and would allow 
miniaturization of the fluidic system and be more easily combined with the 
nanoelectrospray ion source (Williams and Tomer, 2004). If bacterial lysates are to be 
assessed, then a cross-reactive antibody ligand could be used to concentrate a biomarker 
protein if there is insufficient protein present for conclusive analysis, but a C8 reversed- 
phase guard column may be more effective to simply concentrate all protein present. A
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liquid chromatography step would then be used to separate the protein before ESMS 
analysis. If intact bacterial cells are to be assessed, specific antibody could be used to 
concentrate bacteria (Molloy et al., 1995), but a selection of carbohydrates could be used 
as a capture surface to concentrate bacteria by binding to lectins on the cell surface 
(Bundy and Fenselau, 2001). This approach is likely to be more applicable to MALDI.
At Dstl, a demonstrator was produced that incorporated all the fluidics in one system and 
was successfully used to purify and identify HSP60 from lysates of the bacterial species 
from which HSP60 was successfully purified in this project. Current work has focused on 
identifying toxins by digesting with trypsin and performing liquid chromatography 
tandem mass spectrometry analysis. The resulting data-file is then used to search protein 
sequence databases to identify the toxin by comparing the MW of the digested toxin 
peptides with the theoretical digested toxin peptide MWs. As trypsin digests the protein at 
lysine and arginine residues, it is possible to search databases with this peptide 
fingerprint. MALDI-TOF analysis of the proteolytic peptides of a trypsin digestion of 
target proteins captured on an immunoaffinity chip resulted in detection of BSA, 
lyzozyme and ferritin at 100 femtomoles (Seok et al., 2005). In the future, this work will 
be expanded to include bacteria and assessment of lysate digests by ESMS.
In summary, a clean-up and concentration step is required to allow ESMS-analysis of 
complex bacterial samples, but the immunoaffinity purification of a single bacterial 
biomarker protein may not be the most appropriate approach. By concentrating on a 
single protein, information regarding other proteins that could be used to identify a threat 
agent is lost. A study is required to determine if assessment of bacterial lysate digests by 
ESMS can lead to bacterial identification and whether bacterial species identification can 
be made from complex samples and mixtures of different bacterial species. A 
carbohydrate capture surface or C8 reversed-phase column in combination with liquid 
chromatography may be more suitable than immunoaffinity purification to process the 
sample before introduction into the ionization source.
264
References
Achtman, M., Zurth, K., Morelli, G., Torrea, G., Guiyoule, A. and Camiel, E. (1999). 
Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia 
pseudotuberculosis. PNAS 96(24): 14043-14048.
Agraz, A., Duarte, C. A., Costa, L., Perez, L., Paez, R., Pujol, V. and Fontirrochi, G. 
(1994). Immunoaffinity purification of recombinant hepatitis B surface antigen from 
yeast using a monoclonal antibody. J. Chromatog. A 672: 25-33.
Amit, A. G., Mariuzza, R. A, Phillips, S. E. V. and Poljak, R. J. (1986). Three- 
dimensional structure of an antibody complex at 2.8 A resolution. Science 233: 747-753.
Amott, D., Shabanowitz, J. and Hunt, D. F. (1993). Mass spectrometry of proteins and 
peptides: sensitive and accurate mass measurement and sequence analysis. Clin. Chem. 
39(9): 2005-2010.
Arnold, R. J. and Reilly, J. P. (1998). Fingerprint matching of E. coli strains with matrix- 
assisted laser desorption/ionization time-of-flight mass spectrometry of whole cells using 
a modified correlation approach. Rapid Commun. Mass Spectrom. 12: 630-636.
van Baar, B. L. M. (2000). Characterisation of bacteria by matrix-assisted laser 
desorption/ionization and electrospray mass spectrometry. FEMS Microbiol. Rev. 24: 
193-219.
Bajic, S., Doerge, D. R., Lu, L. and Hansen Jr., E. B. (2000). Analysis of erythromycin by 
liquid chromatography / mass spectrometry using involatile mobile phases with a novel 
atmospheric pressure ionization source. Rapid Commun. Mass Spectrom. 14: 156-160.
265
Barbas 3rd, C. F., Bain, J. D., Hoekstra, D. M. and Learner, R. A. (1992). Semisynthetic 
combinational antibody libraries: a chemical solution to the diversity problem. Proc. Natl. 
Acad. Sci. USA 89(10): 3576-80.
Bayer, E. A. and Wilchek, M. (1990). Protein biotinylation. Methods Enzymol. 184: 138- 
60.
Beck, I., Gerlach, H., Burkhardt, E. and Kaleta, E. F. (2003). Investigation of several 
selected adjuvants regarding their efficacy and side effects for the production of a vaccine 
for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine 21(9-10): 
1006-1022 February 14.
Berry, J. D. (2005). Rational monoclonal antibody development to emerging pathogens, 
biothreat agents and agents of foreign animal disease: The antigen scale. Vet. J. 170: 193- 
211.
Berry, M. B., Meador, B., Bilderback, T., Liang, P., Glaser, M. and Phillips, G. N.
(1994). The closed conformation of a highly flexible protein: The structure of E. coli 
adenylate kinase with bound AMP and AMPPNP. Proteins 19: 183-198.
Berry, M. B. (1995). Structure and dynamics of E. coli adenylate kinase. Doctoral 
dissertation, Rice University, Houston.
Berry, M. B. and Phillips, G. N. (1998). Crystal structures of Bacillus stearothermophilus
94- 94-adenylate kinase with bound ApsA, Mg Ap5A, and Mn ApsA reveal an intermediate 
lid position and six coordinate octahedral geometry for bound Mg2+ and Mn2+. Proteins 
32: 276-288.
Bhalla, D. K. and Washeit, D. B. (2004). Biological agents with potential for misuse: a 
historical perspective and defensive measures. Toxicol. Appl. Pharacol. 199: 71-84.
266
Bhat, T. N., Bentley, G. A., Fischmann, T. G., Boulet, G. and Poljak, R. N. (1990). Small 
rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen 
binding. Nature 347: 483-485.
Binz, H. K. and Pliickthun, A. (2005). Engineered proteins as specific binding reagents. 
Curr. Opin. Biotechnol. 16: 459-469.
Bimie, D. H., Holme, E. R., McCay, I. C., Hood, S., McColl, K. E. L. and Hillis, W. S. 
(1998). Association between antibodies to heat shock protein 65 and coronary 
atherosclerosis. Eur. Heart J. 19: 387-394.
Bodrossy, L. and Sessitsch, A. (2004). Oligonucleotide microarrays in microbial 
diagnostics. Curr. Opin. Microbiol. 7: 245-254.
Bonde, M., Frokier, H. and Pepper, D. S. (1991). Selection of monoclonal antibodies for 
immunoaffinity chromatography: model studies with antibodies against soy bean trypsin 
inhibitor. J. Biochem. Biophys. Methods 23: 73-82.
Borthwick, K. A. J., Love, T. E., McDonnell, M. B. and Coakley, W. T. (2005). 
Improvement of immunodetection of bacterial spore antigen by ultrasonic cavitation. 
Anal. Chem. 77: 7242-7245.
Bradbury, A. R. M. and Marks, J. D. (2004). Antibodies from phage antibody libraries. J. 
Immunol. Methods 290: 29-49.
Braig, K., Otwinowski, Z., Hegde, R., Boisvert, D. C., Joachimiak, A., Horwich, A. L. 
and Sigler, P. B. (1994). The crystal structure of the bacterial chaperonin GroEL at 2.8A. 
Nature 371: 578-586 October 13.
Braig, K. (1998). Chaperonins. Curr. Opin. Struct. Biol. 8(2): 159-165.
267
Braden, B. C., Souchon, H., Eisele, J-L., Bently, G. A., Bhat, T. A., Navaza, J., and 
Poljak, R. J. (1994). Three dimensional structures of the free and the antigen-complexed 
Fab from monoclonal anti-lysozyme antibody D44.1. J. Mol. Biol. 243: 767-781.
Brockmann, E-C., Cooper, M., Stromsten, Vehniainen, M. and Saviranta, P. (2005). 
Selecting for antibody scFv fragments with improved stability using phage display with 
denaturation under reducing conditions. J. Immunol. Methods 296: 159-170.
Bruno, J. G. and Yu, H. (1996). Immunomagnetic-electrochemiluminescent detection of 
Bacillus anthracis spores in soil matrices. Appl. Environ. Microbiol. 62(9): 3474-3476.
Buchanan, T. M., Nomaguchi, H., Anderson, D. C., Young, R. A., Gillis, T. P., Britton, 
W. J., Ivanyi, J., Kolk, A. H. J., Closs, O., Bloom, B. R. and Mehra, V. (1987). 
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of 
Mycobacterium leprae. Infect. Immun. 55(4): 1000-1003.
Bucher, M. H., Evdokimov, A. G. and Waugh, D. S. (2002). Differential effects of short 
affinity tags on the crystallisation of Pyrococcus furiosus maltodextrin-binding protein. 
Acta Crystallogr. D58: 392-397.
Buckle, A. M., Zahn, R. and Fersht, A. R. (1997). A structural model for GroEL- 
polypeptide recognition. Proc. Natl. Acad. Sci. USA 94: 3571-3575.
Bukau, B. and Horwich, A. L. (1998). The Hsp70 and Hsp60 chaperone machines. Cell 
92: 351-366.
Bundy, J. L. and Fenselau, C. (2001). Lectin and carbohydrate affinity capture surfaces 
for mass spectrometric analysis of microorganisms. Anal. Chem. 73: 751-757.
Burgess, R. R. and Thompson, N. E. (2002). Advances in gentle immunoaffinity 
chromatography. Curr. Opin. Biotechnol. 13: 304-308.
268
Cai, J. and Henion, J. (1996). On-line immunoaffinity extraction-coupled column 
capillary liquid chromatography/tandem mass spectrometry: Trace analysis of LSD 
analogs and metabolites in human urine. Anal. Chem. 68: 72-78.
Callahan, J. H., Shefcheck, K. J., Williams, T. L. and Musser, S. M. (2006). Detection, 
confirmation, and quantification of staphylococcal enterotoxin B in food matrixes using 
liquid chromatography-mass spectrometry. Anal. Chem. 78: 1789-1800.
Campbell, D. H., Luescher, E. and Lerman, L. S. (1951). Immunological adsorbants. 
Isolation of antibody by means of a cellulose-protein antigen. Proc. Natl. Acad. Sci. USA 
37: 575-578.
Cereghino, J. L. and Cregg, J. M. (2000). Heterologous protein expression in the 
methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24: 45-66.
Chain, P. S. G., Camiel, E., Larimer. F. W., Lamerdin, J., Stoutland, P. O., Regala, W. 
M., Georgescu, A. M., Vergez, L. M., Land, M. L., Motin, V. L., Brubaker, R. R.,
Fowler, J., Hinnebusch, J., Marceau, M., Medigue, C., Simonet, M., Chenal-Francisque, 
V., Souza, B., Dacheux, D., Elliot, J. M., Derbise, A., Hauser, L. J. and Garcia, E. (2004). 
Insights into the evolution of Yersinia pestis through whole-genome comparison with 
Yersinia pseudotuberculosis. PNAS 101(38): 13826-13831.
Chapnick, E. K. and Abter, E. I. (1996). Necrotizing soft-tissue infections. Infect. Dis. 
Clin. North Am. 10: 835-855.
Chase, H. A. (1983). Affinity separations utilising immobilised monoclonal antibodies-a 
new tool for the biochemical engineer. Chem. Eng. Sci. 39(7-8): 1099-1125.
Chen, C. Y., Li, W. J. and Peng, K. Y. (2005). Determination of aflatoxin Mi in milk and 
milk powder using high-flow solid-phase extraction and liquid chromatography-tandem 
mass spectrometry. J. Agri. Food Chem. 53: 8474-8480.
269
Clackson, T., Hoogenboom, H. R., Griffiths, A. D. and Winter, G. (1991). Making 
antibody fragments using phage display libraries. Nature 352: 624-628.
Conti, E., Franks, N. P. and Brick, P. (1996). Crystal structure of firefly luciferase throws 
light on a superfamily of adenylate-forming enzymes. Structure 4: 287-298.
Corbitt, A. J., Bennion, N. and Forsythe, S. J. (2000). Adenylate kinase amplification of 
ATP bioluminescence for hygine monitoring in the food and beverage industry. Lett. 
App. Microbiol. 30: 443-447.
Danforth, H. D. and Augustine, P. C. (1983). Specificity and crossreactivity of immune 
serum and hybridoma antibodies to various antibodies to various species of avian 
coccidia. Poult Sci. 62(11): 2145-51.
Dasch, G. A., Ching, W-M., Kim, P. Y., Pham, H., Stover, C. K., Oaks, E. V., Dobson, 
M. E. and Weiss, E. (1990). A structural and immunological comparison of rickettsial 
HSP60 antigens with those of other species. Ann. N. Y. Acad. Sci. 590: 352-69.
de Wildt, R. M. T., Mundy, C. R., Gorick, B. D. and Tomlinson, I. M. (2000). Antibody 
arrays for high-throughput screening of antibody-antigen interactions. Nat. Biotechnol. 
18: 989-994.
Derewenda, Z. S. (2004). Rational protein crystallisation by mutational surface 
engineering. Structure 12: 529-535.
Despeyroux, D., Walker, N., Pearce, M., Fisher, M., McDonnell, M., Bailey, S. C., 
Griffiths, G. D. and Watts, P. (1999). Characterization of ricin heterogeneity by 
electrospray mass spectrometery, capillary electrophoresis, and resonant mirror. Anal. 
Biochem. 279: 23-36.
270
Dhillon, J. K. (2004). Novel antibody based molecules for the detection of the microbial 
pathogen Yersinia pestis. Ph.D thesis, University of Aberdeen. 54-14313.
Dodge, A., Fluri, K., Verpoorte, E. and de Rooji, N. F. (2001). Electrokinetically driven 
microfluidic chips with surface-modified chambers for the heterogeneous immunoassays. 
Anal. Chem. 73: 3400-3409.
Dougan, D. A., Malby, R. L., Gruen, L. C., Kortt, A. A. and Hudson, P. J. (1998). Effects 
of substitutions in the binding surface of an antibody on antigen affinity. Protein Eng. 
11(1): 65-74.
Van Emon, J. M., Gerlach, C. L. and Bowman, K. (1998). Bioseparation and 
bioanalytical techniques in environmental monitoring. J. Chromatog. B 715: 211-228.
Fayet, O., Ziegelhoffer, T. and Georgopoulos, C. (1989). The groES and groEL heat 
shock gene products of Escherichia coli are essential for bacterial growth at all 
temperatures. J. Bacteriology 171(3): 1379-1385.
Feige, U. and van Eden, W. (1996). Infection, autoimmunity and autoimmune disease. 
EXS. 77: 359-73.
Fenn, J. B., Mann, M., Mng, C. K., Wong, S. F. and Whitehouse, C. M. (1989). 
Electrospray ionization for mass spectrometry of large biomolecules. Science 246: 64-71.
Ferber, D. M., Haney, P. J., Berk, H., Lynn, D. Konisky, J. (1997). The adenylate kinase 
genes of M. voltae, M. thermolithotrophicus, M. jannaschii and M. igneus define a new 
family of adenylate kinases. Gene 185: 239-244.
Fink, A. L. (1999). Chaperone-mediated protein folding. Physiol. Rev. 79(2): 425-448.
271
Firer, M. A. (2001). Efficient elution of functional proteins in affinity chromatography. J. 
Biochem. Biophys. Methods 49: 433-442.
Findlay, B. B. and McFadden, G. (2006). Anti-immunology: evasion of the host immune 
system by bacterial and viral pathogens. Cell 124(4): 767-82.
Gelpi, E. (1995). Biomedical and biochemical applications of liquid chromatography- 
mass spectrometry. J. Chromatogr. A 703: 59-80.
Goodacre, R., Heald, J. K. and Kell, D. B. (1999). Characterisation of intact 
microorganisms using electrospray ionisation mass spectrometry. FEMS Microbiol. Lett. 
176: 17-24.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosley, 
W. L., Kontermann, R. E., Jones, P. T., Low, N. M., Allison, T. J., Prospero, T. D., 
Hoogenboom, H. R., Nissim, A., Cox, J. P. L., Harrison, J. L., Zaccolo, M., Gherardi, E. 
and Winter, G. (1994). Isolation of high affinity human antibodies directly from large 
synthetic repertoires. EMBO 13(14): 3245-3260.
Griffiths, A. D. and Duncan, A. R. (1998). Strategies for selection of antibodies by phage 
display. Curr. Opin. Biotechnol. 9: 102-108.
Guetens, G., Van Cauwenberghe, K., De Boeck, G., Maes, R., Tjaden, U. R., van der 
Greef, J., Highley, M., van Oosterom, A. T. and de Bruijn, E. A. (2000). Nanotechnology 
in bio/clinical analysis. J. Chromatography B 739: 139-150.
Guzman, N. A. (2003). Improved solid-phase microextraction device for use in on-line 
immunoaffinity capillary electrophoresis. Electrophoresis 24(21): 3718-27.
Hage, D. S. (1999). Affinity chromatography: a review of clinical applications. Clin. 
Chem. 45(5): 593-615.
272
Hao, C., Marsh, R. E., Croley, T. R., Smith, J. C. and Rafferty, S. P. (2001). Electrospray 
ionization tandem mass spectrometric study of salt cluster ions. Part 1--investigations of 
alkali metal chloride and sodium salt cluster ions. J. Mass Spectrom. 36(1): 79-96.
Harlow, E. and Lane, D. (1988). Antibodies: A laboratory manual. Cold Spring Harbor, 
New York: Cold Spring Harbor Laboratory: 56-100.
Holland, R. D., Wilkes, J. G., Rafii, W. F., Sutherland, J. B., Persons, C. C., Voorhees, K. 
J. and Lay, Jr., J. O. (1996). Rapid identification of intact whole bacteria based on 
spectral patterns using matrix-assisted laser desorption/ionization with time-of-flight 
mass spectrometry. Rapid Commun. Mass Spectrom. 10: 1227-1232.
Hoogenboom, H. R. and Winter, G. (1992). By-passing immunization. Human antibodies 
from synthetic repertoires of germline VH gene segments re-arranged in vitro. J. Mol. 
Biol. 227(2): 381-8.
Hoogenboom, H. R., de Brui’ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J-W. and 
Roovers, S. E. (1998). Antibody phage display technology and its applications. 
Immunotechnology 4: 1-20.
Howell, S., Kenmore, M., Kirkland, M. and Badley, R. A. (1998). High-density 
immobilization of an antibody fragment to a carboxymethylated dextran-linked biosensor 
surface. J. Mol. Recognit. 11(1-6): 200-3.
Hudson, P. J. and Kortt, A. A. (1999). High avidity scFv multimers; diabodies and 
tribodies. J. Immunol. Methods 231: 177-189.
Hudson, P. J. and Souriau C. (2003). Engineered antibodies. Nature Med. 9(1): 129-134.
273
Hunte, C. and Michel, H. (2002). Crystallisation of membrane proteins mediated by 
antibody fragments. Curr. Opin. Struct. Biol. 12:503-508.
Hust, M. and Dubel, S. (2005). Phage display vectors for the in vitro generation of human 
antibody fragments. Methods Mol. Biol. 295: 71-96.
Iqbal, S. S., Mayo, M. W., Bruno, J. G., Bronk, B. V., Batt, C. A. and Chambers, J. P. 
(2000). A review of molecular recognition technologies for detection of biological threat 
agents. Biosens. Bioelectron. 15: 549-578.
Iwata, S., Ostermeier, C., Ludwig, B. and Michel, H. (1995). Structure at 2.8A resolution 
of cytochrome c oxidase from Paracoccus denitrificans. Nature 376: 660-669.
Jack, G. W. (1994). Immunoaffinity chromatography. Mol. Biotechnol. 1(1): 59-86
Johne, B., Gadnell, M. and Hansen, K. (1993). Epitope mapping and binding kinetics of 
monoclonal antibodies studied by real time biospecific interaction analysis using surface 
plasmon resonance. J. Immuno. Methods 160: 191-198.
Johnson, J. R. (2000). Development of polymerase chain reaction-based assays for 
bacterial gene detection. J. Microbiol. Methods 41: 201-209.
Jonsson, A. P. (2001). Mass spectrometry for protein and peptide characterisation. Cell. 
Mol. Life Sci. 58: 868-884.
Jung, S., Honegger, A. and Pluckthun, A. (1999). Selection for improved protein stability 
by phage display. J. Mol. Biol. 294: 163-180.
Karlsson, R., Michaelsson A. and Mattsson, L. (1991). Kinetic analysis of monoclonal 
antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. 
Methods. 145: 229-240.
274
Kearney, J. F., Radbruch, A., Liesegang, B., Rajewsky, K. (1979). A new mouse 
myeloma cell line that has lost immunoglobulin expression but permits the construction 
of antibody-secreting hybrid cell lines. J. Immunol. Oct; 123(4): 1548-50.
Keys, C. J., Dare, D. J., Sutton, H., Wells, G., Lunt, M., McKenna, T., McDowall, M. and 
Shah, H. N. (2004). Compilation of a MALDI-TOF mass spectral database for the rapid 
screening and characterisation of bacteria implicated in human infectious diseases. Infect. 
Genet. Evol. 4: 221-242.
Khan, I., Desai, D. V. and Kumar, A. (2004). Carbochips: a new technology for old 
biobuilders. J. Biosci. Bioeng. 98(5): 331-337.
Klietmann, W. F. and Ruoff, K. L. (2001). Bioterrorism: implications for the clinical 
microbiologist. Clin. Microbiol. Rev. 14(2): 364-381.
Kohler, G. and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody 
of prefined specificity. Nature 256: 495-497.
Kortepeter, M. G. and Parker, G. W. (1999). Potential biological weapon threats. Emerg. 
Infect. Dis. 5: 523-527.
Kovari, L. C., Momany, C. and Rossmann, M. G. (1995). The use of antibody fragments 
for crystallization and structure determinations. Structure 3:1291-1293.
Krebber, A., Bomhauser, S., Burmester, J., Honegger, A., Willuda, J., Bosshard, H. R. 
and Pliickthun, A. (1997). Reliable cloning of functional antibody variable domains from 
hybridomas and spleen cell repertoires employing a reengineered phage display system. J. 
Immunol. Methods 201: 35-55.
275
Krishnamurthy, T., Ross, P. L. and Rajamani, U. (1996) Detection of pathogenic and non- 
pathogenic bacteria by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry. Rapid Commun. Mass Spectrom. 10: 883-888.
Krishnamurthy, T., Davis, M. T., Stahl, D. C. and Lee, T. D. (1999). Liquid 
chromatography / microspray spectroscopy for bacterial investigations. Rapid Commun. 
Mass Spectrom. 13: 39-49.
Kuske, C. R., Banton, K. L., Adorada, D. L., Stark, P. C., Hill, K. K. and Jackson, P. J. 
(1998). Small-scale DNA sample preparation method for field PCR detection of 
microbial cells and spores in soil. Appl. Environ. Microbiol. 64(7): 2463-2472.
Lacey, J. M., Bergen, H. R., Magera, M. J., Naylor, S. and O'Brien, J. F. (2001). Rapid 
determination of transferrin isoforms by immunoaffinity liquid chromatography and 
electrospray mass spectrometry. Clin. Chem. 47(3): 513-518
Lebedev, A. T. (2005). Mass spectrometry in identification of ecotoxicants including 
chemical and biological warfare threat agents. Toxicol. Appl. Pharmacol. 207: 451-458.
Leenaars, M. and Hendriksen, C. F. M. (2005). Critical steps in the production of 
polyclonal and monoclonal antibodies: evaluation and recommendations. ILAR J. 46(3): 
269-279.
Leonard, P., Hearty, S., Quinn, J. and O'Kennedy, R. (2004). A generic approach for the 
detection of whole Listeria monocytogenes cells in contaminated samples using surface 
plasmon resonance. Biosens. Bioelectron. 19: 1331-1335.
Lescar, J., Pellegrini, M., Souchon, H., Tello, D., Poljak, R. J., Peterson, N., Greene, M. 
and Alzari, P. M. (1995). Crystal structure of a cross-reaction complex between Fab 
F9.13.7 and guinea fowl lysozyme. J. Biol. Chem. 270(30): 18067-18076.
276
Li., J., LeRiche, T., Tremblay, T-L., Wang, C., Bonneil, E., Harrison, D. J. and Thibault, 
P. (2002). Application of microfluidic devices to proteomics research. Mol. Cell 
Proteomics 1(2): 157-68.
Li, L., Golding, R. E. and Whittal, R. M. (1996). Analysis of single mammalian cell 
lysates by mass spectrometry. J. Am. Chem. Soc. 118: 11662-11663.
Liang, X., Zheng, K., Qian, M. G. and Lubman, D. M. (1996). Determination of bacterial 
protein profiles by matrix-assisted laser desorption/ionization mass spectrometry with 
high-performance liquid chromatography. Rapid Commun. Mass Spectrom. 10: 1219- 
1226.
Lim, C. K. and Lord, G. (2002). Current developments in LC-MS for pharmaceutical 
analysis. Biol. Pharm. Bull. 25(5): 547-557.
Lim, D. V., Simpson, J. M., Kearns, E. A. and Kramer, M. F. (2005). Current and 
developing technologies for monitoring agents of bioterrorism and biowarfare. Clin. 
Microbiol. Rev. 18(4): 583-607.
Lipman, N. S., Jackson, L. R., Trudel, L. J. and Weis-Garcia, F. (2005). Monoclonal 
versus polyclonal antibodies: distinguishing characteristics, applications, and information 
resources. ILAR J. 46(3): 258-268.
Luppa, P. B., Sokoll, L. J. and Chan, D. W. (2001). Immunosensors- principles and 
application to clinical chemistry. Clinica Chimica Acta 314: 1-24.
Madonna, A. J., Basile, F., Furlong, E. and Voorhees, K. J. (2001). Detection of bacteria 
from biological mixtures using immunomagnetic separation combined with matrix- 
assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. 
Mass Spectrom. 15: 1068-1074.
277
Makino, S-I. and Cheun, H-I. (2003). Application of the real-time PCR for the detection 
of airborne microbial pathogens in reference to the anthrax spores. J. Microbiol. Methods 
53: 141-147.
Malmborg, A-C. and Borrebaeck, C. A. K. (1995). BIAcore as a tool in antibody 
engineering. J. Immuno. Methods 183: 7-13.
Mannelli, I., Minunni, M., Tombelli, S., Wang, R., Spiriti, M. M. and Mascini, M. (2005). 
Direct immobilization of DNA probes for the development of affinity biosensors. 
Bioelectrochemistry 66: 129-138.
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths A. D. and 
Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries 
displayed on phage. J. Mol. Biol. 222: 581-597.
Marquet, P. and Lachatre, G. (1999). Liquid chromatography-mass spectrometry: 
potential in forensic and clinical toxicology. J. Chromatogr. B 733: 93-118.
Miyazaki, C., Iba, Y., Yamada, Y., Takahashi, H., Sawada, J. I. and Kurosawa, Y. (1999). 
Changes in the specificity of antibodies by site-specific mutagenesis followed by random 
mutagenesis. Protein Eng. 12(5): 407-415.
Molloy, P., Brydon, L., Porter, A. J. and Harris, W. J. (1995). Separation and 
concentration of bacteria with immobilized antibody fragments. J. Appl. Bacteriol. 78: 
359-365.
Muller, C. W. and Schulz, G. E. (1992). Structure of the complex between adenylate 
kinase from Escherichia coli and the inhibitor ApsA refined at 1.9A resolution. J. Mol. 
Biol. 224: 159-177.
278
Munk, M. E., Schoel, B., Modrow, S., Karr, R. W., Young, R. A. and Kaufmann, S. H. E. 
(1989). T lymphocytes from healthy individuals with specificity to self-epitopes shared 
by the mycobacterial and human 65-kilodalton heat shock protein. J. Immunol. 143: 
2844-2849.
Needleman, S. B. and Wunsch, C. D. (1970). A general method applicable to the search 
for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48(3): 443-453.
Neidhardt, F. C., VanBogelen, R. A and Vaughn, V. (1984). The genetics and regulation 
of heat-shock proteins. Ann. Rev. Genet. 18: 295-329.
Nevanen, T. K., Heilman M.-L., Munck N., Wohlfahrt G., Koivula A. and Soderlund H.
(2003). Model-based mutagenesis to improve the enantioselective fractionation properties 
of an antibody. Protein Eng. 16(12): 1089-1097.
Ngundi, M. M., Taitt, C. R., McMurry, S. A., Kahne, D. and Ligler, F. S. (2006). 
Detection of bacterial toxins with monosaccharide arrays. Biosens. Bioelectron. 21: 1195- 
1201.
Niessen, W. M. A. (1998). Advances in instrumentation in liquid chromatography-mass 
spectrometry and related liquid-introduction techniques. J. Chromatogr. A 794: 407-435.
Nisnevitch, M. and Firer, M. A. (2001). The solid phase in affinity chromatography: 
strategies for antibody attachment. J. Biochem. Biophys. Methods 49: 467-480.
Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D. and 
Winter, G. (1994). Antibody fragments from a ‘single pot’ phage display library as 
immunochemical reagents. EMBO 13(3): 692-698.
279
Oliveira, S. D., Santos, L. R., Schuch, D. M. T., Silva, A. B., Salle, C. T. P. and Canal,
C. W. (2002). Detection and identification of salmonellas from poultry-related samples 
by PCR. Vet. Microbiol. 87: 25-35.
Otwinowski, Z. and Minor, W. (1997). Processing of X-ray diffraction data collected in 
oscillation mode. Methods in Enyzmology 276: 307-326. Macromolecular
Crystallography, Part A. Carter Jr, C. W. and Sweet, R. M., Eds. Academic Press.
Peruski, Jr., L. F. and Peruski, A. H. (2003). Rapid diagnostic assays in the genomic 
biology era: detection and identification of infectious disease and biological weapon 
agents. Biotechniques 35(4): 840-846.
Pfister, G., Stroh, C. M., Perschinka, H., Kind, M., Knoflach, M., Hinterdorfer, P. and 
Wick, G. (2005). Detection of HSP60 on the membrane surface of stressed human 
endothelial cells by atomic force and confocal microscopy. J. Cell Science 118(8): 1587- 
1594.
Phillips, T. M and Wellner, E. (2006). Measurement of neuropeptides in clinical samples 
using chip-based immunoaffinity capillary electrophoresis. J. Chromatography A. E- 
published ahead of publication.
Piervincenzi, R. T., Reichert, W. M. and Hellinga, H. W. (1997). Genetic engineering of 
a single-chain antibody fragment for surface immobilization in an optical biosensor. 
Biosens. Bioelectron. 13(3-4): 305-312.
Preisler, J., Foret, F. and Karger, B. L. (1998). On-line MALDI-TOF MS using a 
continuous vacuum deposition interface. Anal. Chem. 70: 5278-5287.
280
Pribil, P. A., Patton, E., Black, G., Doroshenko, V. and Fenselau, C. (2005). Rapid 
characterization of Bacillus spores targeting species-unique peptides produced with an 
atmospheric pressure matrix-assisted laser desorption/ionization source. J. Mass 
Spectrom. 40: 464-474.
Puerta, A., Diez-Masa, J. C. and Frutos, M. (2004). Use of immunodotting to select the 
desorption agent for immunochromatography. J. Immunol. Methods 289: 225-237.
Reiche, N., Jung, A., Brabletz, T., Vater, T., Kirchner, T. and Faller, G. (2002). 
Generation and characterization of human monoclonal scFv antibodies against 
Helicobacter pylori antigens. Infect. Immun. 70(8): 4158-4165.
Redmond, C., Bailie, L. W. J., Hibbs, S., Moir, A. J. G. and Moir, A. (2004). 
Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 150: 
355-363.
Rhoads, D. G. and Lowenstein, J. M. (1968). Initial velocity and equilibrium kinetics of 
myokinase. J. Biol. Chem. 243(14): 3963-3972.
Riechmann, L., Weill, M. and Cavanagh, J. (1992). Improving the antigen affinity of an 
antibody Fv-fragment by protein design. J. Mol. Biol. 224: 913-918.
Roberts, S., Cheetham, J. C. and Rees, A. R. (1987). Generation of an antibody with 
enhanced affinity and specificity for its antigen by protein engineering. Nature. 
328(6132): 731-734.
Rowe, C. A., Tender, L. M., Feldstein, M. J., Golden, J. P., Scruggs, S. B, MacCraith, B.
D., Cras, J. J. and Ligler, F. S. (1999). Array biosensor for simultaneous identification of 
bacterial, viral and protein analytes. Anal. Chem. 71: 3846-3852.
281
Sawaga, N., Takino, T. and Kurogochi, S. (2006). A simple method with liquid 
chromatography/tandem mass spectrometry for the determination of the six trichothecene 
mycotoxins in rice medium. Biosci. Biotechnol. Biochem. 70(1): 230-236.
Schiweck, W. and Skerra, A. (1997). The rational design of an antibody fragment against 
cystatin: Lessons from the crystal structure of an artificial Fab fragment. J. Mol. Biol. 
268: 934-951.
Schmechel, D., Simpson, J. P., Beezhold, D. and Lewis, D. W. (2006). The development 
of species-specific immunodiagnostics for Stachybotrys chartarum: The role of cross­
reactivity. J. Immunol. Methods 309: 150-159.
Schulz, G. E., Schitz, E., Tomasselli, A. G., Frank, R., Brune, M., Wittinghofer, A. and 
Schirmer, R. H. (1986). Structural relationships in the adenylate kinase family. Eur. J. 
Biochem. 161(1): 127-32.
Schunk, M. K. and Macallum, G. E. (2005). Applications and optimization of 
immunization procedures. ILAR J. 46(3): 241-257.
Schweigert, F. J. (2005). Characterisation of protein microheterogeneity and protein 
complexes using on-chip immunoaffinity purification-mass spectrometry. Brief. Funct. 
Genomic Proteomic. 4(1): 7-15.
Sen, J. W., Bergen 3rd, H. R. and Heegaard, N. H. H. (2003). On-line immunoaffinity- 
liquid chromatography-mass spectrometry for identification of amyloid disease markers 
in biological fluids. Anal. Chem. 75: 1196-1202.
Seok, H. J., Hong, M. Y., Kim, Y. J., Han, M. K., Lee, D., Lee, J. H., Yoo, J. S. and Kim, 
H. S. (2005). Mass spectrometric analysis of affinity-captured proteins on a dendrimer- 
based immunosensing surface: investigation of on-chip proteolytic digestion. Anal. 
Biochem. 337: 294-307.
282
Sergeev, N., Distler, M., Courtney, S., Al-Khaldi, S. F., Volokhov, D., Chizhikov, V. and 
Rasooly, A. (2004). Multipathogen oligonucleotide microarray for environmental and 
biodefense applications. Biosens. Bioelectron. 20: 684-698.
Sheriff, S., Silverton, E. W., Padlan, E. A., Cohen, G. H., Smith-Gill, S. J. and Davies, D. 
R. (1987). Three-dimensional structure of an antibody-antigen complex. Proc. Natl. Acad. 
Sci. 84: 8075-8079.
Shi, Y., Xiang, R., Horvath, C. and Wilkins, J. A. (2004). The role of liquid 
chromatography in proteomics. J. Chromatog. A 1053: 27-36.
Shinnick, T. M., Vodkin, M H. and Williams, J. C. (1987). The Mycobacterium 
tuberculosis 65-kilodalton antigen is a heat shock protein which corresponds to common 
antigen and to the Escherichia coli GroEL protein. Infect. Immun. 56(2): 446-451.
Shuntao, W., Jiannan, F., Jianwei, G., Leiming, G., Yan, L., Yingxun, S., Weisong, Q., 
Meiru, H., Gencheng, H. and Beifen, S. (2005). A novel designed single domain antibody 
on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity. Mol. 
Immunol. (Epub ahead of print).
Sidhu, S., S. (2001). Engineering M13 for phage display. Biomol. Eng. 18: 57-63.
Sigler, P. B., Hays, S. R., Burston, S. G., Fenton, W. A. and Horwich, A. L. (1998). 
Structure and function in Gro-EL-mediated protein folding. Annu. Rev. Biochem. 67: 
581-608.
Siuzdak. G. (1996). Mass spectrometry for biotechnology. Academic Press, San Diego, 
California. ISBN 0-12-647471-0
Smith, T. F. and Waterman, M. S. (1981). Identification of common molecular 
subsequences. J. Mol. Biol. 147: 195-197.
283
Smyth, D. R., Mrozkiewicz, M. K., McGrath, W. J., Listwan, P. and Kobe, B. (2003). 
Crystal structures of fusion proteins with large-afflnity tags. Protein Sci. 12: 1313-1322.
Squirrell, D. J. and Murphy, M. J. (1994). Adenylate kinase as a cell marker in 
bioluminescence assays. In Bioluminescence and Chemiluminescence; Fundamental and 
Applied Aspects ed. Campbell, A. K., Krika, I. J. and Stanley, P. E. pp 486-489. 
Chichester: John Wiley & Sons.
Squirrell, D. J., Murphy, M. J., Price, R. L., White, P. J. and Willey, T. L. (2003). Patent 
number: ZA200203170. Classification: international. European: application number: 
ZA200220003170 20020422 Priority number(s): GB 19990025161 19991026.
Stanley, P. E. (1989). A review of bioluminescent ATP techniques in rapid microbiology. 
J. Biolumin. Chemilumin. 4: 375-380.
Stevens, D. L. (2000). The pathogenesis of clostridial myonecrosis. Int. J. Med. 
Microbiol. 290: 492-502.
Stills Jr., H. F. (2005). Adjuvants and antibody production: dispelling the myths 
associated with Freund's complete and other adjuvants. ILAR J. 46(3): 280-293.
Stills Jr., H. F. and Bailey, M. Q. (1991). The use of Freund's complete adjuvant. Lab 
Animal. April:20(4): 25-30.
Strachan, N. J. C. and Ogden, I. D. (2000). A sensitive microsphere coagulation ELISA 
for Escherichia coli 0157:H7 using Russell's viper venom. FEMS Microbiol. Lett. 186: 
79-84.
Strege, M. A. (1999). High-performance liquid chromatographic-electrospray ionization 
mass spectrometric analyses for the integration of natural products with modem high- 
throughput screening. J. Chromatogr. B 725: 67-78.
284
Sugasawara, R. J., Cahoon, B. E. and Kani, A. E. (1985). The influence of murine 
macrophage-conditioned medium on cloning efficiency, antibody synthesis, and growth 
rate of hybridomas. J. Immunol. Methods 79(2): 263-75.
Stuart, D. A., Haes, A. J., Yonzon, C. R., Hicks, E. M. and Van Duyne, R. P. (2005). 
Biological applications of localised surface plasmonic phenomenae. IEE Proc 
Nanobiotechnol. 152(1): 13-32.
Swatkoski, S., Russell, S. C., Edwards, N. and Fenselau, C. (2006). Rapid chemical 
digestion of small acid-soluble spore proteins for analysis of Bacillus spores. Anal. Chem. 
78(1): 181-8.
Thomas, J. J., Falk, B. and Fenselau, C. (1998). Viral characterization by direct analysis 
of capsid proteins. Anal. Chem. 70: 3863-3867.
Thompson, J. D., Higgins, D. G. and Gibson, T. J. (1994). CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence weighting, 
position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22(22): 
4673-4680.
Tisi, L. C., White, P. J., Squirrell, D. J., Murphy, M. J., Lowe, C. R. and Murray, J. A. H. 
(2002). Development of a thermostable firefly luciferase. Anal. Chim. Acta 457: 115-123.
Titball, R. W. and Despeyroux, D. (2002). Identifying micro-organisms. UK patent 
application GB 0112428.8 prior art date: 21 May 2002. International patent application 
No. PCT/GB02/02208.
Tsai, M-D. and Yan, H. (1991). Mechanism of adenylate kinase: site-directed 
mutagenesis versus X-ray and NMR. Biochemistry 30: 6806-6818.
285
Vaidyanathan, S., Rowland, J. J., Kell, D. B. and Goodacre, R. (2001). Discrimination of 
aerobic endospore-forming bacteria via electrospray-ionization mass spectrometry of 
whole cell suspensions. Anal. Chem. 73: 4134-4144.
Vaidyanathan, S., Kell, D. B. and Goodacre, R. (2002). Flow-injection electrospray 
ionization mass spectrometry of crude cell extracts for high-throughput bacterial 
identification. J. Am. Soc. Mass Spectrom. 13: 118-128.
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Eamshaw, J. 
C., McCafferty, J., Hodits, R. A., Wilton, J. and Johnson, K. S. (1996). Human antibodies 
with sub-nanomolar affinities isolated from a large non-immunized phage display library. 
Nat. Biotechnol. 14(3): 309-14.
Verheesen, P., ten Haaft, M. R., Linder, N., Verrips, C. T. and de Haard, J. J. W. (2003). 
Beneficial properties of single-domain antibody fragments for application in 
immunoaffinity purification and immuno-perfusion chromatography. Biochimica et 
Biophysica Acta 1624: 21-28.
Vonrhein, C., Bonisch, H., Schafer, G. and Schulz, G. E. (1998). The structure of a 
trimeric archaeal adenylate kinase. J. Mol. Biol. 282: 167-179.
Wahl, L. M., Bittner, B. and Newak, M. A. (2000). Immunological transitions in response 
to antigenic mutation during viral infection. Int. Immunol. 12(10): 1371-80.
Wang, S. H., Wen, J. K., Zhou, Y. F., Zhang, Z. P., Yang, R. F., Zhang, J. B., Chen, J. 
and Zhang, X. E. (2004). Identification and characterisation of Bacillus anthracis by 
multiplex PCR on DNA chip. Biosens. Bioelectron. 20: 807-813.
286
Wei, H., Nolkrantz, K., Powell, D. H., Woods, J. H., Ko, M-C. and Kennedy, R. T.
(2004). Electrospray sample deposition for matrix-assisted laser desorption/ionization 
(MALDI) and atmospheric pressure MALDI mass spectrometry with attomole detection 
limits. Rapid Commun. Mass Spectrom. 18: 1193-1200.
Welham, K. J., Domin, M. A., Scannell, D. E., Cohen, E. and Ashton, D. S. (1998). The 
characterization of micro-organisms by matrix-assisted laser desportion/ionization time- 
of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 12: 176-180.
Wick, G., Perschinka, H. and Millonig, G. (2001). Atherosclerosis as an autoimmune 
disease: an update. Trends Immunol. 22(12): 665-669.
Williams, D. D. and Tumbough, Jr., C. L. (2004). Surface layer protein EA1 is not a 
component of Bacillus anthracis spores but is a persistent contaminant in spore 
preparations. J. Bacteriol. 186(2): 566-569.
Williams, J. G. and Tomer, K. B. (2004). Disposable chromatography for a high- 
throughput nano-ESI/MS and nano-ESI/MS-MS platform. J. Am. Soc. Mass Spectrom. 
15: 1333-1340.
Wilm, M. and Mann, M. (1996). Analytical properties of the nanoelectrospray ion source. 
Anal. Chem. 68: 1-8.
Winter, G., Griffiths, A. D., Hawkins, R. E. and Hoogenboom, H. R. (1994). Making 
antibodies by phage display technology. Annu. Rev. Immunol. 12: 433-55.
Worn, A. and Pliickthun, A. (2001). Stability engineering of antibody single-chain Fv 
fragments. J. Mol. Biol. 305: 989-1010.
Wong, R. S. and Chow, A. W. (2002). Identification of enteric pathogens by heat shock 
protein 60 kDa (HSP60) gene sequences. FEMS Microbiol. Lett. 206(1): 107-13.
287
van der Woude, M. W. and Baumler, A. J. (2004). Phase and antigenic variation in 
bacteria. Clin. Microbiol. Rev. 17(3): 581-611.
Xu, W., Huang, K., Zhao, H. and Luo, Y. (2005). Application of immunoaffmity column 
as cleanup tool for an enzyme-linked immunosorbent assay of phosphinothricin-N- 
acetyltransferase detection in genetically modified maize and rape. J. Agric. Food Chem. 
53:4315-4321.
Xu, Z., Horwich, A. L. and Sigler, P. B. (1997). The crystal structure of the asymmetric 
GroEL-GroES-(ADP) 7  chaperonin complex. Nature 388: 741-750.
Yamaguchi, H., Osaki, T., Taguchi, H., Hanawa, T., Yamamoto, T. and Kamiya, S. 
(1997). Production and characterisation of monoclonal antibodies to heat-shock protein 
60 of Helicobacter pylori. J. Med. Micro. 46(10): 819-824.
Yan, H. and Tsai, M. D. (1999). Nucleoside monophosphate kinases: structure, 
mechanism, and substrate specificity. Adv. Enzymol. Relat. Areas Mol. Biol. 73: 85-93.
Yarmush, M. L., Antonsen, K. P., Sundaram, S. and Yarmush, D. M. (1992). 
Immunoadsorption: strategies for antigen elution and production of reusable adsorbents. 
Biotechnol. Prog. 8: 168-178.
Yarmush, M. L., Weiss, A. M., Antonsen, K. P., Odde, D. J. and Yarmush, D. M. (1992). 
Immunoaffmity purification: basic principles and operational considerations. Biotech. 
Adv. 10: 413-446.
Yarmush, M. L., Patankar, D. B. and Yarmush, D. M. (1996). An analysis of transport 
resistances in the operation of BIAcore™; implications for kinetic studies of biospecific 
interactions. Mol. Immuno. 33(15): 1203-1214.
288
Yoder, J. D., Chen, T. S., Gagnier, C. R., Vemulapalli, S., Maier, C. S. and Hruby, D. E. 
(2006). Pox protemics: mass spectroscopy analysis and identification of Vaccinia virion 
proteins. Virol. J. 3(1) Epub ahead of print.
Young, N. M., MacKenzie, C. R., Narang, S. A., Oomen, R. P. and Baenziger, J. E.
(1995). Thermal stabilization of a single-chain Fv antibody fragment by introduction of a 
disulphide bond. FEBS Lett. 377: 135-139.
Yuan, Y., Lyng, K., Zhang, Y-X., Rockey, D. D. and Morrison, R. P. (1992). Monoclonal 
antibodies define genus-specific, species-specific, and cross-reactive epitopes of the 
chlamydial 60-kilodalton heat shock protein 60 (HSP60): Specific immunodetection and 
purification of Chlamydial HSP60. Infect. Immun. 60(6): 2288-2296.
Zeilstra-Ryalls, J., Fayet, O. and Georgopoulos, C. (1991). The universally conserved 
GroE (Hsp60) chaperonins. Annu. Rev. Microbiol. 45: 301-25.
Zhang, H and Caprioli, R. M. (1996). Capillary electrophoresis combined with matrix- 
assisted laser desorption/ionization mass spectrometry; continuous sample deposition on a 
matrix-precoated membrane target. J. Mass Spectrom. 31: 1039-1046.
Zhang, X., Yonzon, C. R., Young, M. A., Stuart, D. A. and Van Duyne, R. P. (2005). 
Surface-enhanced Raman spectroscopy biosensors: excitation spectroscopy for
optimisation of substrates fabricated by nanosphere lithography. IEE Proc. 
Nanobiotechnol. 152(6): 195-206.
Ziigel, U. and Kaufinann, S. H. E. (1999). Role of heat shock proteins in protection from 
and pathogenesis of infectious diseases. Clin. Microbiol. Rev. 12(1): 19-39.
289
